WorldWideScience

Sample records for ampliscreen hbv test

  1. Interpreting Liver Function Test in HIV-HBV Coinfection.

    Directory of Open Access Journals (Sweden)

    Tamal Mukherjee

    2013-08-01

    Such co-infected individuals also face increased risk of hepatotoxicity from anti-retroviral therapy. Individuals with HIV-HBV co-infection should have both the infections completely assessed in order to decide on the best therapeutic option for both viruses. [Natl J Med Res 2013; 3(4.000: 342-345

  2. HBV-DNA positive women postpartum cord blood and breast milk HBV-DNA capacity testing analysis%HBV-DNA阳性孕妇产后脐带血及乳汁中HBV-DNA载量分析

    Institute of Scientific and Technical Information of China (English)

    黄霞; 杨文东

    2013-01-01

    目的 通过荧光定量PCR(FQ-PCR)方法检测血清HBV-DNA阳性产妇产后脐带血及乳汁HBV-DNA载量,探讨胎儿宫内感染HBV及乳汁携带HBV与产妇HBV-DNA载量的相关性.方法 2010年1月至2012年11月,选取在产科住院分娩的HBV-DNA阳性产妇149例,采用FQ-PCR方法检测产妇产前血清、产后脐带血和乳汁HBV-DNA载量.结果 ①选择有HBV感染史产妇304例中149例HBV-DNA阳性,阳性率为49.01%(149/304);②149例HBV-DNA阳性产妇胎儿宫内感染为42.95%;HBV-DNA阳性孕妇乳汁中HBV-DNA阳性率(71.14%)显著高于脐血(42.95%)(P<0.01);HBV-DNA≥1×105组脐带血、初乳及满月乳中HBV-DNA阳性率(61.29%、82.80%、100.00%)显著高于1×103≤HBV-DNA<1×105组(12.50%、51.79%、75.00%)(P< 0.01);满月乳中HBV-DNA阳性率(90.60%)显著高于初乳(71.14%)(P<0.01).结论HBV-DNA阳性孕妇胎儿HBV的宫内感染率及乳汁中携带HBV的阳性率高,与孕妇血清HBV-DNA载量正相关,阻断HBV的宫内感染及减少乳汁携带HBV者,必须有效的降低孕妇血中的HBV-DNA载量水平.

  3. An in-house real-time polymerase chain reaction: standardisation and comparison with the Cobas Amplicor HBV monitor and Cobas AmpliPrep/Cobas TaqMan HBV tests for the quantification of hepatitis B virus DNA

    Science.gov (United States)

    Santos, Ana Paula de Torres; Levi, José Eduardo; Lemos, Marcilio Figueiredo; Calux, Samira Julien; Oba, Isabel Takano; Moreira, Regina Célia

    2016-01-01

    This study aimed to standardise an in-house real-time polymerase chain reaction (rtPCR) to allow quantification of hepatitis B virus (HBV) DNA in serum or plasma samples, and to compare this method with two commercial assays, the Cobas Amplicor HBV monitor and the Cobas AmpliPrep/Cobas TaqMan HBV test. Samples from 397 patients from the state of São Paulo were analysed by all three methods. Fifty-two samples were from patients who were human immunodeficiency virus and hepatitis C virus positive, but HBV negative. Genotypes were characterised, and the viral load was measure in each sample. The in-house rtPCR showed an excellent success rate compared with commercial tests; inter-assay and intra-assay coefficients correlated with commercial tests (r = 0.96 and r = 0.913, p < 0.001) and the in-house test showed no genotype-dependent differences in detection and quantification rates. The in-house assay tested in this study could be used for screening and quantifying HBV DNA in order to monitor patients during therapy. PMID:26872342

  4. 聚合酶链反应检测血清HBV-DNA的临床价值%Clinical Value of testing Blood HBV-DNA By PCR

    Institute of Scientific and Technical Information of China (English)

    高蓬

    1998-01-01

    @@ 聚合酶链反应(polymerase chain reaction,PCR)是一种体外DNA扩增技术,本文采用PCR技术检测乙型肝炎病毒(HBV-DNA),并与乙肝病毒标志物进行对比,以探讨HBV感染状态及与乙肝标志物(HBV-M)之间的关系.

  5. Hepatitis B virus DNA is more powerful than HBeAg in predicting peripheral T-lymphocyte subpopulations in chronic HBV-infected individuals with normal liver function tests

    Institute of Scientific and Technical Information of China (English)

    Jing You; Hutcha Sriplung; Alan Geater; Virasakdi Chongsuvivatwong; Lin Zhuang; Hong-Ying Chen; Jun-Hua Huang; Bao-Zhang Tang

    2008-01-01

    AIM: To investigate the peripheral T-lymphocyte subpopulation profile, and its correlations with hepatitis B virus (HBV) replication level in chronic HBV-infected (CHI) individuals with normal liver function tests (LFTs). METHODS: Frequencies of T-lymphocyte subpopulations in peripheral blood were measured by flow cytometry in 216 CHI individuals. HBV markers were detected with ELISA. Serum HBV DNA load was assessed with quantitative real-time PCR. Information of age at HBV infection, and maternal HBV infection status was collected. ANOVA linear trend test and linear regression were used in statistical analysis.RESULTS: CHI individuals had significantly decreased relative frequencies of CD+3, CD+4 subpopulations and CD+4/CD+8 ratio, and increased CD+8 subset percentage compared with uninfected individuals (all P<0.001). There was a significant linear relationship between the load of HBV DNA and the parameters of T-lymphocyte subpopulations (ANOVA linear trend test P<0.01). The parameters were also significantly worse among individuals whose mothers were known to be HBV carriers, and those having gained infection before the age of 8 years. In multiple regressions, after adjustment for age at HBV infection and status of maternal HBV infection, log copies of HBV DNA maintained its highly significant predictive coefficient on T-lymphocyte subpopulations, whereas the effect of HBeAg was not significant.CONCLUSION: HBV DNA correlates with modification in the relative T-lymphocyte subpopulation frequencies. High viral load is more powerful than HBeAg in predicting the impaired balance of T-cell subsets.

  6. Development of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic Hepatitis B patients

    OpenAIRE

    Dammermann, Werner; Bentzien, Frank; Stiel, Eva-Maria; Kühne, Claudia; Ullrich, Sebastian; zur Wiesch, Julian Schulze; Lüth, Stefan

    2015-01-01

    Background Interferon gamma release assays (IGRA) have been developed to support easy and fast diagnosis of diseases like tuberculosis, and CMV in transplant patients. IGRAs focus on cellular immunity especially memory T cells and thus also allow rapid screening prior to complex flow cytometric testing. Here, we describe a novel, sensitive whole blood based cytokine release assay capable of assessing T cell responsiveness to HBV antigens in Hepatitis B patients and assessing hepatitis B vacci...

  7. Clinical Significance of Establishing Relationship between the HBsAg Test and HBV DNA%乙肝五项测定结果与HBV DNA的关系及其临床意义

    Institute of Scientific and Technical Information of China (English)

    李昕; 张荣波

    2011-01-01

    Objective To explore the internal relationship and the clinical significance of HBVM( HBsAg, Anti-HBs,HBeAg,Anti-HBe, Anti-HBc )and HBV DNA( Hepatitis B Virus DNA ). Methods HBVM and HBV-DNA of 300 HBV patients were examined by enzyme linked immunosorbent assay( ELISA )and quantitative fluorescence PCR technique respectively. Results Of all the clinical results of 300 HBV patients,110 patients showed HBsAg( + ),HBeAg( + ),HBcAb( + )( HBV DNA positive rate 99. 1% ),85 patients showing HBsAg( + ), HBeAb( + ),HBcAb( + )( HBV DNA positive rate 69.4% ), 39 patients showing HBsAg( + ),HBcAb( + )( HBV DNA positive rate 53.8% ),53 patients showing HBeAb( + ),HBcAb( + )( HBV DNA positive rate 35.8% ). HBV DNA positive rate of HBsAg( + ),HBeAg( + ),HBcAb( + ) and HBsAg( + ), HBeAb( + ), HBcAb( + ) were different significantly( x2 = 35. 406, P < 0.05 ). Conclusion The results of HBsAg and HBV-DNA are closely related with different clinical meanings,which makes it necessary to combine the two results for a correct diagnosis and treatment.%目的探讨乙型肝炎(乙肝)五项结果和HBV DNA检出情况间的关系和临床意义.方法运用聚合酶链反应法检测300例乙肝血清的HBV DNA,并用酶联免疫吸附实验法进行乙肝五项的测定,对结果进行比较分析.结果 300例乙肝门诊的患者中乙肝五项的结果为110例HBsAg(+)、HBeAg(+)、HBcAb(+)(大三阳),其HBV DNA的阳性率为99.1%,85例HBsAg(+)、HBeAb(+)、HBcAb(+)(小三阳),其HBV DNA的阳性率为69.4%,39例HBsAg(+)、HBcAb(+),其HBV DNA的阳性率为53.8%,53例HBeAb(+)、HBcAb(+),其HBV DNA的阳性率为35.8%.大三阳和小三阳的HBV DNA阳性率比较差异有统计学意义(χ2=35.406,P<0.05).结论乙肝五项的结果与HBV DNA的结果有着密切的联系,并且都具备各自的临床意义,因此两者必须结合才能正确地对乙肝患者的病情作出正确分析和判断.

  8. Correlation of quantititive measurements between HBV-DNA and HBV-M%HBV-DNA和HBV-M定量检测的相关性研究

    Institute of Scientific and Technical Information of China (English)

    陈跃琼; 曾婉云

    2010-01-01

    目的 探讨HBV-DNA和乙型肝炎五项(HBV-M)定量检测之间的相关性及其在乙型肝炎感染诊断中的应用价值.方法 收集我院363例乙型肝炎和既往感染HBV患者血清,实时荧光定量PCR检测HBV-DNA,同时以时间分辨免疫荧光技术(TRFIA)定量检测HBV-M,用统计软件分析两者之间的关系.结果 乙型肝炎大三阳(HBsAg、HBeAg、HBcAb阳性)患者外周血HBV-DNA阳性率为92.9%(79/85),平均DNA含量(4.31±1.64)×106 Copies/ml.乙型肝炎小三阳患者(HBsAg、HBeAb、HBcAb阳性)外周血HBV-DNA阳性率为47.7%(105/220),平均DNA含量(2.47±2.21)×104 Copies/ml.HBsAg、HBcAb阳性3例,HBV-DNA均阳性,HBV-DNA为(5.73±1.14)×105Copies/ml.余人群外周血HBV-DNA均阴性.HBV-DNA拷贝量与HBeAg载量呈正相关(r=0.59,P=0.041);HBV-DNA拷贝量与HBsAg含量相关一致性不明显(r=0.221,P=0.077).结论 HBV-M与HBV-DNA之间既有联系又有不同,临床上可以多项检测来估计病情,判断疗效.%Objective To explore the correlation between HBV-DNA and serum HBV markers quantitative detection and determine its diagnosis value in hepatitis B virus infection. Methods The HBV-DNA was measured by fluorescence quantitative PCR and hepatitis B virus was detected by time-resolved fluorescence immunoassay (TRFIA). The relationship between the two tests was analyzed statistically using software. Results Detection of HBV-DNA in the peripheral blood of patients with HBsAg (+), HBeAg (+), HBcAb ( + ) showed 92. 9% (79/85) positive rate,and the average DNA copy number was (4.31 ± 1.64) × 106 copies/ml. While the detection of HBV-DNA in the peripheral blood of patients with HBsAg ( + ), HBeAb ( + ), HBcAb ( + ) showed 47.7% (105/220) positive rate, and the average DNA copy number was (2.47 ± 2. 21 ) × 104 copies/ml. In normal controls,blood HBV-DNA detection was negative. Furthermore, HBV-DNA copy number correlated positively with HbeAg quantitation (r = 0. 59, P = 0. 041 ). However, we found no

  9. HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors

    Directory of Open Access Journals (Sweden)

    J.S.F. Pereira

    2006-04-01

    Full Text Available Anti-HBc positivity is a frequent cause of donation rejection at blood banks. Hepatitis B virus (HBV infection may also occur in HBsAg-negative patients, a situation denoted occult infection. Similarly, very low levels of HBV-DNA have also been found in the sera of patients with chronic hepatitis C virus (HCV infection, even in the absence of serum HBsAg. Initially we searched for HBV-DNA in serum of 100 blood donors and 50 HCV-infected patients who were HBsAg negative/anti-HBc positive by nested-PCR and by an HBV monitor commercial test for HBV-DNA. Anti-HBs seroconversion rates were measured in 100 blood donors and in 22 patients with chronic HCV infection after HBV vaccination to determine if the HBV vaccination could eliminate an occult HBV infection in these individuals. Occult HBV infection was detected in proportionally fewer blood donors (6/100 = 6% than chronic hepatitis C patients (12/50 = 24% (P 0.05. All subjects who were HBV-DNA(+ before the first dose of HBV vaccine (D1, became HBV-DNA(- after D1, D2, and D3. Among 22 HCV-positive patients, 10 HBV-DNA(+ and 12 HBV-DNA(-, seroconversion was observed in 9/10 (90% HBV-DNA(+ and in 9/12 (75% HBV-DNA(- subjects (P > 0.05. The disappearance of HBV-DNA in the majority of vaccinated patients suggests that residual HBV can be eliminated in patients with occult infection.

  10. Hepatitis B (HBV)

    Science.gov (United States)

    ... Can I Help a Friend Who Cuts? Hepatitis B (HBV) KidsHealth > For Teens > Hepatitis B (HBV) Print A A A Text Size What's ... There are several different types of hepatitis . Hepatitis B is a type that can move from one ...

  11. Analysis by ELISA test important factors of HBV markers%ELISA法检验乙肝标志物影响因素分析

    Institute of Scientific and Technical Information of China (English)

    郭盼

    2013-01-01

    Objective:To analyze by ELISA test important factors of HBV markers specimen storage time and storage conditions on the measurement results .Methods:52 cases in our hospital by ELISA test HBV markers positive sample the retention samples at room tem -perature three days,five days and 10 days,2 ~6℃retention samples 3 days,5 days and 10 days,respectively,again by ELISA assay anal-ysis of specimen storage time and storage conditions on the test results .Results:52 cases of samples using ELISA testing ,store the day samples of HBV markers was positive at room temperature 3 days after the sample was positive ,5 days after four cases of samples into the negative ,and 10 days after 11 cases of sample into a negative .2~6℃for 3 days ,5 days after the samples were positive ,and 10 days af-ter the eight cases of samples into the negative .Conclusion:HBV markers by ELISA test samples at room temperature for 3 days or 2 ~6℃stored for 5 days,had no effect on HBV markers detection results .%目的:分析ELISA法检验乙肝标志物重要影响因素标本存放时间及存放条件对测定结果的影响。方法:对我院52例采用ELISA法检验乙肝标志物为阳性的样本,室温留样3天、5天和10天,2~6℃留样3天、5天和10天,分别再次采用ELISA法检测,分析标本存放时间及存放条件对检测结果的影响。结果:52例样本采用ELISA法检测,当天样本乙肝标志物为阳性,室温存放3天后的样本为阳性,5天后有4例样本转变成阴性,10天后有11例样本转变成阴性。2~6℃存放3天、5天后样本均为阳性,10天后有8例样本转变为阴性。结论:采用ELISA法检验乙肝标志物,样本室温存放3天或2~6℃存放5天,对乙肝标志物检测结果无影响。

  12. HCV and HBV coexist in HBsAg-negative patients with HCV viremia; possibility of coinfection in these patients must be considered in HBV-high endemic area

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Dong Soon [Korea Cancer Center Hospital, Seoul (Korea, Republic of)

    1998-01-01

    Hepatocellular carcinoma (HCC) is one of the most common cancers and is highly associated with HBV infection in Korea. It has been suggested that HCV core protein may impair the polymerase activity of HBV in vitro, potentially lowering HBV titre in coinfected patients. The aim of this study was to confirm the coexistence of HBV viremia in HCV infected patients HCC who have apparent HBsAg seronegativity. The serological profiles of HBV and HCV in 616 patients with HCC were analysed and coinfection rate of HBV and HCV investigated. Sera were obtained from 16 patients who were both anti-HCV and HCV RNA positive but HbsAg negative, and tested for HBV BY PCR. As a control group, sera were obtained from 15 patients with HCC and 30 non-A abd non-B chronic hepatitis patients without HCC; both were anti-HCV, HCV-RNA, and HBsAg negative and tested for HBV PCR. Of 616 patients with HCC, 450 (73.1 %) had current HBV infection, 48 (7.8 %) had anti-HCV antibodies, and nine (1.5 %) had viral markers of both HCV abd HBV by serological profiles. Of 27 the patients with HCV viremia and HBsAg seronegativity, 14 (51.9 %) showed HBV viremia by PCR. In contrast, of the 75 patients in the control group who were both HCV PCR negative and HBsAg negative, five (11.1 %) showed HBV viremia by PCR. The PCR for HBV revealed coexistent HBV viremia in HCV viremia patients, despite HBsAg negativity by EIA. In HBV-endemic areas, the possibility of coinfection of HBV in HBsAg-negative patients with HCV viremia should be considered and molecular analysis for HBV-DNA performed. (author). 18 refs., 4 tabs.

  13. Analysis of test results of HBV markers for 482 cases of placental blood and maternal blood%482例胎盘血和母体血 HBV标志物测定结果分析

    Institute of Scientific and Technical Information of China (English)

    吉晓云

    2014-01-01

    Objective:To investigate relationship of HBV markers in placental blood and maternal blood. Methods:The HBV markers in 482 cases of placental blood and maternal blood were determined and analyzed statistically. Results:The test results of the HBV markers in the 482 cases of placental blood and maternal blood were not completely consistent. Conclusions:There is no obvious difference in the HBV markers in placental blood and maternal blood and its reason remains to be further discussed.%目的:探讨胎盘血与母体血HBV标志物的关系。方法:将482例胎盘血与母体血进行HBV标志物测定,然后统计分析。结果:482例人次的胎盘血与母体血HBV标志和检测,发现其结果并非完全一致。结论:胎盘血和母体血二者的结果差异不大,其原因有待进一步探讨。

  14. Multicenter Evaluation of a Semiautomated, Standardized Assay for Detection of Hepatitis B Virus DNA in Blood Donations

    OpenAIRE

    Romanò, Luisa; Velati, Claudio; Baruffi, Lorella; Fomiatti, Laura; Colucci, Giuseppe; Zanetti, Alessandro R.

    2005-01-01

    We evaluated the COBAS Ampliscreen hepatitis B virus (HBV) test using standards, seroconversion panels, consecutive donations, and samples from patients with abnormal alanine aminotransferase and chronic hepatitis C. Specificity was 100% and sensitivity was 20 IU/ml. In seroconversion panels, HBV DNA was detected up to 4 to 18 days before HBsAg, suggesting that this assay is useful in shortening the infectious window phase.

  15. Occult HBV infection and HCC

    Directory of Open Access Journals (Sweden)

    Isabelle Chemin

    2007-02-01

    Full Text Available

    A number of risk factors appear to play a role in Hepatocellularcinoma (HCC, HBV infection being one of the most important. Chronic inflammation and cytokines are key determinants in the development of fibrosis and liver cell proliferation. HBV DNA integration into host cellular DNA, has been extensively studied and may disrupt or promote expression of cellular genes that are important in cell growth and differentiation. Moreover, expression of HBV proteins may have a direct effect on cellular functions, and some of these gene products may lead to malignant transformation. Several HBV genes have been frequently found in infected tissues including truncated pre-S2/S, hepatitis B X gene, and a novel spliced transcript of HBV (hepatitis B spliced protein. The proteins expressed from these integrated genes have been shown to have intracellular activities, including effects on cellular growth and apoptosis. Occult hepatitis B virus (HBV infection is characterized by persistence of HBV DNA into the tissue of hep atitis B surface antigen-negative individuals. The clinical relevance of this peculiar infection, in particular, the impact of occult HBV infection in cases of HCC has been a matter of debate. Prevalence and molecular status of occult HBV in patients with HCC has been investigated in several studies. HCC patients from Italy, France, Japan, Morocco, the United States, Canada etc…..who had no detectable HBsAg in their serum have been studied. In these HBsAg-negative HCC patients, HBV DNA was detected in tumorous and/or in adjacent non tumorous liver tissue using polymerase chain reaction (PCR in almost half of the patients, being anti-HCV positive or not. Some of the patients are positive for anti-HBc antibodies as the only marker of HBV infection, but not all. Covalently closed circular HBV DNA may be detected indicating that at least some of these patients

  16. HBV cure: why, how, when?

    Science.gov (United States)

    Levrero, Massimo; Testoni, Barbara; Zoulim, Fabien

    2016-06-01

    Current HBV treatments control replication and liver disease progression in the vast majority of treated patients. However, HBV patients often require lifelong therapies due to the persistence of transcriptionally active viral cccDNA mini-chromosome in the nucleus, which is not directly targeted by current antiviral therapies. A true complete cure of HBV would require clearance of intranuclear cccDNA from all infected hepatocytes. An intermediate but still relevant step forward that would allow treatment cessation would be reaching a functional cure, equivalent to resolved acute infection, with a durable HBsAg loss±anti-HBs seroconversion, undetectable serum DNA and persistence of cccDNA in a transcriptionally inactive status. Recent advances in technologies and pharmaceutical sciences, including the cloning of the mayor HBV receptor (i.e. the NTCP transporter) and the development in vitro HBV infection models, have heralded a new horizon of innovative antiviral and immune-therapeutic approaches. PMID:27447092

  17. Relationship between serum HBV DNA level and HBV-specific,nonspecific cytotoxic T lymphocytes and natural killer cells in patients with chronic hepatitis B

    Institute of Scientific and Technical Information of China (English)

    GU Xi-bing; YANG Xiao-juan; WANG Dong; HUA Zhong; XU Yue-qin; LU Zhong-hua

    2009-01-01

    Background The response of patients with chronic hepatitis B (CHB) to antiviral therapy against hepatitis B virus (HBV) is related to the base line level of HBV DNA, but the mechanism is not clear. The present study aimed to understand the possible relationship between the level of HBV DNA and HBV-specific, nonspecific cytotoxic T lymphocytes (CTL) and natural killer (NK) cells of CHB patients and the mechanism how the HBV DNA level influences the antiviral therapeutic effect.Methods Totally 100 adult patients with CHB who were positive for HBV DNA, HBeAg and (HLA)-A2 were enrolled into this study. HBV DNA was tested by real time fluorescence quantitative polymerase chain reaction (PCR). HBV specific and nonspecific CTL and NK cells were tested by flowcytometry. Serum alanine aminotransferase (ALT) and total bilirubin (Tbil) were determined for each patient using routine biochemical tests. The 100 cases were assigned to two groups based on their HBV DNA level: group A had 48 cases, their HBV DNA level was 104-105 copies/ml, group B had 52 cases, their HBV DNA level was 106-107 copies/ml. HBV specific CTL, nonspecific CTL, NK cells, ALT and Tbil of the two groups were compared.Results HBV DNA level of groups A and B was (4.81±0.39) log10 copies/ml and (6.81±0.40) log10 copies/ml, respectively (t=25.32, P <0.001). HBV specific CTL and NK cells of group A were significantly higher than those of group B (P <0.001 for both). Nonspecific CTL of group A was significantly lower than that of group B (P <0.01). ALT and Tbil of group A were significantly lower than those of group B (P <0.01 and P <0.05, respectively).Conclusions Serum HBV DNA level of patients with CHB is related to HBV specific CTL, nonspecific CTL and NK cells, which might result in inflammatory reaction of liver and cause more damage to liver function. Mechanism of HBV DNA level affecting the efficacy of anti-viral treatment may be related to the levels of HBV specific CTL and NK cells.

  18. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial.

    Directory of Open Access Journals (Sweden)

    Prudence Ive

    Full Text Available BACKGROUND: Hepatitis B virus (HBV infection is endemic in South Africa however, there is limited data on the degree of liver disease and geographic variation in HIV/HBV coinfected individuals. In this study, we analysed data from the CIPRA-SA 'Safeguard the household study' in order to assess baseline HBV characteristics in HIV/HBV co-infection participants prior to antiretroviral therapy (ART initiation. METHODS: 812 participants from two South African townships Soweto and Masiphumelele were enrolled in a randomized trial of ART (CIPRA-SA. Participants were tested for hepatitis B surface antigen (HBsAg, hepatitis B e antigen (HBeAg, and HBV DNA. FIB-4 scores were calculated at baseline. RESULTS: Forty-eight (5.9% were HBsAg positive, of whom 28 (58.3% were HBeAg positive. Of those with HBV, 29.8% had an HBV DNA<2000 IU/ml and ALT<40 IU/ml ; 83.0% had a FIB-4 score <1.45, consistent with absent or minimal liver disease. HBV prevalence was 8.5% in Masiphumelele compared to 3.8% in Soweto (relative risk 2.3; 95% CI: 1.3-4.0. More participants in Masiphumelele had HBeAg-negative disease (58% vs. 12%, p = 0.002 and HBV DNA levels ≤2000 IU/ml, (43% vs. 6% p<0.007. CONCLUSION: One third of HIV/HBV co-infected subjects had low HBV DNA levels and ALT while the majority had indicators of only mild liver disease. There were substantial regional differences in HBsAg and HbeAg prevalence in HIV/HBV co-infection between two regions in South Africa. This study highlights the absence of severe liver disease and the marked regional differences in HIV/HBV co-infection in South Africa and will inform treatment decisions in these populations.

  19. Animal models for HCV and HBV studies

    Directory of Open Access Journals (Sweden)

    Isabelle Chemin

    2007-02-01

    develop fulminant hepatitis, acute hepatitis, or chronic liver disease after adoptive transfer, and others spontaneously develop hepatocellular carcinoma (HCC. Among HCV transgenic mice, most develop no disease, but acute hepatitis has been observed in one model, and HCC in another. Although mice are not susceptible to HBV and HCV, their ability to replicate these viruses and to develop liver diseases characteristic of human infections provides opportunities to study pathogenesis and develop novel therapeutics In the search for the mechanism of hepatocarcinogenesis in hepatitis viral infection, two viral proteins, the core protein of hepatitis C virus (HCV and the HBx protein of hepatitis B virus (HBV, have been shown to possess oncogenic potential through transgenic mouse studies, indicating the direct involvement of the hepatitis viruses in hepatocarcinogenesis.

    This may explain the very high frequency of HCC in patients with HCV or HBV infection.

    Chimpanzees remain the only recognized animal model for the study of hepatitis C virus (HCV. Studies performed in chimpanzees played a critical role in the discovery of HCV and are continuing to play an essential role in defining the natural history of this important human pathogen. In the absence of a reproducible cell culture system, the infectivity titer of HCV challenge pools can be determined only in chimpanzees.

    Recent studies in chimpanzees have provided new insight into the nature of host immune responses-particularly the intrahepatic responses-following primary and secondary experimental HCV infections. The immunogenicity and efficacy of vaccine candidates against HCV can be tested only in chimpanzees. Finally, it would not have been possible to demonstrate

  20. Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load

    Institute of Scientific and Technical Information of China (English)

    Jing You; Lin Zhuang; Yi-Feng Zhang; Hong-Ying Chen; Hutcha Sriplung; Alan Geater; Virasakdi Chongsuvivatwong; Teerha Piratvisuth; Edward McNeil; Lan Yu; Bao-Zhang Tang; Jun-Hua Huang

    2009-01-01

    AIM: To characterize the peripheral T-cell subpopulation profiles and their correlation with hepatitis B virus (HBV) replication in different clinical stages of chronic HBV infection.METHODS: A total of 422 patients with chronic HBV infection were enrolled in this study. The patients were divided into three stages: immune-tolerant stage, immune active stage, and immune-inactive carrier stage. Composition of peripheral T-cell subpopulations was determined by flow cytometry. HBV markers were detected by enzyme-linked immunosorbent assay. Serum HBV DNA load was assessed by quantitative real-time polymerase chain reaction.RESULTS: CD8± T-cells were significantly higher in patients at the immune-tolerant stage than in patients at the immune-active and -inactive carrier stages (36.87 ± 7.58 vs 34.37± 9.07, 36.87± 7.58 vs 28.09 ± 5.64, P < 0.001). The peripheral blood in patients at the immune-tolerant and immune active stages contained 30.23 ± 6.35, 34.37 ± 9.07 vs 30.92 ± 7.40, P < 0.01),whereas the peripheral blood in patients at the immuneinactive carrier stage and in normal controls contained less CD8+ T-cells than CD4+ T-cells (28.09 ± 5.64 vs 36.85 ± 6.06, 24.02 ± 4.35 vs 38.94 ±3.39, P < 0.01).ANOVA linear trend test showed that CD8+ T-cells were significantly increased in patients with a high viral load 5.71, P < 0.001), while CD4+ T-cells were significantlyincreased in patients with a low HBV DNA load (37.45 ±6.14, 33.33 ± 5.61, 31.58 ± 6.99 and 27.56 ± 5.49, P< 0.001). Multiple regression analysis displayed that logcopies of HBV DNA still maintained its highly significant coefficients for T-cell subpopulations, and was the strongest predictors for variations in CD3+, CD4+ and CD8+ cells and CD4+/CD8+ ratio after adjustment for age at HBV-infection, maternal HBV-infection status,presence of hepatitis B e antigen and HBV mutation.CONCLUSION: Differences in peripheral T-cell subpopulation profiles can be found in different clinical stages of

  1. Anti-HBV effect of TAT- HBV targeted ribonuclease

    Institute of Scientific and Technical Information of China (English)

    Jin Ding; Jun Liu; Cai-Fang Xue; Wei-Dong Gong; Ying-Hui Li; Ya Zhao

    2003-01-01

    AIM: To prepare and purify TAT-HBV targeted ribonuclease fusion protein, evaluate its transduction activity and investigate its effect on HBV replication in 2.2.15 cells.METHODS: The prokaryotic expression vector pTAT containing TR gene was used in transforming E. coli BL21(DE3) LysS and TR was expressed with the induction of IPTG. The TAT-TR fusion protein was purified using Ni-NTA-agrose and PD-10 desalting columns, and analyzed by SDSPAGE. Transduction efficiency of TAT-TR was detected with immunofluorescence assay and the concentration of HBeAg in the supernatant of the 2.2.15 cells was determined via solid-phase radioimmunoassay (spRIA). MTT assay was used to detect the cytotoxicity of TAT-TR.RESULTS: The SDS-PAGE showed that the TAT-TR fusion protein was purified successfully, and the purity of TAT-TR was 90 %. The visualization of TAT-TR by immunofiuorescence assay indicated its high efficiency in transducing 2.2.15 cells.RIA result suggests that TAT-TR could inhibit the replication of HBV effectively, it didn′t affect cell growth and had no cytotoxicity.CONCLUSION: TAT-TR possesses a significant anti-HBV activity and the preparation of TAT-TR fusion protein has laid the foundation for the use of TR in the therapeutic trial of HBV infection.

  2. Know HBV: What Every Asian and Pacific Islander Should Know About Hepatitis B and Liver Cancer

    Science.gov (United States)

    ... Donate! » Get Tested Ask your doctor for these blood tests: HBV Hepatitis B sur face antigen (HBs Ag) : Tells if you ... you are protected against HBV. Only the HBsAg blood test can tell if you have chronic hepatitis B. For more information visit http://liver.stanford.edu » ...

  3. HBV genotypic variability in Cuba.

    Science.gov (United States)

    Loureiro, Carmen L; Aguilar, Julio C; Aguiar, Jorge; Muzio, Verena; Pentón, Eduardo; Garcia, Daymir; Guillen, Gerardo; Pujol, Flor H

    2015-01-01

    The genetic diversity of HBV in human population is often a reflection of its genetic admixture. The aim of this study was to explore the genotypic diversity of HBV in Cuba. The S genomic region of Cuban HBV isolates was sequenced and for selected isolates the complete genome or precore-core sequence was analyzed. The most frequent genotype was A (167/250, 67%), mainly A2 (149, 60%) but also A1 and one A4. A total of 77 isolates were classified as genotype D (31%), with co-circulation of several subgenotypes (56 D4, 2 D1, 5 D2, 7 D3/6 and 7 D7). Three isolates belonged to genotype E, two to H and one to B3. Complete genome sequence analysis of selected isolates confirmed the phylogenetic analysis performed with the S region. Mutations or polymorphisms in precore region were more common among genotype D compared to genotype A isolates. The HBV genotypic distribution in this Caribbean island correlates with the Y lineage genetic background of the population, where a European and African origin prevails. HBV genotypes E, B3 and H isolates might represent more recent introductions.

  4. The HBV E Genotype Discover in Dai Nationality in Xishuangbanna, Yunnan Province

    Institute of Scientific and Technical Information of China (English)

    Hai-ping ZHAO; Yuan-ying SHEN; Ru SHEN; Yuan-yi WANG; Mei-ya FU

    2009-01-01

    To investigate the distribution of Hepatitis B virus (HBV) genotypes among the population of Dai nationality in Xishuangbanna, Yurman Province HBV genotypes of the Serum samples were tested by PCR-RFLP. This is the first time to discover the B+E genotypes in China. This finding provides new information for understanding the distribution of HBV genotype in China and a provides a basis for establishing a Chinese gene bank.

  5. A new polymorphism in the GRP78 is not associated with HBV invasion

    Institute of Scientific and Technical Information of China (English)

    Xiao Zhu; Yi Wang; Tao Tao; Dong-Pei Li; Fei-Fei Lan; Wei Zhu; Dan Xie; Hsiang-Fu Kung

    2009-01-01

    AIM: To examine the association between-86 bp (T > A) in the glucose-regulated protein 78 gene ( GRP78) and hepatitis B virus (HBV) invasion.METHODS: DNA was genotyped for the single-nucleotide polymorphism by polymerase chain reaction followed by sequencing in a sample of 382 unrelated HBV carriers and a total of 350 sex-and age-matched healthy controls. Serological markers for HBV infection were determined by enzyme-linked immunosorbent assay kits or clinical chemistry testing.RESULTS: The distributions of allelotype and genotype in cases were not signi.cantly different from those in controls. In addition, our .ndings suggested that neither alanine aminotransferase/hepatitis B e antigen nor HBV-DNA were associated with the allele/genotype variation in HBV infected individuals.CONCLUSION:-86 bp T > A polymorphism in GRP78 gene is not related to the clinical risk and acute exacerbation of HBV invasion.

  6. Distribution of HBV genotypes among HBV carriers in Benin:phylogenetic analysis and virological characteristics of HBV genotype E

    Institute of Scientific and Technical Information of China (English)

    Kei Fujiwara; Atsushi Ozasa; Yuko Sakamoto; Isao Arita; Ahmed El-Gohary; Agossou Benoit; Sophie I Ogoundele-Akplogan; Namiko Yoshihara; Ryuzo Ueda; Masashi Mizokami; Yasuhito Tanaka; Etsuro Orito; Tomoyoshi Ohno; Takanobu Kato; Kanji Sugihara; Izumi Hasegawa; Mayumi Sakurai; Kiyoaki Ito

    2005-01-01

    AIM: To determine the distribution of Hepatitis B virus (HBV) genotypes in Benin, and to clarify the virological characteristics of the dominant genotype.METHODS: Among 500 blood donors in Benin, 21 HBsAg-positive donors were enrolled in the study. HBV genotypes were determined by enzyme immunoassay and restriction fragment length polymorphism. Complete genome sequences were determined by PCR and direct sequencing.RESULTS: HBV genotype E (HBV/E) was detected in 20/21 (95.2%), and HBV/A in 1/21 (4.8%). From the age-specific prevalence of HBeAg to anti-HBe seroconversion (SC) in 19 HBV/E subjects, SC was estimated to occur frequently in late teens in HBV/E.The comparison of four complete HBV/E genomes from HBeAg-positive subjects in this study and five HBV/E sequences recruited from the database revealed that HBV/E was distributed throughout West Africa with very low genetic divers ity (nucleotide homology 96.7-99.2%).Based on the sequences in the basic core promoter (BCP)to precore region of the nine HBV/E isolates compared to those of the other genotypes, a nucleotide substitution in the BCP, G1757A, was observed in HBV/E.CONCLUSION: HBV/E is predominant in the Republic of Benin, and SC is estimated to occur in late teens in HBV/E. The specific nucleotide substitution G1757A in BCP, which might influence the virological characteristics,is observed in HBV/E.

  7. Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (- chronic inactive HBV patients from active carriers

    Directory of Open Access Journals (Sweden)

    Gull Sana

    2011-02-01

    Full Text Available Abstract Background and Aims ELISA is still used as primary test for diagnosis HBV disease. However, ELISA-positive patients were marked as HBV inactive after confirmation with PCR and vice versa. Our aim was to assess the performance of new cut-off value of ALT, HBV DNA load and significance of AST as screening tool for HBeAg (- chronic active or inactive patients in Pakistani population. Materials and methods In a cross-sectional, cohort study, 567 HBeAg (- patients followed for one year were selected. Patients with persistent elevated ALT than normal and HBV DNA ≥ 100,000 copies/mL were taken as active chronic. Diagnostic values for ALT, AST and HBV DNA load in HBV HBeAg (- chronic active and inactive patients compared using receiver operation characteristic (ROC curves. Results Of 567 HBeAg (- patients, 228 were classified as chronic inactive and 339 as active. HBV infection was dominant in male. Serum ALT, AST and HBV DNA levels showed significant and high AUROC to differentiate chronic HBeAg (- inactive patients from active. AUROC for Serum ALT, AST and HBV DNA were observed 0.997, 0.969 and 1.000, respectively. For revised cut off value for ALT (30 IU/L for male and 19 IU/L for female and HBV DNA load ≥100,000 copies/mL, a PPV of 97%, NPV of 94%, a sensitivity of 98%, and a specificity of 92% was observed to discriminate active carriers from inactive carriers. We also observed 93.5% specificity, 83.1% sensitivity, 82% PPV and 89.5% NPV for AST ≤20 IU/L to differentiate inactive carriers from active ones in our study group. Conclusions Revised cut off value of ALT and NIH derived HBV DNA value can better discriminate between HBeAg (- chronic active and inactive patients.

  8. HBV markers in haemodialysis Brazilian patients: a prospective 12-month follow-up

    Directory of Open Access Journals (Sweden)

    Regina Célia Moreira

    2010-02-01

    Full Text Available The aim of this study was to determine the prevalence and the incidence of hepatitis B virus (HBV among haemodialysis (HD subjects and to evaluate whether testing for serological markers at the time of admission is suitable for HBV screening in this population. One hundred twenty-three patients belonging to two HD centres from São Paulo, Brazil, were tested prospectively. HBV DNA was detected by polymerase chain reaction (PCR in each of the prospective subjects (n = 123 during one year. Additionally, all samples (n = 1,476 were analysed for HBV serological markers. The prevalence of hepatitis B core antibody (anti-HBc, hepatitis B surface antigen (HBsAg and HBV DNA were 34.1%, 15.4% and 8.1%, respectively, while the incidence was null. Fluctuation in HBV serology was observed in one patient. Only 37.8% (17/45 of cases responded to the HBV vaccine. Our results suggest that employing more than one HBV marker and repeated follow-up evaluations may improve HBV screening in HD units.

  9. Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon

    Science.gov (United States)

    Bivigou-Mboumba, Berthold; François-Souquière, Sandrine; Deleplancque, Luc; Sica, Jeanne; Mouinga-Ondémé, Augustin; Amougou-Atsama, Marie; Chaix, Marie-Laure; Njouom, Richard; Rouet, François

    2016-01-01

    Integrated data on hepatitis B virus (HBV) patterns, HBV genotypes and mutations are lacking in human immunodeficiency virus type 1 (HIV-1) co-infected patients from Africa. This survey was conducted in 2010–2013 among 762 HIV-1-positive adults from Gabon who were predominantly treated with 3TC-based antiretroviral treatment. HBV patterns were identified using immunoassays detecting total antibody to hepatitis B core antigen (HBcAb), hepatitis B surface antigen (HBsAg), IgM HBcAb, hepatitis B e antigen (HBeAg), antibody to HBsAg (HBsAb) and an in-house real-time PCR test for HBV DNA quantification. Occult hepatitis B (OBI) was defined by the presence of isolated anti-HBc with detectable serum HBV DNA. HBV genotypes and HBV mutations were analyzed by PCR-direct sequencing method. Seventy-one (9.3%) patients tested positive for HBsAg, including one with acute hepatitis B (0.1%; 95% CI, 0.0%-0.2%), nine with HBeAg-positive chronic hepatitis B (CHB) (1.2%; 95% CI, 0.6%–2.2%), 16 with HBeAg-negative CHB (2.1%; 95% CI, 1.2%–3.3%) and 45 inactive HBV carriers (5.9%; 95% CI, 4.4%–7.8%). Sixty-one (8.0%; 95% CI, 6.2%–10.1%) patients showed OBI. Treated patients showed similar HBV DNA levels to those obtained in untreated patients, regardless of HBV patterns. Around 15.0% of OBI patients showed high (>1,000 UI/mL) viremia. The mutation M204V/I conferring resistance to 3TC was more common in HBV/A (47.4%) than in HBV/E isolates (0%) (P = .04). Our findings encouraged clinicians to promote HBV vaccination in patients with no exposure to HBV and to switch 3TC to universal TDF in those with CHB. PMID:26764909

  10. Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon.

    Science.gov (United States)

    Bivigou-Mboumba, Berthold; François-Souquière, Sandrine; Deleplancque, Luc; Sica, Jeanne; Mouinga-Ondémé, Augustin; Amougou-Atsama, Marie; Chaix, Marie-Laure; Njouom, Richard; Rouet, François

    2016-01-01

    Integrated data on hepatitis B virus (HBV) patterns, HBV genotypes and mutations are lacking in human immunodeficiency virus type 1 (HIV-1) co-infected patients from Africa. This survey was conducted in 2010-2013 among 762 HIV-1-positive adults from Gabon who were predominantly treated with 3TC-based antiretroviral treatment. HBV patterns were identified using immunoassays detecting total antibody to hepatitis B core antigen (HBcAb), hepatitis B surface antigen (HBsAg), IgM HBcAb, hepatitis B e antigen (HBeAg), antibody to HBsAg (HBsAb) and an in-house real-time PCR test for HBV DNA quantification. Occult hepatitis B (OBI) was defined by the presence of isolated anti-HBc with detectable serum HBV DNA. HBV genotypes and HBV mutations were analyzed by PCR-direct sequencing method. Seventy-one (9.3%) patients tested positive for HBsAg, including one with acute hepatitis B (0.1%; 95% CI, 0.0%-0.2%), nine with HBeAg-positive chronic hepatitis B (CHB) (1.2%; 95% CI, 0.6%-2.2%), 16 with HBeAg-negative CHB (2.1%; 95% CI, 1.2%-3.3%) and 45 inactive HBV carriers (5.9%; 95% CI, 4.4%-7.8%). Sixty-one (8.0%; 95% CI, 6.2%-10.1%) patients showed OBI. Treated patients showed similar HBV DNA levels to those obtained in untreated patients, regardless of HBV patterns. Around 15.0% of OBI patients showed high (>1,000 UI/mL) viremia. The mutation M204V/I conferring resistance to 3TC was more common in HBV/A (47.4%) than in HBV/E isolates (0%) (P = .04). Our findings encouraged clinicians to promote HBV vaccination in patients with no exposure to HBV and to switch 3TC to universal TDF in those with CHB.

  11. HBV And HCV Molecular Evolution

    Directory of Open Access Journals (Sweden)

    Flor H. Pujol

    2007-02-01

    Full Text Available

    Hepatitis B virus (HBV infection is still a significant health concern in in the world, since around 2 billion persons have been infected by this virus (HBV and around 350 millions of them are chronic carriers, in spite of a highly effective vaccine against this virus. Bearing a reverse transcriptase necessary for its replication but with a highly compacted genome, this hepadnavirus exhibits a degree of variability intermediate between DNA and RNA viruses. This plasticiy leads to the generation of several mutants and genotypic variability. HBV mutants develop during the natural course of infection and play an important role in the evasion of the selective pressure applied by the host (immune or chemotherapeutic. Eight HBV genotypes (A-H have been described, based on a minimum divergence of 8% of the complete genome sequences. HBV genotype F is the most divergent of the HBV genotypes, is autochthonous to South America and is highly predominant in the Northen region of South America. The recently described HBV genotype H is closely related to genotype F and seems to be restricted to Central and North America. Recombination among different HBV strains seems to be frequent. Several subgenotypes have also been described inside HBV genotypes, which exhibit a geographic pattern of distribution. The clinical and biologic importance of the genotypic diversity of HBV is of major concern at the present moment and has been studied in Asia and Europe. The origin of HBV is still an open question. Depending on the model used for the phylogenetic analysis, an Asian or an American origin of HBV has been proposed. By revisiting the genotypic diversity of HBV, an alternative explanation is that human HBV genotypes might have emerged by several zoonotic introductions, both in the Old and the New World. Around 170 millions persons in the world are thought to be infected with

  12. A mouse model for HBV immunotolerance and immunotherapy

    OpenAIRE

    Yang, Dan; Liu, Longchao; Zhu, Danming; Peng, Hua; Su, Lishan; Fu, Yang-Xin; Zhang, Liguo

    2013-01-01

    Lack of an appropriate small animal model remains a major hurdle for studying the immunotolerance and immunopathogenesis induced by hepatitis B virus (HBV) infection. In this study, we report a mouse model with sustained HBV viremia after infection with a recombinant adeno-associated virus (AAV) carrying a replicable HBV genome (AAV/HBV). Similar to the clinical HBV carriers, the mice infected with AAV/HBV were sero-negative for antibodies against HBV surface antigen (HBsAg). Immunization wit...

  13. Overview of HBV whole genome data in public repositories and the Chinese HBV reference sequences

    Institute of Scientific and Technical Information of China (English)

    2008-01-01

    The number of Hepatitis B virus (HBV) whole genomic sequences in public nucleotide databases (GenBank, EMBL, and DDBJ) had reached 866 by January 1, 2007. Coming from 46 countries and regions, these sequences were categorized as eight genotypes (A-H). With the statistical and phylogenetic analysis on all available complete genomic data of HBV, we here present an overview of HBV sequences in public databases. From all registered 229 HBV genomes in Chinese regions as well as 59 sequencing data from our research group, we report the establishment of reference sequences of HBV strains prevailing in China. These analyses provide clues for the effects of HBV genotypes in host clinical progressions, geographic distribution of the infection, and the viral evolutionary history. Moreover, the viral sequence reference would be helpful in the identification of various HBV mutations. Based on the analysis of various public databases,we suggest that the Chinese HBV database with the clinical information should be constructed.

  14. HBV and neurological impairment in HIV-infected patients

    Directory of Open Access Journals (Sweden)

    L Manolescu

    2012-11-01

    Full Text Available Objective: HIV can affect CNS in early stages of disease and determine neurological impairment. HBV DNA was found in CSF of HIV co-infected patients, but little is known about the neurotropic character of this virus. Here we assessed the degree of association between HBV infection and neurological impairment in a large cohort of long-term survivors, HIV-infected patients that experienced multiple therapeutic schemes over time. Methods: A total of 462 HIV-1-infected patients were retrospectively followed up for 10 years for HBV infection and neurological impairment. The patients were tested for immune (flow cytometry and virological parameters of HIV infection (Roche Amplicor, version 1.5/ COBAS AmpliPrep/COBAS TaqMan HIV-1 test and for HBV infection markers (HBsAg, anti HBc: Murex Biotech ELISA tests. Many of these patients have experienced between one and six regimens such as: 2 NRTIs, 3 NRTIs, 2 NRTIs+1 NNRTI, 1 NRTI+1 NNRTI+1 PI, 2 NRTIs+2 PIs. Results: After 10 years 29.87% of the patients presented neurological impairment. Out of them 56.52% were HBV-infected. The prevalence of HIV encephalopathy (HE in our studied cohort was 22.7% and 50.4% of these patients were HBV-infected. The median HIV diagnosis age was 7 and the median age of HE diagnosis was 10. In order to establish a possible correlation between HBV infection and HE we first reviewed and excluded the main risk factors associated with HE at the moment of diagnosis: low weight, anemia, constitutional symptoms, low CD4+count, high plasma HIV-RNA load. No patient was infected with HCV. The groups of patients that presented HE and HBsAg and HE without HBsAg were balanced regarding sex, number of deceased patients, number of class C3 patients, but the patients in first group presented lower CD4 values at HE diagnosis vs patients from second group 2: 44.5 vs 95 cells/µL, p=0.3; lower nadir CD4 count: 38 vs 51 cell/µL, p=0.1; and slightly higher HIV viral load: 5.2 vs 5 log10 copies

  15. Hepatitis B virus (HBV) DNA levels and the management of HBV-infected health care workers

    NARCIS (Netherlands)

    van der Eijk, A A; de Man, R A; Niesters, H G M; Schalm, S W; Zaaijer, H L

    2006-01-01

    Different guidelines exist for the management of hepatitis B virus (HBV)-infected health care workers (HCWs). Various HBV DNA levels are used as a cutoff level to determine whether an HBV-infected HCW is allowed to perform exposure-prone procedures (EPPs) or not. In this paper we discuss the factors

  16. Co-infection rate of HIV, HBV and Syphilis among HCV seropositive identified blood donors in Kathmandu, Nepal

    OpenAIRE

    Shrestha, Ashish Chandra; Ghimire, Prakash; Tiwar, Bishnu Raj; Rajkarnikar, Manita

    2012-01-01

    Background: HIV, HBV, Syphilis and HCV share common modes of transmission. Objective: The study was aimed to determine the co-infection rate of HIV, HBV and Syphilis among HCV seropositive identified blood donors. Methods: The study was conducted on blood samples screened as HCV seropositive at Nepal Red Cross Society, Central Blood Transfusion Service, Kathmandu, Nepal. HCV seropositive samples were further tested for HIV, HBV and Syphilis. Results: Eight co-infections were observed in 139 H...

  17. Leukocyte Telomere Length-Related rs621559 and rs398652 Genetic Variants Influence Risk of HBV-Related Hepatocellular Carcinoma

    OpenAIRE

    Wenting Pan; Guangxia Cheng; Huaixin Xing; Juan Shi; Chao Lu; Jinyu Wei; Lichao Li; Changchun Zhou; Qipeng Yuan; Liqing Zhou; Ming Yang

    2014-01-01

    Recent genome-wide association studies (GWAS) have identified eleven leukocyte telomere length (LTL)-related single nucleotide polymorphisms (SNPs). Since LTL has been associated with risk of many malignancies, LTL-related SNPs may contribute to cancer susceptibility. To test this hypothesis in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), we genotyped these eleven LTL-related SNPs in a case-control set including 1186 HBV-related HCC cases, 508 chronic HBV carriers and 1308 ...

  18. HBV-DNA in hemodialysis patients infected by HCV

    Directory of Open Access Journals (Sweden)

    Arababadi Mohammad

    2009-01-01

    Full Text Available End-stage renal disease patients on chronic hemodialysis (HD patients are at risk for both hepatitis B virus (HBV and hepatitis C virus (HCV infection, and they may coexist. To de-termine the prevalence and clinical impact of HBV and HCV infection, we studied poly chain reaction (PCR and reverse transcription (RT-PCR on the blood samples of 90 HD patients in Kerman, Iran. ELISA test was used to detect anti-HBc, anti-HBs and HBsAg. We found that 30 out of 90 (33.3% patients were PCR-RT-PCR positive for HCV-RNA. No HBV-DNA (0% was detected through the PCR study in both positive and negative HCV-RNA patient groups. Though none of the samples was HBsAg positive, 10 (33.3% HCV-RNA positive patients were anti-HBc positive, and 12 (40.7% were anti-HBs positive. We conclude that prevalence of hepatitis C infection is high in HD patients in our region, but not associated with active HBV infection.

  19. 金标法和ELISA法检测乙型肝炎病毒血清标志物的比较%Comparative Study on Colloidal Gold-labeled Method and ELISA of Testing Five Serological Markers of HBV

    Institute of Scientific and Technical Information of China (English)

    丁邦胜; 潘健

    2012-01-01

    目的 探讨金标法检测乙型肝炎病毒(HBV)HBsAg、HBsAb、HBeAg、HBeAb、HBcAb五项血清标志物的敏感性、特异性.方法 采用ELISA法和金标法对256例血清样本同时进行HBV五项血清标志物的检测,并且对结果进行对比分析.结果 256例样本中:ELISA法“全阴性”(HBsAg,HBsAb,HBeAg,HBeAb,HBcAb均阴性)结果模式,金标法结果相同;ELISA法HBsAg、HBeAb、HBcAb阳性,HBsAb、HBeAg阴性(简称模式1);HBsAg、HBeAg、HBcAb阳性,HBeAb、HBsAb阴性(简称模式2)结果模式,金标法检测样本的结果模式发生改变.256例样本两法各单项指标检测结果经x2检验:HBsAb和HBeAg两项结果的差异无统计学意义(P>0.05);HB-sAg,HBeAb,HBcAb三项结果的差异有统计学意义(P<0.05),少数ELISA法阳性或OD为临界值的样本金标法检测结果为阴性;无ELISA法阴性而金标法为阳性的标本.结论 两种方法对HBV五项血清标志物测定的特异性相近,但是金标法敏感性不如ELISA法.%Objective To investigate the sensitivity and specificity of testing HBsAg. HBsAb, HBeAg, HBeAb and HBcAb with colloidal gold-labeled method. Methods 256 serological cases were tested with both colloidal gold-labeled method and ELISA. The results of two methods were analyzed. Results All five negative results samples by ELISA were the same with colloidal gold-labeled method.but for the results HBsAg. HBeAb, HBcAb are positive)HBsAb,HBeAg are negative and HBsAg.HBeAg. HBcAb are positive; HBeAb.HBsAb are negative by ELISA. some were changed by colloidal gold-labeled method. The chi-aquare test(x2) showed that the result differences of HBsAb and HBeAg were not statistically significant with two methods (P>0.05 ). But X2 test showed the differences were significant on HBsAg,HBeAb and HBcAb with two methods. The weak positive results by ELISA always were negative by colloidal gold-labeled method. but no negative results by ELISA were found positive tested by colloidal gold

  20. Presence of anti-HBc is associated to high rates of HBV resolved infection and low threshold for Occult HBV Infection in HIV patients with negative HBsAg in Chile.

    Science.gov (United States)

    Vargas, Jose Ignacio; Jensen, Daniela; Sarmiento, Valeska; Peirano, Felipe; Acuña, Pedro; Fuster, Felipe; Soto, Sabrina; Ahumada, Rodrigo; Huilcaman, Marco; Bruna, Mario; Jensen, Werner; Fuster, Francisco

    2016-04-01

    HBV-HIV coinfection is prevalent. Frequently, anti-HBc is the only serological marker of HBV, which can be indicative of HBV resolved infection, when found together with anti-HBs reactivity; or present as "isolated anti-HBc," related to HBV occult infection with presence of detectable DNA HBV, more prevalent in HIV-positive individuals. Regional data about this condition are scarce. Anti-HBc rapid test has been used as screening, but its performance has not been described in HIV-positive patients. The aim of this study was determine prevalence of anti-HBc in HIV-positive patients, serological pattern of HBV resolved infection and isolated anti-HBc, evaluating presence of HBV occult infection. Assess anti-HBc rapid test compared to ECLIA. Methods included measurement of anti-HBc and anti-HBs in HIV-positive patients with negative HBsAg. Serum HBV DNA quantification and HBV booster vaccination to "isolated anti-HBc" individuals. Detection of anti-HBc by rapid test and ECLIA. In 192 patients, prevalence of anti-HBc was 42.7% (82/192); associated to male gender, drug use, men-sex-men, positive-VDRL, and longer time HIV diagnosis. 34.4% (66/192) had presence of anti-HBs, mean titers of 637 ui/ml. Isolated anti-HBc in 8.3% (16/192), associated to detectable HIV viral load and no-use of HAART; in them, HBV DNA was undetectable, and 60% responded to HBV vaccination booster. Anti-HBc rapid test showed low sensibility (32.9%) compared to ECLIA. These results show that prevalence of anti-HBc in HIV-positive individuals is high, in most cases accompanied with anti-HBs as HBV resolved infection. Low prevalence of "isolated anti-HBc," with undetectable HBV DNA, and most had anamnestic response to HBV vaccination; suggest low possibility of occult HBV infection. Anti-HBc rapid test cannot be recommended as screening method for anti-HBc. PMID:26381185

  1. Analysis of HBV-DNA Replication Level Distribution in Hepatitis B associated with Liver Cancer of Chongqing%重庆地区乙肝相关性肝癌患者HBV-DNA复制水平分布情况分析

    Institute of Scientific and Technical Information of China (English)

    秦晓波; 胡鹏

    2013-01-01

    Objective To Analyze the HBV-DNA replication level distribution in Hepatitis B associated with Liver Cancer of Chongqing. Methods 238 cases of HCC patients were collected, HBV-DNA replication level detection was tested. Result In 238 cases, HBV-DNA of 202 cases (84.87%) could be detected, except 36 cases (15.13%). The HBV-DNA in 103, 104, 105, 106 copies/mL was the most, that was significantly higher than the others (P<0.05 or 0.01). Conclusion HBV-DNA Replication Level Distribution in Hepatitis B associated with Liver Cancer of Chongqing is higher relatively.%目的:分析重庆地区乙肝相关-原发性肝癌(HBV-HCC)患者HBV-DNA复制水平分布情况。方法收集HBV-HCC患者238例,入选者在确诊肝癌时监测HBV-DNA复制水平。结果238例HBV-HCC患者中,检测出外周血检查出HBV-DNA者202例(84.87%)、未检出者36例(15.13%)。HBV-HCC患者HBV-DNA以103、104、105、106拷贝/mL复制水平分布例数较多,显著高于其他HBV-DNA复制水平组(P<0.05或0.01)。结论重庆地区HBV-HCC患者HBV-DNA复制水平较高。

  2. Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV).

    Science.gov (United States)

    Han, Anyue; Li, Lingna; Qing, Kuiyou; Qi, Xiaolu; Hou, Leping; Luo, Xintong; Shi, Shaohua; Ye, Faqing

    2013-03-01

    Hepatitis B virus (HBV) infection causes major public health problems worldwide. Acyclovir (ACV) is mainly used to inhibit herpes simplex virus (HSV) rather than HBV. In this study, we used the combination principle to design and synthesize nucleoside analogues that contain silatrane on the basis of the structure of ACV. We found that the compounds were effective inhibitors of HBV, both in vitro and in vivo. All of the compounds showed suppressive activity on the expression of HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) in the HepG2.2.15 cell line with low cytotoxicity. One of compounds was studied in HBV transgenic mice model, and the test results showed its ability to reduce the levels of HBsAg, HBeAg and HBV DNA by ELASE and qPCR. Furthermore, significant improvement of T lymphocyte was observed after treatment, as evaluated by flow cytometry (FCM).

  3. DETECTION AND SIGNIFICANCE OF HBV IN RENAL TISSUE OF HBV ASSOCIATED GLOMERULONEPHRITIS PATIENTS

    Institute of Scientific and Technical Information of China (English)

    任淑婷; 于琳华; 徐长福; 李恒力; 党双锁; 成少利; 郑黎明

    2002-01-01

    Objective To study the pathogenesis of hepatitis B virus ( HBV ) on kidney tissues. Methods HBsAg and HBcAg in paraffin-embedded renal biopsy tissues from 27 cases of glomerulonephritis with positive serum HBV markers were observed by using immunohistochemistry. In addition, in situ polymerse chain reaction (IS-PCR) was performed in 5 cases with positive HBsAg and HBcAg in renal tissue of the 27-case glomerulonephritis to reveal the state of renal HBV DNA. Results Twenty cases (20/27,74.07%) were positive with HBAg which were mainly diffusely distributed in epithelial cells of renal tubule. Four cases (4/5,80% ) were positive with HBV DNA whose distribution was the same of that of HBAg. Conclusion Renal lesions due to HBV are not only the results of immunologic response, but also the outcome of direct invasion and duplication of HBV in epithelial cells of renal tubule.

  4. 昆明市2008年-2009年从业人员HBV血清学检测结果分析%Analysis of HBV serological test results of employees in Yunnan from 2008 to 2009

    Institute of Scientific and Technical Information of China (English)

    普兴福; 杨文华; 李梅春; 金鑫

    2012-01-01

    目的:为掌握昆明市饮食及公共场所从业人员HBV感染状况.方法:用ELISA法检测HBsAg和HBeAg.结果:①检测40975人次,HBsAg阳性率1.65%( 677/40975),HBsAg、HBeAg两者均阳性的阳性率0.61%(249/40975).②男性HBsAg阳性率和HBsAg、HBeAg两者均阳性的阳性率均明最高于女性,且以男性16岁~19岁年龄组阳性率为最高;男、女16岁~19岁、20岁~ 30岁、31岁~40岁年龄组的HBsAg阳性率及HBsAg、HBeAg两者均阳性的阳性率差别显著,而41岁~56岁年龄组差别无统计学意义.③各年龄组HBsAg阳性率及HBsAg、HBeAg两者均阳性的阳性率差别显著,均以16岁~19岁年龄组为高,而女性自身比较,HBsAg阳性率以41岁~56岁年龄组为高.结论:男性20岁以下,女性20岁以下及41岁~56岁年龄组是防控HBV感染的重点监控对象.%Objective:To master the HBV infection status of employees in catering industry and public place. Methods: ELISA was employed to detect HBsAg and HBeAg in sampled serum. Results; 1. 40975 person were involved in this test, the positive rate of HBsAg was 1. 65% (677/40975) , the rate of both HBsAg and HBeAg positive was 0. 61% (249/40975). 2. The rates of males with HBsAg positive and both HBsAg and HBeAg positive were both higher than those of females, and the highest positive rate was found in males aged 16 to 19. The rates of HBsAg positive and both HBsAg and HBeAg positive had significant difference among the age groups of 16 ~ 19, 20 -30 and 31 ~40 between males and females, while the differences in group 41-56 had no statistical significance. 3. The rates of HBsAg positive and both HBsAg and HBeAg positive had significant difference among different age groups of males and females. In males, the highest positive rates were both found in group agedl6 ~ 19, while in females, HBsAg had the highest positive rate in group aged 41 ~56. Conclusion; Male under 20 years old, females under 20 years old and between 41 - 56 years old

  5. The Prevention of Liver Cancer by HBV Vaccine Program

    Institute of Scientific and Technical Information of China (English)

    TAO Xiong

    2002-01-01

    Objective To recognize the HBV vaccine program for prevention of the hepatic cancer.Methods To discuss the relation between the HBV and hepatic cancer arising, and to discuss the immunology respond of the HBV vaccine (HBV surface antigen protein) in our patient group. Result Our data indicates that the predisposing of the HBV infection is required for the hepatic cancer arising and for the high expression of the AFP gene, and our data indicates that the HBV vaccine can induce highly immuno respond in about 78.8 % of the adult for achieving the HBV prevention status and the hepatic cancer prevention status.

  6. Establishment and use of HBV-replication transgenic mice

    Directory of Open Access Journals (Sweden)

    Xiang-ping KONG

    2011-09-01

    Full Text Available Despite the existence of a preventive vaccine,hepatitis B virus(HBV infection is still a major worldwide health problem,especially in China.As HBV naturally Despite of the existence of a preventive vaccine,hepatitis B virus(HBV infection is still a major worldwide healthy problem,especially in China.As HBV naturally infects only human and chimpanzees,many issues pertaining to the biology and the therapeutic of HBV infection remain unresolved due to the limitation of the establishment of a HBV model.However,the establishment of HBV-replication transgenic mice has greatly improved our understanding of life cycle,immunobiology and pathogensis of HBV.The establishment of HBV transgenic mice and its use in assessing the antiviral potential of pharmacological agents and HBV immunopathogenesis are herewith briefly described in the present paper.

  7. Correlation between Serum Markers of Hepatitis B Virus and DNA HBV%乙肝病毒血清标志物与HBV DNA的相关性研究

    Institute of Scientific and Technical Information of China (English)

    张智贤; 何秋莹; 温英梦; 曾华

    2015-01-01

    目的探讨乙型肝炎血清标志物(HBsAg、抗HBs、HBeAg、抗HBe、抗HBc)与乙肝病毒基因(HBV DNA)的相关性和临床意义。方法回顾性分析553例乙肝患者的HBV DNA定量及乙肝两对半定量结果,计算不同乙肝血清学标志物组合模式中HBV DNA阳性率及分布情况,分析乙型肝炎血清标志物与HBV DNA相关性。结果6组血清学模式对应的HBV DNA阳性率在9.5~80.0%不等,以HBsAg(+)HBeAg(+)抗HBc(±)组对应的DNA阳性率及DNA拷贝数为最高。 HBsAg、抗HBs、HBeAg、抗HBe、HBcAg与HBV DNA对数spearman结果分别为r=0.009,>0.05;r=-0.155,>0.05;r=0.541,0.05。结论 HBeAg含量与HBV DNA含量存在正相关(<0.05),抗HBe含量与HBV DNA含量存在负相关(<0.05)。联合检测乙肝血清学标志物定量和HBV DNA定量,可以为乙型肝炎的诊断、治疗及疗效评价提供一个更准确的依据。%Objective To detect and investigate the cor elation and clinical significance of HBV DNA and HBV M in Hepatitis B patients. Methods The test results of the quantity of HBV DNA and HBV M in 553 hepatitis B patients were analyzed retrospectively, and the the correlation between HBV DNA and HBV M was analyzed. Results Al the 6 models held HBV DNA positive rates ranging from 9.5%to 80.0%and 80.0%for the model of positive HBsAg(+)HBeAg(+) Anti-HBc(±). There was statistical significance among the spearman's rank cor elation coef icient between HBV DNA and HBeAg (r=0.541,<0.05) as wel as HBV DNA and Anti-HBe (r=-0.493,<0.05). Conclusion HBV DNA was positively cor elated with HBeAg and negatively cor elated with Anti-HBe statistical y. Combined detection of HBV DNA and HBV M can ef ectively monitor HBV replication,it has important value in monitoring curative ef ect and judging prognosis.

  8. Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection

    Institute of Scientific and Technical Information of China (English)

    JianLin Chen; XiaoJun Lin; Qian Zhou; Ming Shi; ShengPing Li; XiangMing Lao

    2016-01-01

    Background: It remains unclear what the antiviral therapy affects disease‑free survival (DFS) and overall survival (OS) of patients with hepatitis B virus (HBV)‑related hepatocellular carcinoma (HCC) at different tumor stages and baseline HBV DNA levels. In this study, we analyzed the association of antiviral treatment with DFS and OS based on the stratifi‑cation of baseline HBV DNA load in early‑stage (stages I and II) HCC patients. Methods: We included 445 patients with early‑stage HBV‑related HCC who underwent curative resection, and then classified them into four subgroups based on baseline HBV DNA load and antiviral therapy stratification. The Kaplan–Meier and Cox regression analyses were performed to determine the association of clinical characteristics with survival. Results: The median follow‑up period was 74 months. For all patients, cumulative OS rates in the antiviral group were significantly higher than those in the non‑antiviral group (log‑rank test, P = 0.023), whereas no significant differencesin DFS rates were observed. High baseline HBV DNA level was a risk factor associated with short DFS and OS in all patients. In patients with baseline HBV DNA levels ≥2000 IU/mL, antiviral treatment was significantly associated withprolonged DFS and OS (log‑rank test, P or undetectable, antiviral treatment did not show a significant benefit in prolonging DFS and OS. Conclusions: High baseline HBV DNA levels are associated with poor prognosis in the patients with early‑stage HCC, and the antiviral treatment could generate survival benefits for the patients. Therefore, antiviral treatment should be given for these patients. However, the effect of antiviral treatment on the patients with low viral load remains unclear, and further investigation is warranted.

  9. 乙肝孕产妇血清HBV-DNA与乳汁HBV-DNA相关性的比较

    Institute of Scientific and Technical Information of China (English)

    刘晓燕

    2006-01-01

    目的:孕产妇各种血清学标志的乳汁HBV-DNA与血清HBV-DNA相关性的探讨.方法:用全自动荧光定量分析仪对已确认的乙肝孕产妇血清HBV-DNA与乳汁HBV-DNA的检测.结果:85例乙肝孕产妇其各种血清学标志的血清HBV-DNA与乳汁HBV-DNA是一致的.其同一种血清模式的血清HBV-DNA含量高,则乳汁的HBV-DNA相应高.反之,血清HBV-DNA含量低,则乳汁HBV-DNA含量低.

  10. Inhibition of hepatitis B virus (HBV) by LNA-mediated nuclear interference with HBV DNA transcription

    Energy Technology Data Exchange (ETDEWEB)

    Sun, Zhen [The State Key Laboratory of Genetic Engineering and The MOE Key Laboratory of Contemporary Anthropology, School of Life Science, Fudan University, Shanghai 200433 (China); Department of Biochemistry and Molecular Biology, Program in Molecular Cell Biology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058 (China); Xiang, Wenqing; Guo, Yajuan [Department of Biochemistry and Molecular Biology, Program in Molecular Cell Biology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058 (China); Chen, Zhi [The State Key Laboratory for Infectious Disease, Institute of Infectious Disease, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003 (China); Liu, Wei, E-mail: liuwei666@zju.edu.cn [Department of Biochemistry and Molecular Biology, Program in Molecular Cell Biology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058 (China); Lu, Daru, E-mail: drlu@fudan.edu.cn [The State Key Laboratory of Genetic Engineering and The MOE Key Laboratory of Contemporary Anthropology, School of Life Science, Fudan University, Shanghai 200433 (China)

    2011-06-10

    Highlights: {yields} LNA-modified oligonucleotides can pass through the plasma membrane of cultured cells even without using transfection machinery. {yields} LNA-modified oligonucleotides passed efficiently across the cell membrane, and lipid-coating facilitated translocation from the cytoplasm to the nucleus. {yields} LNA-oligonucleotide designed to target nuclear HBV DNA efficiently suppresses HBV replication and transcription in cultured hepatic cells. -- Abstract: Silencing target genes with small regulatory RNAs is widely used to investigate gene function and therapeutic drug development. Recently, triplex-based approaches have provided another attractive means to achieve targeted gene regulation and gene manipulation at the molecular and cellular levels. Nuclear entry of oligonucleotides and enhancement of their affinity to the DNA targets are key points of such approaches. In this study, we developed lipid-based transport of a locked-nucleic-acid (LNA)-modified oligonucleotide for hepatitis B virus (HBV) DNA interference in human hepatocytes expressing HBV genomic DNA. In these cells, the LNA-modified oligonucleotides passed efficiently across the cell membrane, and lipid-coating facilitated translocation from the cytoplasm to the nucleus. The oligonucleotide specifically targeting HBV DNA clearly interfered with HBV DNA transcription as shown by a block in pregenomic RNA (pgRNA) production. The HBV DNA-targeted oligonucleotide suppressed HBV DNA replication and HBV protein production more efficiently than small interfering RNAs directed to the pgRNA. These results demonstrate that fusion with lipid can carry LNA-modified oligonucleotides to the nucleus where they regulate gene expression. Interfering with HBV DNA transcription by LNA-modified oligonucleotides has strong potential as a new strategy for HBV inhibition.

  11. Inhibition of hepatitis B virus (HBV) by LNA-mediated nuclear interference with HBV DNA transcription

    International Nuclear Information System (INIS)

    Highlights: → LNA-modified oligonucleotides can pass through the plasma membrane of cultured cells even without using transfection machinery. → LNA-modified oligonucleotides passed efficiently across the cell membrane, and lipid-coating facilitated translocation from the cytoplasm to the nucleus. → LNA-oligonucleotide designed to target nuclear HBV DNA efficiently suppresses HBV replication and transcription in cultured hepatic cells. -- Abstract: Silencing target genes with small regulatory RNAs is widely used to investigate gene function and therapeutic drug development. Recently, triplex-based approaches have provided another attractive means to achieve targeted gene regulation and gene manipulation at the molecular and cellular levels. Nuclear entry of oligonucleotides and enhancement of their affinity to the DNA targets are key points of such approaches. In this study, we developed lipid-based transport of a locked-nucleic-acid (LNA)-modified oligonucleotide for hepatitis B virus (HBV) DNA interference in human hepatocytes expressing HBV genomic DNA. In these cells, the LNA-modified oligonucleotides passed efficiently across the cell membrane, and lipid-coating facilitated translocation from the cytoplasm to the nucleus. The oligonucleotide specifically targeting HBV DNA clearly interfered with HBV DNA transcription as shown by a block in pregenomic RNA (pgRNA) production. The HBV DNA-targeted oligonucleotide suppressed HBV DNA replication and HBV protein production more efficiently than small interfering RNAs directed to the pgRNA. These results demonstrate that fusion with lipid can carry LNA-modified oligonucleotides to the nucleus where they regulate gene expression. Interfering with HBV DNA transcription by LNA-modified oligonucleotides has strong potential as a new strategy for HBV inhibition.

  12. 乙肝血清标志物模式与HBV-DNA含量的关系探讨%Correlation between HBV serological markers and HBV-DNA

    Institute of Scientific and Technical Information of China (English)

    张海业; 孙溯荫; 韦兰

    2011-01-01

    Objective To analyze the correlation between the lovel of HBV semiogloat markers and HBV-DNA.Mothods Serum samples of 800 patients from Xinyi Pepole's Hospital clinic department suffering HBV were detected by ELISA and HBV-DNA were detected by FQ-PCR.then analyze the correlation between HBV serological markers and HBV-DNA.Results The HBV-DNA was detoeted in some HBV serological markerg groups and each group was different in the result.HBsAg positive.such as HBsAg,HBeAg and Anti-HBc positive samples has higher amount of copies of HBV-DNA;the low level of HBV-DNA copies were detected in the group of HBsAg.HBeAg or Anti-HBe,Anti-HBo lmsitive; and the HBV-DNA copies rate is 2.98%in the single HBsAg positive.Among 120 HBe Ag positive samples.there were 118 HBV-DNA positive,the positive rate of HBV-DNA was 98.33%and the level of HBeAg positive wail correlated to HBV-DNA(r=0.993).Conclusion Both the detection of HBeAg and HBV-DNA cab reflect the active level of duplicate of HBV-M.The HBV-DNA level showed all obvious correlation to the HBeAg contend in Bera.%目的 探讨不同的乙肝血清标志物(HBV-M)模式与HBV-DNA定量检测结果之间的关系.方法 选择800例经酶联免疫吸附试验(ELISA)检测HBsAg结果为阳性的血清样本,采用实时荧光定量PCR技术(FQ-PCR)检测其HBV-DNA含量;并根据患者HBV-M的不同模式进行分组统计,分析探讨HBV-M模式与HBV-DNA含量之间的关系.结果 不同HBV-M模式中HBV-DNA阳性检出率和含量存在明显差异.①"大三阳"组HBV-DNA含量以中、高拷贝为主;②"小三阳"组及HBsAg(+)&Anti-HBc(+)组HBV-DNA含量以中、低拷贝为主;③单纯HBsAg(+)组HBV-DNA的检出率仅为2.98%.④HBeAg(+)血样中HBV-DNA的阳性检出率高达98.33%(118/120),两者之间存在明显正相关(r=0.993).结论 HBV-M与HBV-DNA的检测都能反映HBV感染、传染性及体内复制的情况;HBeAg与HBV-DNA含量存在明显正相关.两者联合检测对乙肝的临床诊疗具有重要指导意义.

  13. Clearance of HBV DNA in immunized children born to HBsAg-positive mothers, years after being diagnosed with occult HBV infection.

    Science.gov (United States)

    Sadeghi, A; Yahyapour, Y; Poortahmasebi, V; Shahmoradi, S; Roggendorf, M; Karimzadeh, H; Alavian, S M; Jazayeri, S M

    2016-04-01

    In a previous study, we observed immunoprophylaxis failure due to occult hepatitis B virus (HBV) infection (OBI) despite the presence of adequate levels of anti-HBs in 21 (28%) of 75 children born to HBsAg-positive mothers. The aim of the study was to explore the maintenance of this cryptic condition in this population. Of 21 OBI-positive children, 17 were enrolled. HBV serological profiles were determined by enzyme-linked immunosorbent assay. Highly sensitive real-time and standard PCR followed by direct sequencing were applied in positive cases. The mean age (±SD) of studied patients was 6.57 ± 2.75 years. All children still were negative for HBsAg. All but one (94%) were negative for HBV DNA. Only two children were positive for anti-HBc. The results of the most recent anti-HBs titration showed that 4 (23.5%) and 13 (76.5%) had low (10 IU/mL) levels of anti-HBs, respectively. The only still OBI-positive patient had an HBV DNA level of 50 copy/mL, carried the G145R mutation when tested in 2009 and again in 2013 in the 'a' determinant region of the surface protein. Further follow-up showed that after 18 months, he was negative for HBV DNA. In high-risk children, the initial HBV DNA positivity early in the life (vertical infection) does not necessarily indicate a prolonged persistence of HBV DNA (occult infection). Adequate levels of anti-HBs after vaccine and hepatitis B immune globulin immunoprophylaxis following birth could eventually clear the virus as time goes by. Periodic monitoring of these children at certain time intervals is highly recommended.

  14. Occult HBV Infection: A Faceless Enemy in Liver Cancer Development

    Directory of Open Access Journals (Sweden)

    Jaime Morales-Romero

    2014-04-01

    Full Text Available The hepatitis B virus (HBV represents a worldwide public health problem; the virus is present in one third of the global population. However, this rate may in fact be higher due to occult hepatitis B virus infection (OBI. This condition is characterized by the presence of the viral genome in the liver of individuals sero-negative for the virus surface antigen (HBsAg. The causes of the absence of HBsAg in serum are unknown, however, mutations have been identified that produce variants not recognized by current immunoassays. Epigenetic and immunological host mechanisms also appear to be involved in HBsAg suppression. Current evidence suggests that OBI maintains its carcinogenic potential, favoring the progression of fibrosis and cirrhosis of the liver. In common with open HBV infection, OBI can contribute to the establishment of hepatocellular carcinoma. Epidemiological data regarding the global prevalence of OBI vary due to the use of detection methods of different sensitivity and specificity. In Latin America, which is considered an area of low prevalence for HBV, diagnostic screening methods using gene amplification tests for confirmation of OBI are not conducted. This prevents determination of the actual prevalence of OBI, highlighting the need for the implementation of cutting edge technology in epidemiological surveillance systems.

  15. A mouse model for HBV immunotolerance and immunotherapy.

    Science.gov (United States)

    Yang, Dan; Liu, Longchao; Zhu, Danming; Peng, Hua; Su, Lishan; Fu, Yang-Xin; Zhang, Liguo

    2014-01-01

    Lack of an appropriate small animal model remains a major hurdle for studying the immunotolerance and immunopathogenesis induced by hepatitis B virus (HBV) infection. In this study, we report a mouse model with sustained HBV viremia after infection with a recombinant adeno-associated virus (AAV) carrying a replicable HBV genome (AAV/HBV). Similar to the clinical HBV carriers, the mice infected with AAV/HBV were sero-negative for antibodies against HBV surface antigen (HBsAg). Immunization with the conventional HBV vaccine in the presence of aluminum adjuvant failed to elicit an immune response against HBV in these mice. To identify a vaccine that can potentially circumvent this tolerance, the TLR9 agonist CpG was added to HBsAg as an adjuvant. Vaccination of mice with HBsAg/CpG induced not only clearance of viremia, but also strong antibody production and T-cell responses. Furthermore, both the DNA replication and protein expression of HBV were significantly reduced in the livers of AAV/HBV-infected mice. Accordingly, AAV/HBV-infected mice may be used as a robust model for investigating the underlying mechanism(s) of HBV immunotolerance and for developing novel immunotherapies to eradicate HBV infections. PMID:24076617

  16. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection

    Institute of Scientific and Technical Information of China (English)

    Xiao-Mao Li; Min-Feng Shi; Yue-Bo Yang; Zhong-Jie Shi; Hong-Ying Hou; Hui-Min Shen; Ben-Qi Teng

    2004-01-01

    AIM: To evaluate the efficacy of hepatitis B immunoglobulin (HBIG) in interrupting hepatitis B virus (HBV) intrauterine infection during late pregnancy.METHODS: We allocated 112 HBsAg positive pregnant women into 2 groups randomly. Fifty seven cases in the HBIG group received 200 IU (unit) HBIG intramuscularly every 4 wk from the 28 wk of gestation to the time of delivery, while 55 cases in the control group received no special treatment.HBsAg, HBeAg, HBcAb, HBeAb, HBsAb and HBV DNA levels were tested in the peripheral blood specimens from all of the mothers at 28 wk of gestation, just before delivery, and in blood from their newborns within 24 h before administration of immune prophylaxis.RESULTS: The intrauterine infection rate in HBIG group and control group were 10.5% and 27.3%, respectively, with significant difference (P<0.05). It showed ascendant trend as HBV DNA levels in the peripheral blood increased before delivery.CONCLUSION: HBIG is potent to cut down HBV intrauterine infection rate significantly when administered to pregnant women regularly during late pregnancy. The possibility of HBV intrauterine infection increases if maternal blood HBV DNA ≥ 108 copies/mL.

  17. Pediatric HIV-HBV Coinfection in Lusaka, Zambia: Prevalence and Short-Term Treatment Outcomes.

    Science.gov (United States)

    Peebles, Kathryn; Nchimba, Lweendo; Chilengi, Roma; Bolton Moore, Carolyn; Mubiana-Mbewe, Mwangelwa; Vinikoor, Michael J

    2015-12-01

    Hepatitis B virus (HBV) is endemic in Africa, where it may occur as an HIV coinfection. Data remain limited on HIV-HBV epidemiology in Africa, particularly in children. Using programmatic data from pediatric HIV clinics in Lusaka, Zambia during 2011-2014, we analyzed the prevalence of chronic HBV coinfection (defined as a single positive hepatitis B surface antigen [HBsAg] test) and its impact on immune recovery and liver enzyme elevation (LEE) during the first year of antiretroviral therapy. Among 411 children and adolescents, 10.4% (95% confidence interval, 7.6-14.1) had HIV-HBV. Coinfected patients were more likely to have World Health Organization stage 3/4, LEE and CD4 <14% at care entry (all p < 0.05). During treatment, CD4 increases and LEE incidence were similar by HBsAg status. HBsAg positivity decreased (11.8% vs. 6.6%; p = 0.24) following HBV vaccine introduction. These findings support screening pediatric HIV patients in Africa for HBV coinfection. Dedicated cohorts are needed to assess long-term outcomes of coinfection.

  18. Prevention of de novo HBV infection by the presence of antiHBs in transplanted patients receiving core antibody-positive livers

    Institute of Scientific and Technical Information of China (English)

    Rafael Barcena; Gloria Moraleda; Javier Moreno; M Dolores Martín; Emilio de Vicente; Jesús Nu(n)o; M Luisa Mateos; Santos del Campo

    2006-01-01

    AIM: To analyze whether the presence of anti-HBs in liver transplant recipients is effective in preventing HBV infection.METHODS: Twenty-three patients receiving anti-HBc positive liver were studied. Nine recipients were anti HBc positive as a result of previous HBV infection. Of them, one also received HBV vaccine during the pre-liver transplantation period. Fourteen recipients were anti-HBs positive due to HBV vaccine administered during the pretransplant period. Liver biopsy was obtained in 10/14anti-HBc negative/anti-HBs positive recipients and in 4/9anti-HBc positive recipients.RESULTS: After a mean follow-up period of 46 months,1 recipient with protective serum anti-HBs levels developed de novo HBV infection as a consequence of immune escape HBV mutants. Among the 14 vaccinated anti-HBc negative/anti-HBs positive recipients, 1/10patients with available liver biopsy (10%) had liver HBVDNA at 13 mo post-liver transplantation without serum viral markers and did not develop de novo HBV infection.The vaccinated anti-HBc positive recipient without HBV vaccine response was HBV-DNA positive in serum and liver, viral DNA was continuously negative in the followlng tests, so a spontaneous seroconversion was diagnosed.CONCLUSION: The presence of anti-HBs as a result of HBV vaccine or past HBV infection seems to be effective at protecting patients receiving livers from anti-HBc positive donors. However, the emergence of immune escape HBV mutants, which can evade the anti-HBs protection, should be considered as a risk of HBV infection.

  19. DIFFERENT COURSES OF HBV INFECTION AFTER LIVER TRANSPLANTATION

    Directory of Open Access Journals (Sweden)

    V. E. Syutkin

    2011-01-01

    Full Text Available To compare clinical and virologic course of de novo and recurrent HBV infection 104 liver graft recipients with 6 months and more follow-up after cadaveric transplantation have been analyzed. Recurred HBV infection occurred in 7 (30.4% out of 23 HBsAg-positive and de novo HBV infection – in 11 out of 81 (13.6% HBsAg- negative recipients. HBeAg and IgM anti-HBc appeared in 8 recipients with de novo and in one case – with recurrent infection. Two recipients with de novo HBV developed acute hepatitis with jaundice and one – chronic hepatitis with graft cirrhosis. Only one recipient with recurrent HBV developed severe acute hepatitis HBV/ HDV, with anti-HBs seroconversion after 12 weeks of peginterferon alfa treatment. Nucleoside analogs (NA were started in all 11 de novo HBV cases and in 5 cases of recurrent HBV infection. Treatment with NA effec- tively suppressed HBV DNA replication in both recurrent and de novo infections; HBsAg clearance occurred in 64% of de novo HBV and in 20% – of recurrent HBV cases. No secondary drug resistance occurred. De novo HBV infection is a self-limited disease in most cases, and preemptive NA treatment is the best treatment choice. Recurrent HBV infection is usually chronic, and pegylated interferon may be under consideration as well as NA. 

  20. A randomized control trial on interruption of HBV transmission in uterus

    Institute of Scientific and Technical Information of China (English)

    朱启镕; 于广军; 俞蕙; 吕晴; 顾新焕; 董左权; 张秀珍

    2003-01-01

    Objective To study the interruptive effect of hepatitis B virus (HBV) specific immunolobulin (HBIG) before delivery in attempt to prevent intrauterine transmission of HBV.Methods Nine hundred and eighty HBsAg carrier pregnant women were randomly divided into HBIG group and control group. Each subject in the HBIG group received 200 IU or 400 IU of HBIG intramuscularly at 3, 2 and 1 month before delivery. The subjects in the control group did not receive any specific treatment. All newborn infants received 100 IU of HBIG intramascularty after venous blood samples were taken at birth and 2 weeks after birth, followed by 30 μg plasma-derived HB vaccine or 5 μg recombinant yeast-derived hepatitis B vaccine at 1, 2 and 7 months of age. Blood tests were performed for all the lying-in women and their neonates. Blood specimens were tested for HBsAg and HBeAg by enzyme immunoassay. All infants were followed up for 1 year.Results In the HBIG group, 491 neonates were born to 487 HBV carrier mothers; and in the control group, 496 neonates were born to 493 HBV carrier mothers. The rates of intrauterine transmission in the two groups were 14.3% and 5.7% respectively (χ2=20.280, P<0.001), and the rates of chronic hepatitis B in the two groups were 2.2% and 7.3% respectively (χ2=13.696, P<0.001). The high risk factors of intrauterine HBV infection included HBsAg HBeAg double positive and HBV DNA positive in the peripheral blood of pregnant women.Conclusion HBV infection in the uterus may be interrupted by injecting multiple intramuscular HBIG injections before delivery without causing any side-effects.

  1. Poly(I:C/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boosting.

    Directory of Open Access Journals (Sweden)

    Xia Chuai

    Full Text Available BACKGROUND: Virus-specific cellular immune responses play a critical role in virus clearance during acute or chronic HBV infection. Currently, the commercially available HBV vaccine is combined with alum adjuvant, which stimulates mainly Th2 immune responses. Therefore, development of new therapeutic HBV vaccine adjuvants and immune strategies that also promote Th1 and CTL responses is urgently needed. METHODOLOGY/PRINCIPAL FINDINGS: To improve the immunity induced by the novel HBSS1 HBV vaccine, we evaluated the ability of adjuvants, including alum, CpG and polyriboinosinic polyribocytidylic acid [poly(I:C], to enhance the response when boosted with the recombinant adenoviral vector vaccine rAdSS1. The immune responses to different adjuvant combinations were assessed in C57BL/6 mice by enzyme-linked immunosorbent assay (ELISA, ELISpot and cytokine release assays. Among the combinations tested, a HBV protein particle vaccine with CpG/alum and poly(I:C/alum priming combinations accelerated specific seroconversion and produced high antibody (anti-PreS1, anti-S antibody titres with a Th1 bias. After boosting with recombinant adenoviral vector vaccine rAdSS1, both groups produced a strong multi-antigen (S and PreS1-specific cellular immune response. HBSS1 immunisation with poly(I:C/alum priming also generated high-level CD4(+ and CD8(+ T cell responses in terms of Th1 cytokines (IFN-γ and IL-2. CONCLUSIONS: The protein-vaccine HBSS1 with mixed poly(I:C/alum adjuvant priming, followed by a rAdSS1 vaccine boost, maximises specific antibody and Th1-biased cellular immune responses. This regime might prove useful in the development of HBV therapeutic vaccines. Furthermore, this promising strategy might be applied to vaccines against other persistent infections, such as human immunodeficiency virus and tuberculosis.

  2. The application of combination detection of hepatitis B serological markers quantifi-cation and HBV DNA quantification in the diagnosis of hepatitis B virus infection%乙肝血清学标志物定量和HBV DNA定量联合检测在乙肝病毒感染诊断中的应用

    Institute of Scientific and Technical Information of China (English)

    吴洪秋; 张永良; 黄坚尧; 张汉运

    2016-01-01

    Objective To analyze the application value of combination detection in the diagnosis of hepatitis B virus ( HBV) infection by the quantitative detection of serological markers and HBV DNA of hepatitis B patients. Methods The serum samples of 120 hepatitis B patients from Jun. 2013 to Jun. 2015 were collected, and the ELISA qualitative test and RT-PCR were used to detect the contents of HBV serological markers ( HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc) and HBV DNA. Results The HBV DNA positive rate was 96. 15% in Ⅰ group; the HBV DNA positive rate was 48. 08% in Ⅱ group;the HBV DNA positive rate was 4. 76% inⅢgroup. The quantitative HBV DNA inⅠgroup was significantly higher than that in Ⅱ and Ⅲ groups ( P0. 05). Conclusion The combination detection of HBV serological markers and HBV DNA quantification plays a complementary role in the diagnosis of HBV infection, and has a more accurate diagnosis as well as can provide a more effective reference.%目的:分析乙肝患者的血清标志物和乙肝病毒( HBV) DNA联合检测在HBV感染诊断中的应用价值。方法以2013年6月-2015年6月在珠海市妇幼保健院就诊的120例乙肝患者血清样本作为研究资料,分别采用ELISA定性试验和实时荧光定量PCR( RT-PCR)检测HBV血清标志物( HBsAg、抗-HBs、HBeAg、抗-HBe、抗-HBc)和HBV DNA含量。结果Ⅰ组HBV DNA阳性率为96.15%;Ⅱ组HBV DNA阳性率为48.08%;Ⅲ组HBV DNA阳性率为4.76%。Ⅰ组HBV DNA定量显著高于Ⅱ、Ⅲ两组( P0.05)。结论乙肝血清标志物定量与HBV DNA定量联合检测在诊断HBV感染过程中起互相补充的作用,诊断结果更加准确,可提供更有效的参考依据。

  3. Clinical Characteristics in Patients with Liver Cirrhosis Induced by HBV Infection and Combined with Mild Alcohol Intake

    Institute of Scientific and Technical Information of China (English)

    Ha-lida Xiaerfuhazi; Hai-lin Ma; Xiu-jiang Shi; Xiao-tang Fan; Xi-ernayi Abuduheilili; Fang-ping He

    2014-01-01

    Objective To investigate the differences of clinical and biochemical characteristics between patients with liver cirrhosis induced by HBV infection combined with and without mild alcohol intake. Methods Data of patients with liver cirrhosis who were hospitalized in the First Hospital Afifliated to Xinjiang Medical University were retrospectively analyzed. Patients were divided into three groups: patients with liver cirrhosis induced by HBV infection and combined with mild alcohol intake, patients with HBV-related cirrhosis, and patients with alcohol-related cirrhosis. Biochemical detections including liver function, fasting lipid proifles, lipoprotein, kidney function, glucose, uric acid and regular blood tests were carried out and results were compared among three groups. Data were analyzed through STATA software and co-variant analysis. Results Total of 2 350 patients with liver cirrhosis were included, 732 patients had cirrhosis induced by HBV infection combined with mild alcohol intake, 1 316 patients had HBV-related liver cirrhosis, 302 patients had alcohol-related cirrhosis. The highest mean level of white cell count, mean corpuscular volume,γ-glutamyltranspeptidase and uric acid were observed in HBV infection combined with mild alcohol intake group. Multivariate regression analysis revealed that HBV infection, excessive alcohol intake, male and age were risk factors for hepatocellular carcinoma (HCC) in patients with liver cirrhosis. Conclusions HBV infection combined with mild alcoholic-related liver cirrhosis group showed the highest oxidative stress compared with alcoholic liver cirrhosis group, which suggested that mild alcohol intake may increase the incidence of liver cirrhosis in HBV infected patients and may not increase the incidence of HCC.

  4. Leukocyte telomere length-related rs621559 and rs398652 genetic variants influence risk of HBV-related hepatocellular carcinoma.

    Directory of Open Access Journals (Sweden)

    Wenting Pan

    Full Text Available Recent genome-wide association studies (GWAS have identified eleven leukocyte telomere length (LTL-related single nucleotide polymorphisms (SNPs. Since LTL has been associated with risk of many malignancies, LTL-related SNPs may contribute to cancer susceptibility. To test this hypothesis in hepatitis B virus (HBV-related hepatocellular carcinoma (HCC, we genotyped these eleven LTL-related SNPs in a case-control set including 1186 HBV-related HCC cases, 508 chronic HBV carriers and 1308 healthy controls at the discovery stage. The associations of HCC risk with these SNPs were further confirmed in an independent case-control set. We found that 1p34.2 rs621559 and 14q21 rs398652 were significantly associated with HBV-related HCC risk (both P<0.005 after Bonferroni corrections. There was no significant difference of either rs621559 or rs398652 genotypes between chronic HBV carriers and healthy controls, demonstrating that the association was not due to predisposition to HBV infection. In the pooled analyses (1806 HBV-related HCC cases and 1954 controls, we observed a decreased HCC risk, 0.72-times, associated with the 1p34.2 rs621559 AA genotype compared to the GG genotype (P = 1.6×10(-6. Additionally, there was an increased HCC risk, 1.27-fold, associated with the rs398652 GG genotype (P = 3.3×10(-6. A statistical joint effect between the rs621559 GG and rs398652 GG genotypes may exist in elevating risk of HBV-related HCC. We show, for the first time, that rs398652 and rs621559 might be marker genetic variants for risk of HBV-related HCC in the Chinese population.

  5. Association of preS/S Mutations with Occult Hepatitis B Virus (HBV) Infection in South Korea: Transmission Potential of Distinct Occult HBV Variants

    OpenAIRE

    Hong Kim; Bum-Joon Kim

    2015-01-01

    Occult hepatitis B virus infection (HBV) is characterized by HBV DNA positivity but HBV surface antigen (HBsAg) negativity. Occult HBV infection is associated with a risk of HBV transmission through blood transfusion, hemodialysis, and liver transplantation. Furthermore, occult HBV infection contributes to the development of cirrhosis and hepatocellular carcinoma. We recently reported the characteristic molecular features of mutations in the preS/S regions among Korean individuals with occult...

  6. Co-infection rate of HIV, HBV and Syphilis among HCV seropositive identified blood donors in Kathmandu, Nepal

    Directory of Open Access Journals (Sweden)

    Ashish Chandra Shrestha

    2012-02-01

    Full Text Available Background: HIV, HBV, Syphilis and HCV share common modes of transmission. Objective: The study was aimed to determine the co-infection rate of HIV, HBV and Syphilis among HCV seropositive identified blood donors. Methods: The study was conducted on blood samples screened as HCV seropositive at Nepal Red Cross Society, Central Blood Transfusion Service, Kathmandu, Nepal. HCV seropositive samples were further tested for HIV, HBV and Syphilis. Results: Eight co-infections were observed in 139 HCV seropositives with total co-infection rate of 5.75% (95% CI = 2.52-11.03. Conclusion: Co-infection of HIV, HBV and Syphilis with HCV is prevalent in the healthy looking blood donors of Kathmandu, Nepal.

  7. HBV X-gene: A new serum marker for anti-HBV therapy monitoring

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    Objective: To address HBV serum nucleic acid markers for stages without apparent replication. Methods: DNA and RNA sequence segments from the X, C and pre C/C regions produced successively during replication were used as targets for quantitative PCR and RT/PCR. Results: The assays confirmed the preferential formation of intermediates blocked at early stages. They persisted as the only detectable type of serum HBV DNA even after one year of therapy. At reentry into viral replication due to emergence of drug resistant mutants, lamivudine resistance produced exclusively incomplete DNA minus strands, whereas the wild type virus immediately synthesized complete DNA minus strands. Conclusion:PCR assays used for monitoring complete suppression of HBV replication must target the X gene region.

  8. HBV cccDNA in patients′ sera as an indicator for HBV reactivation and an early signal of liver damage

    Institute of Scientific and Technical Information of China (English)

    Ying Chen; Johnny Sze; Ming-Liang He

    2004-01-01

    AIM: To evaluate the covalently closed circle DNA (cccDNA)level of hepatitis B virus (HBV) in patients′ liver and sera.METHODS: HBV DNA was isolated from patients′liver biopsies and sera. A sensitive real-time PCR method, which is capable of differentiation of HBV viral genomic DNA and cccDNA, was used to quantify the total HBV cccDNA. The total HBV viral DNA was quantitated by real-time PCR using a HBV diagnostic kit (PG Biotech, LTD, Shenzhen, China)described previously.RESULTS: For the first time, we measured the level of HBV DNA and cccDNA isolated from ten HBV patients′liver biopsies and sera. In the liver biopsies, cccDNA was detected from all the biopsy samples. The copy number of cccDNA ranged from from 0.03 to 173.1 per cell, the copy number of total HBV DNA ranged from 0.08 to 3 717 per cell. The ratio of total HBV DNA to cccDNA ranged from 1 to 3 406. In the sera,cccDNA was only detected from six samples whereas HBV viral DNA was detected from all ten samples. The ratio of cccDNA to total HBV DNA ranged from 0 to 1.77%. To further investigate the reason why cccDNA could only be detected in some patients′sera, we performed longitudinal studies. The cccDNA was detected from the patients′sera with HBV reactivation but not from the patients′sera without HBV reactivation. The level of cccDNA in the sera was correlated with ALT and viral load in the HBV reactivation patients.CONCLUSION: HBV cccDNA is actively transcribed and replicated in some patients′hepatocytes, which is reflected by a high ratio of HBV total DNA vs cccDNA. Detection of cccDNA in the liver biopsy will provide an end-point for the anti-HBV therapy. The occurrence of cccDNA in the sera is an early signal of liver damage, which may be another important clinical parameter.

  9. A rare HBV subgenotype D4 with unique genomic signatures identified in north-eastern India--an emerging clinical challenge?

    Directory of Open Access Journals (Sweden)

    Priyanka Banerjee

    Full Text Available BACKGROUND/AIMS: HBV has been classified into ten genotypes (A-J and multiple subgenotypes, some of which strongly influence disease outcome and their distribution also correlate with human migration. HBV infection is highly prevalent in India and its diverse population provides an excellent opportunity to study the distinctiveness of HBV, its evolution and disease biology in variegated ethnic groups. The North-East India, having international frontiers on three sides, is one of the most ethnically and linguistically diverse region of the country. Given the paucity of information on molecular epidemiology of HBV in this region, the study aimed to carry out an in-depth genetic characterization of HBV prevailing in North-East state of Tripura. METHODS: From sera of chronically HBV infected patients biochemical/serological tests, HBV DNA quantification, PCR-amplification, sequencing of PreS/S or full-length HBV genomes were done. HBV genotype/subgenotype determination and sequence variability were assessed by MEGA5-software. The evolutionary divergence times of different HBV subgenotypes were estimated by DNAMLK/PHYLIP program while jpHMM method was used to detect any recombination event in HBV genomes. RESULTS: HBV genotypes D (89.5%, C (6.6% and A (3.9% were detected among chronic carriers. While all HBV/A and HBV/C isolates belonged to subgenotype-A1 and C1 respectively, five subgenotypes of HBV/D (D1-D5 were identified including the first detection of rare D4. These non-recombinant Indian D4 (IndD4 formed a distinct phylogenetic clade, had 2.7% nucleotide divergence and recent evolutionary radiation than other global D4. Ten unique amino acids and 9 novel nucleotide substitutions were identified as IndD4 signatures. All IndD4 carried T120 and R129 in ORF-S that may cause immune/vaccine/diagnostic escape and N128 in ORF-P, implicated as compensatory Lamivudine resistance mutation. CONCLUSIONS: IndD4 has potential to undermine vaccination

  10. Hepatitis B virus (HBV status of children born to HIV/HBV co-infected women in a French hospital: a cross-sectional study

    Directory of Open Access Journals (Sweden)

    Pierre Sellier

    2014-11-01

    Full Text Available Introduction: Human Immunodeficiency Virus (HIV Mother-To-Child-Transmission (MTCT and prevention by combined antiretroviral therapy (cART have been extensively studied. Hepatitis B Virus (HBV MTCT from HIV/HBV co-infected women and prevention by antiretroviral therapy with dual activity have been poorly studied. The aim of the study was to assess HBV MTCT from HIV/HBV co-infected women in a developed country with a large access to cART. Materials and Methods: HIV/HBV co-infected pregnant women attending the Obstetrics Department from 1st January 2000 to 1st January 2012 could be included in the study (NCT02044068. Antiretroviral therapy during pregnancy, injection of immunoglobulin and/or vaccine to newborns was retrospectively recorded. We assessed HBV status of children at least as old as two years. Results: Forty nine (9.2% from 530 HIV-infected women followed in the hospital were HIV/HBV co-infected. 34 (69.4% had given birth to 57 children in the hospital. 13 of these women (22 children were lost-to-follow-up, 21 women (35 children could be studied. Twenty six children (74.3% had HBs Ab at a protective level, 22 of them had received immunoglobulin at birth; 24 had received a complete vaccine schedule during the first six months of life (with immunoglobulin in 21 cases. The women had been given lamivudine or tenofovir/emtricitabine during eight and nine pregnancies respectively. Eight children (22.8% were tested negative for HBs Ag, HBs Ab and HBc Ab: 4 (11.4% had received immunoglobulin and a complete vaccine schedule; in two children, immunoglobulin was uncertain; in one child, the vaccine schedule was incomplete; in the last one, data about immunoglobulin and the vaccine schedule were lacking. The women had been given lamivudine or tenofovir/emtricitabine during five and two pregnancies respectively. One child had HBc Ab and HBs Ab, immunoglobulin was uncertain and the vaccine schedule was incomplete. The woman had been given lamivudine

  11. Functional analysis of 'a' determinant mutations associated with occult HBV in HIV-positive South Africans.

    Science.gov (United States)

    Powell, Eleanor A; Boyce, Ceejay L; Gededzha, Maemu P; Selabe, Selokela G; Mphahlele, M Jeffrey; Blackard, Jason T

    2016-07-01

    Occult hepatitis B is defined by the presence of hepatitis B virus (HBV) DNA in the absence of hepatitis B surface antigen (HBsAg). Occult HBV is associated with the development of hepatocellular carcinoma, reactivation during immune suppression, and virus transmission. Viral mutations contribute significantly to the occult HBV phenotype. Mutations in the 'a' determinant of HBsAg are of particular interest, as these mutations are associated with immune escape, vaccine escape and diagnostic failure. We examined the effects of selected occult HBV-associated mutations identified in a population of HIV-positive South Africans on HBsAg production in vitro. Mutations were inserted into two different chronic HBV backbones and transfected into a hepatocyte-derived cell line. HBsAg levels were quantified by enzyme-linked immunosorbent assay (ELISA), while the detectability of mutant HBsAg was determined using an HA-tagged HBsAg expression system. Of the seven mutations analysed, four (S132P, C138Y, N146D and C147Y) resulted in decreased HBsAg expression in one viral background but not in the second viral background. One mutation (N146D) led to a decrease in HBsAg detected as compared to HA-tag, indicating that this mutation compromises the ability of the ELISA to detect HBsAg. The contribution of occult-associated mutations to the HBsAg-negative phenotype of occult HBV cannot be determined adequately by testing the effect of the mutation in a single viral background, and rigorous analysis of these mutations is required.

  12. Functional analysis of 'a' determinant mutations associated with occult HBV in HIV-positive South Africans.

    Science.gov (United States)

    Powell, Eleanor A; Boyce, Ceejay L; Gededzha, Maemu P; Selabe, Selokela G; Mphahlele, M Jeffrey; Blackard, Jason T

    2016-07-01

    Occult hepatitis B is defined by the presence of hepatitis B virus (HBV) DNA in the absence of hepatitis B surface antigen (HBsAg). Occult HBV is associated with the development of hepatocellular carcinoma, reactivation during immune suppression, and virus transmission. Viral mutations contribute significantly to the occult HBV phenotype. Mutations in the 'a' determinant of HBsAg are of particular interest, as these mutations are associated with immune escape, vaccine escape and diagnostic failure. We examined the effects of selected occult HBV-associated mutations identified in a population of HIV-positive South Africans on HBsAg production in vitro. Mutations were inserted into two different chronic HBV backbones and transfected into a hepatocyte-derived cell line. HBsAg levels were quantified by enzyme-linked immunosorbent assay (ELISA), while the detectability of mutant HBsAg was determined using an HA-tagged HBsAg expression system. Of the seven mutations analysed, four (S132P, C138Y, N146D and C147Y) resulted in decreased HBsAg expression in one viral background but not in the second viral background. One mutation (N146D) led to a decrease in HBsAg detected as compared to HA-tag, indicating that this mutation compromises the ability of the ELISA to detect HBsAg. The contribution of occult-associated mutations to the HBsAg-negative phenotype of occult HBV cannot be determined adequately by testing the effect of the mutation in a single viral background, and rigorous analysis of these mutations is required. PMID:27031988

  13. Sieroprevalenza di infezione da HBV e HCV tra pazienti in dialisi

    Directory of Open Access Journals (Sweden)

    Rosa Anna Leone

    2003-12-01

    Full Text Available The aim of the present study was to investigate the seroprevalence of HBV and HCV among dialysis patients in the Lamezia Terme (CZ area during the period 1999-2002. Sera from 63 patients in haemodialysis (HD and 10 patients in peritoneal dialysis (PD were analyzed with a follow-up every three months for HBsAg, HBcAb, HBsAb, anti-HCV and anti-HIV (Elisa Test,AxSYM,Abbott;we analyzed reactive sera for anti-HCV by using supplemental test (RIBA Test, Ortho; we also looked for viremia (RT-PCR Amplicor, Roche Diagnostics and HCV genotypes (Inno-Lipa HCV II, Innogenetics.The results show that, among the HD patients, 3 were HBsAg positive (Chronic Infection and 7 HBcAb and HBsAb positive/HBsAg negative (Passed Infection; 14 individuals were anti-HCV positive. No patients in PD were positive for HBV and HCV markers.The prevalence of chronic HBV infection was 4.8% (instead of 3% in other Dialysis Units, that of anti-HCV positive was 22% (in others 24%- 33%; among anti-HCV positive patients, the HCV-RNA prevalence was 79% (instead of 80%; the most recurrent HCV genotype was 2a/2c (instead of 1b in general population.These findings lead us to hypothesize that the environmental transmission in the dialysis setting is tightly correlated to the risk of HBV and HCV infection.

  14. MANAGEMENT OF HBV INFECTION DURING IMMUNOSUPPRESIVE TREATMENT

    Directory of Open Access Journals (Sweden)

    Alfredo Marzano

    2009-11-01

    Full Text Available

    The literature on hepatitis B virus (HBV in immunocompromised patients is heterogeneous and refers mainly to the pre-antivirals era. Currently, a rational approach to the problem of hepatitis B in these patients provides for: a the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline, b the treatment with antivirals (therapy of active carriers, c the pre-emptive use of antivirals (prophylaxis in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, d the biochemical and HBsAg monitoring (or universal prophylaxis in case of high risk immunosuppression, as in onco-haematologic patients and bone marrow transplantation in subjects with markers of previous contact with HBV (HBsAg-negative and antiHBc-positive, in order to prevent reverse seroconversion.

    Moreover in solid organ transplants it is suggested a strict adherence to the criteria of allocation based on the virological characteristics of both recipients and donors  and the universal prophylaxis or therapy with nucleos(tides analogs

  15. Leukocyte telomere length-related rs621559 and rs398652 genetic variants influence risk of HBV-related hepatocellular carcinoma.

    Science.gov (United States)

    Pan, Wenting; Cheng, Guangxia; Xing, Huaixin; Shi, Juan; Lu, Chao; Wei, Jinyu; Li, Lichao; Zhou, Changchun; Yuan, Qipeng; Zhou, Liqing; Yang, Ming

    2014-01-01

    Recent genome-wide association studies (GWAS) have identified eleven leukocyte telomere length (LTL)-related single nucleotide polymorphisms (SNPs). Since LTL has been associated with risk of many malignancies, LTL-related SNPs may contribute to cancer susceptibility. To test this hypothesis in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), we genotyped these eleven LTL-related SNPs in a case-control set including 1186 HBV-related HCC cases, 508 chronic HBV carriers and 1308 healthy controls at the discovery stage. The associations of HCC risk with these SNPs were further confirmed in an independent case-control set. We found that 1p34.2 rs621559 and 14q21 rs398652 were significantly associated with HBV-related HCC risk (both PHCC cases and 1954 controls), we observed a decreased HCC risk, 0.72-times, associated with the 1p34.2 rs621559 AA genotype compared to the GG genotype (P = 1.6×10(-6)). Additionally, there was an increased HCC risk, 1.27-fold, associated with the rs398652 GG genotype (P = 3.3×10(-6)). A statistical joint effect between the rs621559 GG and rs398652 GG genotypes may exist in elevating risk of HBV-related HCC. We show, for the first time, that rs398652 and rs621559 might be marker genetic variants for risk of HBV-related HCC in the Chinese population. PMID:25365256

  16. HIV, HBV and HCV Coinfection Prevalence in Iran - A Systematic Review and Meta-Analysis

    Science.gov (United States)

    Bagheri Amiri, Fahimeh; Mostafavi, Ehsan; Mirzazadeh, Ali

    2016-01-01

    Background worldwide, hepatitis C and B virus infections (HCV and HCV), are the two most common coinfections with human immunodeficiency virus (HIV) and has become a major threat to the survival of HIV-infected persons. The review aimed to estimate the prevalence of HIV, HBV, HCV, HIV/HCV and HIV/HBV and triple coinfections in different subpopulations in Iran. Method Following PRISMA guidelines, we conducted a systematic review and meta-analysis of reports on prevalence of HIV, HBV, HCV and HIV coinfections in different subpopulations in Iran. We systematically reviewed the literature to identify eligible studies from January 1996 to March 2012 in English or Persian/Farsi databases. We extracted the prevalence of HIV antibodies (diagnosed by Elisa confirmed with Western Blot test), HCV antibodies and HBsAg (with confirmatory laboratory test) as the main primary outcome. We reported the prevalence of the three infections and coinfections as point and 95% confidence intervals. Findings HIV prevalence varied from %0.00 (95% CI: 0.00–0.003) in the general population to %17.25 (95% CI: 2.94–31.57) in people who inject drugs (PWID). HBV prevalence ranged from % 0.00 (95% CI: 0.00–7.87) in health care workers to % 30.9 (95% CI: 27.88–33.92) in PWID. HCV prevalence ranged from %0.19 (95% CI: 0.00–0.66) in health care workers to %51.46 (95% CI: 34.30–68.62) in PWID. The coinfection of HIV/HBV and also HIV/HCV in the general population and in health care workers was zero, while the most common coinfections were HIV/HCV (10.95%), HIV/HBV (1.88%) and triple infections (1.25%) in PWID. Conclusions We found that PWID are severely and disproportionately affected by HIV and the other two infections, HCV and HBV. Screenings of such coinfections need to be reinforced to prevent new infections and also reduce further transmission in their community and to others. PMID:27031352

  17. Application of CRISPR/Cas9 Technology to HBV

    Directory of Open Access Journals (Sweden)

    Guigao Lin

    2015-11-01

    Full Text Available More than 240 million people around the world are chronically infected with hepatitis B virus (HBV. Nucleos(tide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (cccDNA, which acts as a transcription template for viral mRNA and pre-genomic RNA synthesis and secures virus persistence. Thus, the fact that only a small number of patients treated achieve sustained viral response (SVR or cure, highlights the need for new therapies against HBV. The clustered regularly interspaced short palindromic repeats (CRISPR/Cas9 gene editing system can specifically target the conserved regions of the HBV genome. This results in robust viral suppression and provides a promising tool for eradicating the virus. In this review, we discuss the function and application of the CRISPR/Cas9 system as a novel therapy for HBV.

  18. Study on correlation of hepatitis B maternal serum HBV-DNA with HBV-DNA in milk%乙肝孕产妇血清HBV-DNA与乳汁HBV-DNA相关性的比较

    Institute of Scientific and Technical Information of China (English)

    李国航; 庄桂龙; 瞿志军; 骆欢

    2012-01-01

    目的 探讨乙型病毒性肝炎(乙肝)孕产妇血清HBV-DNA与乳汁HBV-DNA的相关性,以期指导乙肝产妇的喂养方式.方法 选取2008年12月至2009年12月收治的70例血清HBV抗原阳性孕产妇(乙肝组)及20例健康产妇(对照组)为研究对象,采用酶联免疫吸附试验(ELISA)检测血清及乳汁中免疫血清学标志物;采用荧光定量PCR法(FQ-PCR)检测血清及乳汁中HBV-DNA含量情况,并对所检测的指标进行相关性分析.结果 采用ELISA检测到乙肝组产妇大三阳18例,小三阳27例,HBsAg、HBcAb均为阳性的有35例,乳汁HBV-DNA在各组中的检出的阳性率、病毒载量均小于血清HBV-DNA,但两者无显著性差异(P>0.05).乳汁HBV-DNA的含量随血清HBV-DNA含量的升高而增大(P 0.05 ). The level of HBV - DNA in milk was elevated following the increase of serum level of HBV - DNA, P <0.05. Conclusion The choice of feeding mode should be selected according to milk and serum levels of HBV -DNA, and breast feeding can be taking only at the time when HBV - DNA in milk and serum of mother turned to negative level.

  19. Detection of HBsAg, HBcAg, and HBV DNA in ovarian tissues from patients with HBV infection

    Institute of Scientific and Technical Information of China (English)

    Li-Zhang Chen; Xue-Gong Fan; Jian-Ming Gao

    2005-01-01

    AIM: To investigate the presence of HBsAg, HBcAg, and HBV DNA in ovarian tissues from patients with HBV infection.METHODS: HBsAg and HBcAg were examined in ovarian biopsy tissues from 26 patients with HBV infection by immunocytochemistry, and HBV DNA was detected in ovarian tissues by PCR.RESULTS: HBsAg and HBcAg were present with the same positive rate of 34.6% (9/26). The total positive rate was 46.2% (12/26). HBsAg and HBcAg were positive in 6 (23.1%) of the 26 patients. Brown positive particles were diffusely distributed in ovarian cells. The positive rate of HBV DNA was 58.3% (7/12).CONCLUSION: HBsAg, HBcAg, and HBV DNA can be detected in ovarian tissues from patients with HBV infection. The presence of HBsAg and HBcAg in ovarian tissues does not correlate with the HBV markers in serum.

  20. The correlation among HBV DNA load, HBeAg/Anti-HBe and Alanine Aminotransferase in patients with chronic hepatitis B infection%慢性HBV感染者血清HBV DNA载量与HBeAg/抗-HBe、ALT之间的关系

    Institute of Scientific and Technical Information of China (English)

    徐军; 王芳; 杨帆

    2010-01-01

    目的 探讨慢性HBV感染者血清HBV DNA载量与HBeAg/抗-Hbe以及丙氨酸转氨酶(ALT)水平之间的关系.方法 采用酶联免疫吸附法(ELISA)检测134例慢性HBV感染者HBV血清标志物,根据HBeAg/抗-Hbe检测结果将患者分为Ⅰ组(HBeAg+/抗-Hbe-,43例);Ⅱ组(HBeAg-/抗-Hbe+,69例);Ⅲ组(HBeAg-/抗-Hbe-,22例).同时应用实时荧光定量PCR方法以及连续监测法检HBV DNA载量以及ALT水平.结果 Ⅰ组HBV DNA阳性率和HBV DNA载量明显高于Ⅱ、Ⅲ组(P<0.01).HBV DNA阳性患者ALT异常率高于HBV DNA阴性患者(P<0.01).HBV DNA阳性患者HBV DNA载量与ALT水平之间无相关性(r=0.174,P=0.156).结论 血清HBV DNA载量与HBeAg/抗-Hbe以及ALT之间存在一定的关系,但不能单纯依靠HBeAg/抗-Hbe以及ALT来判断HBV在体内的复制情况,三项指标联合检测对HBV慢性感染者的病情检测、治疗具有重要意义.%Objective To explore the relationship among HBV DNA load, HBeAg/Anti-HBe and ALT in patients with chronic hepatitis B infection. Methods HBV markers in 134 patients with chronic HBV infection were detected by ELISA,and patients were divided into group Ⅰ (HBeAg +/Anti-HBe-,43 patients) ,group Ⅱ (HBeAg-/Anti-HBe + ,69 patients)and group Ⅲ (HBeAg-/Anti-Hbe-,22 patients)according to the results of presence of HBeAg/Anti-HBe. HBV DNA load and ALT were tested respectively by fluorescence quantitative polymerase chain reaction technology and successive monitor reaction. Results Both the positive rate and the HBV DNA load quantification in group Ⅰ were higher than in group Ⅱ and Ⅲ (P<0.01). Abnormality rate of ALT in HBV DNA positive patients was higher than the patients with HBV DNA negitive(P<0.01). There was no relationship between HBV DNA load and ALT in HBV DNA positive patients. Conclusion There was a certain corelation among HBV DNA load, HBeAg/Anti-HBe and ALT,but the active degree of HBV replication could not to be assessed by HBeAg/Anti-HBe or ALT alone

  1. The Early Results of a New Health Care Program Implementation in HBV Screening: an Iranian Experience

    Science.gov (United States)

    Sharifian, Afsaneh; Naderi, Nostratollah; Sanati, Azar; Mohebi, Seyed Reza; Azimzadeh, Pedram; Golmohamadi, Ali; Nori, Simin; Khanyaghma, Mahsa; Sheikhesmaeili, Farshad; Zali, Mohamad Reza

    2015-01-01

    BACKGROUND According to the reports of World Health Organization (WHO) and Centers for Disease Control and Prevention, the prevalence of chronic hepatitis B infection in Iran has decreased from 2-7% in 2001 to 1.3-0.8% in children aged 2-14 years. In 2010 the Institute of Medicine recommended more comprehensive screening by primary care physicians (PCPs) for evaluation, vaccination, and management of infected patients for further decrease in the prevalence of chronic HBV infection. Thus, with contribution of the Health Department, we developed a practical flowchart for PCPs to start active screening of hepatitis B virus (HBV) in all visited patients and refer the positive cases for further evaluation and management to Taleghani Hospital. METHODS With collaboration of Health Department of Shahid Beheshti University of Medical Sciences), physicians of health centers were asked to screen all their patients for HBsAg. Positive cases were referred to Taleghani Hospital. They were first registered and educated about their disease, life style, and prevention methods. Their first degree families were screened for HBV infection too and were referred for vaccination if needed. According to the results of lab tests, appropriate management was done by a hepatologist. RESULTS Since implementation of this program, we have encountered a significant rise in patient detection (even in high risk groups). Many of them were not aware of their disease and most of those who were aware of their disease were not managed appropriately. Family screening and vaccination were inadequate and need more emphasis. CONCLUSION Although health system is active about screening of HBV infection in high risk populations, it is not perfect. It seems that health system needs to upgrade the screening and management programs of HBV infection. PMID:26609351

  2. The Early Results of a New Health Care Program Implementation in HBV Screening: an Iranian Experience.

    Science.gov (United States)

    Sharifian, Afsaneh; Naderi, Nostratollah; Sanati, Azar; Mohebi, Seyed Reza; Azimzadeh, Pedram; Golmohamadi, Ali; Nori, Simin; Khanyaghma, Mahsa; Sheikhesmaeili, Farshad; Zali, Mohamad Reza

    2015-10-01

    BACKGROUND According to the reports of World Health Organization (WHO) and Centers for Disease Control and Prevention, the prevalence of chronic hepatitis B infection in Iran has decreased from 2-7% in 2001 to 1.3-0.8% in children aged 2-14 years. In 2010 the Institute of Medicine recommended more comprehensive screening by primary care physicians (PCPs) for evaluation, vaccination, and management of infected patients for further decrease in the prevalence of chronic HBV infection. Thus, with contribution of the Health Department, we developed a practical flowchart for PCPs to start active screening of hepatitis B virus (HBV) in all visited patients and refer the positive cases for further evaluation and management to Taleghani Hospital. METHODS With collaboration of Health Department of Shahid Beheshti University of Medical Sciences), physicians of health centers were asked to screen all their patients for HBsAg. Positive cases were referred to Taleghani Hospital. They were first registered and educated about their disease, life style, and prevention methods. Their first degree families were screened for HBV infection too and were referred for vaccination if needed. According to the results of lab tests, appropriate management was done by a hepatologist. RESULTS Since implementation of this program, we have encountered a significant rise in patient detection (even in high risk groups). Many of them were not aware of their disease and most of those who were aware of their disease were not managed appropriately. Family screening and vaccination were inadequate and need more emphasis. CONCLUSION Although health system is active about screening of HBV infection in high risk populations, it is not perfect. It seems that health system needs to upgrade the screening and management programs of HBV infection.

  3. [Risk Management of HBV Reactivation: Construction of Check System].

    Science.gov (United States)

    Tanaka, Yasuhito

    2015-09-01

    In recent years, reactivation of HBV in patients receiving cancer chemotherapy or immunosuppressive therapy has been a problem. Generally, HBV-DNA levels are elevated prior to HBsAg concentration, and then hepatic dysfunction is observed in the process of hepatitis by HBV reactivation. Therefore, the monitoring of HBV-DNA is useful for the prediction of hepatic dysfunction, and nucleoside/nucleoside analogue (NA) administration is able to prevent this HBV reactivation. According to these facts, "Guidelines for the Prevention of HBV Reactivation in Patients Receiving Immunosuppressive Therapy or Chemotherapy", 2009 (revised as "JSH Guidelines for the Management of Hepatitis B Virus Infection", 2013) is established, and the diagnostic algorithm of HBsAg, anti-HBc, anti-HBs, and HBV-DNA has relevant descriptions. Combination therapy with rituximab and steroid for malignant lymphoma has a high risk of leading to fulminant hepatitis and, consequently, the guidelines are widely followed in such cases. We introduced the improvement of electronic medical recording and ordering systems in collaboration with hepatologists, and such a system has been widely used. Although the monitoring of HBV-DNA levels is required every 1-3 months, the guidelines are not followed strictly in cases such as rheumatoid disease and solid tumors only with chemotherapy or steroid treatment. Since a DNA assay is complicated and expensive, cost-effective, time-saving, and highly sensitive/specific measurements are required as well. Therefore, Lumipulse HBsAg-HQ (CLIA method) with high sensitivity is expected to be used for the monitoring of HBV reactivation.

  4. The detection of HBV DNA with gold nanoparticle gene probes

    Institute of Scientific and Technical Information of China (English)

    Dong Xi; Xiaoping Luo; Qin Ning; Qianghua Lu; Kailun Yao; Zuli Liu

    2007-01-01

    Objective:Gold nanoparticle Hepatitis B virus (HBV) DNA probes were prepared, and their application for HBV DNA measurement was studied. Methods:Alkanethiol modified oligonucleotide was bound with self-made Au nanoparticles to form nanoparticle HBV DNA gene probes, through covalent binding of Au-S. By using a fluorescence-based method, the number of thiol-derivatized, single-stranded oligonucleotides and their hybridization efficiency with complementary oligonucleotides in solution was determined. With the aid of Au nanoparticle-supported mercapto-modified oligonucleotides serving as detection probes, and oligonucleotides immobilized on a nylon membrane surface acting as capturing probes,HBV DNA was detected visually by sandwich hybridization based on highly sensitive aggregation and silver staining. The modified nanoparticle HBV DNA gene probes were also used to detect the HBV DNA extracted from serum in patients with hepatitis B. Results:Compared with bare Au nanoparticles, oligonucleotide modified nanoparticles had a higher stability in NaCl solution or under high temperature environment and the absorbance peak of modified Au nanoparticles shifted from 520nm to 524nm. For Au nanoparticles, the maximal oligonucleotide surface coverage of hexaethiol 30-mer oligonucleotide was (132 ± 10) oligonucleotides per nanoparticle, and the percentage of hybridization strands on nanoparticles was (22 ± 3% ). Based on a two-probe sandwich hybridization/nanoparticle amplification/silver staining enhancement method, Au nanoparticle gene probes could detect as low as 10-11 mol/L composite HBV DNA molecules on a nylon membrane and the PCR products of HBV DNA visually. As made evident by transmission electron microscopy, the nanoparticles assembled into large network aggregates when nanoparticle HBV DNA gene probes were applied to detect HBV DNA molecules in liquid. Conclusion:Our results showed that successfully prepared Au nanoparticle HBV DNA gene probes could be used to

  5. Seroprevalences of HBV, HCV and HIV among healthcare workers in a state hospital

    OpenAIRE

    Tekin, Alicem; Deveci, Özcan

    2010-01-01

    Objectives: In present study was aimed to investigate the seroprevalences of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) among healthcare workers in Mardin Obstetric and Children Hospital between 2008 and 2009. Methods: In sera samples obtained from 180 healthcare workers, hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), HCV antibody (anti-HCV) and HIV antibody (anti-HIV) markers were tested by chemiluminescent immun...

  6. Seroprevalences of HBV, HCV and HIV among healthcare workers in a state hospital

    OpenAIRE

    Özcan Deveci; Alicem Tekin

    2010-01-01

    Objectives: In present study was aimed to investigate the seroprevalences of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) among healthcare workers in Mardin Obstetric and Children Hospital between 2008 and 2009.Methods: In sera samples obtained from 180 healthcare workers, hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), HCV antibody (anti-HCV) and HIV antibody (anti-HIV) markers were tested by chemiluminescent immunoassa...

  7. Construction and Immunological Evaluation of Multivalent Hepatitis B Virus (HBV) Core Virus-Like Particles Carrying HBV and HCV Epitopes▿

    OpenAIRE

    Sominskaya, Irina; Skrastina, Dace; Dislers, Andris; Vasiljev, Denis; Mihailova, Marija; Ose, Velta; Dreilina, Dzidra; Pumpens, Paul

    2010-01-01

    A multivalent vaccine candidate against hepatitis B virus (HBV) and hepatitis C virus (HCV) infections was constructed on the basis of HBV core (HBc) virus-like particles (VLPs) as carriers. Chimeric VLPs that carried a virus-neutralizing HBV pre-S1 epitope corresponding to amino acids (aa) 20 to 47 in the major immunodominant region (MIR) and a highly conserved N-terminal HCV core epitope corresponding to aa 1 to 60 at the C terminus of the truncated HBcΔ protein (N-terminal aa 1 to 144 of f...

  8. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma

    DEFF Research Database (Denmark)

    Sung, Wing-Kin; Zheng, Hancheng; Li, Shuyu;

    2012-01-01

    To survey hepatitis B virus (HBV) integration in liver cancer genomes, we conducted massively parallel sequencing of 81 HBV-positive and 7 HBV-negative hepatocellular carcinomas (HCCs) and adjacent normal tissues. We found that HBV integration is observed more frequently in the tumors (86.4%) than...

  9. Clinical Observation of Pregnant Woman Quantitative HBV-DNA and Mother to Infant Vertical Transmission%孕妇HBV-DNA定量与母婴垂直传播的临床观察

    Institute of Scientific and Technical Information of China (English)

    高卓; 俞洋

    2015-01-01

    目的:探讨HBV-DNA定量与孕妇母婴阻断后的HBV宫内感染的临床观察。方法:将286例HBsAg阳性孕妇分为研究组143例,其中乙肝大三阳46例,乙肝小三阳45例,HBsAg阳性者52例,HBV-DNA定量均高于正常值或几倍不等;对照组143例,其中乙肝大三阳47例,乙肝小三阳50例,HBsAg阳性者46例,HBV-DNA定量均在正常范围内。两组均于孕28、32、36周分别肌注HBIG 200 IU,采用酶联免疫吸附试验检测两组新生儿的五项指标。结果:研究组、对照组新生儿脐血检测结果HBsAg阳性率分别为34.2%、11.2%,两组比较差异有统计学意义(P0.05)。结论:HBV-DNA含量均在正常范围内,HBIG能够有效阻断HBsAg阳性和乙肝小三阳的母婴传播,但不能阻断乙肝大三阳和HBV-DNA定量异常的乙肝小三阳和HBsAg阳性患者的母婴传播。%Objective:To investigate the clinical observation on HBV intrauterine infection of maternal and child block after the implementation of quantitative HBV-DNA with pregnant women.Method:In this paper,286 cases of HBsAg positive pregnant women were divided into the study group(n=143), 46 cases of HBsAg,HBeAg,and HBcAb test positive,45 cases of hepatitis B small Sanyang,52 cases of HBsAg positive,quantitative HBV-DNA was higher than the normal value ora few times ranging from.The control group(n=143),47 cases of HBsAg,HBeAg,and HBcAb test positive,50 cases of hepatitis B small Sanyang,46 cases of HBsAg positive,quantitative HBV-DNA were within the normal range.Among them,the study group and the control group were injected with 200 IU of hepatitis B immunoglobulin for 1 injection at 28th,32th,and 36th weeks of pregnancy respectively.The samples of cord blood from the newborns were collected and tested for HBsAg,HBsAb,HBeAg,HBeAb and HBcAb by ElISA and FQ-PCR.Result:The study group and the control group positive rates of detection results of neonatal cord blood HBsAg were 34.2%,11.2%,there was

  10. HBV Vaccination in Chronic Renal Failure Patients

    Directory of Open Access Journals (Sweden)

    Mir-davood Omrani

    2006-12-01

    Full Text Available HBV infection in chronic renal failure (CRF becomes chronic in 30 to 60% compared with less than 10% in nonuremic patients. Immunological dysfunction in patients on hemodialysis may be related to imbalanced cytokine systems, such as tumor necrosis factor (TNF-|α| and interleukin (IL 6,1 by retention of renal metabolite in uremia and chronic inflammation and have a poor immunological reaction to T-cell-dependent antigens, like hepatitis B vaccination. Immunocompromised patients who are unresponsive to hepatitis B vaccination seem to be unable to enhance IL-10 synthesis for control of monokine overproduction. Moreover, human leukocyte antigen (HLA genes, which play a major role in the antigen presentation to immunocompetent cells, have also been shown to modulate this immune response. Unfortunately, seroconversion to anti-HBS has been reported to occur in only 40 to 50% of the vaccine, a significantly lower rate than that observed in healthy adults. Various methods including adjutants such as zinc, gamma interferon, thymopentine, GM-CSF and Levamisol for improving immune responses have been advised. Experience with Pres1/s2, third-generation vaccines is limited and they have not been proven more effective than intradermally (ID administered second-generation S antigen vaccines. Both intramuscular (IM and intradermal (ID vaccinations against hepatitis B have variable efficiency in hemodialysis and non-responders should be retreated by ID route.

  11. TLR3 Plays Significant Roles against HBV-Associated HCC

    Directory of Open Access Journals (Sweden)

    Xiao-lan Chen

    2015-01-01

    Full Text Available Toll-like receptor 3 (TLR3 is a pattern-recognizing receptor that is involved in immune signaling and plays a crucial role in survival by being able to recognize various viral components including double-stranded RNA (dsRNA. The role of TLR3 in hepatocellular carcinoma (HCC with hepatitis B virus (HBV infections is not well understood. To investigate the ability of TLR3 in regulating HBV replication in HCC, 80 cases of human HCC were collected and their tissue microarray was made. In HCC cells, the expression and location of TLR3, hepatitis-associated virus, and interstitial immunoreactive cells were assayed with immunohistochemical staining. The apoptosis of tumor cells was also detected by TUNEL stain. Correlations between TLR3 expression and HBV infection, interstitial immunoreactive cells, and cells apoptosis in HCC were investigated. In addition, we explored whether TLR3 agonist dsRNA can inhibit HepG2.2.15 cells secreting HBV. We found that the cytoplasmic expression of TLR3 in HCC is positively related to HBsAg infection and HCC with cirrhosis and promotes interstitial immunoreactive cells infiltration and cancer cells apoptosis. In HepG2.2.15 cells, dsRNA inhibited the secretion of HBV and induced apoptosis. These results indicate that TLR3 signaling activity may be involved in immune responses against HBV in HCC.

  12. Mutation analyses of integrated HBV genome in hepatitis B patients

    Institute of Scientific and Technical Information of China (English)

    Peilin Wang; Xiuhai Wang; Shuying Cong; Hongming Ma; Xuecheng Zhang

    2008-01-01

    Little has been learnt in the last 30 years about detection of HBV genome as well as its mutation analysis between hepatitis B fathers (HBF) and their children. In this study, we used nest polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), and DNA sequencing analysis, to examine the integrated HBV genome in paraffin-embedded testis tissues, which were taken as samples from HBF, and in peripheral blood mononuclear cells (PBMC) from 74 cases of HBFs and their children who were born after their fathers' HBV infection (caHBF). We found that HBV DNA existed in testis tissues, mainly in the basilar parts of the seminiferous tubules, and also in PBMC of HBF. It was also documented that there were point mutations of poly-loci, insertions and deletions of nucleotides in integrated HBV genomes, and the types of gene mutations in the HBFs were similar to those in caHBF. This study addresses the major types of gene mutations in integrated HBV genome in human patients and also presents reliable evidence of possible genetic transmission of hepatitis B.

  13. Design and choice of TFO binding and cleaving HBV core promoter

    Institute of Scientific and Technical Information of China (English)

    光丽霞; 袁发焕; 任平; 奚敏; 艾友平

    2003-01-01

    Objective: To screen a triple helix-forming oligodeoxyribonucleotide (TFO) that can bind HBV core promoter at target site with high affinity and specificity, and to observe the ability of manganese porphyrin modified TFO to combine and cleave HBV DNA.Methods: Similar homopurine domain (1 734-1 754) in HBV core promoter was selected as target sequence.Several corresponding TFOs were synthesized.The affinities and specificities of TFOs binding target sequence were tested with electrophoretic mobility shift and DNase Ⅰ footprinting assays.The selected best TFO was modified with manganese porphyrin and acridine.The ability of the TFO derivative to cleave HBV DNA was observed with cleavage experiment.Results: Under the condition of 37℃ and pH 7.4, the TFO consisting of cytidylate and thymidylate (CT-TFO) and the parallel TFO consisting of guanylate and thymidylate (GT-TFOp) bound the target sequence weakly with Kd values much more than 10-6 mol/L.The affinities of anti-parallel GT-TFO (GT-TFOap) and short TFO consisting of adenine nucleotide and guanylate (AG-TFOsh) binding the target sequence were higher than those of the formers, with Kd values of 5×10-7 mol/L and 2.5×10-8 mol/L respectively.Long AG-TFO (AG-TFOl) had the highest binding affinity with a Kd value of 3×10-9 mol/L among all the TFOs studied for sequence specificity.In the presence of potassium monopersulfate, KHSO5, TFO modified with manganese porphyrin and acridine cleaved the target sequence where the triplex DNA formed.Conclusion: TFO containing AG or GT binds homopurine in HBV core promoter in adverse parallel direction to form triple helix.AG-TFOl has the highest binding affinity among all the TFOs studied.After modified with manganese porphyrin, AG-TFOl completely binds and cleaves the target HBV DNA sequence where triplex DNA is formed.

  14. Development and Implementation of Autoverification Rules for ELISA Results of HBV Serological Markers.

    Science.gov (United States)

    Li, Jiancheng; Cheng, Bizhen; Yang, Li; Zhao, Ying; Pan, Meichen; Zheng, Gaozhe; Xu, Xiaoyan; Hu, Jing; Xiao, Tongtong; Cai, Yingmu

    2016-10-01

    Autoverification is a process of using computer-based rules to verify clinical laboratory test results without manual review. But to date, there are few published articles on the use of autoverification over the course of years in a clinical laboratory. In our study, we firstly described the development and implementation of autoverification rules for enzyme-linked immunosorbent assay (ELISA) results of hepatitis B virus (HBV) serological markers in a clinical immunology laboratory. We designed the autoverification rules for HBV by using Boolean logic on five clinically used serological markers in accordance with the framework of AUTO-10A, issued by the American Clinical Laboratory Standards Institute in 2006. The rules were written into the laboratory information system (LIS) and installed in the computer, so we could use the LIS to screen the test results. If the results passed the autoverification rules, they could be sent to doctors immediately. To evaluate the autoverification rules, we applied the real-time data of 11,585 patients with the autoverification rules. The autoverification rate of the five HBV serological markers was 79.5%. Furthermore, the turnaround time (TAT) was reduced by 38% (78 minutes vs. 126 minutes). The error rate was nearly eliminated. These results show that using LIS with autoverification rules can shorten TAT, enhance efficiency, and reduce manual review errors.

  15. Prevalence of HBV and HBV vaccination coverage in health care workers of tertiary hospitals of Peshawar, Pakistan

    OpenAIRE

    Ali Ijaz; Khan Shahid; Ayaz Sultan; Naseemullah,; Khan Sanaullah; Attaullah Sobia; Hoti Naseruddin; Siraj Sami

    2011-01-01

    Abstract Background Hepatitis B Virus (HBV) may progress to serious consequences and increase dramatically beyond endemic dimensions that transmits to or from health care workers (HCWs) during routine investigation in their work places. Basic aim of this study was to canvass the safety of HCWs and determine the prevalence of HBV and its possible association with occupational and non-occupational risk factors. Hepatitis B vaccination coverage level and main barriers to vaccination were also ta...

  16. Evaluation of the Procleix Ultrio Plus ID NAT assay for detection of HIV 1, HBV and HCV in blood donors

    Directory of Open Access Journals (Sweden)

    Raj Nath Makroo

    2015-01-01

    Full Text Available Introduction: The Procleix Ultrio Plusassay is a new-generation qualitative in vitro nucleic acid amplification test used to screen for human immunodeficiency virus type 1 (HIV-1 RNA, hepatitis C virus (HCV RNA and hepatitis B virus (HBV DNA in blood donors. This study was performed to compare the Procleix Ultrio assay with the new-generation Procleix Ultrio Plus Nucleic Acid Test (NAT assays. Materials and Methods: Ten thousand three hundred and two donor samples were run in parallel for ID NAT using the Procleix Ultrio and the Procleix Ultrio Plus assay. Simultaneously, enzyme-linked immunosorbent assay testing was performed on an EVOLIS Walk away System for HIV, HCV, HBsAg and anti-HBc. Reactive samples were confirmed using polymerase chain reaction. Results: In the 10,302 samples tested during the study period, we identified 15 NAT yields, and all these revealed HBV DNA in the discriminatory assays. Eight of these were exclusive yields from the Ultrio Plus assay and the remaining seven cases were determined as HBV NAT yield, both by the Procleix Ultrio as well as the Ultrio Plus assays, i.e. "Combined" yields. No HCV or HIV 1 yields were detected during the study period by either of two assays. Conclusion: With an overall yield rate of 1 in 687 and an exclusive yield rate of 1 in 1287, the Procleix Ultrio Plus assay proved to be highly sensitive in detecting occult HBV infections.

  17. 腹水细胞HBV DNA荧光PCR检测方法的建立及意义研究%Studying and the significance of the HBV DNA from ascite cells with time fluoresceence quantitative PCR

    Institute of Scientific and Technical Information of China (English)

    李妍; 马洪滨; 朱剑功; 王海滨; 洪炜; 庞君丽; 王大刚; 杨宁; 李永利; 刘立明; 王雪飞; 陈厦

    2011-01-01

    Objective:The Cyto- megalovirus CMV Lysis Solution , which can extraction the HBV DNA from ascite cells, has been used in detecting HBV DNA with time fluoresceence quantitative PCR , and then we can study the change and the clinical significance. Methods: 10 ml ascite from cirrhosis patients originating hepatitis B infection centrifuged immediately by 1500 g for 5 minutes. The liquid supernatant was discarded thoroughly. The HBV DNA in ascite cells from the bottom of tube is detected with real time PCR technology. Results:The detected numerical attain abilities was 102 IU/ml, which using fluorescence PCR technology testing ascite cell HBV DNA it showed theoretical gradient according to the terms of diluted times. and then the Correlation coefficient is 0.91, making it clear that the method has a good sensitivity. By making repeated study we find that the 5 repeated times leafs CV is 14.4% ,9.8% and 11.2%, and the declination meet the NCCL Requirements. There is about 0.5 to 1. 5 LOG of HBV DNA in different ascite cells from patients with cirrhosis,which explaining ascite cells not only contains a lot of HBV, but also has much individual differences apparently. The HBV DNA in three times of dynamic detecting in one case of hepatocellular carcinoma is gradually decreased both in ascite and ascite cells along with the deterioration of disease. Conclusion:Our real - time PCR system of HBV DNA detection from ascite cells by the Cyto - megalo virus CMV Lysis Solution , can provide an accurate and highly sensitive rapid method to quantify Hepatitis B virus with low artificial positive and lower negative artificial results. It is suitable for studying the significance of HBV DNA from ascite cells in clinic.%目的:采用细胞病毒裂解液快速提取腹水细胞内的HBV DNA,建立实时荧光定量PCR检测HBV DNA的技术,并初步研究其临床意义.方法:采用乙肝肝硬化患者腹水10 ml,1500 g/min离心5 min,全部吸出上清,对沉渣细胞进

  18. Chemoprevention of HBV-related hepatocellular carcinoma by the combined product of resveratrol and silymarin in transgenic mice

    Directory of Open Access Journals (Sweden)

    Wen-Chuan Hsieh

    2013-09-01

    Full Text Available ABSTRACTBackground: Patients with chronic hepatitis B virus (HBV infection are at a high risk to develop hepatocellular carcinoma (HCC. Recently, metabolic syndrome has been found to carry a risk for HCC development. Considering the limitation of chemotherapeutic drugs for HCCs, the development of chemopreventive agents for high risk chronic HBV carriers is urgently demanded. In this study, we used combined silymarin and resveratrol extract which have been shown to exhibit biologic effects on activating peroxisome proliferator activated receptors (PPAR and inhibiting mTOR signaling in a transgenic mice model harboring HBV viral oncoproteins.Methods: The transgenic mice model harboring HBx and pre-S2 mutant constructs which develop HCC was adopted. First, we in vitro tested the ideal combination dosages of the silymarin and resveratrol product, and then we fed the natural product to the transgenic mice.The chemopreventive effects on preventing the development of HCC were evaluated.Results: MTT assay showed an enhanced effect of the combined silymarin and resveratrol product on the reduction of cell proliferation in two hepatoma cell lines, Huh-7 and Hep G2. In vitro reporter assay and Western blot analyses revealed that the combined product couldactivate PPAR/PGC-1 signaling and inhibit mTOR expression. In vivo, the combined products could significantly ameliorate fatty liver and reduce HCCs in transgenic miceharboring HBV oncoproteins.Conclusions: The combined silymarin and resveratrol product exhibits a synergistic effect on the reduction of HCC development in transgenic mice model and may represent a potential agent for the prevention of HCC in high risk chronic HBV carriers.Key words: HBV, HCC, Transgenic mice, Chemoprevention

  19. Anti-HBV activity of TRL mediated by recombinant adenovirus

    Institute of Scientific and Technical Information of China (English)

    Wei-Dong Gong; Ya Zhao; Jun Yi; Jin Ding; Jun Liu; Cai-Fang Xue

    2005-01-01

    AIM: To investigate the inhibitive effect of hepatitis B virus (HBV)-TRL on HBV replication. METHODS: Based on previously constructed pcDNA3.1 (-)/TRL, TR, TRmut, HBV core protein (HBVc) and hEDN, interest gene sequences TRL, TR, HBVc and hEDN were inserted into adenovirus shuttle plasmid pDC316 respectively and co-transfected HEK293 cells with rescue plasmid pBHGlox(delta)E1,3Cre to acquire RAd/TRL, TR, HBVcand hEDN. And then RAds were identified, amplified and the titers in HEK293 cells were determined. RAd/TRL and TR were named as the experimental groups, and others were control ones. After HepG2.2.15 cells were infected, RAd/TRL expression was identified by indirect immunofluorescence staining. Supernatant HBV-DNA content was determined by fluorescent quantification PCR. Meanwhile, metabolism of HepG2.2.15 cells was evaluated by MTT colorimetry.RESULTS: RAd vectors with distinct interest gene sequence were successfully constructed. Effective expression of RAd/TRL in HepG2.2.15 cells resulted in a significant decrease of supernatant HBV-DNA content compared to RAd/TR (0.63±0.14 vs 1.60±0.47, P = 0.0266, <0.05) andother control groups (0.63±0.14 vs 8.50±2.78, 8.25±2.26,8.25±2.29, 8.50±1.51, 8.57±1.63, P<0.01). MTT assaysuggested that there were no significant differences in cell metabolic activity between groups (P>0.05).CONCLUSION: The construction and expression of RAd/TRL has been achieved and it could inhibit HBV replication successfully, which has laid the foundation for further research on anti-HBV activity in vivo.

  20. 分析乙肝血清学检验中的三种不常见现象%Analysis of HBV Serological Test Three of the Unusual Phenomenon

    Institute of Scientific and Technical Information of China (English)

    杜琼; 涂云贵

    2015-01-01

    Objective Hepatitis B serology three of the unusual phenomenon. Explore the use of different reagents whether it will affect the test results. Methods Randomly selected in January 2012 to January 2015, January serological examination hospital 200 cases of hepatitis B patients as research subjects. All patients taking 3ml venous blood as the test sample, the same samples were taken to two different ELISA reagents for clinical testing. Analysis of the test results and, and statistical probability of the occur-rence is not common. Results A set of test results showed that a total of 10 patients had three hepatitis B serological testing is not a common phenomenon, Group B test results showed that nine patients had three hepatitis B serological testing is not a common phenomenon. Using statistical software comparison of the two test results showed no significant difference in contrast showed no statistically significant (P>0.05) between the two groups. In which a total of 10 patients had unusual phenomenon, 5.0%of the total number of cases. Conclusion Different reagents will not have hepatitis B serology unusual phenomenon affecting, for hepatitis B serology is not a common phenomenon, should be combined with clinical symptoms and other clinical indicators detect a compre-hensive analysis and review, rule out the possibility everything for interference, for in order to increase the accuracy and reliability of test results.%目的 分析研究乙肝血清学检验中的三种不常见现象. 探究使用试剂的不同是否会对检测结果造成影响. 方法 随机选取2012年1月-2015年1月于该院进行血清学检验的200例乙肝患者作为研究对象. 所有患者取3 mL静脉血作为检验样本,同一样本分别采取两种不同的ELISA试剂进行临床检验. 分析检测结果,并统计不常见现象的发生几率. 结果 A组检测结果显示共有10例患者出现三种乙肝血清检测不常见现象,B组检测结果显示共有9例患者

  1. Analysis of clinical characters of HBV related HCC%HBV相关性HCC的临床特征分析

    Institute of Scientific and Technical Information of China (English)

    张雅芳; 曾庆磊; 徐光华; 李春霞; 古巧燕

    2011-01-01

    Objective To analyze clinical characters of HBV related HCC. Methods 50 patients with HBV related HCC were recruited. The serological indexes including quantity of HBV M, HBV DNA, AFP, HA and ALT were measured. The imaging tests including B ultrasound, CT and MRI were measured. Results The male patients were 88%. The average age was 40-60 year old. 72% cases with the hepatitis B infection most likely acquired at birth or in early childhood. AFP of 74% patients was more than the upper limited normal. 92% of the tumor were in the right lobe of liver. HBsAg, HBeAb and HBcAb positive mode (80%) was the most common mode in HBV related HCC. Statistical analysis showed that HBeAb was positive correlation with HBV DNA ( r= 0. 374, P=0. 018 ). Conclusion The tumor were more likely occurred in male cases who were 40-60 year-old, and always with the hepatitis B infection most likely acquired at birth or in early childhood, not all the cases with high AFP, the mode of HBsAg, HBeAb, HBcAb positive cases always with HBV DNA replication.%目的 探讨HBV相关性HCC的临床特征.方法 收集HBV相关性HCC患者50例资料,检测患者血清HBV M定量、HBV DNA定量、肝纤维化指标、AFP、肝功能指标.用彩色超声、64层螺旋CT、1.5T核磁共振检查患者肝脏影像学情况.用相应的统计学方法对上述指标进行分析.结果 HBV相关性HCC好发于40~60岁男性,72%的患者有乙肝家族史,74%的患者AFP升高,92%的患者肿块发生在肝右叶.HBsAg、HBeAb、HBcAb大于ULN是HBV相关性HCC主要的HBV M模式(80%),这种模式的患者多伴HBV DNA复制(χ2=38.093,P<0.001),且HBeAb定量与HBV DNA定量呈正相关(r=0.374,P=0.018).结论 HBV相关性HCC多发于40~60岁男性,多伴乙肝家族史,且并非所有患者都伴AFP升高,在监测中要高度重视HBsAg、HBeAb、HBcAb大于ULN且有HBVDNA复制的患者,特别注意肝右叶的表现,必要时可缩短其监测周期.

  2. Relationship between serum HBV DNA level and follicular helper T lymphocyte in patients with chronic hepatitis B and its significance%慢性乙型肝炎患者血清HBV DNA水平与滤泡辅助性T淋巴细胞的关系和意义

    Institute of Scientific and Technical Information of China (English)

    王娟华; 顾锡炳; 朱银芳; 华忠; 王栋; 杨小娟; 徐月琴; 陆忠华

    2013-01-01

    目的 探讨慢性乙型肝炎(CHB)患者HBV DNA水平与外周血滤泡辅助性T淋巴细胞(Tfh)的关系和意义.方法 179例HBV DNA阳性、HBeAg阳性、人白细胞抗原(HLA)-A2阳性的CHB患者,用实时荧光定量PCR检测HBV DNA,流式细胞术检测Tfh、HBV特异性CTL,并作IL-21的检测.将179例CHB患者根据HBV DNA水平分为甲、乙两组,甲组86例,HBV DNA水平为104 ~105拷贝/ml,乙组93例,HBV DNA水平为106 ~ 107拷贝/ml,对两组患者进行以上检测指标的比较.结果 甲组HBV DNA水平为(4.85±0.37) log10拷贝/ml,乙组HBV DNA水平为(6.83±0.31) log10拷贝/ml,t=27.31,P<0.001,甲组Tfh(5.96±1.59)%,高于乙组(3.71±2.15)%,t=4.92,P<0.01,IL-21(42.61 ±15.11)ng/L,高于乙组(14.91 ±3.15) ng/L,t=8.62,P<0.01,HBV特异性CTL(0.36±0.08)%,高于乙组(0.18±0.06)%,=19.99,P<0.001.结论 CHB患者血清HBVDNA水平与外周血Tfh水平有关:HBV DNA水平低者,Tfh水平高,IL-21水平和HBV特异性CTL水平也高.HBV DNA水平高者,Tfh水平低,IL-21水平和HBV特异性CTL水平也低.基线HBV DNA水平影响抗病毒疗效的机制可能与Tfh水平有关.%Objective To explore relationship between HBV DNA level and peripheral blood follicular helper T lymphocyte (Tfh) in patients with chronic hepatitis B (CHB) and its significance.Methods HBV DNA levels of 179 cases of CHB patients with positive HBV DNA,positive HBeAg and positive human leukocyte antigen (HLA)-A2 were tested with real time fluorescent quantitative PCR.Tfh and HBV specific CTL were tested with flow cytometry.IL-21 was also tested.179 cases of CHB patients were divided into group A and group B based on HBV DNA levels,86 cases in group A,HBV DNA levels were 104-105copies/ml,93 cases in group B,HBV DNA levels were 106-107 copies/ml.Above testing indexes of the two groups were compared.Results HBV DNA levels of group A were (4.85 ± 0.37) log10 copies/ml,HBV DNA levels of group B were(6.83 ±0.31) log10copies/ml,t =27.31,P <0

  3. Seroprevalence of HBV, HCV & HIV co-infection and risk factors analysis in Tripoli-Libya.

    Directory of Open Access Journals (Sweden)

    Mohamed A Daw

    Full Text Available BACKGROUND: In 1998 Libya experienced a major outbreak of multiple blood borne viral hepatitis and HIV infections. Since then, no studies have been done on the epidemic features and risk factors of HBV, HCV, HIV and co-infection among the general population. METHODS: A prospective study was carried out using a multi-centre clustering method to collect samples from the general population. The participants were interviewed, and relevant information was collected, including socio-demographic, ethnic, and geographic variables. This information was correlated with the risk factors involved in the transmission of HBV, HCV and HIV. Blood samples were collected and the sera were tested for HBsAg, anti-HCV and anti-HIV using enzyme immunoassay. RESULTS: A total of 9,170 participants from the nine districts of Tripoli were enrolled. The average prevalence of HBsAg was 3.7%, anti-HCV 0.9%, anti-HIV 0.15% and co-infection 0.02%. The prevalence varied from one district to another. HBV was more prevalent among those aged over 50 years and was associated with family history. Anti-HCV and anti-HIV were more prevalent among those aged 20-40 years. Intravenous drug use and blood transfusion were the main risk factors for HCV and HIV infection. CONCLUSION: HBV, HCV, HIV and co-infection are relatively common in Libya. High prevalence was associated with geographic, ethnic and socioeconomic variability within the community. HCV and HIV infections among the younger age groups are becoming an alarming issue. Regulations and health care education need to be implemented and longer term follow-up should be planned.

  4. Decreased serum hepcidin concentration correlates with brain iron deposition in patients with HBV-related cirrhosis.

    Directory of Open Access Journals (Sweden)

    Dong Lin

    Full Text Available PURPOSE: Excessive brain iron accumulation contributes to cognitive impairments in hepatitis B virus (HBV-related cirrhotic patients. The underlying mechanism remains unclear. Hepcidin, a liver-produced, 25-aminoacid peptide, is the major regulator of systemic iron metabolism. Abnormal hepcidin level is a key factor in some body iron accumulation or deficiency disorders, especially in those associated with liver diseases. Our study was aimed to explore the relationship between brain iron content in patients with HBV-related cirrhosis and serum hepcidin level. METHODS: Seventy HBV-related cirrhotic patients and forty age- sex-matched healthy controls were enrolled. Brain iron content was quantified by susceptibility weighted phase imaging technique. Serum hepcidin as well as serum iron, serum transferrin, ferritin, soluble transferrin receptor, total iron binding capacity, and transferrin saturation were tested in thirty cirrhotic patients and nineteen healthy controls. Pearson correlation analysis was performed to investigate correlation between brain iron concentrations and serum hepcidin, or other iron parameters. RESULTS: Cirrhotic patients had increased brain iron accumulation compared to controls in the left red nuclear, the bilateral substantia nigra, the bilateral thalamus, the right caudate, and the right putamen. Cirrhotic patients had significantly decreased serum hepcidin concentration, as well as lower serum transferring level, lower total iron binding capacity and higher transferrin saturation, compared to controls. Serum hepcidin level negatively correlated with the iron content in the right caudate, while serum ferritin level positively correlated with the iron content in the bilateral putamen in cirrhotic patients. CONCLUSIONS: Decreased serum hepcidin level correlated with excessive iron accumulation in the basal ganglia in HBV-related cirrhotic patients. Our results indicated that systemic iron overload underlined regional

  5. [Establishment of hepatitis B virus (HBV) chronic infection mouse model by in vivo transduction with a recombinant adeno-associated virus 8 carrying 1. 3 copies of HBV genome (rAAN8-1. 3HBV)].

    Science.gov (United States)

    Dong, Xiao-Yan; Yu, Chi-Jie; Wang, Gang; Tian, Wen-Hong; Lu, Yue; Zhang, Feng-Wei; Wang, Wen; Wang, Yue; Tan, Wen-Jie; Wu, Xiao-Bing

    2010-11-01

    In this report, we developed a HBV infection model in C57BL/6 mouse line by in vivo injection of a recombinant adeno-associated virus 8 vector carrying 1. 3 copies of HBV genome (ayw subtype) (rAAV8-1. 3HBV). We firstly prepared and purified the rAAV8-1. 3HBV and then injected it into three C57BL/6 mice with the dose of 2 x 10e11vg, respectively. HBsAg and HBeAg were assayed in sera collected at different time points post injection. Ten weeks post injection, the three mice were sacrificed and blood and liver tissue were taken for assay. Copies of HBV DNA were detected by real time PCR and the way of HBV DNA replication was identified by PCR. Subsequently, detection of HBV antigen by immunohistochemistry and pathology analysis of liver tissue of mice were performed. The results suggested that expression of HBsAg and HBeAg lasted for at least 10 weeks in mice sera. Among mice injected with rAAV8-1. 3HBV, HBsAg levels were showed an 'increasing-decreasing-increasing' pattern (the lowest level at the 4th week post injection), while HBeAg levels were kept high and relatively stable. HBV DNA copies were 4.2 x 10(3), 3.6 x 10(3), 2.5 x 10(3) copies/mL in sera and 8.0 x 10(6), 5.7 x 10(6), 2.6 x 10(6) copies/g in hepatic tissues of three mice, respectively. We found that the linear 1. 3HBV DNA in the rAAV8-1. 3HBV could self form into circular HBV genome and replicate in livers of HBV transfected mice. HBsAg and HBcAg were both positive in liver tissue of mice injected with rAAV8-1. 3HBV and no obvious pathological characters were found in liver of mice injected with rAAV8-1. 3HBV. In conclusion, we successfully developed a HBV chronic infection model in C57BL/6 mouse line by in vivo transduction with the recombinant virus rAAV8-1. 3HBV, in which HBV genes could be continuously expressed and replicated over 10 weeks, and paved a way for further characterization of the human chronic hepatitis B virus infection and evaluation of vaccine and anti-HBV agents. PMID:21344744

  6. Differences in antiproliferative effect of STAT3 inhibition in HCC cells with versus without HBV expression

    Energy Technology Data Exchange (ETDEWEB)

    Hong, Yun; Zhou, Lin; Xie, Haiyang; Wang, Weilin [Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, Zhejiang 310003 (China); Key Laboratory of Combined Multi-organ Transplantation of Ministry of Public Health, Qingchun Road 79, Hangzhou, Zhejiang 310003 (China); Zheng, Shusen, E-mail: shusenzheng@zju.edu.cn [Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, Zhejiang 310003 (China); Key Laboratory of Combined Multi-organ Transplantation of Ministry of Public Health, Qingchun Road 79, Hangzhou, Zhejiang 310003 (China)

    2015-06-05

    Chronic infection with hepatitis B virus (HBV) plays an important role in the etiology of hepatocellular carcinoma (HCC). Signal transducer and activator of transcription 3 (STAT3) inactivation could inhibit the tumor growth of HCC. In this study, differential antiproliferative effect of STAT3 inhibition was observed with HBV-related HCC cells being more resistant than non-HBV-related HCC cells. Resistance of HBV-related HCC cells to STAT3 inhibition was positively correlated to the expression of HBV. Enhanced ERK activation after STAT3 blockade was detected in HBV-related HCC cells but not in non-HBV-related HCC cells. Combined ERK and STAT3 inhibition eliminates the discrepancy between the two types of HCC cells. Moderate reduced HBV expression was found after STAT3 inhibition. These findings disclose a discrepancy in cellular response to STAT3 inhibition between non-HBV-related and HBV-related HCC cells and underscore the complexity of antiproliferative effect of STAT3 inactivation in HBV-related HCC cells. - Highlights: • HBV endows HCC cells with resistance to STAT3 inactivation on proliferation. • Abnormal ERK activation after STAT3 inhibition in HBV-related HCC cells. • Combined ERK and STAT3 inhibition eliminates the discrepancy. • STAT3 inhibition moderately reduces HBV expression.

  7. People with multiple tattoos and/or piercings are not at increased risk for HBV or HCV in The Netherlands.

    Directory of Open Access Journals (Sweden)

    Anouk T Urbanus

    Full Text Available BACKGROUND: Although published results are inconsistent, it has been suggested that tattooing and piercing are risk factors for HBV and HCV infections. To examine whether tattooing and piercing do indeed increase the risk of infection, we conducted a study among people with multiple tattoos and/or piercings in The Netherlands who acquired their tattoos and piercings in The Netherlands and/or abroad. METHODS: Tattoo artists, piercers, and people with multiple tattoos and/or piercings were recruited at tattoo conventions, shops (N = 182, and a biannual survey at our STI-outpatient clinic (N = 252 in Amsterdam. Participants were interviewed and tested for anti-HBc and anti-HCV. Determinants of HBV and HCV infections were analysed using logistic regression analysis. RESULTS: The median number of tattoos and piercings was 5 (IQR 2-10 and 2 (IQR 2-4, respectively. Almost 40% acquired their tattoo of piercing abroad. In total, 18/434 (4.2%, 95%CI: 2.64%-6.46% participants were anti-HBc positive and 1 was anti-HCV positive (0.2%, 95%CI: 0.01%-1.29%. Being anti-HBc positive was independently associated with older age (OR 1.68, 95%CI: 1.03-2.75 per 10 years older and being born in an HBV-endemic country (OR 7.39, 95%CI: 2.77-19.7. Tattoo- and/or piercing-related variables, like having a tattoo or piercing in an HBV endemic country, surface percentage tattooed, number of tattoos and piercings etc., were not associated with either HBV or HCV. CONCLUSIONS: We found no evidence for an increased HBV/HCV seroprevalence among persons with multiple tattoos and/or piercings, which might be due to the introduction of hygiene guidelines for tattoo and piercing shops in combination with the low observed prevalence of HBV/HCV in the general population. Tattoos and/or piercings, therefore, should not be considered risk factors for HBV/HCV in the Dutch population. These findings imply the importance of implementation of hygiene guidelines in other countries.

  8. [HCV and HBV prevalence in hemodialyzed pediatric patients. Multicenter study].

    Science.gov (United States)

    Cañero-Velasco, M C; Mutti, J E; Gonzalez, J E; Alonso, A; Otegui, L; Adragna, M; Antonuccio, M; Laso, M; Montenegro, M; Repetto, L; Brandi, M; Canepa, J; Baimberg, E

    1998-01-01

    Hemodialized pediatric patients are a risk population for the hepatitis B and C virus infection. The aim of this paper was to study the serum prevalence of HBV and HCV infection in hemodialized children. We study 61 pediatric patients at hemodialisis, 12 on renal transplant, range between 2 and 20 years old (mean: 12.9 years), 23 male and 38 female. The specific anti-HCV IgC were measured by enzyme immunoassay (ELISA Abbott) and confirmed by LIA-TEK (Organon). The anti-HBV were measured by ELISA Abbott and transaminases by cinetic method (ASAT: 29 UI/L and ALT: 33 UI/L). The 19.7% of studied children were HCV (+) and 29.5% were HBV (+), 38.9% of them were HbsAg (+) and 50% anti-HBs (+). The HCV and HBV infection was more elevated in relation to the transfusion number and the hemodilisis time. The elevation of ALT/ASAT activity isn't a right infection index for HCV and HBV in this children. PMID:9773156

  9. Bayesian Inference of the Evolution of HBV/E

    Science.gov (United States)

    Andernach, Iris E.; Hunewald, Oliver E.; Muller, Claude P.

    2013-01-01

    Despite its wide spread and high prevalence in sub-Saharan Africa, hepatitis B virus genotype E (HBV/E) has a surprisingly low genetic diversity, indicating an only recent emergence of this genotype in the general African population. Here, we performed extensive phylogeographic analyses, including Bayesian MCMC modeling. Our results indicate a mutation rate of 1.9×10−4 substitutions per site and year (s/s/y) and confirm a recent emergence of HBV/E, most likely within the last 130 years, and only after the transatlantic slave-trade had come to an end. Our analyses suggest that HBV/E originated from the area of Nigeria, before rapidly spreading throughout sub-Saharan Africa. Interestingly, viral strains found in Haiti seem to be the result of multiple introductions only in the second half of the 20th century, corroborating an absence of a significant number of HBV/E strains in West Africa several centuries ago. Our results confirm that the hyperendemicity of HBV(E) in today's Africa is a recent phenomenon and likely the result of dramatic changes in the routes of viral transmission in a relatively recent past. PMID:24312336

  10. Combination and cleavage of HBV DNA fragments by triple helix-forming oligonucleotides modified with manganese porphyrin in vitro

    Institute of Scientific and Technical Information of China (English)

    光丽霞; 袁发焕; 奚敏; 赵聪敏; 刘立; 温恩懿; 艾友萍

    2003-01-01

    Objective To observe the ability of triple helix-forming oligonucleotides (TFOs) modified with manganese porphyrin to combine with and cleave HBV DNA fractions. Methods TFO were modified with manganese porphyrin and acridines, and then reacted with the 32P labeled HBV DNA fragments at 37℃ in vitro (pH 7.4). Electrophoretic mobility shift assays and Dnase Ⅰ footprinting tests were used to show the affinity and specificity of TFO to bind to target sequences. The ability of TFO to cleave HBV DNA fragments was tested by cleavage experiments. Results TFO modified with manganese porphyrin and acridine could bind to the target sequence in a sequence-dependent manner, with a Kd value of 3.5×10-7 mol/L and a relative affinity of 0.008. In the presence of potassium monopersulfate (KHSO5), TFO modified with manganese porphyrin and acridine could cleave the target sequence where the triplex DNA was formed. Conclusion In the presence of KHSO5, TFO modified with manganese porphyrin and acridine could bind and cleave the target HBV-DNA in a sequence-dependent manner.

  11. Association of preS/S Mutations with Occult Hepatitis B Virus (HBV) Infection in South Korea: Transmission Potential of Distinct Occult HBV Variants.

    Science.gov (United States)

    Kim, Hong; Kim, Bum-Joon

    2015-01-01

    Occult hepatitis B virus infection (HBV) is characterized by HBV DNA positivity but HBV surface antigen (HBsAg) negativity. Occult HBV infection is associated with a risk of HBV transmission through blood transfusion, hemodialysis, and liver transplantation. Furthermore, occult HBV infection contributes to the development of cirrhosis and hepatocellular carcinoma. We recently reported the characteristic molecular features of mutations in the preS/S regions among Korean individuals with occult infections caused by HBV genotype C2; the variants of preS and S related to severe liver diseases among chronically infected patients were also responsible for the majority of HBV occult infections. We also reported that HBsAg variants from occult-infected Korean individuals exhibit lower HBsAg secretion capacity but not reduced HBV DNA levels. In addition, these variants exhibit increased ROS-inducing capacity compared with the wild-type strain, linking HBV occult infections to liver cell damage. Taken together, our previous reports suggest the transmission potential of distinct HBV occult infection-related variants in South Korea.

  12. Defective Natural Killer cell antiviral capacity in paediatric HBV infection

    DEFF Research Database (Denmark)

    Heiberg, Ida Louise; Laura J., Pallett; Winther, Thilde Nordmann;

    2015-01-01

    Natural Killer (NK) cells exhibit dysregulated effector function in adult chronic HBV infection (CHB), which may contribute to virus persistence. The role of NK cells in children infected perinatally with HBV is less studied. Access to a unique cohort enabled the cross-sectional evaluation of NK...... cell frequency, phenotype and function in HBV-infected children relative to uninfected children. We observed a selective defect in NK cell IFN-γ production, with conserved cytolytic function, mirroring the functional dichotomy observed in adult infection. Reduced expression of NKp30 on NK cells...... suggests a role of impaired NK-Dendritic Cell (DC) cellular interactions as a potential mechanism leading to reduced IFN-γ production. The finding that NK cells are already defective in paediatric CHB, albeit less extensively than in adult CHB, has potential implications for the timing of antiviral therapy...

  13. Prevalence of HBV and HBV vaccination coverage in health care workers of tertiary hospitals of Peshawar, Pakistan

    Directory of Open Access Journals (Sweden)

    Ali Ijaz

    2011-06-01

    Full Text Available Abstract Background Hepatitis B Virus (HBV may progress to serious consequences and increase dramatically beyond endemic dimensions that transmits to or from health care workers (HCWs during routine investigation in their work places. Basic aim of this study was to canvass the safety of HCWs and determine the prevalence of HBV and its possible association with occupational and non-occupational risk factors. Hepatitis B vaccination coverage level and main barriers to vaccination were also taken in account. Results A total of 824 health care workers were randomly selected from three major hospitals of Peshawar, Khyber Pakhtunkhwa. Blood samples were analyzed in Department of Zoology, Kohat University of Science and Technology Kohat, and relevant information was obtained by means of preset questionnaire. HCWs in the studied hospitals showed 2.18% prevalence of positive HBV. Nurses and technicians were more prone to occupational exposure and to HBV infection. There was significant difference between vaccinated and non-vaccinated HCWs as well as between the doctors and all other categories. Barriers to complete vaccination, in spite of good knowledge of subjects in this regard were work pressure (39.8%, negligence (38.8% un-affordability (20.9%, and unavailability (0.5%. Conclusions Special preventive measures (universal precaution and vaccination, which are fundamental way to protect HCW against HBV infection should be adopted.

  14. Emergence of HBV resistance to lamivudine (3TC in HIV/HBV co-infected patients in The Gambia, West Africa

    Directory of Open Access Journals (Sweden)

    Stewart Balint

    2011-12-01

    Full Text Available Abstract Background Lamivudine (3TC is a potent inhibitor of both Hepatitis B virus (HBV and Human Immunodeficiency Virus (HIV replication and is part of first-line highly active antiretroviral therapy (HAART in the Gambia. Unfortunately, the effectiveness of 3TC against HBV is limited by the emergence of resistant strains. Aim The aim of this retrospective study was to characterise 3TC-resistant mutations in HBV from co-infected patients receiving HAART, by generating HBV polymerase sequence data and viral loads from HBV genotype E infected patients, both at initiation and during a course of 3TC therapy. Method Samples from 21 HBV chronic carriers co-infected with HIV-1 (n = 18, HIV-2 (n = 2 and HIV-dual (n = 1 receiving HAART for a period of 6-52 months were analysed for the emergence of 3TC-resistance mutations. Findings Sixteen out of 21 HBV/HIV co-infected patients responded well to HAART treatment maintaining suppression of HBV viraemia to low (≤ 104 copies/mL (n = 5 or undetectable levels (+ L180M+ V173L+ triple mutation associated with a vaccine escape phenotype, which could be of public health concern in a country with a national HBV vaccination programme. All except one patient was infected with HBV genotype E. Conclusions Our findings confirm the risk of 3TC mutations in HAART patients following monotherapy. This is a novel study on 3TC resistance in HBV genotype E patients and encourage the use of tenofovir (in association with 3TC, which has not shown unequivocally documented HBV resistance to date, as part of first-line therapy in HIV/HBV co-infected patients in West Africa. HBV- hepatitis B infection; HIV- human immunodeficiency virus; HAART- antiretroviral therapy.

  15. Inhibitory effect of oxymatrine on serum hepatitis B virus DNA in HBV transgenic mice

    Institute of Scientific and Technical Information of China (English)

    Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Jing-Yuan Fang; Yu-Lin Song; Zhao-Hui Shen; Ai-Ping Cao

    2004-01-01

    AIM: To study the inhibitory effect of oxymatrine on serum hepatitis B virus (HBV) DNA in HBV transgenic mice.METHODS: HBV transgenic mice model was established by microinjection, and identified by HBV DNA integration and replication. Transgenic mice with replicating HBV were divided into 3 groups, and injected with normal saline (group A, n=9), 50 mg/kg (group B, n=8) and 100 mg/kg (group C, n=9) oxymatrine intraperitoneally once a day for 30 d, respectively. Quantitation of serum HBV DNA in HBV transgenic mice was performed by competitive polymerase chain reaction (PCR) in combination with DNA hybridization quantitative detection technique before and after treatment.RESULTS: Compared with pre-treatment, the serum HBV DNA in group A (F=1.04, P=0.9612) and group B (F=1.13,P=0.8739) had no changes after treatment. However, in group C serum HBV DNA was significantly decreased (F=13.97,P=0.0012). The serum HBV DNA after treatment was lower in group C than in groups B and A (F=8.65, P=0.0068;F=12.35, P=0.0018; respectively). The serum HBV DNA after treatment was lower in group B than in group A, but there was no statistical significance (F=1.43, P=0.652).CONCLUSION: Oxymatrine has inhibitory effects on serum HBV DNA in HBV transgenic mice.

  16. Expression and Purification of a Novel Computationally Designed Antigen for Simultaneously Detection of HTLV-1 and HBV Antibodies.

    Directory of Open Access Journals (Sweden)

    Hafez Heydari Zarnagh

    2015-04-01

    Full Text Available Computational tools are reliable alternatives to laborious work in chimeric protein design. In this study, a chimeric antigen was designed using computational techniques for simultaneous detection of anti-HTLV-I and anti-HBV in infected sera. Databases were searched for amino acid sequences of HBV/HLV-I diagnostic antigens. The immunodominant fragments were selected based on propensity scales. The diagnostic antigen was designed using these fragments. Secondary and tertiary structures were predicted and the B-cell epitopes were mapped on the surface of built model. The synthetic DNA coding antigen was sub-cloned into pGS21a expression vector. SDS-PAGE analysis showed that glutathione fused antigen was highly expressed in E. coli BL21 (DE3 cells. The recombinant antigen was purified by nickel affinity chromatography. ELISA results showed that soluble antigen could specifically react with the HTLV-I and HBV infected sera. This specific antigen could be used as suitable agent for antibody-antigen based screening tests and can help clinicians in order to perform quick and precise screening of the HBV and HTLV-I infections.

  17. Study on the relationship between semen HBV-DNA load and offspring-paternal-vertical-transmission of HBV%HBV感染者精液HBV-DNA载量对子代垂直传播的影响

    Institute of Scientific and Technical Information of China (English)

    张荣莲; 王梅颖; 陈起燕; 任坤海; 修晓燕; 邱丽茵; 黄艳红

    2014-01-01

    Objective To explore the relationship between HBV-DNA load and the offspring vertical transmission of HBV.Methods 138 families who had taken the examination between August 2009 and November 2011 but the HBsAg of the housewife was negative,were chosen as research objects.Blood from the couples and sperms from the husbands during pregnancy were followed and collected for detection on related indicators.Cord blood was sampled after delivery for HBVM and HBV-DNA quantification.Those with HBV-DNA load ≥5 × 102 copies/ml were chosen as cases while those <5 × 102 copies/ml were formed as controls,respectively.Results 1) The positive rates of HBV-DNA was 34.8% (48/138) in the neonatal cord blood while the positive rates of cord blood HBsAg and HBeAg were 28.3% (39/138) and 15.2% (21/138) respectively.2) The positive rate of semen HBV-DNA was 21.0% (29/138) while the positive rates of paternal serum HBV-DNA and HBeAg were 76.8% (106/138)and 42.8% (59/138).3)Among the positive ones on paternal serum HBV-DNA,paternal serum HBeAg,semen HBV-DNA,items as measures taken for HBV vertical transmission and prevention on the fathers and the first class family histories on HBV appeared to be the risk factors for HBV paternal transmission (P<0.05).4)Data from Multivariate analysis showed that positivities on patemal serum HBV-DNA,paternal serum HBeAg and semen HBV-DNA were risk factors for HBV paternal transmission (OR=5.7,95%CI:1.1-29.1 ; OR=4.2,95%CI:1.7-10.0; OR=6.7,95% CI:2.4-18.9).5)Dose-response relationships were seen between levels of paternal serum HBV-DNA load and cord blood HBV-DNA load,between levels of paternal serum HBV-DNA load and semen HBV-DNA load,between levels of semen HBV-DNA load and cord blood HBV-DNA load.6)Results from the analysis on ROC curve showed that paternal serum HBV-DNA load level (105 copies/ml) and semen HBV-DNA load level (103 copies/ml)were better demarcation points to forecast the occurrence of paternal transmission of

  18. [Control of HCV, HBV and HIV Infections in Hemodialysis].

    Science.gov (United States)

    Fabrizi, Fabrizio; Martin, Paul; Messa, Piergiorgio

    2013-01-01

    Infections with blood-borne pathogens are still common among patients on maintenance dialysis all over the world. The control of infection due to blood-borne viruses (particularly HBV) within dialysis units has been a major goal in the management of patients with chronic kidney disease in the industrialized world. Standard precautions and specific procedures have been recommended to prevent infections with HBV, HCV and HIV within dialysis units. Isolation of HBsAg positive patients by dialysis rooms, staff and machines continues to be an important step to control HBV infection within dialysis units, according to the CDC and other regulatory agencies. Some prospective observational studies have reported the complete prevention of HCV transmission to hemodialysis patients in the absence of any isolation policy, and the use of dedicated dialysis machines for HCV-infected patients is not recommended by clinical guidelines. Isolation of HCV-infected patients should be considered in special circumstances only. Vaccination is an important tool against transmission of HBV among patients on long-term dialysis even if the immune response towards the hepatitis B vaccine remains unsatisfactory. Hemodialysis is considered a low risk setting for the transmission of human immunodeficiency virus (HIV) infection, providing that standard and specific procedures are carefully observed. HIV-infected patients do not have to be isolated from other patients or dialyzed separately on dedicated machines.

  19. Expression and immunoreactivity of HCV/HBV epitopes

    Institute of Scientific and Technical Information of China (English)

    Xin-Yu Xiong; Xiao Liu; Yuan-Ding Chen

    2005-01-01

    AIM: To develop the epitope-based vaccines to prevent Hepatitis C virus (HCV)/Hepatitis B virus (HBV) infections.METHODS: The HCV core epitopes C1 STNPKPQRKTKRNTNRRPQD (residuals aa2-21) and C2 VKFPGGGQIVGGVYLLPRR (residuals aa22-40), envelope epitope E GHRMAWDMMMNWSP (residuals aa315-328) and HBsAg epitope S CTTPAQGNSMFPSCCCTKPTDGNC (residuals aa124-147) were displayed in five different sites of the flock house virus capsid protein as a vector, and expressed in E. coli cells (pET-3 system).Immunoreactivity of the epitopes with anti-HCV and anti-HBV antibodies in the serum from hepatitis C and hepatitis B patients were determined.RESULTS: The expressed chimeric protein carrying the HCV epitopes C1, C2, E (two times), L3C1-I2E-L1C2-L2E could react with anti-HCV antibodies. The expressed chimeric protein carrying the HBV epitopes S, I3S could react with anti-HBs antibodies. The expressed chimeric proteins carrying the HCV epitopes C1, C2, E plus HBV epitope S, L3C1-I2E-L1C2-L2E-I3S could react with antiHCV and anti-HBs antibodies.CONCLUSION: These epitopes have highly specific and sensitive immunoreaction and are useful in the development of epitope-based vaccines.

  20. Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients

    NARCIS (Netherlands)

    Punyawudho, B.; Thammajaruk, N.; Thongpeang, P.; Matthews, G.; Lewin, S.R.; Burger, D.M.; Ruxrungtham, K.; Avihingsanon, A.

    2015-01-01

    OBJECTIVE: Tenofovir is an efficacious drug with a long half-life and high activity against both HIV and HBV. However, the pharmacokinetics of tenofovir have not been studied in HIV/HBV co-infected patients. Data from HIV mono-infected patients may not be transferable to HIV/HBV co-infected populati

  1. 乳汁HBV-DNA定量时标本处理的优选及临床应用%Optimization and clinical application of treatment of specimens in HBV-DNA quantitation

    Institute of Scientific and Technical Information of China (English)

    方有兵; 黄晨艳; 刘贵育

    2011-01-01

    Objective: To choose a method with high sensitivity and good repeatability of drawing HBV - DNA quantitative specimens from colostrum used for colostrum detection of lying - in women with hepatitis B. Methods: 14 colostrum specimens from 14 lying - in women carrying positive HBsAg, HBeAg and HBcAb were selected, and every colostrum specimen was divided into 3 groups: original specimen, centrifugal specimen at middle level and centrifugal sediment at low level, then HBV - DNA was extracted respectively and the content was detected, rank sum test was used to analyze the difference of results; centrifugal specimens at middle level were used to detect the content of HBV - DNA in 316 lying - in women with hepatitis B. Results: The sensitivity of centrifugal specimen at middle level was higher than that of original specimen, and the repeatability of centrifugal specimen at middle level was higher than that of centrifugal sediment at low level. Among 316 lying - in women with hepatitis B, in positive serum HBsAg, HBeAg and HBcAb group, the positive rate of HBV - DNA in colostrum was 77. 60%; in positive serum HBsAg, HBeAb and HBcAb group, the positive rate of HBV - DNA in colostrum was 0. 73%; in positive serum HBsAg and HBeAg group, the positive rate of HBV - DNA in colostrum was 80.00%; in positive serum HBsAg and HBcAb group, the positive rate of HBV -DNA in colostrum was 5.17%; in other groups, the positive rates of HBV - DNA in colostrum were all 0. Conclusion: The colostrum of lying - in women with hepatitis B can be used to assess the safety of breastfeeding. The infants fed with breastfeeding of colostrum from the lying - in women with positive serum HBsAg, HBeAg and HBcAb or positive serum HBsAg, HBeAg have high risk of hepatitis B virus infection.%目的:选择灵敏度高、重复性较好的乳汁HBV-DNA定量标本提取方法应用于乙肝携带产妇的乳汁检测.方法:选择14例乙肝"大三阳"产妇乳汁,每份分为乳汁原标本,乳汁

  2. Detection of HBV DNA by PCR on HBsAg negative blood donors%HBV DNA PCR检测在HBsAg阴性献血人群中的应用

    Institute of Scientific and Technical Information of China (English)

    陈筱华; 林碧; 刘保林; 孔令光

    2008-01-01

    Objective To define the application value of HBV DNA detection on HBsAg-negative blood donors and assess the necessity for nucleic acid detection.Methods Real-time PCR was used to detect HBV DNA on HBsAg negative blood donors.Pools of eight donor samples were used for NAT testing.Viruses were concentrated by centrifugation and the viral DNA extraction was performed using magnetic beads.If HBV DNA wag positive,serological indicators including HBsAg,anti-HBs,HBeAg, anti-Hbe,total anti-HBc was further detected.Results The HBV DNA detection limit was 25 U/ml.There were four HBV DNA positive cases among 23 225 specimens.and the detection rate was 0.17‰ The further serological examination showed anti-Hbe(+),anti-HBc(+) in the two cases and anti-HBc(+) in one case and anti-Hbs(+),anti-HBc(+)in 1 case.The viral load can range form 50 to 200 U/ml. Conclusions The results indicate that there is false negative possibility in blood screening by ELISA.It is necessary to employ anti-Hbe screening or NAT to blood donors screening.%目的 探讨HBsAg阴性献血者HBV DNA榆测的应用价值,评估核酸检测的必要性.方法 采用PCR检测HBsAg阴性献血者HBV DNA.采用8人份混合血样测定,超离心浓缩病毒,磁珠法提取病毒核酸.如HBV DNA为阳性,则进一步检测乙型肝炎病毒血清标志物5项.结果 HBVDNA检测限量为25 U/ml,23 225份标本中有4份为HBV DNA阳性,检出率为0.17‰.进一步检测其他HBV感染的血清学指标,发现这4份标本中有2份为抗HBe和抗HBc阳性,1份为抗HBc阳性,1份为抗HBs、抗HBc阳性.对HBV DNA的定量测定表明,其含量在50~200 U/ml.结论 现行的2次酶联免疫技术的血液筛查存在HBV漏检,有必要在现有的血液筛查模式中增加抗HBc检测,或增加病毒核酸筛查.

  3. HBV serological test results comparing the use of chemiluminescence and en-zyme-linked immunosorbent assay of%乙肝病毒血清学检验采用化学发光法与酶联免疫法的效果对比

    Institute of Scientific and Technical Information of China (English)

    张怡莎

    2014-01-01

    目的:探讨化学发光免疫分析技术(ECLIA)和酶联免疫吸附试验(ELISA)在乙肝病毒血清学检验中的应用效果。方法选取2012年1月-2014年1月在我院就诊的疑似乙肝患者150例,分离血清后分别应用ELISA和ECLIA进行检测,比较两种检测方法的效果。结果ELISA和ECLIA检测出HBsAg阳性分别63例和82例,两者比较差异显著(P<0.05),同时ECLIA法检测的批内CV和批间CV的重复性均明显高于ELISA法(P<0.05)。结论与ELISA检验法比较,ECLIA法具有更高的HBsAg阳性检出率,且能进行精确的定性定量检测,值得临床推广应用。%Objective To investigate chemiluminescence immunoassay (ECLIA) and enzyme-linked immunosorbent assay (ELISA) in HBV serological test the application results. Methods Select suspected hepatitis B patients from January 2012 to January 2014 in our hospital 150 cases, respectively, after the application of separation of serum ELISA and ECLIA detection, the effect of two detection methods.Results ELISA and ECLIA detection of HBsAg positive 63 cases and 82 cases respectively,the difference was significant (P<0.05),while intra-assay and inter-assay CV CV ECLIA assay reproducibility were significantly higher than the ELISA method(P<0.05). Conclusion Compared with ELISA test method, ECLIA method has higher HBsAg positive rate,and can be accurate qualitative and quantitative detection,worthy of clinical application.

  4. Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan-based HBV vaccine.

    Directory of Open Access Journals (Sweden)

    Hong Chen

    Full Text Available BACKGROUND: A therapeutic vaccine for chronic hepatitis B virus (HBV infection that enhances virus-specific cellular immune responses is urgently needed. The "prime-boost" regimen is a widely used vaccine strategy against many persistence infections. However, few reports have addressed this strategy applying for HBV therapeutic vaccine development. METHODOLOGY/PRINCIPAL FINDINGS: To develop an effective HBV therapeutic vaccine, we constructed a recombinant vaccinia virus (Tiantan containing the S+PreS1 fusion antigen (RVJSS1 combined with the HBV particle-like subunit vaccine HBVSS1 to explore the most effective prime-boost regimen against HBV. The immune responses to different prime-boost regimens were assessed in C57BL/C mice by ELISA, ELISpot assay and Intracellular cytokine staining analysis. Among the combinations tested, an HBV protein particle vaccine priming and recombinant vaccinia virus boosting strategy accelerated specific seroconversion and produced high antibody (anti-PreS1, anti-S antibody titres as well as the strongest multi-antigen (PreS1, and S-specific cellular immune response. HBSS1 protein prime/RVJSS1 boost immunization was also generated more significant level of both CD4+ and CD8+ T cell responses for Th1 cytokines (TNF-α and IFN-γ. CONCLUSIONS: The HBSS1 protein-vaccine prime plus RVJSS1 vector boost elicits specific antibody as well as CD4 and CD8 cells secreting Th1-like cytokines, and these immune responses may be important parameters for the future HBV therapeutic vaccines.

  5. Knowledge of HBV and HCV and individuals' attitudes toward HBV- and HCV-infected colleagues: a national cross-sectional study among a working population in Japan.

    Directory of Open Access Journals (Sweden)

    Hisashi Eguchi

    Full Text Available Prejudice and discrimination in the workplace regarding the risk of transmission of Hepatitis B virus (HBV and Hepatitis C virus (HCV are increased by excess concerns due to a lack of relevant knowledge. Education to increase knowledge about HBV and HCV and their prevention could be the first step to reduce prejudice and discrimination. This study aimed to determine the association between the level of knowledge and negative attitudes toward HBV- and HCV-infected colleagues among the Japanese working population. An online anonymous nationwide survey involving about 3,000 individuals was conducted in Japan. The questionnaire consisted of knowledge of HBV and HCV, and attitudes toward HBV- and HCV-infected colleagues in the workplace. Knowledge was divided into three categories: "ensuring daily activities not to be infected"; "risk of infection"; and "characteristics of HBV/HCV hepatitis", based on the result of factor analysis. Multiple logistic regression analysis was applied. A total of 3,129 persons responded to the survey: 36.0% reported they worried about the possibility of transmission of HBV and HCV from infected colleagues; 32.1% avoided contact with infected colleagues; and 23.7% had prejudiced opinions about HBV and HCV infection. The participants were classified into tertiles. A higher level of knowledge of HBV and HCV was significantly associated with these three negative attitudes (P for trend < 0.005. This study suggests that increasing knowledge may decrease individuals' negative attitudes towards HBV- and HCV-infected colleagues. Thus, we should promote increased knowledge of HBV and HCV in stages to reduce negative attitudes toward HBV- and HCV-infected colleagues.

  6. Serum sphingolipids reflect the severity of chronic HBV infection and predict the mortality of HBV-acute-on-chronic liver failure.

    Directory of Open Access Journals (Sweden)

    Feng Qu

    Full Text Available Patients with HBV-acute-on-chronic liver failure (HBV-ACLF have high mortality and frequently require liver transplantation; few reliable prognostic markers are available. As a class of functional lipids, sphingolipids are extensively involved in the process of HBV infection. However, their role in chronic HBV infection remains unknown. The aim of this study was to determine the serum sphingolipid profile in a population of patients with chronic HBV infection, paying special attention to exploring novel prognostic markers in HBV-ACLF. High performance liquid chromatography tandem mass spectrometry was used to examine the levels of 41 sphingolipids in 156 serum samples prospectively collected from two independent cohorts. The training and validation cohorts comprised 20 and 28 healthy controls (CTRL, 29 and 23 patients with chronic hepatitis B (CHB, and 30 and 26 patients with HBV-ACLF, respectively. Biometric analysis was used to evaluate the association between sphingolipid levels and disease stages. Multivariate analysis revealed difference of sphingolipid profiles between CHB and HBV-ACLF was more drastic than that between CTRL and CHB, which indicated that serum sphingolipid levels were more likely to associate with the progression HBV-ACLF rather than CHB. Furthermore, a 3-month mortality evaluation of HBV-ACLF patients showed that dhCer(d18 : 0/24 : 0 was significantly higher in survivors than in non-survivors (including deceased patients and those undergoing liver transplantation, p < 0.05, and showed a prognostic performance similar to that of the MELD score. The serum sphingolipid composition varies between CTRL and chronic HBV infection patients. In addition, dhCer(d18 : 0/24 : 0 may be a useful prognostic indicator for the early prediction of HBV-ACLF.

  7. Hepatitis B Test

    Science.gov (United States)

    ... limited. Home Visit Global Sites Search Help? Hepatitis B Testing Share this page: Was this page helpful? Also known as: HBV Tests; Hep B; anti-HBs; Hepatitis B Surface Antibody; HBsAg; Hepatitis ...

  8. Molecular analysis of hepatitis B virus (HBV in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy

    Directory of Open Access Journals (Sweden)

    Costantini Andrea

    2011-11-01

    Full Text Available Abstract Background Occult hepatitis B virus (HBV infection (OBI is characterized by HBV DNA persistence even though the pattern of serological markers indicates an otherwise resolved HBV infection. Although OBI is usually clinically silent, immunocompromised patients may experience reactivation of the liver disease. Case presentation We report the case of an individual with human immunodeficiency virus (HIV infection and anti-HBV core antibody positivity, who experienced severe HBV reactivation after discontinuation of lamivudine-including antiretroviral therapy (ART. HBV sequencing analysis showed a hepatitis B surface antigen escape mutant whose presence in an earlier sample excluded reinfection. Molecular sequencing showed some differences between two isolates collected at a 9-year interval, indicating HBV evolution. Resumption of ART containing an emtricitabine/tenofovir combination allowed control of plasma HBV DNA, which fell to undetectable levels. Conclusion This case stresses the ability of HBV to evolve continuously, even during occult infection, and the effectiveness of ART in controlling OBI reactivation in HIV-infected individuals.

  9. Safety of breast-feeding with HBV-DNA positive breast milk%HBV-DNA阳性乳汁喂养的安全性探讨

    Institute of Scientific and Technical Information of China (English)

    周冬生; 林秋香; 蒋就喜

    2013-01-01

    Objective To investigate the safety of breast-feeding by puerpera with HBV-DNA positive breast milk.Methods 117 puerpera with HBV-DNA positive breast milk (2 cases with twins) were studied.119 infants were given with HBV active and passive immunization.34 infants were provided with breast feeding and 85 infants were provided with artificial-feeding.Results 34 out of 119 infants (28.57%) were found to have chronic HBV infection.The rate of HBV infection in the breast-feeding group (32.35%,11/34) was similar to artificial-feeding froup (27.06%,23/85) (P>0.05).However,it has statistical significant difference that the amount of breast milk HBV-DNA loads between the group of chronic HBV infection in infants and the group of no infection(P<0.05).Conclusions Chronic HBV infection in infants is correlated with the amount of HBV-DNA in maternal milk.Breast-feeding with HBV-DNA positive breast milk may not increase the risk of chronic HBV infection in infants.%目的 探讨乳汁HBV-DNA阳性产妇母乳喂养的安全性.方法 乳汁HBV-DNA阳性产妇117例(双胞2例),119例幼儿出生时均接受HBV主动+被动免疫,自由选择喂养方式,其中母乳喂养34例(母乳喂养组),人工喂养85例(人工喂养组),观察两组幼儿慢性感染HBV情况.结果 119例幼儿慢性感染HBV 34例,慢性感染率为28.57%;其中母乳喂养组幼儿慢性感染率为32.35%(11/34),人工喂养组为27.06%(23/85),差异无统计学意义(P>0.05);但幼儿HBV慢性感染组与未感染组母亲乳汁HBV-DNA水平差异有统计学意义(P<0.05).结论 幼儿慢性感染HBV与产妇乳汁HBV-DNA载量有关,但母乳喂养并未增加感染HBV的风险.

  10. Associated factors for recommending HBV vaccination to children among Georgian health care workers

    Directory of Open Access Journals (Sweden)

    Butsashvili Maia

    2012-12-01

    Full Text Available Abstract Background Most cases of hepatitis B virus (HBV infection and subsequent liver diseases can be prevented with universal newborn HBV vaccination. The attitudes of health care workers about HBV vaccination and their willingness to recommend vaccine have been shown to impact HBV vaccination coverage and the prevention of vertical transmission of HBV. The purpose of this study was to ascertain the factors associated with health care worker recommendations regarding newborn HBV vaccination. Methods A cross-sectional study of prevalence and awareness of hepatitis B and hepatitis B vaccine was conducted among randomly selected physicians and nurses employed in seven hospitals in Georgia in 2006 and 2007. Self-administered questionnaires included a module on recommendations for HBV, HCV and HIV. Results Of the 1328 participants included in this analysis, 36% reported recommending against hepatitis B vaccination for children, including 33% of paediatricians. Among the 70.6% who provided a reason for not recommending HBV vaccine, the most common concern was an adverse vaccine event. Unvaccinated physicians and nurses were more likely to recommend against HBV vaccine (40.4% vs 11.4%, PR 3.54; 95% CI: 2.38, 5.29. Additionally, health care worker age was inversely correlated with recommendations for HBV vaccine with older workers less likely to recommend it. Conclusion Vaccinating health care workers against HBV may provide a dual benefit by boosting occupational safety as well as strengthening universal coverage programs for newborns.

  11. Study on HBV Vertical Transmission via the in vitro Fertilization(IVF)Technique

    Institute of Scientific and Technical Information of China (English)

    Jing-ning YANG; Qing-bin LUO; Chang-jun ZHANG; Hua WANG

    2009-01-01

    Objective To study the hepatitis B virus(HB V)vertical transmission via infected spermatozoa.Methods Eighteen male patients with HBV infection who underwent in vitro fertilization (IVF)were studied,5 HBV negative patients were selected as the control.Fluorescence in situ hybridization(FISH)analysis using the partial-length HBV DNA as the hybridization probe was performed to explore the existence of HBV DNA in the sperm and in the host embryonic genome.Results FISH showed that 5 of 18 patients' sperm presented positive signals and 2 of 18 embryos presented positive signals,while no positive signals were found in control group.Conclusion The HBV DNA was found in human sperm and embryos of HBV patients.These results provide direct evidence that HBV DNA could transmit to foetus via human infected spermatozoa.

  12. The influence of HBV model calibration on flood predictions for future climate

    Science.gov (United States)

    Osuch, Marzena; Romanowicz, Renata

    2014-05-01

    The temporal variability of HBV rainfall-runoff model parameters was tested to address the influence of climate characteristics on the values of model optimal parameters. HBV is a conceptual model with a physically-based structure that takes into account soil moisture, snow-melt and dynamic runoff components. The model parameters were optimized by the DEGL method (Differential Evolution with Global and Local neighbours) for a set of catchments located in Poland. The methodology consisted of the calibration and cross-validation of the HBV models on a series of five-year periods within a moving window. The optimal parameter values show large temporal variability and dependence on climatic conditions described by the mean and standard deviation of precipitation, air temperature and PET. Derived regressions models between parameters and climatic indices were statistically significant at the 0.05 level. The set of model optimal values was applied to simulate future flows in a changed climate. We used the precipitation and temperature series from 6 RCM/GCM models for 2071-2100 following the A1B climate change scenario. The climatic variables were obtained from the KLIMADA project. The resulting flow series for the future climate scenario were used to derive flow indices, including the flood quantiles. Results indicate a large influence of climatic variability on flow indices. This work was partly supported by the project "Stochastic flood forecasting system (The River Vistula reach from Zawichost to Warsaw)" carried out by the Institute of Geophysics, Polish Academy of Sciences by order of the National Science Centre (contract No. 2011/01/B/ST10/06866). The rainfall and flow data were provided by the Institute of Meteorology and Water Management (IMGW), Poland.

  13. Quantitative analysis of plasma HBV DNA for early evaluation of the response to transcatheter arterial embolization for HBV-related hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    Ying-Wen Su; Yu-Wen Huang; Sheng-Hsuan Chen; Chin-Yuan Tzen

    2005-01-01

    AIM: To assesse changes in plasma HBV DNA after TAE in HBV-related HCC and correlate the levels with the pattern of lipiodol accumulation on CT.METHODS: Between April and June 2001, 14 patients with HBV-associated HCC who underwent TAE for inoperable or recurrent tumor were studied. Levels of plasma HBV DNA were measured by real-time quantitative PCR daily for five consecutive days after TAE. More than twofold elevation of circulating HBV DNA was considered as a definite elevation. Abdominal CT was performed 1-2 mo after TAE for the measurement of lipiodol retention.RESULTS: Circulating HBV DNA in 10 out of 13 patients was elevated after TAE, except for one patient whose plasma HBV DNA was undetectable before and after TAE.In group Ⅰ patients (n = 6), the HBV DNA elevation persisted for more than 2 d, while in group Ⅱ (n = 7), the HBV DNA elevation only appeared for 1 d or did not reach a definite elevation. There were no significant differences in age or tumor size between the two groups. Patients in group Ⅰ had significantly better lipiodol retention (79.31±28.79%)on subsequent abdominal CT than group Ⅱ (18.43± 10.61%)(P = 0.02).CONCLUSION: Patients with durable HBV DNA elevation for more than 2 d correlated with good lipiodol retention measured 1 mo later, while others associated with poor lipiodol retention. Thus, circulating HBV DNA may be an early indicator of the success or failure of TAE.

  14. 初乳HBV-DNA定量检测对乙肝产妇哺乳的指导价值%The value of colostrum HBV DNA quantities among HBV-positive lying-in women

    Institute of Scientific and Technical Information of China (English)

    邹红霞; 杨庆民; 王金环

    2014-01-01

    Objective The value of colostrum HBV DNA quantities among HBV-positive lying-in Women Methods 325 lying-in women were selected according to the principle of inform consent.These women were classified into 5 groups.Group A:65 lying-in women with strong-infectious HBV (three positives),group B:9 lying-in women with strong-infectious HBV (four positives),group C:152 lying-in women with weak-infectious HBV (three positives),group D:47 lying-in women with the first and the fifth positive HBV,group E:52 HBV-negative lying-in women.The HBV markers in the blood serum and colostrum of selected women were detected by Chemiluminescence (CL).Furthermore PCR was utilized to measure the serum HBV DNA quantities and colostrum HBV DNA quantities from the lying-in women.The data was analyzed after been collected.Results The blood serum and colostrum HBV DNA positive-rate among the lying-in women in group A respectively were 100.00% (65/65)and 83.08% (54/65),and the average colostrum HBV DNA quantity was 3.82 × 104copies ml-1.The blood serum and colostrum HBV DNA positive-rate among the lying-in women in group B respectively were 100% (9/9) and 77.78% (7/9),and the average colostrum HBV DNA quantity was 1.26 × 104copies ml-1.The blood serum and colostrum HBV DNA positive-rate among the lying-in women in group C respectively were 17.10% (26/152) and 1.97% (3/152),and the average colostrum HBV DNA quantity was 2.31 × 103copies ml-1.The blood serum and colostrum HBV DNA positive-rate among the lying-in women in group D respectively were 44.68% (21/47) and 23.40% (11/47),and the average colostrum HBV DNA quantity was 6.17 × 103copies ml-1.The blood serum and colostrum HBV DNA positive-rate among the lying-in women in group E respeetively were 0 (0/52) and 0(0/52) and the average colostrum HBV DNA quantity was < 1.0 × 103copies ml-1.There were significant difference in positive individuals which were detected by colostrum HBV DNA experiments between group A,B and C

  15. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients?

    Institute of Scientific and Technical Information of China (English)

    Ying Yan; Li Mai; Yu-Bao Zheng; Shao-Quan Zhang; Wen-Xiong Xu; Zhi-Liang Gao; Wei-Min Ke

    2012-01-01

    AIM:To investigate optimal timing for therapeutic efficacy of entecavir for acute-on-chronic hepatitis B liver failure (ACLF-HBV) in hepatitis B e antigen (HBeAg)-negative patients.METHODS:A total of 109 inpatients with ACLF-HBV were recruited from the Department of Infectious Diseases of the Third Affiliated Hospital,Sun Yat-sen University from October 2007 to October 2010.Entecavir 0.5 mg/d was added to each patient's comprehensive therapeutic regimen.Patients were divided into three groups according to model for end-stage liver disease (MELD) score:high (≥ 30,20 males and 4 females,mean age 47.8 ± 13.5 years); intermediate (22-30,49 males and 5 females,45.9 ± 12.4 years); and low (≤22,28 males and 3 females,43.4 ± 9.4 years).Statistical analysis were performed using SPSS 11.0 software.Data with normal distribution were expressed as mean ± SD and comparisons were made with Student's t tests.A value of P < 0.05 was considered statistically significant.Viral loads were related exponentially and logarithmic data were used for analysis.RESULTS:For 24 patients with MELD score ≥ 30,treatment lasted 17.2 ± 16.5 d.Scores before and after treatment were significantly different (35.97 ± 4.87 and 40.48 ± 8.17,respectively,t =-2.762,P =0.011); HBV DNA load was reduced (4.882 ± 1.847 copies log10/mL to 3.685 ± 1.436 copies log10/mL); and mortality rate was 95.83% (23/24).Of 54 patients with scores of 22-30,treatment lasted for 54.0 ± 43.2 d; scores before and after treatment were 25.87 ± 2.33 and 25.82 ± 13.92,respectively (t =-0.030,P =0.976); HBV DNA load decreased from 6.308 ± 1.607 to 3.473 ± 2.097 copies log10/mL; and mortality was 51.85% (28/54).Of 31 patients with scores ≤ 22,treatment lasted for 66.1 ± 41.9 d; scores before and after treatment were 18.88 ± 2.44 and 12.39 ± 7.80,respectively,(t =4.860,P =0.000);HBV DNA load decreased from 5.841 ± 1.734 to 2.657 ± 1.154 copies log10/mL; and mortality was 3.23% (1/31).CONCLUSION:For HBe

  16. A case of Gianotti Crosti syndrome with HBV infection.

    Science.gov (United States)

    Dikici, B; Uzun, H; Konca, C; Kocamaz, H; Yel, S

    2008-01-01

    Gianotti-Crosti syndrome (papular acrodermatitis of childhood), which was first described in 1955, is a nonspecific rash that usually consists of the abrupt onset of pink flesh coloring, smooth or lichenoid, flat-topped papules. It was first related to hepatitis B virus (HBV) infection; however, cases not associated with HBV infection were reported as well. Although a type of delayed hypersensitivity reaction is speculated as a cause, exact pathogenesis still remains unclear. The prognosis is favorable and successful management relies upon general supportive and symptomatic care. We report a seven-year-old boy diagnosed with Gianotti-Crosti syndrome with monomorphous papules on his cheeks, buttocks and extremities associated with hepatitis B virus infection.

  17. HBV influence on Response to Antiretroviral Therapy in Horizontally HIV-HBV Coinfected Patient during Early Childhood

    Science.gov (United States)

    Niculescu, Irina; Cupşa, A.M.; Stoian, Andreea Cristina; Dumitrescu, FLorentina; Giubelan, L.I.; Alexandru, D.O.

    2013-01-01

    Background: There are few studies on pediatric HIV-HBV coinfection, so evidences about relationships between the two viruses are scarce. Objectives: influence of HBV infection on virological and immunological response to antiretroviral therapy (ART) in antiretroviral-naïve horizontally HIV-HBV coinfected subjects during early childhood. Material and methods: observational study on 826 HIV+ subjects in evidence of Craiova Regional Centre (CRC); we analyzed the immunological and virological response at 6-12 months after starting first antiretroviral regimens compared in 2 groups: horizontally HIV-HBV coinfected subjects during early childhood (CoS) versus horizontally HIV infected subjects during early childhood without HBV infection (non-CoS). Results: Number of subjects: CoS-66 subjects, non-CoS-132 subjects. Demographic data: CoS-gender ratio F:M=0.886, the majority lived in rural area (57.58%), mean age on diagnosis-9.288±4.607 years, non-CoS-gender ratio F:M=0.859, the majority lived in urban area (53.79%), mean age on diagnosis-10.742±5.107 years. At baseline, HIV category was: CoS-A-1.52%, B-80.30%, C-18.18%, non-CoS-A-2.27%, B-70.45%, C-27.27% (p Chi2=0.332), the mean CD4+ cell count was: CoS-148.33±148.10 cells/ml, non-CoS-163.17±155.39 cells/ml (p Student=0.521) and the mean HIV viral load (HIV VL) was: CoS-5.06±0.80 lgcopies/ml (for 29 subjects), non-CoS-5.04±0.84 lgcopies/ml (for 61 subjects) (p Student=0.978). At the end of the studied period, the mean increase in CD4+ cell count was: CoS-177.068±141.676 cells/ml, non-CoS-176.015±191.751 cells/ml (p Student=0.969) and the mean decrease in HIV VL was: CoS-5.04±0.79 lgcopies/ml, non-COS-4.69±2.04 lgcopies/ml (p Student=0.911). Conclusions: The presence of HBV coinfection does not influence immunological or virological response to ART. PMID:24778861

  18. Justification for screening programs for early detection of HBV infections

    OpenAIRE

    Małgorzata Leźnicka; Krzysztof Gierlotka; Tomasz Prycel

    2014-01-01

    Background: The objective of the study was to collect the data on undetected hepatitis B virus (HBV) in the frequently hospitalized (at least twice in the last 5 years) population of the Kujawsko-Pomorskie voivodship. The study results could be used by occupational health services and local governments to take preventive actions. Material and Methods: The study focused on empirical data derived from hepatitis B Screening Programme in the Kujawsko-Pomorskie voivodship. The study comprised 6332...

  19. HBV infection in relation to consistent condom use: a population-based study in Peru.

    Directory of Open Access Journals (Sweden)

    Antonio Bernabe-Ortiz

    Full Text Available BACKGROUND: Data on hepatitis B virus (HBV prevalence are limited in developing countries. There is also limited information of consistent condom use efficacy for reducing HBV transmission at the population level. The study goal was to evaluate the prevalence and factors associated with HBV infection in Peru, and the relationship between anti-HBc positivity and consistent condom use. METHODS AND FINDINGS: Data from two different surveys performed in 28 mid-sized Peruvian cities were analyzed. Participants aged 18-29 years were selected using a multistage cluster sampling. Information was collected through a validated two-part questionnaire. The first part (face-to-face concerned demographic data, while the second part (self-administered using handheld computers concerned sexual behavior. Hepatitis B core antibody (anti-HBc was tested in 7,000 blood samples. Prevalences and associations were adjusted for sample strata, primary sampling units and population weights. Anti-HBc prevalence was 5.0% (95%CI 4.1%-5.9%, with the highest prevalence among jungle cities: 16.3% (95%CI 13.8%-19.1%. In the multivariable analysis, Anti-HBc positivity was directly associated with geographic region (highlands OR = 2.05; 95%CI 1.28-3.27, and jungle OR = 4.86; 95%CI 3.05-7.74; compared to coastal region; and inversely associated with age at sexual debut (OR = 0.90; 95%CI 0.85-0.97. Consistent condom use, evaluated in about 40% of participants, was associated with reduced prevalence (OR = 0.34; 95%CI 0.15-0.79 after adjusting for gender, geographic region, education level, lifetime number of sex partners, age at sexual debut and year of survey. CONCLUSION: Residence in highlands or jungle cities is associated with higher anti-HBc prevalences, whereas increasing age at sexual debut were associated with lower prevalences. Consistent condom use was associated with decreased risk of anti-HBc. Findings from this study emphasize the need of primary

  20. 乙肝两对半与HBV-DNA的血清学检测结果分析%Analysis of serological detection results of HBV-M and HBV-DNA

    Institute of Scientific and Technical Information of China (English)

    孔小祥; 王春伟

    2016-01-01

    Objective:To analyze the serological detection results of HBV-M and HBV-DNA.Methods:Serum was collected in 480 cases.We detected hepatitis B surface antigen (HBsAg),hepatitis B core antibody(anti-HBc),anti hepatitis B surface antibody (anti-HBs),hepatitis B E antigen(HBeAg) and hepatitis Be antibody(anti HBe),and detected its HBV-DNA.Results:The hepatitis B virus markers were negative,and the positive rate of HBV-DNA was 10.19%,while the hepatitis B surface antigen was positive, other hepatitis B virus markers were negative,the HBV-DNA detection rate was 38.64%.Hepatitis B surface antigen was negative, other HBV markers were positive,the detection rate of HBV-DNA was 16.22%(P<0.05);hepatitis B surface antigen was positive, other hepatitis B virus markers were positive,the detection rate of HBV-DNA was 73.89%.Its data compared with the HBV-DNA detection rate when hepatitis B surface antigen was positive,and other hepatitis B virus markers were negative has significant differences(P<0.05).Conclusion:The serum HBV markers were closely related to the replication of HBV-DNA,the positive serum hepatitis B virus markers not only on behalf of the patients infected with hepatitis B virus,but also has a certain infectivity.%目的:探析乙肝两对半与 HBV-DNA 的血清学检测结果。方法:采集血清480份,检测乙肝表面抗原(HBsAg)、乙肝核心抗体(抗-HBc)、乙肝表面抗体(抗-HBs)、乙肝E抗原(HBeAg)和乙肝e抗体(抗HBe),同时检测其HBV-DNA。结果:乙肝病毒标志物阴性,HBV-DNA的检出率10.19%,乙肝表面抗原阳性,其他乙肝病毒标志物阴性,HBV-DNA 的检出率38.64%。乙肝表面抗原阴性,其他乙肝病毒标志物阳性,HBV-DNA 的检出率16.22%(P<0.05),乙肝表面抗原阳性,其他乙肝病毒标志物阳性,HBV-DNA的检出率73.89%,其数据与乙肝表面抗原阳性,其他乙肝病毒标志物阴性,HBV-DNA的检出率相比,数据差异有统计学意义(P<0.05)。

  1. THE CYTOKINE IP-10 IN CHRONIC HBV AND HCV INFECTION

    Directory of Open Access Journals (Sweden)

    Nina S. Nikolova

    2013-08-01

    Full Text Available Introduction: IP-10 it has been studied as a predictor of treatment response in chronic HCV infected patients. The data for the HBV infection are not enough.Aim: To compare IP-10 levels in patients with chronic HBV /CHB/ and HCV infection /CHC/ and their relation to liver disease and treatment response. Material and methods: 20 patients - with CHC genotype 1 infection /on standard bi-therapy/ and 32 patients with CHB /21 pts - NUC; 11 pts - IFN/. Results: The IP-10 did not correlate with sex, age, ALT and liver fibrosis. The basal IP-10 were lower in patients with CHB (p=0,017. There was a difference in IP-10 baseline levels among the HCV patients with or without RVR (p=0,007. A negative correlation was found between basal IP-10 and RVR (r= -0,508; p=0,008. Conclusion: IP-10 could predict virological response in patients with CHC on standard bi-therapy, but not in HBV infected patients on standard therapy.

  2. Simultaneous detection of HBV and HCV by multiplex PCR normalization

    Institute of Scientific and Technical Information of China (English)

    Ning Wang; Xue-Qin Gao; Jin-Xiang Han

    2004-01-01

    AIM: To design and establish a method of multiplex PCR normalization for simultaneously detecting HBV and HCV.METHODS: Two pairs of primers with a 20 bp joint sequence were used to amplify the target genes of HBV and HCV by two rounds of amplification. After the two rounds of amplification all the products had the joint sequence. Then the joint sequence was used as primers to finish the last amplification. Finally multiplex PCR was normalized to a single PCR system to eliminate multiplex factor interference. Four kinds of nucleic acid extraction methods were compared and screened. A multiplex PCR normalization method was established and optimized by orthogonal design of 6 key factors. Then twenty serum samples were detected to evaluate the validity and authenticity of this method.RESULTS: The sensitivity, specificity, diagnostic index and efficiency were 83.3%, 70%, 153.3% and 72.2%,respectively for both HBsAg and anti-HCV positive patients,and were 78.6%, 80%, 258.6% and 79.2%, respectively for HBsAg positive patients, and were 75%, 90%, 165%and 83.3%, respectively for anti-HCV positive patients.CONCLUSION: The multiplex PCR normalization method shows a broad prospect in simultaneous amplification of multiple genes of different sources. It is practical, correct and authentic, and can be used to prevent and control HBV and HCV.

  3. Analysis of Risk Factors Associated with the Development of Hepatocellular Carcinoma in Chronic HBV-Infected Chinese: A Meta-Analysis

    Directory of Open Access Journals (Sweden)

    Xiang Lyu

    2016-06-01

    Full Text Available Hepatitis B virus (HBV infection is a major risk factor for the development of hepatocellular carcinoma (HCC in China. At present, there still are 9.3 million chronic HBV-infected Chinese. Numerous studies have explored the association between possible factors and hepatocellular carcinoma risk, however, the results remains inconsistent. Therefore, we did this pooled analysis so as to get a precise result. Here, we took the chronic HBV-infected Chinese as the object. We systematically searched for studies evaluating whether the proposed factors changed HCC risk in PubMed, Chinese National Knowledge Infrastructure, VIP database and Wanfang data. Odds ratios (OR with 95% confidence intervals (CI were calculated by Review Manager 5.0 and publication bias was determined by Begg’s test and Egger’s test. In total, 3165 cases and 10,896 controls from 27 studies were included in this meta-analysis. Our results showed that pooled OR with 95% CI for each of the factors investigated were: non-antiviral treatment 2.70 (2.01, 3.62, high HBV DNA levels 2.61 (1.73, 3.94, alcohol consumption 2.19 (1.53, 3.13, a family history of HCC 3.58 (2.53, 5.06 and male gender 2.14 (1.68, 2.73, respectively. Our meta-analysis supports that high HBV DNA levels, non-antiviral treatment, alcohol consumption, a family history of HCC and male gender contributed to the risk of hepatocellular carcinoma in chronic HBV-infected Chinese from currently available evidence. Given the high prevalence of the non-antiviral treatment and alcohol drinking, behavior interventions for the two factors should be tackled first.

  4. Cloning, Eukaryotic Expression of Human ISG20 and Preliminary Study on the Effect of Its Anti-HBV

    Institute of Scientific and Technical Information of China (English)

    Youhua HAO; Dongliang YANG

    2008-01-01

    Human ISG20 gene was cloned and the effect of its anti-HBV was primarily studied. The ISG20 gene was amplified from HeLa cells by RT-PCR and recombinant vector expressing ISG20 was constructed by genetic engineering. The overexpression of ISG20 in HepG2 cells was detected by Western blot and the levels of secretion of HBs antigen and HBe antigen tested by ELISA. The results showed that: (1) Sequence of ISG20 cloned was consistent to that published in Genebank; (2) Recombinant vector expressing ISG20 could be expressed in HepG2 cells by transfection; (3) The overexpression of ISG20 protein could reduce the levels of the secretion of HBs antigen and HBe an-tigen in transfected HepG2 cells. It was suggested that the overexpression of recombinant ISG20 in culture cells could reduce the synthesis of HBV proteins.

  5. Long-term hepatitis B virus (HBV response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.

    Directory of Open Access Journals (Sweden)

    Woottichai Khamduang

    Full Text Available Approximately 4 million of people are co-infected with HIV and Hepatitis B virus (HBV. In resource-limited settings, the majority of HIV-infected patients initiate first-line highly active antiretroviral therapy containing lamivudine (3TC-containing-HAART and long-term virological response of HBV to lamivudine-containing HAART in co-infected patients is not well known.HIV-HBV co-infected patients enrolled in the PHPT cohort (ClinicalTrials.gov NCT00433030 and initiating a 3TC-containing-HAART regimen were included. HBV-DNA, HIV-RNA, CD4+ T-cell counts and alanine transaminase were measured at baseline, 3 months, 12 months and then every 6 months up to 5 years. Kaplan-Meier analysis was used to estimate the cumulative rates of patients who achieved and maintained HBV-DNA suppression. Of 30 co-infected patients, 19 were positive for HBe antigen (HBeAg. At initiation of 3TC-containing-HAART, median HBV DNA and HIV RNA levels were 7.35 log(10 IU/mL and 4.47 log(10 copies/mL, respectively. At 12 months, 67% of patients achieved HBV DNA suppression: 100% of HBeAg-negative patients and 47% of HBeAg-positive. Seventy-three percent of patients had HIV RNA below 50 copies/mL. The cumulative rates of maintained HBV-DNA suppression among the 23 patients who achieved HBV-DNA suppression were 91%, 87%, and 80% at 1, 2, and 4 years respectively. Of 17 patients who maintained HBV-DNA suppression while still on 3TC, 4 (24% lost HBsAg and 7 of 8 (88% HBeAg-positive patients lost HBeAg at their last visit (median duration, 59 months. HBV breakthrough was observed only in HBeAg-positive patients and 6 of 7 patients presenting HBV breakthrough had the rtM204I/V mutations associated with 3TC resistance along with rtL180M and/or rtV173L.All HBeAg-negative patients and 63% of HBeAg-positive HIV-HBV co-infected patients achieved long-term HBV DNA suppression while on 3TC-containing-HAART. This study provides information useful for the management of co-infected patients

  6. Effects of interferon-α/β on HBV replication determined by viral load.

    Directory of Open Access Journals (Sweden)

    Yongjun Tian

    2011-07-01

    Full Text Available Interferons α and β (IFN-α/β are type I interferons produced by the host to control microbial infections. However, the use of IFN-α to treat hepatitis B virus (HBV patients generated sustained response to only a minority of patients. By using HBV transgenic mice as a model and by using hydrodynamic injection to introduce HBV DNA into the mouse liver, we studied the effect of IFN-α/β on HBV in vivo. Interestingly, our results indicated that IFN-α/β could have opposite effects on HBV: they suppressed HBV replication when viral load was high and enhanced HBV replication when viral load was low. IFN-α/β apparently suppressed HBV replication via transcriptional and post-transcriptional regulations. In contrast, IFN-α/β enhanced viral replication by inducing the transcription factor HNF3γ and activating STAT3, which together stimulated HBV gene expression and replication. Further studies revealed an important role of IFN-α/β in stimulating viral growth and prolonging viremia when viral load is low. This use of an innate immune response to enhance its replication and persistence may represent a novel strategy that HBV uses to enhance its growth and spread in the early stage of viral infection when the viral level is low.

  7. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients

    Institute of Scientific and Technical Information of China (English)

    Wen-Pin Su; Chiun Hsu; Chih-Hung Hsu; Yen-Shen Lu; Hwei-Fan Tien; Tsu-Yi Chao; Li-Tzong Chen; Jacqueline Whang-Peng; Pei-Jer Chen; Chi-Chung Wen; Chao A. Hsiung; Ih-Jen Su; Ann-Lii Cheng; Ming-Chih Chang; Chao-Jung Tsao; Woei-Yao Kao; Wu-Ching Uen

    2005-01-01

    AIM: To investigate the long-term consequences of chemotherapy-related HBV reactivation in patients with lymphoma.METHODS: This study was based on the database of published prospective study evaluating HBV reactivation in HBV lymphoma patients during chemotherapy.Deteriorated liver reserve (DLR) was defined as development of either one of the following conditions during follow-up: (1) newly onset parenchyma liver disease, splenomegaly or ascites without evidence of lymphoma involvement; (2) decrease of the ratio (albumin/globulin ratio) to less than 0.8 or increase of the ratio of INR of prothrombin time to larger than 1.2 without evidence of malnutrition or infection. Liver cirrhosis was diagnosed by imaging studies.RESULTS: A total of 49 patients were included. The median follow-up was 6.2 years (range, 3.9-8.1 years).There were 31 patients with and 18 patients without HBV reactivation. Although there was no difference of overall survival (OS) and chemotherapy response rate between the two groups, DLR developed more frequently in patients with HBV reactivation (48.4% vs 16.7%; P= 0.0342). Among the HBV reactivators, HBV genotype C was associated with a higher risk of developing DLR (P = 0.0768) and liver cirrhosis (P = 0.003). Four of five patients with sustained high titer of HBV DNA and two of three patients with multiple HBV reactivation developed DLR. Further, patients with a sustained high titer of HBV DNA had the shortest OS among the HBV reactivators (P= 0.0000). No patients in the non-HBV reactivation group developed hepatic failure or liver cirrhosis.CONCLUSION: Chemotherapy-related HBV reactivation is associated with the long-term effect of deterioration of hepatic function.

  8. Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine.

    Science.gov (United States)

    Beaumont, Elodie; Roingeard, Philippe

    2015-02-18

    The development of an effective, affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. The recently described chimeric HBV-HCV subviral envelope particles could potentially be used for this purpose, as they could be produced by industrial procedures adapted from those established for the hepatitis B virus (HBV) vaccine. We show here, in an animal model, that pre-existing immunity acquired through HBV vaccination does not influence the immunogenicity of the HCV E2 protein presented by these chimeric particles. Thus, these chimeric HBV-HCV subviral envelope particles could potentially be used as a booster in individuals previously vaccinated against HBV, to induce protective immunity to HCV. PMID:25596457

  9. Seroprevalence of HIV, HBV, HCV and syphilis in blood donors in Southern Haryana.

    Science.gov (United States)

    Arora, Dimple; Arora, Bharti; Khetarpal, Anshul

    2010-01-01

    Blood transfusion is an important mode of transmission of infections to recipients. The aim of the study was to assess the prevalence of transfusion-transmissible infections among blood donors. For this, a 3.5-year retrospective study, from October 2002 to April 2006 was conducted at the blood transfusion centre of Maharaja Agrasen Medical College, Agroha (Hisar) Haryana. Donors were screened for seroprevalence of HIV, HBV, HCV and syphilis. A total of 5849 donors were tested, out of which 4010 (68.6%) were replacement donors and 1839 (31.4%) were voluntary donors. The seroprevalence of HIV was 0.3% in the donors. No voluntary donor was found to be positive for HIV. The low sero-positivity among donors is attributed to pre-donation counseling in donor selection. The seroprevalence of HBV, HCV and syphilis was 1.7%, 1.0% and 0.9% respectively in total donors. The seroprevalence of hepatitis and syphilis was more in replacement donors as compared to voluntary donors. PMID:20551540

  10. 中国株乙型肝炎病毒感染性克隆的构建及在Huh7细胞中的表达%Construction of recombinant eukaryotic expression plasmid containing 1.3-fold-overlength genome of HBV and its expression in Huh7 cells

    Institute of Scientific and Technical Information of China (English)

    陆仁飞; 吴月平; 孙伟; 鲍静

    2015-01-01

    目的:构建乙型肝炎病毒(hepatitis B virus,HBV)中国株的1.3倍基因组长度的感染性克隆质粒,观察质粒在人肝癌细胞株Huh7中的表达,建立中国株HBV体外研究细胞模型。方法:从乙型肝炎患者血清中提取HBV DNA,通过重叠延伸 PCR 技术(gene splicing by overlap extension PCR,SOE-PCR)构建HBV 1.3倍基因组长度的感染性克隆质粒 pHBV1.3(C),将感染性克隆 pHBV1.3(C)质粒转染人肝癌细胞株Huh7,采用Western Blot、ELISA及Real-time PCR 检测病毒复制及表达情况以及该感染性克隆对临床抗病毒药物阿德福韦的敏感性。结果:构建了中国株HBV 感染性克隆pHBV1.3(C)质粒,该质粒能在肝癌细胞株中进行有效复制、转录和表达。阿德福韦能在体外抑制该HBV感染性克隆的复制。结论:构建的中国株HBV 1.3倍基因组感染性克隆在体外具有高水平复制能力,其转染细胞可望成为一种新型的 HBV 体外感染模型。%Objective To construct 1.3-fold-overlength infectious clone of hepatitis B virus isolated from Chinese patients , observe the expression of plasmid in Huh7 of liver cancer cells and establish genome of HBV in vitro. Methods HBV DNA in serum was extracted from HBV patient. SOE-PCR was performed to produce a 1.3-fold-overlength genome of HBV. The plasmid was named pHBV1.3 (C). After that,pHBV1.3 (C) was transfected into Huh7 cells, HBV related viral antigens and DNA were detected by ELISA,Western Blot and Fluorescence quantitative PCR. Furthermore, adefovir dipivoxil, a clinic anti-viral drug, was utilized to test the sensitivity of the new infectious clone. Results An infectious clone of pHBV1.3 (C) was successfully constructed. HBV gene carried in pHBV1.3 (C) could be efficiently replicated and expressed in Huh7 cells. Adefovir could inhibit HBV replication in this HBV cell model. Conclusions A recombinant plasmid containing 1.3-fold

  11. A low proportion of HBeAg among HBsAg-positive pregnant women with known HIV status could suggest low perinatal transmission of HBV in Cameroon

    Directory of Open Access Journals (Sweden)

    Kfutwah Anfumbom KW

    2012-03-01

    Full Text Available Abstract Background Transmission of hepatitis B virus (HBV from HBV-positive mothers to their infants is common and usually occurs when the mother is hepatitis B e antigen (HBeAg positive and/or has a high HBV DNA load. In this study, we determined the prevalence of hepatitis B surface antigen (HBsAg and HBeAg among pregnant women with known HIV status. Findings A total of 650 pregnant women with a mean age of 26.2 years including 301 HIV-positives and 349 HIV-negatives were screened for HBsAg (Monolisa AgHBs Plus Biorad, France. Among the HBsAg-positives, HBeAg and anti-HBe were tested (Monolisa Ag HBe Plus Biorad, France. Overall, 51 (7.85% were positive for HBsAg. The prevalence of HBsAg was not statistically different between HIV-positive and HIV-negative pregnant women [28/301 (9.3% vs 23/349 (6.59%; p = 0.2]. None of the 45 HBsAg-positive samples was reactive for HBeAg. Conclusions Our study indicates a high prevalence of HBsAg with very low proportion of HBeAg in Cameroonian pregnant women. Since perinatal transmission of HBV is mostly effective when the mother is also HBeAg-positive, our data could suggest that perinatal transmissions play a minor role in HBV prevalence in Cameroon. In line with previous African studies, these findings further suggests that horizontal transmission could be the most common mechanism of HBV infections in Cameroon.

  12. Development of fatal acute liver failure in HIV-HBV coinfected patients

    Institute of Scientific and Technical Information of China (English)

    Albert; M; Anderson; Marina; B; Mosunjac; Melody; P; Palmore; Melissa; K; Osborn; Andrew; J; Muir

    2010-01-01

    Coinfection with hepatitis B virus(HBV) is not uncommon in human immunodeficiency virus(HIV)-infected individuals and patients with HIV-HBV coinfection are at high risk for progression of liver disease.Current guidelines regarding the treatment of HIV infection recommend that patients who are coinfected with HIV and HBV receive highly active antiretroviral therapy(HAART) with activity against hepatitis B.While HIVHBV coinfected patients often experience liver enzyme elevations after starting antiretroviral ...

  13. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection

    Directory of Open Access Journals (Sweden)

    Raul Carlos Wahle

    2015-10-01

    Full Text Available ABSTRACTIn coinfected HBV/HCV patients, HBV replication is usually suppressed by HCV over the time. No study to date has evaluated the HBV viremia in long-term follow-up after HCV treatment in hemodialysis patients with HBV/HCV coinfection. This study aimed to assess the evolution of HBV viremia after HCV treatment in this special population. Ten hemodialysis patients with HBV/HCV coinfection with dominant HCV infection (HBV lower than 2000 IU/mL and significant fibrosis were treated with interferon-alpha 3 MU 3×/week for 12 months and could be followed for at least 36 months after HCV treatment. Six cases of HBV reactivation (60% during follow-up were observed and 5/6 had been successfully treated for HCV. Patients with HBV reactivation received anti-HBV therapy. Our preliminary findings indicate that treatment of hepatitis C in HBV/HCV coinfected hemodialysis patients may favor HBV reactivation. Thus, continued monitoring of HBV viremia must be recommended and prompt anti-HBV therapy should be implemented.

  14. High prevalence of human parvovirus 4 infection in HBV and HCV infected individuals in shanghai.

    Science.gov (United States)

    Yu, Xuelian; Zhang, Jing; Hong, Liang; Wang, Jiayu; Yuan, Zhengan; Zhang, Xi; Ghildyal, Reena

    2012-01-01

    Human parvovirus 4 (PARV4) has been detected in blood and diverse tissues samples from HIV/AIDS patients who are injecting drug users. Although B19 virus, the best characterized human parvovirus, has been shown to co-infect patients with hepatitis B or hepatitis C virus (HBV, HCV) infection, the association of PARV4 with HBV or HCV infections is still unknown.The aim of this study was to characterise the association of viruses belonging to PARV4 genotype 1 and 2 with chronic HBV and HCV infection in Shanghai.Serum samples of healthy controls, HCV infected subjects and HBV infected subjects were retrieved from Shanghai Center for Disease Control and Prevention (SCDC) Sample Bank. Parvovirus-specific nested-PCR was performed and results confirmed by sequencing. Sequences were compared with reference sequences obtained from Genbank to derive phylogeny trees.The frequency of parvovirus molecular detection was 16-22%, 33% and 41% in healthy controls, HCV infected and HBV infected subjects respectively, with PARV4 being the only parvovirus detected. HCV infected and HBV infected subjects had a significantly higher PARV4 prevalence than the healthy population. No statistical difference was found in PARV4 prevalence between HBV or HCV infected subjects. PARV4 sequence divergence within study groups was similar in healthy subjects, HBV or HCV infected subjects.Our data clearly demonstrate that PARV4 infection is strongly associated with HCV and HBV infection in Shanghai but may not cause increased disease severity.

  15. How immigration can change the prevalence of HBV infection in an urban area of Northern Italy

    OpenAIRE

    Massimo De Paschale; Maria Teresa Manco; Luisa Belvisi; Carlo Magnani; Tiziana Re; Paolo Viganò; Sara Biagiotti; Francesca Capelli; Antonino Mazzone; Maria Pia Baldacci; Aldo Ferrara; Anna Lisa Neri; Carlo Maria Guastoni; Riccardo Armando Bonazzina; Bruno Brando

    2011-01-01

    The introduction of HBV vaccination in Italy has led to a decline in new HBV infections. Increasing immigration over recent years suggests a change in short-term epidemiology of HBV. The aim of this study was to assess the prevalence of HBV infection in the general population living in the catchment area of Legnano Hospital (Northern Italy). In the period 2007-2008, 22,758 inpatients and outpatients were examined for Hepatitis B surface antigen (HBsAg), of whom 1,654 (7.3%) were of foreign or...

  16. Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication.

    Science.gov (United States)

    Murphy, Christopher M; Xu, Yanping; Li, Feng; Nio, Kouki; Reszka-Blanco, Natalia; Li, Xiaodong; Wu, Yaxu; Yu, Yanbao; Xiong, Yue; Su, Lishan

    2016-09-13

    The hepatitis B virus (HBV) regulatory protein X (HBx) activates gene expression from the HBV covalently closed circular DNA (cccDNA) genome. Interaction of HBx with the DDB1-CUL4-ROC1 (CRL4) E3 ligase is critical for this function. Using substrate-trapping proteomics, we identified the structural maintenance of chromosomes (SMC) complex proteins SMC5 and SMC6 as CRL4(HBx) substrates. HBx expression and HBV infection degraded the SMC5/6 complex in human hepatocytes in vitro and in humanized mice in vivo. HBx targets SMC5/6 for ubiquitylation by the CRL4(HBx) E3 ligase and subsequent degradation by the proteasome. Using a minicircle HBV (mcHBV) reporter system with HBx-dependent activity, we demonstrate that SMC5/6 knockdown, or inhibition with a dominant-negative SMC6, enhance HBx null mcHBV-Gluc gene expression. Furthermore, SMC5/6 knockdown rescued HBx-deficient HBV replication in human hepatocytes. These results indicate that a primary function of HBx is to degrade SMC5/6, which restricts HBV replication by inhibiting HBV gene expression. PMID:27626656

  17. O-glycosylation inhibition induce HBV release%抑制O-糖基化修饰促进乙型肝炎病毒的释放

    Institute of Scientific and Technical Information of China (English)

    肖凡; 乔雍; 张仁雯; 常路丝; 成军; 魏红山

    2013-01-01

    目的:探讨抑制O-糖基化修饰对乙型肝炎病毒颗粒组装的影响。方法采用O-糖基化修饰抑制剂Benzyl-α-GalNAc干预HepG2.2.15细胞。经7-AAD染色,应用流式细胞仪检测细胞凋亡情况。采用实时荧光定量PCR方法检测上清HBV病毒载量。应用酶联免疫吸附试验(ELISA)检测上清乙型肝炎病毒大蛋白(the hepatitis B virus large surface protein,HBV LHBs)水平。采用蛋白免疫印迹(Western blot)方法检测细胞中LHBs蛋白含量。结果 Benzyl-α-GalNAc能显著促进细胞凋亡,上清中HBV DNA和LHBs水平呈剂量依赖性增加;Benzyl-α-GalNAc抑制细胞中LHBs蛋白表达。结论抑制细胞O-糖基化修饰促进细胞凋亡,从而释放HBV LHBs和病毒颗粒;但在某种程度上抑制细胞O-糖基化修饰能够抑制细胞内LHBs合成。%Objective To investigate the effect of the inhibition of O-glycosylation on HBV assembly. Methods HepG2.2.15 cells treated with O-glycosylation inhibitor, Benzyl-α-GalNAc, were dyed with 7-AAD and examined by FACS for cell apoptosis. HBV DNA loading in cell supernatant was determined by real-time PCR. HBV LHBs levels in cell supernatant was tested by ELISA. LHBs levels in cells was analyzed by Western blot. Results Benzyl-α-GalNAc could signiifcantly induce cell apoptosis. HBV DNA and LHBs levels in cell supernatant were increased in a dose dependent manner. However, Benzyl-α-GalNAc inhibited LHBs synthesis. Conclusions Inhibition of O-glycosylation could induce cell apoptosis and release HBV LHBs and virus. In some extent, inhibition of O-glycosylation may inhibit LHBs synthesis.

  18. 核酸检测在血液HBV筛查中的应用研究%Application of NAT detection for HBV in blood screening

    Institute of Scientific and Technical Information of China (English)

    王芳; 金钊; 林松峰; 栾燕; 刘显智

    2010-01-01

    目的:了解沈阳地区乙型肝炎病毒表面抗原(HBsAg)阴性献血者中乙型肝炎病毒(hepatitis B virus,HBV)感染状况,探讨HBV核酸扩增检测(nucleic acid amplification testing,NAT)技术应用于血液筛查的意义.方法:在酶联免疫法(enzyine immunoassay,EIA)检测的基础上,应用TaqMan实时荧光聚合酶链式反应(PCR)方法对HBsAg EIA阴性血液标本进行HBV DNA的NAT检测.对NAT阳性标本进一步做乙型肝炎病毒血清标志物(HBV Marker,HBV-M)及核酸定量检测.结果:共检测了105,152例HBsAg阴性的血液标本,检出HBV DNA阳性标本15例,阳性率0.014%.Abbott酶联免疫试剂检测发现,15例标本中有6例标本的HBV-M五项指标检测全部阴性,9例为HBsAg阴性但其它标志物阳性.其中10例HBV DNA阳性标本再经Roche试剂进行核酸定量检测,HBV DNA核酸含量最高为149 IU/ml.结论:在HBsAg ELA阴性献血者中仍有极少数的HBV感染者;核酸扩增检测和酶联免疫检测互补,能够缩短血液筛查中HBV检测窗口期,特别是对提高HBsAg阴性血液标本中HBV感染检出率具有重要价值.

  19. Combined Detection of Hepatitis B five,Pre S1 antigen and HBV-DNA Value in Clinical Application%联合检测乙型病毒性肝炎五项、前S1抗原与HBV-DNA的临床应用价值

    Institute of Scientific and Technical Information of China (English)

    刘绮婷; 黎阳成; 何秋贤

    2015-01-01

    目的 探讨联合检测乙型病毒性肝炎五项、前S1抗原与乙型肝炎病毒脱氧核糖核酸(HBV-DNA)的临床关系,评估其在乙型肝炎病毒(HBV)检测中的临床价值.方法 将2011年9月至2013年9月于我院接受治疗的100例乙型病毒性肝炎表面抗原阳性患者作为研究对象,收集其临床资料,采集所有患者肘静脉血液,并选用定量法与酶联免疫吸附试验进行乙型病毒性肝炎五项、前S1抗原及HBV-DNA检测,评估其临床价值.结果 在不同的乙型病毒性肝炎五项模式下,前S1抗原与HBV-DNA检测结果比较差异无统计学意义(P>0.05);两组患者HBV-DNA与乙型病毒性肝炎前S1抗原检出符合率比较差异无统计学意义(P>0.05).结论 选用乙型病毒性肝炎前S1抗原与HBV-DNA联合检测能提高乙型病毒性肝炎的检出率,指导其治疗与预后有重要意义.%Objective To investigate the combined detection of hepatitis B five,pre-S1 antigen clinical relationship with HBV-DNA to assess the clinical value of hepatitis B virus(HBV)detection.Methods The September 2011 to September 2013 in our hospital treated 100 cases of hepatitis B surface antigen-positive patients as research subjects,the colection of clinical data colected for al patients cubital vein blood,and the choice of method and quantitative enzyme-linked immunosorbent assay the hepatitis B five,pre-S1 antigen and HBV-DNA detection method to assess the clinical relationship.Results Hepatitis B in five different models,pre-S1 antigen and HBV-DNA test results showed no significant difference(P>0.05);patients were HBV-DNA and HBV pre-S1 antigen detection rate is relatively consistent with the difference was not statisticaly significant(P>0.05).Conclusion Pre-selection of hepatitis B antigen and HBV-DNA S1 joint detection of hepatitis B to improve the detection rate,to guide their treatment and prognosis are important.

  20. Investigation of the relationship between serological markers of hepatitis B virus infection and HBV-DNA%乙型肝炎病毒感染血清学标志物与HBV-DNA的关系探讨

    Institute of Scientific and Technical Information of China (English)

    黄洁; 吴建华

    2014-01-01

    Objective To investigate the relationship between serum hepatitis B virus markers (HBV-M ) and HBV-DNA . Methods Enhanced chemiluminescence enzyme immunoassay (ECLIA ) and real-time fluorescent quantitative polymerase chain re-action(FQ-PCR) were employed to detect HBV-M and HBV-DNA in 262 serum samples ,respectively .HBV surface antigen(HB-sAg) ,anti-HBV surface antibody(HBsAb) ,HBV e antigen(HBeAg) ,anti-HBV e antibody(HBeAb) ,anti-HBV core antibody(HB-cAb) were included in HBV-M .Results Compared the positive rates of HBV-DNA ,HBsAg ,HBeAb in HBeAg-negative patients with those in HBeAg-positive patients ,the differences were statistically significant (P< 0 .01) .29(36 .7% ) patients with HBV-DNA logarithm value not less than 5 were found in HBeAg-negative patients .Differences of HBeAg ,HBeAb positive rates among patients with different ages were statistically significant (P<0 .01) .25 patients with HBsAg less than 250 IU/mL were found in HBV-DNA-positive patients ,12(48 .0% ) of which showed HBV-DNA logarithm value not less than 5 .HBV-DNA logarithm value of HBV-DNA-positive patients was positively correlated to HBeAg and HBeAb (r= 0 .542 ,0 .607 ,P< 0 .01) .Conclusion Com-bined detection of HBV-M and HBV-DNA contributes to estimating the HBV infection .%目的:探讨血清乙型肝炎病毒标志物(HBV-M )与 HBV-DNA之间的关系。方法分别采用增强化学发光酶联免疫分析(ECLIA )技术及实时荧光定量聚合酶链反应(FQ-PCR)对262例血清进行 HBV-M、HBV-DNA检测,HBV-M 包括 HBV表面抗原(HBsAg)、抗HBV表面抗体(HBsAb)、HBV e抗原(HBeAg)、抗 HBV e抗体(HBeAb)、抗 HBV核心抗体(HBcAb)。结果 HBeAg 阴性患者的 HBV-DNA、HBsAg、HBeAb阳性率与 HBeAg 阳性患者比较,差异均有统计学意义( P<0.01)。HBeAg阴性患者 HBV-DNA对数值不低于5的有29例(36.7%)。不同年龄患者 HBeAg、HBeAb阳性率的差异有统计学意义(P<0.01)。HBV

  1. Performance evaluation of new automated hepatitis B viral markers in the clinical laboratory: two quantitative hepatitis B surface antigen assays and an HBV core-related antigen assay.

    Science.gov (United States)

    Park, Yongjung; Hong, Duck Jin; Shin, Saeam; Cho, Yonggeun; Kim, Hyon-Suk

    2012-05-01

    We evaluated quantitative hepatitis B surface antigen (qHBsAg) assays and a hepatitis B virus (HBV) core-related antigen (HBcrAg) assay. A total of 529 serum samples from patients with hepatitis B were tested. HBsAg levels were determined by using the Elecsys (Roche Diagnostics, Indianapolis, IN) and Architect (Abbott Laboratories, Abbott Park, IL) qHBsAg assays. HBcrAg was measured by using Lumipulse HBcrAg assay (Fujirebio, Tokyo, Japan). Serum aminotransferases and HBV DNA were respectively quantified by using the Hitachi 7600 analyzer (Hitachi High-Technologies, Tokyo, Japan) and the Cobas AmpliPrep/Cobas TaqMan test (Roche). Precision of the qHBsAg and HBcrAg assays was assessed, and linearity of the qHBsAg assays was verified. All assays showed good precision performance with coefficients of variation between 4.5% and 5.3% except for some levels. Both qHBsAg assays showed linearity from 0.1 to 12,000.0 IU/mL and correlated well (r = 0.9934). HBsAg levels correlated with HBV DNA (r = 0.3373) and with HBcrAg (r = 0.5164), and HBcrAg also correlated with HBV DNA (r = 0.5198; P HBcrAg assays.

  2. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: A national multicenter study

    Directory of Open Access Journals (Sweden)

    Asare Isaac

    2008-03-01

    Full Text Available Abstract Background Prisons are known to be high-risk environments for the spread of bloodborne and sexually transmitted infections. Prison officers are considered to have an intermittent exposure potential to bloodborne infectious diseases on the job, however there has been no studies on the prevalence of these infections in prison officers in Ghana. Methods A national multicenter cross-sectional study was undertaken on correlates of human immunodeficiency virus (HIV, hepatitis B virus (HBV, hepatitis C virus (HCV, and syphilis infections in sample of prison inmates and officers from eight of ten regional central prisons in Ghana. A total of 1366 inmates and 445 officers were enrolled between May 2004 and December 2005. Subjects completed personal risk-factor questionnaire and provided blood specimens for unlinked anonymous testing for presence of antibodies to HIV, HCV and Treponema pallidum; and surface antigen of HBV (HBsAg. These data were analyzed using both univariate and multivariate techniques. Results Almost 18% (1336 of 7652 eligible inmates and 21% (445 of 2139 eligible officers in eight study prisons took part. Median ages of inmates and officers were 36.5 years (range 16–84 and 38.1 years (range 25–59, respectively. Among inmates, HIV seroprevalence was 5.9%, syphilis seroprevalence was 16.5%, and 25.5% had HBsAg. Among officers tested, HIV seroprevalence was 4.9%, HCV seroprevalence was 18.7%, syphilis seroprevalence was 7.9%, and 11.7% had HBsAg. Independent determinants for HIV, HBV and syphilis infections among inmates were age between 17–46, being unmarried, being illiterate, female gender, being incarcerated for longer than median time served of 36 months, history of homosexuality, history of intravenous drug use, history of sharing syringes and drug paraphernalia, history of participation in paid sexual activity, and history of sexually transmitted diseases. Independent determinants for HIV, HBV, HCV and syphilis

  3. IL-35 inhibits HBV antigen-specific IFN-γ-producing CTLs in vitro.

    Science.gov (United States)

    Li, Xuefen; Tian, Li; Dong, Yuejiao; Zhu, Qiaoyun; Wang, Yiyin; Han, Wenzheng; Liu, Xia; Ni, Qin; Chen, Yu; Li, Lanjuan

    2015-09-01

    Interleukin (IL)-35 is an inhibitory cytokine consisting of IL-12A and Epstein-Barr virus-induced gene 3 (Ebi3) and is required by regulatory T-cells (Tregs) for maximal activity. During chronic hepatitis B virus (HBV) infection, Tregs have immunosuppressive effects on HBV-specific T helper (Th) cells, yet little is known about the complex regulation of Tregs and their contribution to the inadequate immune system response to the virus. In the present study, we investigated whether IL-35 is involved in HBV-related cellular immune responses. Cluster of differentiation (CD)4(+) T-cells from peripheral blood were derived from healthy volunteers, resolved HBV individuals and chronic active hepatitis B patients and stimulated with CD3/28-conjugated beads. We analysed mRNA and protein levels of IL-35 and assessed the inhibitory effect of IL-35 on HBV core antigen-specific cytotoxic T lymphocytes (CTLs), dendritic cells (DCs) and effector T-cells (Teffs). Correlation analyses between liver inflammation and HBV DNA load were conducted. Results show that chronic HBV patients harbour significantly higher levels of Ebi3 mRNA and protein in CD4(+) T-cells compared with healthy volunteers and resolved HBV individuals. IL-35 suppressed the proliferation of HBV antigen-specific CTLs and interferon (IFN)-γ production in vitro. Ex vivo, IL-35 decreased the proliferation of CD4(+)CD45RA(+) naïve T-cells, especially in CD4(+)CD25(-)CD45RA(+) naïve Teffs. IL-35 inhibited the expansion of CD11c(+) DCs. Our data indicate that IL-35 is highly expressed in chronic HBV CD4(+) T-cells and plays an important role in the inhibition of the cellular immune response in chronic HBV.

  4. Sleeping Beauty transposon-based system for rapid generation of HBV-replicating stable cell lines.

    Science.gov (United States)

    Wu, Yong; Zhang, Tian-Ying; Fang, Lin-Lin; Chen, Zi-Xuan; Song, Liu-Wei; Cao, Jia-Li; Yang, Lin; Yuan, Quan; Xia, Ning-Shao

    2016-08-01

    The stable HBV-replicating cell lines, which carry replication-competent HBV genome stably integrated into the genome of host cell, are widely used to evaluate the effects of antiviral agents. However, current methods to generate HBV-replicating cell lines, which are mostly dependent on random integration of foreign DNA via plasmid transfection, are less-efficient and time-consuming. To address this issue, we constructed an all-in-one Sleeping Beauty transposon system (denoted pTSMP-HBV vector) for robust generation of stable cell lines carrying replication-competent HBV genome of different genotype. This vector contains a Sleeping Beauty transposon containing HBV 1.3-copy genome with an expression cassette of the SV40 promoter driving red fluorescent protein (mCherry) and self-cleaving P2A peptide linked puromycin resistance gene (PuroR). In addition, a PGK promoter-driven SB100X hyperactive transposase cassette is placed in the outside of the transposon in the same plasmid.The HBV-replicating stable cells could be obtained from pTSMP-HBV transfected HepG2 cells by red fluorescence-activated cell sorting and puromycin resistant cell selection within 4-week. Using this system, we successfully constructed four cell lines carrying replication-competent HBV genome of genotypes A-D. The replication and viral protein expression profiles of these cells were systematically characterized. In conclusion, our study provides a high-efficiency strategy to generate HBV-replicating stable cell lines, which may facilitate HBV-related virological study.

  5. Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line

    Institute of Scientific and Technical Information of China (English)

    Wei He; Li-Xia Li; Qing-Jiao Liao; Chun-Lan Liu; Xu-Lin Chen

    2011-01-01

    AIM: To analyze the antiviral mechanism of Epigallocatechin gallate (EGCG) against hepatitis B virus (HBV) replication. METHODS: In this research, the HBV-replicating cell line HepG2.117 was used to investigate the antiviral mechanism of EGCG. Cytotoxicity of EGCG was analyzed by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Hepatitis B virus e antigen (HBeAg) and hepatitis B virus surface antigen (HBsAg) in the supernatant were detected by enzyme-linked immunosorbent assay. Precore mRNA and pregenomic RNA (pgRNA) levels were determined by semi-quantitative reverse transcription polymerase chain reaction (PCR) assay. The effect of EGCG on HBV core promoter activity was measured by dual luciferase reporter assay. HBV covalently closed circular DNA and replicative intermediates of DNA were quantified by real-time PCR assay. RESULTS: When HepG2.117 cells were grown in the presence of EGCG, the expression of HBeAg was suppressed, however, the expression of HBsAg was not affected. HBV precore mRNA level was also downregulated by EGCG, while the transcription of precore mRNA was not impaired. The synthesis of both HBV covalently closed circular DNA and replicative intermediates of DNA were reduced by EGCG treatment to a similar extent, however, HBV pgRNA transcripted from chromosome-integrated HBV genome was not affected by EGCG treatment, indicating that EGCG targets only replicative intermediates of DNA synthesis. CONCLUSION: In HepG2.117 cells, EGCG inhibits HBV replication by impairing HBV replicative intermediates of DNA synthesis and such inhibition results in reduced production of HBV covalently closed circular DNA.

  6. Sleeping Beauty transposon-based system for rapid generation of HBV-replicating stable cell lines.

    Science.gov (United States)

    Wu, Yong; Zhang, Tian-Ying; Fang, Lin-Lin; Chen, Zi-Xuan; Song, Liu-Wei; Cao, Jia-Li; Yang, Lin; Yuan, Quan; Xia, Ning-Shao

    2016-08-01

    The stable HBV-replicating cell lines, which carry replication-competent HBV genome stably integrated into the genome of host cell, are widely used to evaluate the effects of antiviral agents. However, current methods to generate HBV-replicating cell lines, which are mostly dependent on random integration of foreign DNA via plasmid transfection, are less-efficient and time-consuming. To address this issue, we constructed an all-in-one Sleeping Beauty transposon system (denoted pTSMP-HBV vector) for robust generation of stable cell lines carrying replication-competent HBV genome of different genotype. This vector contains a Sleeping Beauty transposon containing HBV 1.3-copy genome with an expression cassette of the SV40 promoter driving red fluorescent protein (mCherry) and self-cleaving P2A peptide linked puromycin resistance gene (PuroR). In addition, a PGK promoter-driven SB100X hyperactive transposase cassette is placed in the outside of the transposon in the same plasmid.The HBV-replicating stable cells could be obtained from pTSMP-HBV transfected HepG2 cells by red fluorescence-activated cell sorting and puromycin resistant cell selection within 4-week. Using this system, we successfully constructed four cell lines carrying replication-competent HBV genome of genotypes A-D. The replication and viral protein expression profiles of these cells were systematically characterized. In conclusion, our study provides a high-efficiency strategy to generate HBV-replicating stable cell lines, which may facilitate HBV-related virological study. PMID:27091097

  7. Reactive oxygen species promote heat shock protein 90-mediated HBV capsid assembly

    International Nuclear Information System (INIS)

    Hepatitis B virus (HBV) infection induces reactive oxygen species (ROS) production and has been associated with the development of hepatocellular carcinoma (HCC). ROS are also an important factor in HCC because the accumulated ROS leads to abnormal cell proliferation and chromosome mutation. In oxidative stress, heat shock protein 90 (Hsp90) and glutathione (GSH) function as part of the defense mechanism. Hsp90 prevents cellular component from oxidative stress, and GSH acts as antioxidants scavenging ROS in the cell. However, it is not known whether molecules regulated by oxidative stress are involved in HBV capsid assembly. Based on the previous study that Hsp90 facilitates HBV capsid assembly, which is an important step for the packing of viral particles, here, we show that ROS enrich Hsp90-driven HBV capsid formation. In cell-free system, HBV capsid assembly was facilitated by ROS with Hsp90, whereas it was decreased without Hsp90. In addition, GSH inhibited the function of Hsp90 to decrease HBV capsid assembly. Consistent with the result of cell-free system, ROS and buthionine sulfoximine (BS), an inhibitor of GSH synthesis, increased HBV capsid formation in HepG2.2.15 cells. Thus, our study uncovers the interplay between ROS and Hsp90 during HBV capsid assembly. - Highlights: • We examined H2O2 and GSH modulate HBV capsid assembly. • H2O2 facilitates HBV capsid assembly in the presence of Hsp90. • GSH inhibits function of Hsp90 in facilitating HBV capsid assembly. • H2O2 and GSH induce conformation change of Hsp90

  8. Reactive oxygen species promote heat shock protein 90-mediated HBV capsid assembly

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Yoon Sik, E-mail: yumshak@naver.com; Seo, Hyun Wook, E-mail: suruk@naver.com; Jung, Guhung, E-mail: drjung@snu.ac.kr

    2015-02-13

    Hepatitis B virus (HBV) infection induces reactive oxygen species (ROS) production and has been associated with the development of hepatocellular carcinoma (HCC). ROS are also an important factor in HCC because the accumulated ROS leads to abnormal cell proliferation and chromosome mutation. In oxidative stress, heat shock protein 90 (Hsp90) and glutathione (GSH) function as part of the defense mechanism. Hsp90 prevents cellular component from oxidative stress, and GSH acts as antioxidants scavenging ROS in the cell. However, it is not known whether molecules regulated by oxidative stress are involved in HBV capsid assembly. Based on the previous study that Hsp90 facilitates HBV capsid assembly, which is an important step for the packing of viral particles, here, we show that ROS enrich Hsp90-driven HBV capsid formation. In cell-free system, HBV capsid assembly was facilitated by ROS with Hsp90, whereas it was decreased without Hsp90. In addition, GSH inhibited the function of Hsp90 to decrease HBV capsid assembly. Consistent with the result of cell-free system, ROS and buthionine sulfoximine (BS), an inhibitor of GSH synthesis, increased HBV capsid formation in HepG2.2.15 cells. Thus, our study uncovers the interplay between ROS and Hsp90 during HBV capsid assembly. - Highlights: • We examined H{sub 2}O{sub 2} and GSH modulate HBV capsid assembly. • H{sub 2}O{sub 2} facilitates HBV capsid assembly in the presence of Hsp90. • GSH inhibits function of Hsp90 in facilitating HBV capsid assembly. • H{sub 2}O{sub 2} and GSH induce conformation change of Hsp90.

  9. 携带乙型肝炎病毒产妇血清与初乳HBV DNA载量关联性研究%The Relationship between Serum HBV DNA Quantities and Colostrum HBV DNA Quantities among HBV-positive Lying-in women

    Institute of Scientific and Technical Information of China (English)

    黄晨艳; 陶芳标; 方有兵; 蔡娟; 黛垠之; 陆天慧; 王黎; 李启发; 孟祥莲; 张育苗

    2011-01-01

    目的 研究产妇血清与其初乳汁乙型肝炎病毒(HBV) DNA载量的关联性.方法 选取住院分娩产妇共522例,依据HBV五项血清学指标,分为A组:乙肝"HBsAg、HBeAg、HBcAb均阳性"103例,B组:乙肝"HBsAg、HBeAb、HBcAb均阳性"221例,C组:HBsAg、HBeAg阳性20例,D组:HBsAg、HBcAb阳性43例,E组:乙肝其他血清模式49例,另选F组:HBV模式全阴性的产妇86例作为对照组;均采用ELISA法检测产妇血清、乳汁中HBV标志物HBsAg、HBsAb、HBeAg、HBeAb、HBcAb,阳性者采用该项目胶体金标试纸复核,同时采用实时荧光定量PCR检测产妇血清和乳汁HBV DNA载量,对相关数据进行统计分析.结果 对年龄18~44岁围产期妇女体检乙肝感染指标,A组乙肝"HBsAg、HBeAg、HBcAb均阳性"产妇血清和乳汁HBV DNA诊断灵敏度分别为100.00%(103/103)和86.41%(89/103)、血清HBV DNA载量平均为4.11×108 copies/ml;B组乙肝"HBsAg、HBeAb、HBcAb均阳性"产妇血清和乳汁HBV DNA诊断灵敏度分别为19.46%(43/221)和2.71%(6/221),血清HBV DNA载量平均为6.85×104 copies/ml ;C组乙肝HBsAg、HBeAg阳性产妇血清和乳汁HBV DNA诊断灵敏度分别为100.00%(20/20)和80.00%(16/20),血清HBV DNA载量平均为8.27×106 copies/ml ;D组HBsAg、HBcAb阳性产妇血清和乳汁HBV DNA诊断灵敏度分别为65.12%(28/43)和25.58%(11/43),血清HBV DNA载量平均为2.89×105 copies/ml ;E组HBV其他模式产妇血清和乳汁HBV DNA诊断灵敏度分别为10.20%(5/49)和2.04%(1/49),血清HBV DNA载量平均为1.59×104 copies/ml ;F组乙肝五项全阴性产妇血清和乳汁HBV DNA诊断灵敏度分别为1.16%(1/86)和0(0/86),血清HBV DNA载量<1.00×103 copies/ml.A组与B组间乳汁HBV DNA实验诊断阳性差异有统计学意义(χ2=237.45,P<0.01).HBV携带者乳汁HBV DNA载量与其血液HBV DNA载量呈正相关(r=0.721).结论 携带HBV产妇乳汁HBV DNA载量远低于血液HBV DNA载量;乳汁中HBV传染性也低于血液传染性;研究证实A组产

  10. 皖北地区乙型肝炎患者HBV血清标志物与HBV-DNA定量检测的比较%Comparison of HBV-M and HBV-DNA detection in HBV infectors in the North of Anhui

    Institute of Scientific and Technical Information of China (English)

    昝丽娜; 石秀芳; 孙峰

    2013-01-01

    Objective: To compare the detection results of HBV-M and HBV-DNA. Methods: All 388 HBV patients were detected for the HBV-M by ELISA and HBV-DNA by FQ-PCR. Results:The positive rate of HBV-DNA in the group of HBsAg(+)/HBeAg(+)/ HBcAb(+) was 91.25% ,and the majority of the virus replication was 107 IU/ml; while the majority of the virus replication in the group of HBsAg(+)/HBeAb(+)/ HBcAb(+) was 103 IU/ml. The positive rate of HBV-DNA in the group of HBsAgAb(+)/ HBeAg(+)/HBc(+) was higher than that in the group of HBsAg(+)/HBeAb(+)/HBcAb(+) (P <0.05) . The positive rate of HBV-DNA in the group of HBsAg(+)/HBeAg(±)/ HBc(+) Ab was 66. 67% . The majority of the virus replication was 105 IU/ml and 106 IU/ml in patients with positive HBsAg(+)/HBeAg(+)/HBc(-) Ab. The positive rate of HBV-DNA in the group of HBsAg (+)/HBeAg(-)/HBcAb(+) was 30.77%. Conclusions: Patients with HBeAg(+) have the highest replication level in all the groups,which is closely associated with HBV-DNA. Virus replication in patients with HBeAb(+) and HBcAb(+) does not stop completely, but obviously decreases. Combination detection of HBV-M and HBV-DNA may display the immune status and virus replication level of patients with hepatitis B, which would provide experimental basis for clinical monitoring and drug administration.%目的:比较乙型肝炎病毒血清标志物(HBV-M)与HBV-DNA定量检测的结果.方法:采用酶联免疫法检测388例患者血清HBV-M,同时用荧光定量-聚合酶链反应检测其HBV-DNA含量.结果:乙型肝炎大三阳组患者血清HBV-DNA阳性率为91.25%,阳性患者中HBV拷贝数为107 IU/ml的所占比例最多,小三阳组阳性患者中HBV拷贝数以103 IU/ml为主,大三阳组患者血清HBV-DNA阳性率高于小三阳组(P<0.05);HBsAg(+)、HBeAg(±)、抗-HBc(+)组阳性率为66.67%;HBsAg(+)、HBeAg(+)、抗HBc(-)组阳性患者中以105 IU/ml和106 IU/ml为主;HBsAg(+)、HBeAg(-)、HBcAb(+)组阳性率为30.77%.结论:乙型肝炎患者中HBeAg(+)者

  11. BCG vaccine combined with dipyridamole in the treatment of HBV infection

    Institute of Scientific and Technical Information of China (English)

    Xu Wen Gao; Shi Ying Jia; Xue Mei Liu

    2000-01-01

    AIM To investigate the effect of BCG vaccine and dipyridamole in treating hepatitis B due to their anti-virus effects.METHODS Among 602 patients with positive HBeAg, 512 were allocated to the treatment group and 90patients to the control group. There was no significant difference in disease and age between the two groups.All the patients in the treatment group with no abnormal findings by chest X-ray fluoroscopy, whose localskin scleromata diameters were less than 7 mm after the 1:2000 OT test, were given BCG vaccine 0.1 mlintracutaneously at the deltoid once a month, and simultaneously took dipyridamole 50 mg twice a day forfour to eight months. The hepatic function, B-mode ultrasound and the five markers of hepatitis B wereroutinely examined before each injection. The results at one month after the last injection in the treatmentgroup were compared with those of the control group.RESULTS The recovery rates of hepatic functions and the rates of improvement of the symptoms and signsin the treatment group were better than those in the control group. The negative transformation rates ofHBeAg and the positive transformation rates of HBeAb were 60.3% and 31.6% in the treatment group vs.13.3% and 13.0% in the control group (P0.05. Test x2, x2=1.11, 0.22).CONCLUSION The application of BCG vaccine in combination with dipyridamole increased the negativetransformation rate of HBeAg and the positive transformation rate of HBeAb, improved the clinicalsymptoms, signs and hepatic function of the patients. These two drugs had significant anti-HBV effect andshowed good efficacy in the treatment of HBV infection.

  12. Sieropositivitá per HIV, HBV e HCV negli utenti del Servizio di Tossicodipendenza di Formia (ASL di Latina

    Directory of Open Access Journals (Sweden)

    G. La Torre

    2003-05-01

    Full Text Available

    Obiettivi: valutare la prevalenza sieropositività per HIV, HBV e HCV nei tossicodipendenti afferenti al Ser.T di Formia (LT.

    Materiali e metodi: sono state consultate le cartelle cliniche degli afferenti al Ser.T. nel 2002, estraendo dati relativi ai parametri socio-demografici ed alle sieropositività. L’analisi statistica ha previsto l’impiego del test del χ2 e della regressione logistica multipla.

    Risultati: sono stati presi in considerazione 135 tossicodipendenti, di cui 103 (76.3% maschi e 32 (23.7% femmine. L’età mediana dell’inizio della tossicodipendenza e della presa in carico presso il servizio erano, rispettivamente, di 18 e di 23 anni. Il 94.1% dei tossicodipendenti risulta dipendente primariamente da eroina, il 5.2% da cocaina e lo 0.7% da alcol. Relativamente alle positività per i virus considerati, 7 soggetti (5.2% sono risultati positivi all’HIV, 23 (17% sieropositivi per HBV e 50 (37% sieropositivi per HCV. L’analisi multivariata mostra che sono associate alla sieropositività per HCV la sieropositività per HBV (OR = 3.87 e l’età della presa in carico presso il servizio superiore a 25 anni (OR = 1.88; alla sieropositività per HBV l’occupazione saltuaria (OR = 4.58, la HCV positività (OR = 4.41 e la HIV positività (OR = 5.39; alla sieropositività per HIV l’età della presa in carico presso il servizio superiore a 25 anni (OR = 4.94.

    Discussione: l’indagine ha messo in evidenza prevalenze di sieropositività per HCV, HBV e HIV decisamente inferiori a quelle registrate in altre realtà italiane ed internazionali. Una possibile spiegazione potrebbe essere ricercata nei bassi livelli di sieropositività per questi virus nella popolazione generale del Basso Lazio, o nella scarsa abitudine di scambiarsi le siringhe fra tossicodipendenti di questa area geografica.

  13. Cloning analysis of HBV-specific CD8 T cell receptor gene in patients with acute hepatitis B

    Directory of Open Access Journals (Sweden)

    Ning DING

    2011-05-01

    Full Text Available Objective To investigate the molecular mechanism of T cell receptor(TCR in CD8 T cell-mediated immune response to HBV in patients with acute hepatitis B(AHB.Methods Peripheral blood mononuclear cells(PBMCs were collected from HLA-A2-positive AHB patients.To determine HBsAg183-191 and HBsAg335-343-specific CD8 T cell frequencies,the PBMCs were stained by fluorescence-labeled anti-CD3,anti-CD8 and pentamers,and analyzed by flow cytometry.PBMCs from 6 patients were stimulated with epitopic peptide HBsAg335-343 in vitro for 3 to 4 weeks.HBV-specific CD8 T cells were isolated by magnetic activated cell sorting followed by flow florescence activated cell sorting.The mRNA of sorted cells was extracted after expanding by IL-2,anti-CD3 and anti-CD8.The full-length gene fragments of variable region of TCR α and β chains were gained by 5’-RACE,and then cloned and sequenced(≥50 clones for single chain of each sample.The gene families of TCR α and β chains were identified and the sequence characters of CDR3 were compared.Results Analysis of more than 600 cloned gene sequences of TCR α and β chains showed that the proliferated HBV-specific CD8 T cells from 6 AHB patients presented a predominant expression in TCR α and chains,with 2-4 α chain families and 1-4 chain families in each case.The α2,α14,α15,β3,β13 and 23 families were detected in more than one case.The chain genes were all 13 for all tested clones in one case.For the same α chain or-chain family,CDR3 sequences tended to be identical in one case but different among cases.Conclusions HBV-specific CD8 T cells with antigenic peptide-induced proliferation present predominance in the usage of TCR α and β chains.This property might be one of the important molecular factors influencing anti-HBV immunity.

  14. Design, synthesis, molecular docking studies and anti-HBV activity of phenylpropanoid derivatives.

    Science.gov (United States)

    Liu, Sheng; Li, Yubin; Wei, Wanxing; Wang, Kuiwu; Wang, Lisheng; Wang, Jianyi

    2016-05-01

    In this work, a series of phenylpropanoid derivatives were synthesized, and their anti-hepatitis B virus (HBV) activity was evaluated. Most of the synthesized derivatives showed effective anti-HBV activity. And compound 4d-3 showed the most effective anti-HBV activity, performing strong potent inhibitory not only on the secretion of HBsAg (IC50 = 58.28 μM, SI = 23.26) and HBeAg (IC50 = 97.21 μM, SI = 13.95), but also on the HBV DNA replication (IC50 = 42.28 μM, SI = 32.06). The structure-activity relationships (SARs) of the derivatives had been discussed, which were useful for developing phenylpropanoid derivatives as novel anti-HBV agents. Moreover, the docking study of all synthesized compounds inside the HLA-A protein (PDB ID: 3OX8) active site was carried out to explore the molecular interactions and a molecular target for activity and a modified assay method measuring the interaction between our derivatives and HBcAg was investigated, indicating that the HBV core protein might be their potential target for anti-HBV. This study identified a new class of potent non-nucleoside anti-HBV agents.

  15. HBV Genotype B/C and Response to Lamivudine Therapy: A Systematic Review

    Directory of Open Access Journals (Sweden)

    Xiu-Li Chen

    2013-01-01

    Full Text Available A number of nucleoside analogues such as lamivudine (LAM, actually used for the treatment of chronic hepatitis B, can suppress HBV DNA replication, improve transaminase level and liver histology, and enhance the rate of hepatitis B e antigen (HBeAg clearance. The responses to LAM therapy involve HBeAg clearance and HBV DNA conversion of negative. However, the associations between HBV genotype B/C and response to LAM therapy remain ambiguous. The aim of this meta-analysis is to determine more precise estimations of the relationship. All the publications on the associations between HBV genotype B/C and response to LAM (HBeAg clearance and HBV DNA conversion of negative through June 2013 were collected. Relative risk (RR with 95% confidence intervals (95% CI was calculated in fixed or random model, was calculated to examine heterogeneity, and funnel plots were plotted to examine small study effects with Stata 11 software. Overall, for HBeAg clearance and genotype B/C, the RR (95% CI was 1.27 (0.94–1.71, while for HBV DNA conversion of negative and genotype B/C, the RR (95% CI was 1.07 (0.98–1.17. HBV genotype B/C shows no significance associations with response to lamivudine therapy (HBeAg clearance and HBV DNA conversion of negative.

  16. 慢性乙肝患者石蜡包埋肝组织中HBV cccDNA定量检测方法的建立%Quantification of covalently closed circular DNA of hepatitis B virus in FFPE liver tissues of chronic hepatitis B patients

    Institute of Scientific and Technical Information of China (English)

    韩佳琪; 钟彦伟; 任晓强; 邹正升; 刘树红; 刘学恩; 赵景民; 徐东平

    2011-01-01

    目的 建立慢性乙肝患者微量石蜡包埋肝组织共价闭合环状DNA(HBV cccDNA)定量检测方法.方法 以37例慢性乙肝患者甲醛同定石蜡包埋肝组织为研究对象,提取肝组织HBV DNA,经不降解质粒的ATP依赖的DNA酶(PSAD)消化后,利用滚环扩增加跨缺口实时荧光PCR扩增技术检测肝组织中HBV cccDNA含量,以β-actin为内参照.通过已知浓度的模板DNA进行梯度稀释鉴定该方法的灵敏度,并对该方法进行批内和批间重复性检测.应用该方法分析37例慢性乙肝患者肝组织HBV cccDNA与血清总HBVDNA、肝组织总HBVDNA的关系,以及肝组织HBV cccDNA和HBVDNA与血清HBeAg表达之间的关系.结果 成功建立了微量石蜡包埋肝组织HBV cccDNA的定量检测方法,该方法具有较好的特异性、灵敏度和稳定性.HBeAg阳性者肝组织中cccDNA含量明显高于HBeAg阴性者,HBV cccDNA水平与血清总HBV DNA水平(R2=0.48,P=0.042)及肝组织总HBV DNA水平(R2=0.63,P=0.001)呈正相关.结论 该方法可特异灵敏地定量检测微量石蜡包埋组织切片中的HBV cccDNA.%Objective To establish a method of detecting HBV covalently closed circular DNA (cccDNA) in micro-formalin fixed paraffin imbedding (FFPE) liver biopsy samples.Methods FFPE liver biopsies from 37 patients with chronic hepatitis B were studied.The intrahepatic HBV DNA was extracted and pre-treated with plasmid-safe ATP-dependent DNAse (PSAD), and then amplified by rolling circular amplification (RCA).The HBV cccDNA was quantitatively detected by Taqman real-time PCR with primers located on both sides of the gap of HBV DNA.The human β-actin gene served as the internal control.The sensitivity was tested by serially diluting the DNA templates with known concentrations.The repeatability and stability were evaluated with inter-assay and intra-assay.The level of intrahepatic HBV cccDNA, HBV total DNA, serum HBV DNA and ALT were also compared to find the relations between then

  17. Prevalence, attitudes and knowledge about HIV HBV and HCV infections among inmates in prisons Prilep and Bitola--a pilot study.

    Science.gov (United States)

    Jovanovska, Tanja; Kocic, Biljana; Stojcevska, Viktorija P

    2014-06-01

    Prisons are associates as facilities liable of high risk of infection disease, as a result of the possibility of transmission of infections in prisons surroundings. Investigations carried out in correctional facilities around the world have shown a high prevalence of blood borne hepatitis viruses and HIV. The study was aimed at confirming prevalence of HIV hepatitis B and hepatitis C among prisoners in Bitola's, and Prilep's prisons, existing of co-infection as well to assess knowledge and attitudes related to HIV, HBV and HCV infections. In this cross-sectional study 200 prisoners have participated, providing answers to structured questionnaire and in order to analyze blood for HIV, HBV and HCV, rapid blood tests in detecting antibodies has been used. Prevalence of HCV is 0.20, HBV 0.17 and HIV prevalence is 0. Co-infection prevalence of HCV/HBV is 0.07 from the total number of examinees. As for the manner of infection with HIV virus 22% are familiar with the fact that persons cannot be infected by HIV if they have only one sexual partner who is not infected and have no other partners, and for the protection of HIV and Hepatitis B by correct use of condoms-58% have given correct answers. PMID:25144968

  18. Hepatitis B (HBV), Hepatitis C (HCV) and Hepatitis Delta (HDV) Viruses in the Colombian Population—How Is the Epidemiological Situation?

    Science.gov (United States)

    Alvarado-Mora, Mónica Viviana; Gutierrez Fernandez, María Fernanda; Gomes-Gouvêa, Michele Soares; de Azevedo Neto, Raymundo Soares; Carrilho, Flair José; Pinho, João Renato Rebello

    2011-01-01

    Background Viral hepatitis B, C and delta still remain a serious problem worldwide. In Colombia, data from 1980s described that HBV and HDV infection are important causes of hepatitis, but little is known about HCV infection. The aim of this study was to determine the currently frequency of HBV, HCV and HDV in four different Colombian regions. Methodology/Principal Findings This study was conducted in 697 habitants from 4 Colombian departments: Amazonas, Chocó, Magdalena and San Andres Islands. Epidemiological data were obtained from an interview applied to each individual aiming to evaluate risk factors related to HBV, HCV or HDV infections. All samples were tested for HBsAg, anti-HBc, anti-HBs and anti-HCV markers. Samples that were positive to HBsAg and/or anti-HBc were tested to anti-HDV. Concerning the geographical origin of the samples, the three HBV markers showed a statistically significant difference: HBsAg (p = 0.033) and anti-HBc (pAmazonas and Magdalena departments. Isolated anti-HBs (a marker of previous vaccination) frequencies were: Chocó (53.26%), Amazonas (32.88%), Magdalena (17.0%) and San Andrés (15.33%) - pAmazonas department showed the highest frequency for anti-HCV marker (5.68%), while the lowest frequency was found in San Andrés Island (0.66%). Anti-HDV was found in 9 (5.20%) out of 173 anti-HBc and/or HBsAg positive samples, 8 of them from the Amazonas region and 1 from them Magdalena department. Conclusions/Significance In conclusion, HBV, HCV and HDV infections are detected throughout Colombia in frequency levels that would place some areas as hyperendemic for HBV, especially those found in Amazonas and Magdalena departments. Novel strategies to increase HBV immunization in the rural population and to strengthen HCV surveillance are reinforced by these results. PMID:21559488

  19. Relationship between heterogeneity of HBV preS/S gene and intrauterine transmission

    Institute of Scientific and Technical Information of China (English)

    LI Duan; YAN Yong-ping; XU De-zhong; ZHANG Jing-xia

    2002-01-01

    Objective: To study the relationship of the mutation of HBV preS/S gene in HBsAg carrying pregnant women and intrauterine transmission. Methods: Polymerase chain reaction (PCR) was used to amplify HBV preS/S gene from sera of 8 HBsAg carrying pregnant women, 4 women's neonates infected with HBV,and the other's neonates non-infected with. The PCR products were cloned and 5 clones were chosen from every woman for DNA sequencing. Results: Heterogeneity of HBV preS/S gene in HBsAg carrying pregnant women having intrauterine transmission was much higher than that from having not intrauterine transmission, and the divergence rate of nucleotide sequences also higher strikingly. Conclusion: High heterogeneity of HBV preS/S gene of HBsAg positive pregnant women may be relative to high rate of intrauterine transmission.

  20. Evolutionary dynamics of HBV-D1 genotype epidemic in Turkey.

    Science.gov (United States)

    Ciccozzi, Massimo; Ciccaglione, Anna Rita; Lo Presti, Alessandra; Equestre, Michele; Cella, Eleonora; Ebranati, Erika; Gabanelli, Elena; Villano, Umbertina; Bruni, Roberto; Yalcinkaya, Tulay; Tanzi, Elisabetta; Zehender, Gianguglielmo

    2014-01-01

    Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). Turkey, seems to have played an important role in the penetration of HBV-D1 in the Mediterranean area. The importance of Turkey in the European epidemiology of HBV is also suggested by the observation that the highest spread of HBV infection in the Continent are reported in Turkey with Romania, Bulgaria, Greece, Albania and some southern regions of Italy. In this paper the molecular epidemiology and the epidemiological history of HBV-D in Turkey was studied, by characterizing 34 new Turkish isolates and performing a phylogeographic reconstruction. By using a phylodynamic and phylogeographic Bayesian approach, the analysis suggested that HBV-D1 originated in Turkey about in the early 1940s. The large prevalence of D1 in comparison to the other subgenotypes in Turkey confirms the importance of this Country as epidemiological reservoir of HBV-D1 dispersion. The phylogeny suggests that after each initial introduction of the virus in a specific population, separate transmission clusters have been evolving along independent phylogenetic lineages. Better characterization and continuous monitoring of such groups are going to be crucial to understand in detail the epidemiology of HBV-D1 subgenotype in Turkey and to assess the efficacy of prevention, vaccination and therapy in controlling the epidemic.

  1. Effects of temporal variability on HBV model calibration

    Directory of Open Access Journals (Sweden)

    Steven Reinaldo Rusli

    2015-10-01

    Full Text Available This study aimed to investigate the effect of temporal variability on the optimization of the Hydrologiska Byråns Vattenbalansavedlning (HBV model, as well as the calibration performance using manual optimization and average parameter values. By applying the HBV model to the Jiangwan Catchment, whose geological features include lots of cracks and gaps, simulations under various schemes were developed: short, medium-length, and long temporal calibrations. The results show that, with long temporal calibration, the objective function values of the Nash-Sutcliffe efficiency coefficient (NSE, relative error (RE, root mean square error (RMSE, and high flow ratio generally deliver a preferable simulation. Although NSE and RMSE are relatively stable with different temporal scales, significant improvements to RE and the high flow ratio are seen with longer temporal calibration. It is also noted that use of average parameter values does not lead to better simulation results compared with manual optimization. With medium-length temporal calibration, manual optimization delivers the best simulation results, with NSE, RE, RMSE, and the high flow ratio being 0.563 6, 0.122 3, 0.978 8, and 0.854 7, respectively; and calibration using average parameter values delivers NSE, RE, RMSE, and the high flow ratio of 0.481 1, 0.467 6, 1.021 0, and 2.784 0, respectively. Similar behavior is found with long temporal calibration, when NSE, RE, RMSE, and the high flow ratio using manual optimization are 0.525 3, −0.069 2, 1.058 0, and 0.980 0, respectively, as compared with 0.490 3, 0.224 8, 1.096 2, and 0.547 9, respectively, using average parameter values. This study shows that selection of longer periods of temporal calibration in hydrological analysis delivers better simulation in general for water balance analysis.

  2. Relationship between single nucleotide polymorphism of chemokine CXCL10 G-210A and the chronicity and severity of HBV infection

    Directory of Open Access Journals (Sweden)

    Li-ming LIU

    2011-01-01

    Full Text Available Objective To investigate the single nucleotide polymorphism(SNP in the promoter of chemokine CXCL10 G-201A,and explore the relationship between the SNP and the chronicity and severity of hepatitis B virus(HBV infection.Methods Blood samples were collected from 792 patients with HBV infection,including 200 with acute hepatitis B(AHB,200 with mild/moderate chronic hepatitis B(CHB-M,192 with severe chronic hepatitis B(CHB-S and 200 with acute liver failure of chronic hepatitis(ACLF,and 300 healthy people were enrolled as normal control(NC.DNA were extracted and subjected to PCR amplification of fragment containing C-1596 site that links with G-201 variation,followed by restriction fragment length polymerase(RFLP analysis.Simultaneously,400 samples were randomly extracted from various groups for direct sequencing of G-201 variation.The consistency of SNP typing results of the two methods was analyzed.Results Variation rates of G-201A were 17.77% for AHB group,25.26% for CHB-M group,26.59% for CHB-S group,21.28% for ACLF group,and 13.82% for NC group.The overall P value obtained from the general χ2 test among the 5 groups was 0.0037.The correlation test(P=0.0015 demonstrated that the variation rate was related to different disease status,and the linear trend test(P=0.0029,Z=-2.9748 indicated an increasing trend of variation rate with the disease progression.Paired comparison showed that the differences in variation rate between CHB-M and NC(P=0.0024,CHB-S and NC(P=0.0007,ACLF and NC(P=0.0428,as well as CHB-S and CHB(P=0.0488 were statistically significant.Direct PCR sequencing showed 98.68% identity with the results from PCR-RFLP.Kappa test(U=58.425,P < 0.05 indicated that the consistency of the two assays met the statistical requirements.Conclusion The G-201A variation in CXCL10 promoter is related to chronicity of HBV infection,and the relations between the variation and the severity of HBV infection remains to be further clarified.

  3. HBV, HCV and HIV seroprevalence among blood donors in Istanbul, Turkey: how effective are the changes in the national blood transfusion policies?

    Directory of Open Access Journals (Sweden)

    Ali Acar

    2010-02-01

    Full Text Available The national blood transfusion policies have been changed significantly in recent years in Turkey. The purpose of this study was to determine the prevalence of HBV, HCV, and HIV in blood donors at the Red Crescent Center in Istanbul and to evaluate the effect of changes in the national blood transfusion policies on the prevalence of these infections. The screening results of 72695 blood donations at the Red Crescent Center in Istanbul between January and December 2007 were evaluated retrospectively. HBsAg, anti-HCV, and anti-HIV-1/2 were screened by microparticle enzyme immunoassay (MEIA method. Samples found to be positive for anti-HIV 1/2 and anti-HCV were confirmed by Inno-Lia HCV Ab III and Inno-Lia HIV I/II Score, respectively. The seropositivity rates for HBsAg, anti-HCV, and anti-HIV-1/2 were determined as 1.76%, 0.07%, and 0.008%, respectively. Compared to the previously published data from Red Crescent Centers in Turkey, it was found that HBV and HCV seroprevalances decreased and HIV seroprevalance increased in recent years. In conclusion, we believe that the drop in HBV and HCV prevalence rates are likely multifactorial and may have resulted from more diligent donor questioning upon screening, a higher level of public awareness on viral hepatitis as well as the expansion of HBV vaccination coverage in Turkey. Another factor to contribute to the decreased prevalence of HCV stems from the use of more sensitive confirmation testing on all reactive results, thereby eliminating a fair amount of false positive cases. Despite similar transmission routes, the increase in HIV prevalence in contrast to HBV and HCV may be linked to the increase in AIDS cases in Turkey in recent years.

  4. Hepatitis B virus (HBV) receptors: Deficiency in tumor results in scant HBV infection and overexpression in peritumor leads to higher recurrence risk

    Science.gov (United States)

    Ye, Fei; Fan, Qing-Min; Yu, Guo-Feng; Yu, Dan-Dan; Gao, Lu; Sun, Kai; Han, Zhi-Peng; Li, Rong; Yang, Yang; Zhao, Qiu-Dong; Wu, Meng-Chao; Wang, Hong-Yang; Wei, Li-Xin

    2015-01-01

    Hepatitis B virus (HBV) infection is a risk factor for hepatocarcinogenesis and recurrence. Here, we sought to characterize intratumoral and peritumoral expression of HBsAg and its specific receptors in HBsAg-positive hepatocellular carcinoma (HCC) patients and further examined their correlation with the recurrence-free survival (RFS). HCC tissue and adjacent normal tissue specimens were acquired from HBsAg-positive patients. The presence of HBsAg and receptors, as well as hepatic progenitor cells (HPCs) were detected by tissue microassay and immunohistochemistry. Necroinflammatory activity was evaluated by HE staining. The mean IOD of HBsAg and HBV DNA in the intratumoral tissues was markedly lower than that in the peritumoral tissues (P ASGPR (r = 0.506, P < 0.001) in peritumoral tissues. And the peritumoral HBsAg and receptors presented a positive association with necroinflammatory activity (P < 0.05). Inflammation induced by HBV infection presented a positive association with HPCs activation (P < 0.05). Additionally, due to lack of HBV receptors, HPCs was not preferentially infected with HBV, but activated HPCs had a significant correlation with HBsAg expression in peritumoral tissues, and the peritumoral HPCs activation was associated with RFS of HCC patients, therefore, the overexpression of HBsAg and receptors in peritumor were also with higher recurrence risk (P < 0.05). In conclusion, lack of HBV receptors resulted in scant HBV infection in tumor cells, and overexpression of HBsAg and receptors in peritumor was strongly associated with higher recurrence risk in HCC patients. PMID:26515593

  5. Association of an HLA-G 14-bp Insertion/Deletion polymorphism with high HBV replication in chronic hepatitis.

    Science.gov (United States)

    Laaribi, A B; Zidi, I; Hannachi, N; Ben Yahia, H; Chaouch, H; Bortolotti, D; Zidi, N; Letaief, A; Yacoub, S; Boudabous, A; Rizzo, R; Boukadida, J

    2015-10-01

    Identification of an HLA-G 14-bp Insertion/Deletion (Ins/Del) polymorphism at the 3' untranslated region of HLA-G revealed its importance in HLA-G mRNA stability and HLA-G protein level variation. We evaluated the association between the HLA-G 14-bp Ins/Del polymorphism in patients with chronic Hepatitis B virus (HBV) infection in a case-control study. Genomic DNA was extracted from 263 patients with chronic HBV hepatitis and 246 control subjects and was examined for the HLA-G 14-bp Ins/Del polymorphism by PCR. The polymorphic variants were genotyped in chronic HBV seropositive cases stratified according to HBV DNA levels, fibrosis stages and in a control population. There was no statistical significant association between the 14-bp Ins/Del polymorphism and increased susceptibility to HBV infection neither for alleles (P = 0.09) nor for genotypes (P = 0.18). The stratification of HBV patients based on HBV DNA levels revealed an association between the 14-bp Ins/Del polymorphism and an enhanced HBV activity with high HBV DNA levels. In particular, the Ins allele was significantly associated with high HBV DNA levels (P = 0.0024, OR = 1.71, 95% CI 1.2-2.4). The genotype Ins/Ins was associated with a 2.5-fold (95% CI, 1.29-4.88) increased risk of susceptibility to high HBV replication compared with the Del/Del and Ins/Del genotypes. This susceptibility is linked to the presence of two Ins alleles. No association was observed between the 14-bp Ins/Del polymorphism and fibrosis stage of HBV infection. We observed an association between the 14-bp Ins/Del polymorphism and high HBV replication characterized by high HBV DNA levels in chronic HBV patients. These results suggest a potential prognostic value for disease outcome evaluation. PMID:25619305

  6. HIV, HBV and HCV Coinfection Prevalence in Iran - A Systematic Review and Meta-Analysis

    OpenAIRE

    Fahimeh Bagheri Amiri; Ehsan Mostafavi; Ali Mirzazadeh

    2016-01-01

    Background worldwide, hepatitis C and B virus infections (HCV and HCV), are the two most common coinfections with human immunodeficiency virus (HIV) and has become a major threat to the survival of HIV-infected persons. The review aimed to estimate the prevalence of HIV, HBV, HCV, HIV/HCV and HIV/HBV and triple coinfections in different subpopulations in Iran. Method Following PRISMA guidelines, we conducted a systematic review and meta-analysis of reports on prevalence of HIV, HBV, HCV and H...

  7. Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis:A comparative study

    Institute of Scientific and Technical Information of China (English)

    Ioan; Sporea; Roxana; Sirli; Alexandra; Deleanu; Adriana; Tudora; Alina; Popescu; Manuela; Curescu; Simona; Bota

    2010-01-01

    AIM:To assess the values of liver stiffness (LS) in pa-tients with hepatitis B virus (HBV) chronic hepatitis and to compare them with those in patients with hepatitis C virus (HCV) chronic hepatitis. METHODS: The study included 140 patients with HBV chronic hepatitis, and 317 patients with HCV chronic hepatitis, in which LS was measured (FibroScan-Echo-sens) and liver biopsy was performed in the same session (assessed according to the Metavir score). RESULTS:According to the Metavir score of the 140 HBV p...

  8. Detection of HBV - DNA content in serum and breast milk of parturient women carrying HBV and its clinical significance%HBV携带产妇血清及乳汁中HBV- DNA含量检测及其临床意义

    Institute of Scientific and Technical Information of China (English)

    黄珍贞

    2012-01-01

    目的:探讨HBV携带产妇的血清及乳汁中HBV -DNA含量,以期指导母乳喂养.方法:选取HBV携带产妇100例,采用荧光定量PCR技术检测其血清、乳汁中HBV -DNA含量.结果:HBsAg、HBeAg双阳性组和HBsAg单阳性组中血清HBV-DNA含量、阳性率均高于乳汁,差异有统计学意义(P<0.05),且乳汁HBV-DNA阳性率随着母血清HBV-DNA含量的增加而增加;100例产妇中乳汁HBV-DNA检测阴性及血清病毒含量<104 copy/ml的母乳喂养儿未见婴儿发生乙肝病毒感染.结论:HBV携带产妇乳汁具有一定的传染性,但乳汁的传染性低于血液,血清HBV-DNA阳性产妇在哺乳时应进行HBV -DNA检测,以保证婴儿的安全哺乳环境.%Objective: To explore the contents of HBV - DNA in serum and breast milk of parturient women carrying HBV, in order to direct breast feeding. Methods: 100 parturient women carrying HBV were selected, fluorescence quantitative PCR technique was used to detect the contents of HBV - DNA in serum and breast milk. Results; In positive HBsAg + positive HBeAg group and positive HBsAg group, the contents and positive rates of HBV - DNA in serum were significantly higher than those in breast milk (P < 0.05 ) . The positive rate of HBV - DNA in breast milk increased with the increase of HBV - DNA content in maternal serum; 100 infants who were bom by the parturient women with negative HBV - DNA in breast milk and serum viral content < 104 copy/ml were not found with HBV infection. Conclusion; The breast milk of parturient women carrying HBV have infectivity, but the infectivity of breast milk is lower than that of serum, the parturient women with positive HBV - DNA in serum should receive HBV - DNA detection when they suckle their infants to ensure a safe lactation environment of infants.

  9. Suitable reference genes for real-time PCR in human HBV-related hepatocellular carcinoma with different clinical prognoses

    International Nuclear Information System (INIS)

    Housekeeping genes are routinely used as endogenous references to account for experimental differences in gene expression assays. However, recent reports show that they could be de-regulated in different diseases, model animals, or even under varied experimental conditions, which may lead to unreliable results and consequently misinterpretations. This study focused on the selection of suitable reference genes for quantitative PCR in human hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) with different clinical outcomes. We evaluated 6 commonly used housekeeping genes' expression levels in 108 HBV-related HCCs' matched tumor and non-tomor tissue samples with different clinical outcomes and 26 normal liver specimens by real-time PCR. The expression stability of the 6 genes was compared using the software programs geNorm and NormFinder. To show the impact of reference genes on data analysis, we took PGK1 as a target gene normalized by each reference gene, and performed one-way ANOVA and the equivalence test. With the geNorm and NormFinder software programs, analysis of TBP and HPRT1 showed the best stability in all tissue samples, while 18s and ACTB were less stable. When 18s or ACTB was used for normalization, no significant difference of PGK1 expression (p > 0.05) was found among HCC tissues with and without metastasis, and normal liver specimens; however, dramatically differences (p < 0.001) were observed when either TBP or the combination of TBP and HPRT1 were selected as reference genes. TBP and HPRT1 are the most reliable reference genes for q-PCR normalization in HBV-related HCC specimens. However, the well-used ACTB and 18S are not suitable, which actually lead to the misinterpretation of the results in gene expression analysis

  10. Characteristics of co-infections by HCV and HBV among Brazilian patients infected by HIV-1 and/or HTLV-1

    Directory of Open Access Journals (Sweden)

    Marcia Moreira

    2013-12-01

    Full Text Available BACKGROUND: The human retroviruses HIV-1 and HTLV-1 share the routes of infection with hepatitis viruses B and C. Co-infection by these agents are a common event, but we have scarce knowledge on co-infection by two or more of these agents. OBJECTIVE: To evaluate the characteristics and risk factors for co-infections by HBV and HCV in patients infected by HIV-1 or/and HTLV-1, in Salvador, Brazil. METHODS: In a case-control study we evaluated patients followed in the AIDS and HTLV clinics of Federal University of Bahia Hospital. Clinical and epidemiological characteristics were reviewed, and patients were tested for the presence of serological markers of HBV and HCV infections. HCV-infected patients were tested by PCR to evaluate the presence of viremia. RESULTS: A total of 200 HIV-1, 213 HTLV-1-infected, and 38 HIV-HTLV-co-infected individuals were included. HIV-infected patients were more likely to have had more sexual partners in the lifetime than other patients' groups. HIV-HTLV-co-infected subjects were predominantly male. Patients infected by HTLV or co-infected had a significantly higher frequency of previous syphilis or gonorrhea, while HIV infection was mainly associated with HPV infection. Co-infection was significantly associated to intravenous drug use (IVDU. HBV and/or HCV markers were more frequently found among co-infected patients. HBV markers were more frequently detected among HIV-infected patients, while HCV was clearly associated with IVDU across all groups. AgHBs was strongly associated with co-infection by HIV-HTLV (OR = 22.03, 95% CI: 2.69-469.7, as well as confirmed HCV infection (p = 0.001. Concomitant HCV and HBV infection was also associated with retroviral co-infection. Patients infected by HTLV-1 had a lower chance of detectable HCV viremia (OR = 0.04, 95% CI: 0.002-0.85. CONCLUSIONS: Infection by HCV and/or HBV is frequent among patients presenting retroviral infection, but risk factors and prevalence for each

  11. Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients

    Institute of Scientific and Technical Information of China (English)

    Timothée Noterdaeme; Luc Longrée; Christian Bataille; Arnaud Deroover; Anne Lamproye; Jean Delwaide; Yves Beguin; Pierre Honoré; Olivier Detry

    2011-01-01

    Hepatitis B (HBV) reactivation induced by chemotherapy is problem encountered recently in the management of malignant diseases. Chemotherapy-induced HBV reactivation may ultimately lead to terminal acute liver failure. Liver transplantation (LT) currently remains the only definitive treatment option for such cases, but is generally denied to patients suffering from malignancy. Here, the authors describe 2 cases of cancer-free and HBV graft re-infection-free survival after LT performed for terminal liver failure arising from HBV reactivation induced by chemotherapy for advanced stage lymphoma. These 2 cases, and some other reports in the literature, may suggest that patients suffering from hematologic malignancies and terminal liver disease can be considered for LT if the prognosis of their hematologic malignancy is good.

  12. HBV pathogenesis in animal models: recent advances on the role of platelets.

    Science.gov (United States)

    Iannacone, Matteo; Sitia, Giovanni; Ruggeri, Zaverio M; Guidotti, Luca G

    2007-04-01

    Hepatitis B virus (HBV) causes acute and chronic necroinflammatory liver diseases and hepatocellular carcinoma (HCC). HBV replicates noncytopathically in the hepatocyte, and most of the liver injury associated with this infection reflects the immune response. While the innate immune response may not contribute significantly to the pathogenesis of liver disease or viral clearance, the adaptive immune response, particularly the cytotoxic T lymphocyte (CTL) response, contributes to both. Recent observations also reveal that antigen-nonspecific inflammatory cells enhance CTL-induced liver pathology and, more surprisingly, that platelets facilitate the intrahepatic accumulation of CTLs, suggesting that the host response to HBV infection is a highly complex but coordinated process. The notion that platelets contribute to liver disease and viral clearance by promoting the recruitment of virus-specific CTLs into the liver is a new concept in viral pathogenesis, which may prove useful to implement treatments of chronic HBV infection in man.

  13. New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDT protein chip technology

    Institute of Scientific and Technical Information of China (English)

    Xiao-Dong Zhu; Wei-Hua Zhang; Cheng-Lin Li; Yang Xu; Wei-Jiang Liang; Po Tien

    2004-01-01

    AIM: To find new serum biomarkers for liver cirrhosis (LC)in chronic carriers of hepatitis B virus (HBV).METHODS: Surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry was used to discover biomarkers for differentiating HBV induced LC from non-cirrhotic cohorts. A training population of 25 patients with HBV-induced LC, 20 patients with HCC, and 25 closely age-matched healthy men, was studied.RESULTS: Two biomarkers with Mr 7 772 and 3 933 were detected in sera of non-cirrhotic cohorts, but not in patients with HBV-induced LC. A sensitivity of 80% for all LC patients,a specificity of 81.8% for all non-cirrhotic cohorts and a positive predictive value of 75% for the study population were obtained.CONCLUSION: These two serum biomarkers for HBVinduced LC might be used for diagnosis and assessment of disease progression.

  14. Know HBV: What Every Asian and Pacific Islander Should Know About Hepatitis B and Liver Cancer

    Science.gov (United States)

    ... the skin or eyes) appear, it is often too late for treatment to be effective. » T ransmitted just like HIV 1. A mother-to-child infection For Asians, HBV is commonly transmitted from a chronically infected ...

  15. HBx truncation mutants differentially modulate SREBP-1a and -1c transcription and HBV replication.

    Science.gov (United States)

    Wu, Qi; Liu, Qiang

    2015-12-01

    As master transcription factors for lipogenesis, sterol regulatory element-binding protein-1 (SREBP-1) has two isoforms, SREBP-1a and SREBP-1c. Hepatitis B virus X (HBx) can up-regulate the transcription of both SREBP-1a and SREBP-1c. HBx is a small protein consisting of 154 amino acids. Truncated forms of HBx, often found in the tissues after HBV infection, may have a role in the pathogenesis associated with HBV infection. In this study, we examined the effects of two HBx truncation mutants, HBx aa. 1-127 and HBx aa. 43-154, on the transcription of SREBP-1a and SREBP-1c. HBx 1-127 can up-regulate SREBP-1c, but not SREBP-1a transcription, whereas HBx 43-154 can activate SREBP-1a, but not SREBP-1c transcription. We further determined the activities of two HBV enhancers after the expression of the truncated HBx proteins. HBx 1-127 and HBx 43-154 can only up-regulate HBV enhancer I or HBV enhancer II, respectively. Knocking down SREBP-1 abrogates enhancer activation by HBx proteins, suggesting a role of SREBP-1. In addition, using HBV enhancer mutants, we found that the binding sequence for AP-1 on enhancer I is essential for its activation by HBx 1-127, whereas C/EBP and Sp1 sites are required for enhancer II activation by HBx 43-154. Finally, we showed that both HBx 1-127 and HBx 43-154 can increase HBV transcription and HBV replication dependent upon SREBP-1 because knocking down SREBP-1 abrogates the up-regulation. Furthermore, upon ectopic expression of either SREBP-1a or SREBP-1c, we showed that SREBP-1a is involved in HBV transcription and replication up-regulation by HBx 43-154, whereas SREBP-1c is involved in HBV transcription and replication up-regulation by HBx 1-127. Our results should help understand the interactions between HBV and the SREBP-1-mediated lipogenic pathway.

  16. Basis of HBV persistence and new treatment options.

    Science.gov (United States)

    Thursz, Mark

    2014-09-01

    The majority of the morbidity and mortality associated with hepatitis B virus infection is due to viral persistence and its consequences. The heterogeneity of outcomes from HBV infection suggests that both viral and host factors influence the development of chronic infection. Study of host genetic susceptibility has revealed a number of genes including MHC class II loci and cytokine receptors, which decrease the risk of persistence. On the viral side, the replication system is adapted to generate high levels of virions without stimulating the innate immune system. Secreted viral proteins (HBsAg and HBeAg) suppress innate responses through inhibition of TLR signaling, which leads to a weak adaptive immune response with an exhausted phenotype that is incapable of inducing viral elimination. However, even when the adaptive immune system begins to take effect after HBe seroconversion, the ability of the virus to mutate and evade T and B cell-mediated responses helps to sustain persistent infection. Understanding the mechanisms of persistence is important for the design of therapeutic strategies. Although there are currently no specific drugs that target the viral minichromosome (cccDNA), it is expected that in the future we will be able to use existing drugs more effectively to eliminate the infection. PMID:26201329

  17. Detection of soluble TRAIL in HBV infected patients and its clinical implications

    Institute of Scientific and Technical Information of China (English)

    Li-Hui Han; Wen-Sheng Sun; Chun-Hong Ma; Li-Ning Zhang; Su-Xia Liu; Qiu Zhang; Li-Fen Gao; You-Hai Chen

    2002-01-01

    AIM: To detect the expression of soluble TRAIL (TNF-related apoptosis inducing ligand, TRAIL) in the peripheral blood of HBV infected patients and try to elucidate whether the expression level of sTRAIL have any correlativity with the clinical staging, the expression level of HBV markers and the degree of liver damage.METHODS: 52 cases of HBV infected patients were investigated, induding 8 HBV carriers, 30 chronic hepatitis B, 11 drrhotics and 3 HBV infection related hepatocellular carcinoma. Expression of soluble TRAIL and markers of the hepatitis B were mearsured by enzyme-linked immunosorbent assay.RESULTS: The expression level of sTRAIL in the peripheral blood of the HBV infected patients was significantly higher than that of healthy controls (1378.35±540.23 pg/ml vs 613.75±175.80 pg/ml, P<0.001). In the group of chronic hepatitis, the expression level of sTRAIL was coincident with the status of the disease and was significantly correlated with the level of ALT. In the group of cirrhosis and liver cancer, its expression level was significantly higher than that of the healthy persons and HBV carriers, but lower than that of the hepatitis B patients; meanwhile, the expression of siRAIL did not have any correlativity with the functional indexes of the liver. CONCLUSION: The soluble TRAIL in the HBV infected people may participate in the liver damage. Our results indicated that the expression level of soluble TRAIL may reflect the ravage of liver caused by host immune reaction to a certain degree.

  18. Urban-Rural Comparison of HBV and HCV Infection Prevalence in Eastern China

    Institute of Scientific and Technical Information of China (English)

    2000-01-01

    The present study was initiated to make an urban-rural comparison of the prevalence of cases positive to hepatitis B and C virus (HBV and HCV, respectively) infection markers in densely populated eastern half of China. For this purpose, 10 survey sites were selected, i.e., six sites in urban areas (the city group; Beijing, Shanghai and four provincial capitals) and four sites in rural areas (the village group ; one village each in Jilin and Shandong Provinces, and two villages in Shaanxi Province). About 50 adult women per site volunteered to participate, from whom 494 valid blood samples were collected. Positivities to HBsAg (HBsAg+), anti-HBs (anti-HBs+) and anti-HBc (anti-HBc+) were examined by RIA methods, and that to anti-HCV (anti-HCV+) by either EIA or RIA. Those positive to any one of the three HBV infection markers were taken as HBV infection-positive (HBV+). The prevalence of HBsAg+, HBV+ and anti-HBc+ was 8%, 70% and 2.7% in the city group, and 8%, 65% and 2.0% in the village group, and no significant difference was found between the two groups. The overall prevalence was 8% for HBsAg+, 68% for HBV+, and 2.4% for anti-HCV+. The results were discussed in reference to some 20 papers each on HBV+ and anti-HCV+ prevalence in China published since 1991. The reviewing of these papers confirmed that the prevalence of HBV was high (i.e., in excess of 50%), whereas the prevalence of anti-HCV was low (well below 5%), and that no substantial difference was found between the rural and urban populations.

  19. The Dual Role of an ESCRT-0 Component HGS in HBV Transcription and Naked Capsid Secretion.

    Directory of Open Access Journals (Sweden)

    Shu-Fan Chou

    2015-10-01

    Full Text Available The Endosomal Sorting Complex Required for Transport (ESCRT is an important cellular machinery for the sorting and trafficking of ubiquitinated cargos. It is also known that ESCRT is required for the egress of a number of viruses. To investigate the relationship between ESCRT and hepatitis B virus (HBV, we conducted an siRNA screening of ESCRT components for their potential effect on HBV replication and virion release. We identified a number of ESCRT factors required for HBV replication, and focused our study here on HGS (HRS, hepatocyte growth factor-regulated tyrosine kinase substrate in the ESCRT-0 complex. Aberrant levels of HGS suppressed HBV transcription, replication and virion secretion. Hydrodynamic delivery of HGS in a mouse model significantly suppressed viral replication in the liver and virion secretion in the serum. Surprisingly, overexpression of HGS stimulated the release of HBV naked capsids, irrespective of their viral RNA, DNA, or empty contents. Mutant core protein (HBc 1-147 containing no arginine-rich domain (ARD failed to secrete empty virions with or without HGS. In contrast, empty naked capsids of HBc 1-147 could still be promoted for secretion by HGS. HGS exerted a strong positive effect on the secretion of naked capsids, at the expense of a reduced level of virions. The association between HGS and HBc appears to be ubiquitin-independent. Furthermore, HBc is preferentially co-localized with HGS near the cell periphery, instead of near the punctate endosomes in the cytoplasm. In summary, our work demonstrated the importance of an optimum level of HGS in HBV propagation. In addition to an effect on HBV transcription, HGS can diminish the pool size of intracellular nucleocapsids with ongoing genome maturation, probably in part by promoting the secretion of naked capsids. The secretion routes of HBV virions and naked capsids can be clearly distinguished based on the pleiotropic effect of HGS involved in the ESCRT-0 complex.

  20. Preparation and identification of 1.3 copies C-type HBV transgenic mice

    Directory of Open Access Journals (Sweden)

    Mei-juan CHEN

    2011-09-01

    Full Text Available Objective To prepare 1.3 copies C-type HBV transgenic mice for providing a better model for the prevention and treatment of hepatitis B.Methods The HBV transgenic mice were generated by microinjection of 1.3 copies C-type HBV genome into the pronucleus of FVB /N zygotes.PCR,ELISA,RT-PCR and immunohistochemistry were used to detect the integration,replication and expression of HBV gene in the transgenic mice.Results Tow thousand two hundred and eighty-two fertilized eggs were injected and a total of 2024 survived.The survival rate of injection was 88.7%.The injected eggs were transplanted into 72 pseudo pregnant female mice,among which 59 became pregnant.The pregnancy rate was 81.9%.One hundred and eighty-five F0 offsprings were produced with 19 positive mice as detected by PCR,and the positive rate was 10.3%.RT-PCR revealed that HBV DNA replication of 102-103 copies/ml existed in serum of 6 mice.Ninety-six F1 offsprings were produced,of which 33 were positive for HBV DNA replication as detected by PCR,the positive rate was 34.4%.RT-PCR showed that HBV DNA replication was observed in 10 mice with 102-103 copies/ml.Three mice were randomly chosen from each of F0 and F1 generations to detect the HBsAg expression in livers and kidneys by immunohistochemistry.The results showed that HBsAg expressed in both livers and kidneys,and it was stronger in kidneys than in livers.Conclusion The 1.3 copies C-type HBV gene can not only replicate and express in the transgenic mice produced,but it also can be transmitted to the next generation of these mice.

  1. HBV-DNA levels in serum and saliva of hepatitis B patients%乙型肝炎患者血清和唾液中HBV-DNA的水平

    Institute of Scientific and Technical Information of China (English)

    刘纯成; 李桂珍; 徐云芳

    2012-01-01

    [Objective]To explore the HBV-DNA levels in serum and saliva of hepatitis B patients, and provide clinical evidence for HBV spreading by saliva[ Methods] Real-time PCR was adopted for the determination of HBV-DNA levels in serum and saliva of hepatitis B patients. [ Results ] The positive rate of in serum and saliva of 99 cases of hepatitis B patients was 90.9% (90 cases) and 65.7 % (65 cases). [ Conclusion]The difference of HBV-DNA positive rate between serum and saliva of hepatitis B patients is significant(P <0.01) , and HBV-DNA levels in serum and saliva showed a significant positive correlation (r=0.82).%目的 探讨乙型肝炎(乙肝)患者唾液中HBV-DNA水平,为乙型肝炎病毒(HBV)经唾液传播提供临床依据.方法 采用实时荧光定量PCR法检测乙肝患者血清和唾液中HBV-DNA含量.结果 99例乙肝患者血清和唾液中HBV-DNA的阳性率分别为90例(90.9%)、65例(65.7%).结论 乙肝患者唾液中HBV-DNA的阳性率与血清HBV-DNA的阳性率之间差异有统计学意义(P<0.01),乙肝患者唾液中HBV-DNA含量与血清HBV-DNA含量呈显著正相关(r=0.82).

  2. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV

    Institute of Scientific and Technical Information of China (English)

    Cheng; Peng; Mengji; Lu; Dongliang; Yang

    2015-01-01

    Hepatitis B virus(HBV) infection remains a major global health problem because current therapies rarely eliminate HBV infections to achieve a complete cure. A different treatment paradigm to effectively clear HBV infection and eradicate latent viral reservoirs is urgently required. In recent years, the development of a new RNA-guided gene-editing tool, the CRISPR/Cas9(clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9) system, has greatly facilitated site-specific mutagenesis and represents a very promising potential therapeutic tool for diseases, including for eradication of invasive pathogens such as HBV. Here, we review recent advances in the use of CRISPR/Cas9, which is designed to target HBV specific DNA sequences to inhibit HBV replication and to induce viral genome mutation, in cell lines or animal models. Advantages, limitations and possible solutions, and proposed directions for future research are discussed to highlight the opportunities and challenges of CRISPR/Cas9 as a new, potentially curative therapy for chronic hepatitis B infection.

  3. [Private companies: an opportunity for hepatitis B virus (HBV) prevention and care in Ivory Coast in the wake of HIV/AIDS?].

    Science.gov (United States)

    Bekelynck, A

    2015-02-01

    In the 1990s, defenders of "aids exceptionnalism" have promised that the inequities caused by HIV/AIDS could provide leverage in the care of other health issues later. Fifteen years later, this argument can be rethought at the light of the current context of hepatitis B virus (HBV) in Ivory Coast. In fact, in this country, the challenges caused by HBVecho those of HIV/AIDS fifteen years ago: high prevalence (8-10%), ignorance of the disease, and high cost of care. To this end, this article compares the role of private companies in the fights against HIV/AIDS in the 2000s and its role in the fight against HBV today. Although some private firms played a critical role in the promotion of universal access to ART, today, they are one of the few places where HBV screening, vaccination and treatment are offered in the country. HIV/AIDS opened the door for private companies to address other diseases through their health care systems. However, many challenges still need to be met: the absence of qualitative ongoing training for health professionals, illness representations and the costs of treatments, which are all related to the lack of international and national collective action. In Ivory Coast, at the early stage of the HIV/AIDS epidemic, national authorities took up the leadership in the fight against AIDS in West Africa, by developing extraverted strategies (Xth ICASA's organization, Unaids initiative hosting). The exceptional international mobilization and the creation of innovative funding mechanisms [International Therapeutic Solidarity Fund (ITSF), Global Fund (GM), and President's Emergency Plan for AIDS Relief (PEPFAR)] have facilitated easy access to ARV. Although 380 million people are infected by chronic HBV in the world, even so, international and national collective actions are fledgling and remained weak. Moreover, private firms have represented leverage for testing, treatment, and the provision of universal access to medication in the context of the HIV

  4. ORIGINAL ARTICLE: Blood Donor’s Status of HIV, HBV, HCV and Syphilis in this Region of Marathwada, India

    Directory of Open Access Journals (Sweden)

    Rangrao H. Deshpande

    2012-07-01

    Full Text Available Aims & Objectives: Blood transfusion can cause the transmission of infections to recipients. This is an important mode of infection. The aim of study was to assess the prevalence of such type of infections among blood donors and to compare the seroprevalence of transfusion transmitted diseases in voluntary donors and replacement donors. Retrospective study of five years from Jan. 2007 to Dec. 2011 was done. This study was conducted at Blood bank, MIMSR Medical College Latur, Govt. Medical College, Latur and Bhalchandra Blood bank, Latur. Material & Methods: Total 10, 4925 donors were tested. Donors were screened for seroprevalence of HIV, HBC, HCV and Syphilis. Screening of HIV, HBV & HCV was done by ELISA method & Syphilis was screened by RPR type. Results: The comparison of seroprevalence of HIV, HBV, HCV & Syphilis in voluntary donors and replacement donors showed significant difference only for HIV in the years 2007, 2010, and 2011. Conclusion: The seroprevalence of transfusion transmitted diseases in the study is very low or negligible in voluntary donors as compared to replacement donors. There was a declining trend of seroprevalence for all the disease screened. But in our study the difference is not significant, which indicates that the selection of donors is of low quality. The selection of high quality voluntary donors should be achieved by creation of awareness by education of the prospective donor populations.

  5. HEPATITIS B VIRUS (HBV AND SYPHILIS CO-INFECTIONS AMONG THE PEOPLE OF EKITI, SOUTH-WEST, NIGERIA

    Directory of Open Access Journals (Sweden)

    Akinbolaji Thompson J, Odeyemi Festus A, Adegeye Festus O, Ojo Olalekan I, Akinseye Funmilayo J.

    2015-04-01

    Full Text Available This study was carried out to know the prevalence of hepatitis B, syphilis and co-infection of both among the people of Ekiti, South-West, Nigeria. Individuals and patients who visited the Haematology and Blood Transfusion Unit of Ekiti State University Teaching Hospital, Ado-Ekiti to screen themselves for HBV and Syphilis infections between January to November, 2014 were recruited for this study having obtained their consent. 4ml of blood sample was collected from each subject into a plain bottle and was allowed to stand for 1hour for clotting and clot retraction to take place. Sera were separated into khan tubes labeled appropriately and were screened for the presence of antibodies to HVB and syphilis using One-Stage Rapid Test Kits (DiaSpot Diagnostics and were later confirmed using enzyme linked immune sorbent assay (ELISA (Stat Fax Awareness, England. One Thousand Six Hundred and Thirty-Nine subjects were recruited for this study, out of which Seven Hundred and Seventy-Four were males while Eight Hundred and Sixty-Five were females. 101(6.16% were positive to HBV, 51(0.92% positive to syphilis and 5(0.31% were co-infected with both infections. The results of this study showed higher prevalence of hepatitis B infection than syphilis infection with the highest prevalence found within the age group 31-40 years and 21-30 years indicating that most of the infected people got the infection through sexual intercourse.

  6. HBV X Gene Transfection Upregulates IL-1β and IL-6 Gene Expression and Induces Rat Glomerular Mesangial Cell Proliferation

    Institute of Scientific and Technical Information of China (English)

    Hongzhu LU; Jianhua ZHOU

    2008-01-01

    The X gene of HBV encodes a 17-KD protein, termed HBx, which has been shown to function as a transcriptional trans-activator of a variety of viral and cellular promoter/enhancer elements. The aim of this study was to investigate the effect of HBx on gene expression of interleukin (IL)-1β and IL-6, and proliferation of rat mesangial cells in vitro. The X gene of HBV was amplified by PCR assay, and inserted into the eukaryotic expression vector pCI-neo. The structure of recombinant pCI-neo-X plasmid was proved by restrict endonuclease digestion and sequencing analysis. pCI-neo-X was transfected into cultured rat mesangial cell line in vitro via liposome. HBx expression in transfected mesangial cells was detected by Western blot. The IL-1β and IL-6 mRNA expression in those cells was assayed by semiquantitative RT-PCR. Mesangial cell proliferation was tested by MTT. The results showed that HBx was obviously expressed in cultured mesangial cell line at 36th and 48th h after transfection. The expression of IL-1β and IL-6 mRNA was simultaneously increased. The cell proliferation was also obvious at the same time. It was concluded that HBx gene transfection could induce IL-1β and IL-6 gene expression and mesangial cell proliferation. HBx may play a critical role in mesangial cell proliferation through upregulation of the IL-1β and IL-6 gene expression.

  7. Inflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular Carcinoma.

    Directory of Open Access Journals (Sweden)

    Te-Sheng Chang

    Full Text Available The expression of cancer stemness is believed to reduce the efficacy of current therapies against hepatocellular carcinoma (HCC. Understanding of the stemness-regulating signaling pathways incurred by a specific etiology can facilitate the development of novel targets for individualized therapy against HCC. Niche environments, such as virus-induced inflammation, may play a crucial role. However, the mechanisms linking inflammation and stemness expression in HCC remain unclear. Here we demonstrated the distinct role of inflammatory mediators in expressions of stemness-related properties involving the pluripotent octamer-binding transcription factor 4 (OCT4 in cell migration and drug resistance of hepatitis B virus-related HCC (HBV-HCC. We observed positive immunorecognition for macrophage chemoattractant protein 1 (MCP-1/CD68 and OCT4/NANOG in HBV-HCC tissues. The inflammation-conditioned medium (inflamed-CM generated by lipopolysaccharide-stimulated U937 human leukemia cells significantly increased the mRNA and protein levels of OCT4/NANOG preferentially in HBV-active (HBV+HBsAg+ HCC cells. The inflamed-CM also increased the side population (SP cell percentage, green fluorescent protein (GFP-positive cell population, and luciferase activity of OCT4 promoter-GFP/luciferase in HBV-active HCC cells. Furthermore, the inflamed-CM upregulated the expressions of insulin-like growth factor-I (IGF-I/IGF-I receptor (IGF-IR and activated IGF-IR/Akt signaling in HBV-HCC. The IGF-IR phosphorylation inhibitor picropodophyllin (PPP suppressed inflamed-CM-induced OCT4 and NANOG levels in HBV+HBsAg+ Hep3B cells. Forced expression of OCT4 significantly increased the secondary sphere formation and cell migration, and reduced susceptibility of HBV-HCC cells to cisplatin, bleomycin, and doxorubicin. Taking together, our results show that niche inflammatory mediators play critical roles in inducing the expression of stemness-related properties involving IGF

  8. Pharmacokinetics of anti-HBV polyoxometalate in rats.

    Directory of Open Access Journals (Sweden)

    Juan Wang

    Full Text Available Polyoxometalates are non-nucleoside analogs that have been proven to exhibit broad-spectrum antiviral activity. In particular, Cs2K4Na[SiW9Nb3O40].H2O 1 shows low toxicity and high activity against HBV. The preclinical pharmacokinetics of Compound 1 in rats were characterized by establishing and applying inductively coupled plasma-mass spectrometry method to determine the concentration of W in plasma, urine, feces, bile and organ samples. The quantitative ICP-MS method demonstrated good sensitivity and application in the pharmacokinetics study of polyoxometalates. The pharmacokinetic behavior of Compound 1 after intravenous or oral administration fit a two-compartment model. Tmax ranges from 0.1 h to 3 h and the T1/2 of Compound 1 is between 20 h and 30 h. The absolute bioavailability of Compound 1 at 45, 180 and 720 mg/kg groups were 23.68%, 14.67% and 11.93%, respectively. The rates of plasma protein binding of Compound 1 at 9, 18 and 36 mg/ml of Compound 1 are 62.13±9.41%, 71.20±24.98% and 49.00±25.59%, respectively. Compound 1 was widely distributed throughout the body, and high levels of compound 1 were found in the kidney and liver. The level of Compound 1 in excretion was lower: 30% for urine, 0.28% for feces and 0.42% for bile, respectively. For elaborate pharmacokinetic characteristics to be fully understood, the metabolism of Compound 1 needs to be studied further.

  9. Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes.

    Directory of Open Access Journals (Sweden)

    Edouard Tuaillon

    Full Text Available BACKGROUND: The decline in hepatitis B virus surface antigen (HBsAg may be an early predictor of the viral efficacy of Hepatitis B virus (HBV therapy. The HBsAg levels obtained by different immunoassays now need comparing and the relationships between levels of HBsAg and HBV DNA alongside HBsAg and genotype must be evaluated. METHODOLOGY/PRINCIPAL FINDINGS: HBsAg levels were compared among 80 patients using the Abbott Architect assay, a commercial immunoassay approved for HBsAg detection and quantitation, and three other assays derived from immunoassays approved for HBsAg detection (manufactured by Diasorin, Bio-Rad and Roche. Good correlation was found between the Abbot vs. Diasorin, Bio-Rad and Roche assays with narrow 95% limits of agreement and small mean differences: -0.06 to 0.11, -0.09 log(10 IU/mL; -0.57 to 0.64, -0.04 log(10 IU/mL; -0.09 to 0.45, -0.27 log(10 IU/mL, respectively. These agreements were not affected by genotypes A or D. HBsAg was weakly correlated with HBV DNA, whatever the HBsAg assay used: Abbott, ρ = 0.36 p = 0.001, Diasorin ρ = 0.34, p = 0.002; Bio-Rad ρ = 0.37, p<0.001; or Roche ρ = 0.41, p<0.001. This relationship between levels of HBsAg and HBV DNA seemed to depend on genotypes. Whereas HBsAg (Abbott assay tended to correlate with HBV DNA for genotype A (ρ = 0.44, p = 0.02, no such correlation was significant for genotypes D (ρ = 0.29, p = 0.15. CONCLUSION/SIGNIFICANCE: The quantitation of HBsAg in routine clinical samples is comparable between the reference assay and the adapted assays with acceptable accuracy limits, low levels of variability and minimum discrepancy. While HBsAg quantitation is not affected by HBV genotype, the observed association between levels of HBsAg and HBV DNA seems genotype dependent.

  10. HBV and HIV co-infection: Prevalence and clinical outcomes in tertiary care hospital Malaysia.

    Science.gov (United States)

    Akhtar, Ali; Khan, Amer Hayat; Sulaiman, Syed Azhar Syed; Soo, Chow Ting; Khan, Kashifullah

    2016-03-01

    According to WHO, Malaysia has been classified as a concentrated epidemic country due to progression of HIV infection in the population of injecting drug users. The main objectives of current study are to determine the prevalence of HBV among HIV-positive individuals in a tertiary care hospital of Malaysia and to assess the predictors involved in the outcomes of HIV-HBV co-infected patients. A retrospective, cross-sectional study is conducted at Hospital Palau Pinang, Malaysia. The collection of socio-demographic data as well as clinical data is done with the help of data collection form. Data were analyzed after putting the collected values of required data by using statistical software SPSS version 20.0 and P > 0.05 is considered as significant. Results show that the overall prevalence of HBV was 86 (13%) including 495 (74.5%) males and 169 (25.5%) females among a total of 664 HIV-infected patients. It was observed that there is a high prevalence of HIV-HBV co-infection in males 76 (11.4%) as compared to females 10 (1.5%) (P = 0.002). The median age of the study population was 39 years. The statistical significant risk factors involved in the outcomes of HIV-HBV co-infected patients were observed in the variables of gender, age groups, and injecting drug users. The findings of the present study shows that the prevalence of HBV infection among HIV-positive patients was 13% and the risk factors involved in the outcomes of HIV-HBV co-infected patients were gender, age, and intravenous drug users.

  11. Liver type I regulatory T cells suppress germinal center formation in HBV-tolerant mice.

    Science.gov (United States)

    Xu, Long; Yin, Wenwei; Sun, Rui; Wei, Haiming; Tian, Zhigang

    2013-10-15

    The liver plays a critical role in inducing systemic immune tolerance, for example, during limiting hypersensitivity to food allergy and in rendering acceptance of allotransplant or even hepatotropic pathogens. We investigated the unknown mechanisms of liver tolerance by using an established hepatitis B virus (HBV)-carrier mouse model, and found that these mice exhibited an antigen-specific tolerance toward peripheral HBsAg vaccination, showing unenlarged draining lymph node (DLN), lower number of germinal centers (GC), and inactivation of GC B cells and follicular T helper (Tfh) cells. Both in vivo and in vitro immune responses toward HBsAg were suppressed by mononuclear cells from HBV-carrier mice, which were CD4(+) Foxp3(-) type 1 regulatory T (Tr1)-like cells producing IL-10. Using recipient Rag1(-/-) mice, hepatic Tr1-like cells from day 7 of HBV-persistent mice acquired the ability to inhibit anti-HBV immunity 3 d earlier than splenic Tr1-like cells, implying that hepatic Tr1-like cells were generated before those in spleen. Kupffer cell depletion or IL-10 deficiency led to impairment of Tr1-like cell generation, along with breaking HBV persistence. The purified EGFP(+)CD4(+) T cells (containing Tr1-like cells) from HBV-carrier mice trafficked in higher numbers to DLN in recipient mice after HBsAg vaccination, and subsequently inactivated both Tfh cells and GC B cells via secreting IL-10, resulting in impaired GC formation and anti-HB antibody production. Thus, our results indicate Tr1-like cells migrate from the liver to the DLN and inhibit peripheral anti-HBV immunity by negatively regulating GC B cells and Tfh cells. PMID:24089450

  12. HBVPathDB: A database of HBV infection-related molecular interaction network

    Institute of Scientific and Technical Information of China (English)

    Yi Zhang; Xiao-Chen Bo; Jing Yang; Sheng-Qi Wang

    2005-01-01

    AIM: To describe molecules or genes interaction between hepatitis B viruses (HBV) and host, for understanding how virus' and host's genes and molecules are networked to form a biological system and for perceiving mechanism of HBV infection.METHODS: The knowledge of HBV infection-related reactions was organized into various kinds of pathways with carefully drawn graphs in HBVPathDB. Pathway information is stored with relational database management system (DBMS), which is currently the most efficient way to manage large amounts of data and query is implemented with powerful Structured Query Language (SQL). The search engine is written using Personal Home Page (PHP) with SQL embedded and web retrieval interface is developed for searching with Hypertext Markup Language (HTML).RESULTS: We present the first version of HBVPathDB,which is a HBV infection-related molecular interaction network database composed of 306 pathways with 1050molecules involved. With carefully drawn graphs, pathway information stored in HBVPathDB can be browsed in an intuitive way. We develop an easy-to-use interface for flexible accesses to the details of database. Convenient software is implemented to query and browse the pathway information of HBVPathDB. Four search page layout options-category search, gene search, description search,unitized search-are supported by the search engine ofthe database. The database is freely available at http://www.bio-inf, net/HBVPathDB/HBV/.CONCLUSION: The conventional perspective HBVPathDB have already contained a considerable amount of pathway information with HBV infection related, which is suitable for in-depth analysis of molecular interaction network of virus and host. HBVPathDB integrates pathway data-sets with convenient software for query, browsing,visualization, that provides users more opportunity to identify regulatory key molecules as potential drug targets and to explore the possible mechanism of HBV infection based on gene expression datasets.

  13. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA

    Science.gov (United States)

    Seeger, Christoph; Sohn, Ji A

    2016-01-01

    Hepatitis B virus (HBV) causes chronic infections that cannot yet be cured. The virus persists in infected hepatocytes, because covalently closed circular DNA (cccDNA), the template for the transcription of viral RNAs, is stable in nondividing cells. Antiviral therapies with nucleoside analogues inhibit HBV DNA synthesis in capsids in the cytoplasm of infected hepatocytes, but do not destroy nuclear cccDNA. Because over 200 million people are still infected, a cure for chronic hepatitis B (CHB) has become one of the major challenges in antiviral therapy. As a first step toward the development of curative therapies, we previously demonstrated that the CRISPR/Cas9 system can be used to functionally inactivate cccDNA derived from infectious HBV. Moreover, some evidence suggests that certain cytokines might induce an APOBEC-mediated cascade leading to the destruction of cccDNA. In this report we investigated whether a combination of the two mechanisms could act synergistically to inactivate cccDNA. Using next generation sequencing (NGS), we determined the complete spectrum of mutations in cccDNA following Cas9 cleavage and repair by nonhomologous end joining (NHEJ). We found that over 90% of HBV DNA was cleaved by Cas9. In addition our results showed that editing of HBV DNA after Cas9 cleavage is at least 15,000 times more efficient that APOBEC-mediated cytosine deamination following treatment of infected cells with interferon alpha (IFNα). We also found that a previously used method to detect cytosine deaminated DNA, termed 3D-PCR, overestimates the amount and frequency of edited HBV DNA. Taken together, our results demonstrated that the CRISPR/Cas9 system is so far the best method to functionally inactivate HBV cccDNA and provide a cure for CHB. PMID:27203444

  14. KIR : HLA association with clinical manifestations of HBV infection in Madurai, south India

    Indian Academy of Sciences (India)

    Narayanan Kalyanaraman; Lakshmikanthan Thayumanavan; Mariakuttikan Jayalakshmi

    2016-03-01

    The antiviral action of natural killer (NK) cells is regulated by a wide repertoire of germ-line encoded membrane receptors which recognize the expression of certain self-molecules on target cells. Among the receptors, killer cell immunoglobulinlikereceptor (KIR) which recognizes the expression of human leukocyte antigen (HLA) class I has a predominant role in regulating the effector functions of NK cells, particularly in viral infections. We studied a total of 128 hepatitis B virus (HBV)patients (15 acute, 43 asymptomatic, 27 chronic and 43 with other liver diseases) while attending the Department of Medical Gastroenterology, Government Rajaji Hospital, Madurai, India, and 128 ethnic matched control to find the association between the KIR : HLA genes and differential manifestations of HBV. KIR and its ligand HLA polymorphism were identified by DNAPCR methods. The activatory receptor KIR-2DS1 was significantly elevated in various disease categories, namely asymptomatic, chronic and other HBV, except acute HBV infection. Whereas, KIR 2DS3 in acute and chronic patients and KIR 2DS5 and 3DS1 in asymptomatic individuals. Among various KIR–HLA combinations, homozygous 2DS2:C1 and individuals with 3DSI:BW4 (OR = 3.23, CI = 1.55–6.7, Pc = 0.02) are associated with HBV asymptomatism, while most of the two domain inhibitory receptors with their ligands showed significant risk in other liver diseases. Further, KIR3DL1 : HLA Bw4Iso80 (OR = 3.89, 95% CI = 1.58–9.55, Pc = 0.004) is related with higher risk for asymptomatic infection when compared with chronic HBV. Thus, the select KIR : HLA alleles and combinations seem to direct the NK cell activities and immune response in different directions resulting in varied symptoms and manifestations in the subgroups of HBV-infected patientsstudied.

  15. How immigration can change the prevalence of HBV infection in an urban area of Northern Italy

    Directory of Open Access Journals (Sweden)

    Massimo De Paschale

    2011-11-01

    Full Text Available The introduction of HBV vaccination in Italy has led to a decline in new HBV infections. Increasing immigration over recent years suggests a change in short-term epidemiology of HBV. The aim of this study was to assess the prevalence of HBV infection in the general population living in the catchment area of Legnano Hospital (Northern Italy. In the period 2007-2008, 22,758 inpatients and outpatients were examined for Hepatitis B surface antigen (HBsAg, of whom 1,654 (7.3% were of foreign origin. Of the 488 patients who were positive for HBsAg (2.1%, 381 (1.8% were Italian and 107 (6.5% were born in other countries. In terms of age, the prevalence of HBsAg was significantly higher among non- Italians in every age group (other than those aged >60 and <11 years, and in many of the selected subgroups: the inpatients of some departments (35.4% vs 17.2%, pregnant women (5.3% vs 0.3%, blood donors (4.7% vs 0.1%, and hospital staff (6.4% vs 1.3%. Non- Italians were affected by 16.7% of acute infections and 24.3% of chronic infections; they also accounted for 42.6% of subjects with carrier state, 16.0% of patients with chronic hepatitis, and 12.2% of patients with cirrhosis. In our area, the overall prevalence of HBsAg among Italians is less than 2% (as expected following the introduction of HBV vaccination, but it is significantly higher among patients from areas highly endemic for HBV infection who represent a new reservoir for HBV infection.

  16. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA.

    Science.gov (United States)

    Seeger, Christoph; Sohn, Ji A

    2016-08-01

    Hepatitis B virus (HBV) causes chronic infections that cannot yet be cured. The virus persists in infected hepatocytes, because covalently closed circular DNA (cccDNA), the template for the transcription of viral RNAs, is stable in nondividing cells. Antiviral therapies with nucleoside analogues inhibit HBV DNA synthesis in capsids in the cytoplasm of infected hepatocytes, but do not destroy nuclear cccDNA. Because over 200 million people are still infected, a cure for chronic hepatitis B (CHB) has become one of the major challenges in antiviral therapy. As a first step toward the development of curative therapies, we previously demonstrated that the CRISPR/Cas9 system can be used to functionally inactivate cccDNA derived from infectious HBV. Moreover, some evidence suggests that certain cytokines might induce an APOBEC-mediated cascade leading to the destruction of cccDNA. In this report we investigated whether a combination of the two mechanisms could act synergistically to inactivate cccDNA. Using next generation sequencing (NGS), we determined the complete spectrum of mutations in cccDNA following Cas9 cleavage and repair by nonhomologous end joining (NHEJ). We found that over 90% of HBV DNA was cleaved by Cas9. In addition our results showed that editing of HBV DNA after Cas9 cleavage is at least 15,000 times more efficient that APOBEC-mediated cytosine deamination following treatment of infected cells with interferon alpha (IFNα). We also found that a previously used method to detect cytosine deaminated DNA, termed 3D-PCR, overestimates the amount and frequency of edited HBV DNA. Taken together, our results demonstrated that the CRISPR/Cas9 system is so far the best method to functionally inactivate HBV cccDNA and provide a cure for CHB. PMID:27203444

  17. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial.

    Science.gov (United States)

    Pande, C; Sarin, S K; Patra, S; Kumar, A; Mishra, S; Srivastava, S; Bhutia, K; Gupta, E; Mukhopadhyay, C K; Dutta, A K; Trivedi, S S

    2013-11-01

    Vertical transmission of Hepatitis B virus HBV can result in a state of chronic HBV infection and its complications. HBV vaccination with or without hepatitis B immunoglobulin (HBIG) prevents transmission of overt infection to the babies. However, whether it also prevents occult HBV infection in babies is not known. Consecutive pregnant women of any gestation found to be HBsAg positive were followed till delivery, and their babies were included in the study. Immediately after delivery, babies were randomized to receive either HBIG or placebo in addition to recombinant HBV vaccine (at 0, 6, 10 and 14 weeks). The primary end-point of the study, assessed at 18 weeks of age, was remaining free of any HBV infection (either overt or occult) plus the development of adequate immune response to vaccine. The babies were further followed up for a median of 2 years of age to determine their eventual outcome. Risk factors for HBV transmission and for poor immune response in babies were studied. Of the 283 eligible babies, 259 were included in the trial and randomized to receive either HBIG (n=128) or placebo (n=131) in addition to recombinant HBV vaccine. Of the 222 of 259 (86%) babies who completed 18 weeks of follow-up, only 62/222 (28%) reached primary end-point. Of the remaining, 6/222 (3%) developed overt HBV infection, 142/222 (64%) developed occult HBV infection, and 12/222 (5%) had no HBV infection but had poor immune response. All 6 overt infections occurred in the placebo group (P=0.030), while occult HBV infections were more common in the HBIG group (76/106 [72%] vs. 66/116 [57%]; P=0.025). This may be due to the immune pressure of HBIG. There was no significant difference between the two groups in frequency of babies developing poor immune response or those achieving primary end-point. The final outcome of these babies at 24 months of age was as follows: overt HBV infection 4%, occult HBV infection 42%, no HBV infection but poor immune response 8% and no HBV

  18. Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients

    Institute of Scientific and Technical Information of China (English)

    Hai-Ying Lu; Zhong-Hou Han; Yong Chen; Li-Wei Zhuang; Yan-Yan Yu; Hadad Ivan; Chong-Wen Si; Zheng Zeng; Jun Li; Dong-Ming Hou; Xin-Yue Chen

    2007-01-01

    AIM:To evaluate the effect of antiviral agents on intrahepatic HBV DNA in HBeAg-positive chronic hepatitis B patients.METHODS: Seventy-one patients received treatment with lamivudine, interferon alpha (IFN-α2b) or sequential therapy with lamivudine-IFN-α2b for 48 wk. All subjects were followed up for 24 wk. Serum and intrahepatic HBV DNA were measured quantitatively by PCR. HBV genotypes were analyzed by PCR-RFLP.RESULTS: At the end of treatment, the intrahepatic HBV DNA level in 71 patients decreased from a mean of (6.1 ± 1.0) log10 to (4.9 ± 1.4) log10. Further, a larger decrease was seen in the intrahepatic HBV DNA level in patients with HBeAg seroconversion. Intrahepatic HBV DNA level (before and after treatment) was not significantly affected by the patients'HBV genotype, or by the probability of virological flare after treatment.CONCLUSION: Intrahepatic HBV DNA can be effectively lowered by antiviral agents and is a significant marker for monitoring antivirus treatment. Low intrahepatic HBV DNA level may achieve better efficacy of antivirus treatment.

  19. Abstract efficacy of combined vaccine for the prevention of HBV transmission in highly viremic HBeAg+ mothers and the HBV markers' dynamic change of babies in follow-up%乙型肝炎病毒e抗原阳性孕妇所生婴儿联合免疫接种后乙型肝炎病毒血清学标志物的动态变化

    Institute of Scientific and Technical Information of China (English)

    江红秀; 韩国荣; 王翠敏; 岳欣; 王根菊

    2011-01-01

    followup.Methods HBeAg + mothers with HBV DNA≥1.0×6log10 copies/ml were enrolled and their babies were followed up until 12 months old.The infants received HBIG 200 IU IM in 24 hrs and on day 15,and 20 μg recombinant anti-HBV vaccine at 0,land 6months.The HBV markers and HBV DNA were tested at birth day,and 1,7,12 months after birth respectively.The vertical transmission rate at birth and intrauterine infection rate,the HBsAb positive rate and the HBV markers' dynamic changes during follow up were evaluated.Results (1) 29 out of 127 infants with HBsAg (+) at birth,11 of which were HBV DNA (+),HBV perinatal transmission rate was 22.83%.2 infants' HBsAg were positive at monthl and became negative at month 7 and 10 infants were still HBsAg (+) and HBV DNA (+).HBV intrauterine infection rate was 7.87%.(2) The positive rate of HBeAg and HBcAb in uninfected infants were 96.58% and 98.29% respectively,which declined gradually to undetectable level after immunization.No infants were HBeAb (+).(3) Infants uninfected produced effective HBsAb after vaccination.The level of HBsAb elevated gradually,and the level of HBeAg decreased quickly even to undetectable.Conclusion The combination vaccination of 200 IU HBIG with 20 μg recombinant anti-HBV vaccine in the Infants delivered by HBeAg + and highly viremic mothers reduced obviously the rate of perinatal transmission of HBV,enhanced largely the production of antibody against HBV surface antigen and dropped the maternal HBeAg and HBcAb in infants or even to negative.

  20. Correlation analysis between the load levels of paternal semen HBV-DNA and vertical transmission of HBV from father to infant%父亲精液HBV-D NA载量与HBV父婴垂直传播的相关性分析

    Institute of Scientific and Technical Information of China (English)

    陈顺萍; 张荣莲; 任坤海; 王梅颖

    2014-01-01

    Aim:To explore the impact of the load levels of paternal semen HBV-DNA on vertical transmission of HBV from HBsAg-positive father to infant.Methods:52 families of pregnant women with negative HBsAg and HBV-DNA and husbands with positive,serum HBsAg were selected.Clinical data and blood samples of the parents and their newborns、semen samples of the husbands were collected.Ser-um HBVM and the load levels of paternal blood and semen HBV-DNA were determined.In case-control study,based on the results of neonatal cord blood HBV-DNA detection,1 1 newborns with cord blood posi-tive HBV-DNA were selected as subiects,and 41 newborns with negative HBV-DNA as controls.Results:①The positive rate of neonatal cord blood HBV-DNA was found to be 21.2%(11/52),and that of se-men HBV-DNA was 26.9%(14/52).②The incidence of vertical transmission of HBV in infants with paternal positive semen HBV-DNA was found significantly higher than that in infants with paternal nega-tive semen HBV-DNA(P<0.01).③There was a positive rank correlation between semen and serum of HBV-DNA load levels,while the load levels of semen HBV-DNA was lower than that of serum HBV-DNA load levels.④The analysis of ROC curve showed that the prediction accuracy of semen HBV-DNA in the occurrence of vertical transmission were more accurate than that based on serum HBV-DNA load.Con-clusion:Paternal positive semen HBV-DNA is one of the risk fators for vertical transmission of HBV;re-ducing HBV-DNA load levels in paternal blood and semen before pregnancy may be a way to block father-fetal transmisson of HBV.%目的:探讨乙肝表面抗原(HBsAg)阳性父亲精液乙型肝炎病毒脱氧核糖核酸(HBV-DNA)载量对其新生儿发生HBV父婴垂直传播的影响,以期寻找阻断HBV父婴垂直传播的有效方法.方法:在知情同意的原则,以丈夫血清HBsAg阳性、孕母HBsAg及HBV-DNA均阴性的52个家庭作为研究对象,收集父母及其新生儿的相关资料及血液标

  1. HLA-DRB多态性与HBV感染的相关性研究%The correlation between HLA-DRB polymorphism and HBV infection

    Institute of Scientific and Technical Information of China (English)

    邢文斌; 郭晓楠; 徐慧宁

    2015-01-01

    Objective To analyze the HBV infection status and their HLA-DRB polymorphism among male patients with chronic hepatitis B, meanwhile their spouses and children were collected, to identify the correlation between HLA-DRB and HBV. Methods The serum markers of hepatitis B were tested by ELISA, different HLA-DRB1 allelic fragments in the patients with HBV and their spouses and children were ampliifed by ampliifcation, and the gene fragments were separated by agar gel electrophoresis, UV transmittance reflectance analyzer determine the type of HLA-DRB1. Results The patients with chronic hepatitis B and HBV carriers carrying HLA-DRB1*0201, 0301 genes were signiifcantly higher than those of healthy control group. The frequency of HLA-DRB1*1301 allele in healthy control group were higher than those in HBV patients and carriers. There was no significant difference between the recovery group and healthy control group with HLA-DRB1*0201, 0301, 0701 and 1301 alleles. The frequency of HLA-DRB1*0201, 0301, 0701 and 1301 alleles between the patients with chronic hepatitis B and HBV carriers were no significant difference. The frequency of HLA-DRB1*0201, 0301 and 0701 alleles in the hepatitis group was higher, and HLA-DRB1*1301 allele in recovery group was higher. Conclusions HLA-DRB1*0701, 0301 and 0201 alleles were related to HBV chronic infection, and HLA-DRB1*1301 allele was related to the clearance of HBV.%目的:通过对慢性乙型肝炎男性患者的配偶和子女HBV感染状况及其HLA-DRB多态性分析,揭示HLA-DRB与HBV感染的相关性。方法采用ELISA方法筛查HBV血清标志物,采用PCR/SSP技术扩增HBV感染者及易感人群HLA-DRB1不同位点等位基因片段,琼脂凝胶电泳分离基因片段,紫外透射反射分析仪判定HLA-DRB1型别。结果慢性乙型肝炎患者及HBV携带者携带HLA-DRB1*0201、0301基因显著高于健康对照组;HLA-DRB1*1301在健康对照组的携带率显著高于慢性乙型肝炎患

  2. Analysis the situation of HIV, syphilis and HBV testing services among pregnant women in Guangdong, 2012-2013%广东省2012-2013年孕产妇接受HIV梅毒和HBV检测服务情况

    Institute of Scientific and Technical Information of China (English)

    汤柳英; 赵庆国; 李兵; 高爽; 马远珠; 赖科峰; 夏建红

    2015-01-01

    目的 了解广东省各地区孕产妇接受艾滋病病毒(HIV)、梅毒和乙型肝炎病毒(HBV)检测服务状况,及各地区检测服务的差异,为各地区持续改进HIV、梅毒和HBV检测服务能力提供参考依据.方法 常规收集广东省各地区2012年与2013年孕产妇在医疗保健机构接受HIV、梅毒和HBV检测与咨询服务的相关信息,并通过国家预防艾滋病、梅毒和乙型肝炎母婴传播管理信息系统报告与收集相关数据,采用描述性统计分析与卡方检验分析各地市分娩产妇HIV、梅毒和HBV检测率及孕期检测率.结果 广东省各地区2012-2013年分娩产妇共计3 530 186人,其中,2012年为1 763 034人,2013年为1 767 152人.2013年广东省孕产妇HIV、梅毒和HBV检测率分别为93.33%、83.02%和84.30%,均显著高于2012年的孕产妇检测率.两年间,珠三角地区、东翼地区、西翼地区和山区HIV、梅毒和HBV的检测率分别为97.77%、83.15%和84.48%,74.72%、76.15%和77.14%,92.97%、83.93%和85.60%,94.67%、88.22%和89.24%;珠三角地区HIV、梅毒和HBV检测率显著高于其他地区.结论 广东省孕产妇孕期检测率不高,各地区项目检测现状不均衡,预防梅毒和乙型肝炎母婴传播有待进一步加强.

  3. HBV感染者血清标志物与HBV DNA的关系

    Institute of Scientific and Technical Information of China (English)

    李君莲; 李东军

    2007-01-01

    目的 了解乌鲁木齐地区HBV感染者血清学标志物与HBV DNA的关系.方法 检测234例HBV感染者血清标志物,并用实时荧光定量PCR法检测HBV DNA.结果 在本组234例HBV感染者中,血清前S1抗原阳性率为62.39%(146/234);前S2抗原阳性率为85.47%(200/234);HBV DNA阳性率为49.57%(116/234).在HBsAg/HBeAg/Anti-HBc阳性组,前S1抗原和HBV DNA阳性率较高.结论 前S1抗原和HBV DNA能反映病毒的复制状态.

  4. Quantifying anti-HBV effect of targeted ribonuclease by real-time fluorescent PCR

    Institute of Scientific and Technical Information of China (English)

    Jun Liu; Ying-Hui Li; Jin Ding; Wei-Dong Gong; Cai-Fang Xue; Ya Zhao; Yu-Xiao Huang

    2004-01-01

    AIM: To quantify the inhibition of HBV replication by targeted ribonuclease by using real-time fluorescent PCR.METHODS: Targeted ribonuclease was introduced into 2.2.15cells by liposome-mediated transfection or HIV-TAT mediated protein transduction. Forty-eight hours after the transfection and 24 h after the transduction, supernatants of 2.2.15 cells were collected and HBV DNA in the supernatants was quantified by real-time fluorescent PCR with a commercial kit.RESULTS: HBV DNA concentrations in the supernatants of2.2.15 cells transfected or transducted with targeted ribonuclease were 4.9±2.4×108 copies/L and 8.3±4.0×108copies/L, respectively. Compared with controls, transfection or transduction of targeted ribonuclease reduced HBV DNA concentration in the supernatants of 2.2.15 cells by 90.4%and 90.1%, respectively (P<0.05).CONCLUSION: Targeted ribonuclease can inhibit HBV replication in 2.2.15 cells.

  5. Prevalence of occult HBV infection in haemodialysis patients with chronic HCV

    Institute of Scientific and Technical Information of China (English)

    Vedat Goral; Hamza Ozkul; Selahattin Tekes; Dede Sit; Ali Kemal Kadiroglu

    2006-01-01

    AIM: To study the prevalence and clinical effects of occult HBV infection in haemodialysis patients with chronic HCV.METHODS: Fifty chronic hemodialysis patients with negative HbsAg, and positive anti-HCV were included in the study. These patients were divided into two groups:HCV-RNA positive and HCV-RNA negative, based on the results of HCV-RNA PCR. HBV-DNA was studied using the PCR method in both groups.RESULTS: None of the 22 HCV-RNA positive patients and 28 HCV-RNA negative patients revealed HBV-DNA in serum by PCR method. The average age was 47.2 ± 17.0 in the HCV-RNA positive group and 39.6 ± 15.6 in the HCV-RNA negative group.CONCLUSION: The prevalence of occult HBV infection is not high in haemodialysis patients with chronic HCV in our region. This result of our study has to be evaluated in consideration of the interaction between HBsAg positivity (8%-10%) and frequency of HBV mutants in our region.

  6. Association of the Cellular Apoptosis Susceptibility Protein with HBV Infection in Hepatocellular Carcinoma

    Institute of Scientific and Technical Information of China (English)

    2014-01-01

    Objective The cellular apoptosis susceptibility (CAS) protein plays a regulatory role in the induction of cell death in tumor cells. The objective of this study was to investigate the association of the expression of CAS protein with HBV infection in the development of HCC. Methods The expression level of CAS was measured with immunohistochemistry. The occurrence of HBsAg, HBeAg and HBV DNA in HCC were concurrently examined with immunohistochemistry and in situ hybridization, respectively. Results The results showed that the CAS protein was detected in 86% (43/50), 70% (7/10), 15% (3/20) and none (0/20) of livers from patients with HCC, cholangiocarcinoma, cirrhosis and hepatitis, respectively. Furthermore, the level of CAS protein was higher in poorly differentiated tumors than moderately or well differentiated HCC. Interestingly, the CAS was stained significantly stronger in HBV-infected HCC than in non-HBV infected tissues (P < 0.01). Conclusions The expression of CAS is facilitated by HBV infection in HCC, suggesting that CAS might be a prognostic marker and a putative therapeutic target for HCC.

  7. HBV and HIV co-infection: Impact on liver pathobiology andtherapeutic approaches

    Institute of Scientific and Technical Information of China (English)

    Mohammad Khalid Parvez

    2015-01-01

    The consequences of hepatitis B virus (HBV) andhuman immunodeficiency virus (HIV) co-infection onprogression of severe liver diseases is a serious publichealth issue, worldwide. In the co-infection cases,about 90% of HIV-infected population is seropositivefor HBV where approximately 5%-40% individuals arechronically infected. In HIV co-infected individuals, liverrelatedmortality is estimated over 17 times higher thanthose with HBV mono-infection. The spectrum of HIVinducedliver diseases includes hepatitis, steatohepatitis,endothelialitis, necrosis, granulomatosis, cirrhosis andcarcinoma. Moreover, HIV co-infection significantlyalters the natural history of hepatitis B, and thereforecomplicates the disease management. Though severalstudies have demonstrated impact of HIV proteins onhepatocyte biology, only a few data is available oninteractions between HBV and HIV proteins. Thus,the clinical spectrum as well as the complexity of theco-infection offers challenging fronts to study theunderlying molecular mechanisms, and to designeffective therapeutic strategies.

  8. Immune memory responses to HBV vaccine 13-18 years after primary vaccination.

    Science.gov (United States)

    Hou, L; Li, W; Wei, X; Zhou, Y; Zhuo, Y; Wu, H; Shen, B

    2015-01-01

    The aim of this study was to evaluate the immune memory response 13-18 years after an hepatitis B virus (HBV) vaccine by performing a specific in vitro stimulation experiment. Thirty healthy volunteers who had been inoculated 13-18 years ago with the HBV vaccine were collected from the physical examination center. Peripheral blood mononuclear cells were stimulated with 50 ng/mL recombinant HBsAg. An ELISA kit was used for the detection of antibodies that were produced by these cells in vitro. It was found that even 13-18 years after inoculation with the HBV vaccine, an anamnestic antibody response still existed, and was not correlated with the serum antibody levels (r = -0.177, P = 0.377). In conclusion, our data showed that the individuals after inoculation, including those with anti-HBs B cells. PMID:26345774

  9. Asymmetric PCR method in generation of HBV ssDNA for pyrosequencing

    Institute of Scientific and Technical Information of China (English)

    Nian-cai Peng; Chun-lin Wang; Li-li Zhang; Mao-li Lu; Zhen-xi Zhang

    2009-01-01

    Objective To explore the optimal primer ratio and concentration of asymmetric polymerase chain reaction (A-PCR) in producing hepatitis B virus (HBV) single-stranded DNA (ssDNA) for pyrosequencing. Methods A-PCR was carried out to generate HBV ssDNA with forward to reverse primers of different ratios (50 : 1, 100 : 1) and concentrations (13. 0 pmol/25μL and 0.14 pmol/25μL, 19. 5 pmol/25μL and 0. 21 pmol/25μL), and the product yield and quality were compared respectively. Results The forward to reverse primer ratio of 50 : 1 provided better yield and concentration of 19. 5 pmol/25μL and 0. 21 pmol//25μL generated a clearer band. Conclusion A simple and feasible method to produce HBV ssDNA for pyrosequencing in batch is established.

  10. Age-dependent immune events during HBV infection from birth to adulthood: an alternative interpretation

    Directory of Open Access Journals (Sweden)

    Antonio eBertoletti

    2014-09-01

    Full Text Available Immune responses change during the life of an individual. While this concept has been well accepted for adaptive immunity, only recently it is becoming clear that the innate immune responses also acquire distinct features in different phases of life. We believe that this concept can offer a different interpretation of the pathological manifestations that can be observed in HBV-infected subjects during the patient’s life. Here, we will review the age-related immunopathological features of HBV infection and discuss how the different virological and clinical manifestations might be linked to the developmental pathway of the immune system from newborns to adults. We will discuss how the age of patients can affect the degree of inflammatory responses, but not the levels of antiviral specific immunity. We then propose that the different clinical manifestations occurring during the natural history of HBV infection are related to the host ability to trigger an inflammatory immune response.

  11. Molecular mechanism for the involvement of nuclear receptor FXR in HBV-associated hepatocellular carcinoma

    Directory of Open Access Journals (Sweden)

    Yong-dong Niu

    2011-08-01

    Full Text Available Farnesoid X receptor (FXR, also termed nuclear receptor NR1H4 is critically involved in the regulation of nascent bile formation and bile acid enterohepatic circulation. FXR and bile acids have been shown to play roles in liver regeneration and inflammatory responses. There is increasing evidence suggesting that FXR and the FXR signaling pathway are involved in the pathophysiology of a wide range of liver diseases, such as viral hepatitis, cirrhosis, and hepatocellular carcinoma (HCC. Here we discuss the latest discoveries of FXR functions with relevance to bile acid metabolism and HBV-associated HCC. More specifically, the goal of this review is to discuss the roles of FXR and bile acids in regulating HBV replication and how disregulation of the FXR-bile acid signaling pathway is involved in HBV-associated hepatocarcinogenesis.

  12. Baseline characteristics of HIV & hepatitis B virus (HIV/HBV) co-infected patients from Kolkata, India

    Science.gov (United States)

    Sarkar, Jayeeta; Saha, Debraj; Bandyopadhyay, Bhaswati; Saha, Bibhuti; Kedia, Deepika; Guha Mazumder, D.N.; Chakravarty, Runu; Guha, Subhasish Kamal

    2016-01-01

    Background & objectives: Hepatitis B virus (HBV) and HIV co-infection has variable prevalence worldwide. In comparison to HBV mono-infection, the course of chronic HBV infection is accelerated in HIV/HBV co-infected patients. The present study was carried out to analyse the baseline characteristics (clinical, biochemical, serological and virological) of treatment naïve HIV/HBV co-infected and HIV mono-infected patients. Methods: Between July 2011 and January 2013, a total number of 1331 HIV-seropositive treatment naïve individuals, enrolled in the ART Centre of Calcutta School of Tropical Medicine, Kolkata, India, were screened for hepatitis B surface antigen (HBsAg). A total of 1253 HIV mono-infected and 78 HIV/HBV co-infected patients were characterized. The co-infected patients were evaluated for HBeAg and anti-HBe antibody by ELISA. HIV RNA was quantified for all co-infected patients. HBV DNA was detected and quantified by real time-PCR amplification followed by HBV genotype determination. Results: HIV/HBV co-infected patients had proportionately more advanced HIV disease (WHO clinical stage 3 and 4) than HIV mono-infected individuals (37.1 vs. 19.9%). The co-infected patients had significantly higher serum bilirubin, alanine aminotransferase (ALT), alkaline phosphatase and ALT/platelet ratio index (APRI). CD4 count was non-significantly lower in co-infected patients. Majority (61.5%) were HBeAg positive with higher HIV RNA (PHIV/HBV co-infected patients had significantly higher serum bilirubin, ALT, alkaline phosphatase and lower platelet count. HBeAg positive co-infected patients had higher HIV RNA and HBV DNA compared to HBeAg negative co-infected patients. Prior to initiation of antiretroviral treatment (ART) all patients should be screened for HBsAg to initiate appropriate ART regimen. PMID:27488008

  13. Interleukin-22 as a molecular adjuvant facilitates IL-17-producing CD8+ T cell responses against a HBV DNA vaccine in mice

    OpenAIRE

    Wu, Bing; Zou, Qiang; Hu, Yanxin; Wang, Bin

    2013-01-01

    Interleukin-22 (IL-22) is mainly produced by activated Th1 cells, Th17 cells and NK cells and promotes anti-microbial defense, pro-inflammatory and tissue remodeling responses. However, its potential use as a vaccine adjuvant has not been tested. In this study, we tested if a DNA construct expressing IL-22 (pVAX-IL-22) could be used as a molecular adjuvant to enhance host immune responses induced by HBV DNA vaccination (pcD-S2). After immunizing mice with pcD-S2 combined with pVAX-IL-22, we d...

  14. HBV genotype C is independently associated with cirrhosis in community-based population

    Institute of Scientific and Technical Information of China (English)

    2010-01-01

    AIM:To determine the association of hepatitis B virus (HBV) genotypes with probable cirrhosis and fatty liver in community-based populations.METHODS: A multi-stage cluster probability sampling method was applied to recruit 10 167 subjects aged between 6 and 72 years from our epidemiological bases in Eastern China. After excluding the subjects co-infected with hepatitis C or hepatitis D viruses, the hepatitis B surface antigen (HBsAg)-positive subjects were examined for HBV genotype, serum viral load, alanin...

  15. Immune mediated crescentic MPGN secondary to HBV infection: A rare presentation for a common infection.

    Science.gov (United States)

    Mareddy, Aswani Srinivas; Rangaswamy, Dharshan; Vankalakunti, Mahesha; Attur, Ravindra Prabhu; Nagaraju, Shankar Prasad; Koti, Neeraja

    2016-01-01

    Hepatitis B virus (HBV) infection presenting as crescentic glomerulonephritis in the absence of cryoglobulinemia is an extremely rare phenomenon. We report a case of a 44-year-old male with HBV infection, who underwent kidney biopsy for rapidly progressive renal failure and nephrotic range proteinuria. Histopathological evaluation of the kidney biopsy was consistent with immune complex mediated crescentic membranoproliferative glomerulonephritis (MPGN). The patient achieved complete renal and virological remission with steroids, plasmapheresis and antiviral therapy. This case report summarises the importance of early initiation of immunosuppression and plasmapheresis under antiviral coverage for improved clinical outcomes.

  16. Immune mediated crescentic MPGN secondary to HBV infection: A rare presentation for a common infection

    Directory of Open Access Journals (Sweden)

    Aswani Srinivas Mareddy

    2016-01-01

    Full Text Available Hepatitis B virus (HBV infection presenting as crescentic glomerulonephritis in the absence of cryoglobulinemia is an extremely rare phenomenon. We report a case of a 44-year-old male with HBV infection, who underwent kidney biopsy for rapidly progressive renal failure and nephrotic range proteinuria. Histopathological evaluation of the kidney biopsy was consistent with immune complex mediated crescentic membranoproliferative glomerulonephritis (MPGN. The patient achieved complete renal and virological remission with steroids, plasmapheresis and antiviral therapy. This case report summarises the importance of early initiation of immunosuppression and plasmapheresis under antiviral coverage for improved clinical outcomes.

  17. GLOBAL ASYMPTOTICAL PROPERTIES FOR A DIFFUSED HBV INFECTION MODEL WITH CTL IMMUNE RESPONSE AND NONLINEAR INCIDENCE

    Institute of Scientific and Technical Information of China (English)

    Wang Shaoli; Feng Xinlong; He Yinnian

    2011-01-01

    This article proposes a diffused hepatitis B virus (HBV) model with CTLimmune response and nonlinear incidence for the control of viral infections.By means of different Lyapunov functions,the global asymptotical properties of the viral-free equilibrium and immune-free equilibrium of the model are obtained.Global stability of the positive equilibrium of the model is also considered.The results show that the free diffusion of the virus has no effect on the global stability of such HBV infection problem with Neumann homogeneous boundary conditions.

  18. Osteopontin promotes dendritic cell maturation and function in response to HBV antigens

    Directory of Open Access Journals (Sweden)

    Cui GY

    2015-06-01

    Full Text Available Guangying Cui,1,2 Jianing Chen,1,2 Jianqin He,1,2 Chong Lu,1,2 Yingfeng Wei,1,2 Lin Wang,1,2 Xuejun Xu,3 Lanjuan Li,1,2 Toshimitsu Uede,4 Hongyan Diao1,2 1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 2Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, 3Department of Oral Orthodontics, Affiliated Stomatology Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China; 4Molecular Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan Purpose: Dendritic cells (DCs play critical roles in promoting innate and adaptive immunity in microbial infection. Functional impairment of DCs may mediate the suppression of viral-specific T-cell immune response in chronic hepatitis B (CHB patients. Osteopontin (OPN is involved in several liver diseases and infectious diseases. However, whether OPN affects DC function in hepatitis B virus (HBV infection is unknown.Methods: Twenty CHB patients and 20 healthy volunteers were recruited. OPN secreted by DCs was compared. Peripheral blood mononuclear cells cultured with OPN antibody were examined to study the costimulatory molecular expression and interleukin (IL-12 production of DCs after HBV antigenic stimulation. OPN-deficient mice were used to investigate the influence of OPN on DC maturation and function after HBV antigenic stimulation in vitro and in vivo. Exogenous OPN was administrated to further verify the functioning of DCs from CHB patients upon HBV antigenic stimulation.Results: We found that OPN production of DCs from CHB patients was significantly lower than those from healthy volunteers. The absence of OPN impaired IL-12 production and costimulatory molecular expression of DCs upon stimulation with HBV antigens. Defective DC function led to reduced activation of Th1 response to

  19. HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level

    Directory of Open Access Journals (Sweden)

    Ambreen Ayub

    2013-01-01

    Full Text Available Hepatocellular carcinoma (HCC is a deadly and emerging disease leading to death in Asian countries. High hepatitis B virus (HBV load and chronic hepatitis B (CHB infection increase the risk of developing HCC. HBV is a DNA virus that can integrate DNA into host genome thereby increase the yield of transactivator protein HBxAg that may deregulate many pathways involving in metabolism of cells. Several monogenic and polygenic risk factors are also involved in HCC development. This review summarizes the mechanism involved in HCC development and discusses some promising therapies to make HCC curative.

  20. Treatments of Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection: Treat HBV-related HCC

    Directory of Open Access Journals (Sweden)

    Charing Ching-Ning Chong

    2016-03-01

    Full Text Available There have been major advances recently on the therapeutic approaches of hepatitis B virus (HBV-related hepatocellular carcinoma (HCC. Surgical treatments are the key curative treatments of HCC, whereas local ablative treatments may also achieve clinical remission in selected cases. Trans-arterial locoregional therapies are regarded as palliative but still lead to improved survival. There have been major breakthroughs in the systemic therapies for HCC. The first marketed targeted therapy, sorafenib, was shown to improve survival in patients with advanced HCC. Studies on other targeted therapies also showed promising results. Suppressing HBV with effective antiviral treatment would also benefit HCC patients by reducing recurrence and improving liver function.

  1. Asymmetric PCR method in generation of HBV ssDNA for pyrosequencing

    Institute of Scientific and Technical Information of China (English)

    2009-01-01

    Objective To explore the optimal primer ratio and concentration of asymmetric polymerase chain reaction (A-PCR) in producing hepatitis B virus (HBV) single-stranded DNA (ssDNA) for pyrosequencing. Methods A-PCR was carried out to generate HBV ssDNA with forward to reverse primers of different ratios (50∶1, 100∶1) and concentrations (13.0 pmol/25μL and 0.14 pmol/25μL, 19.5 pmol/25μL and 0.21 pmol/25μL), and the product yield and quality were compared respectively. Results The forward to reverse primer ratio ...

  2. The association of complex liver disorders with HBV genotypes prevalent in Pakistan

    Directory of Open Access Journals (Sweden)

    Qureshi Huma

    2007-11-01

    Full Text Available Abstract Background Genotyping of HBV is generally used for determining the epidemiological relationship between various virus strains and origin of infection mostly in research studies. The utility of genotyping for clinical applications is only beginning to gain importance. Whether HBV genotyping will constitute part of the clinical evaluation of Hepatitis B patients depends largely on the availability of the relevance of the evidence based information. Since Pakistan has a HBV genotype distribution which has been considered less virulent as investigated by earlier studies from south East Asian countries, a study on correlation between HBV genotypes and risk of progression to further complex hepatic infection was much needed Methods A total of 295 patients with HBsAg positive were selected from the Pakistan Medical Research Council's (PMRC out patient clinics. Two hundred and twenty six (77% were males, sixty nine (23% were females (M to F ratio 3.3:1. Results Out of 295 patients, 156 (53.2% had Acute(CAH, 71 (24.2% were HBV Carriers, 54 (18.4% had Chronic liver disease (CLD Hepatitis. 14 (4.7% were Cirrhosis and HCC patients. Genotype D was the most prevalent genotype in all categories of HBV patients, Acute (108, Chronic (39, and Carrier (53. Cirrhosis/HCC (7 were HBV/D positive. Genotype A was the second most prevalent with 28 (13% in acute cases, 12 (22.2% in chronics, 14 (19.7% in carriers and 5 (41.7 in Cirrhosis/HCC patients. Mixed genotype (A/D was found in 20 (12.8% of Acute patients, 3 (5.6% of Chronic and 4 (5.6% of carriers, none in case of severe liver conditions. Conclusion Mixed HBV genotypes A, D and A/D combination were present in all categories of patients except that no A/D combination was detected in severe conditions. Genotype D was the dominant genotype. However, genotype A was found to be more strongly associated with severe liver disease. Mixed genotype (A/D did not significantly appear to influence the clinical outcome.

  3. Moving horizon estimation for assimilating H-SAF remote sensing data into the HBV hydrological model

    Science.gov (United States)

    Montero, Rodolfo Alvarado; Schwanenberg, Dirk; Krahe, Peter; Lisniak, Dmytro; Sensoy, Aynur; Sorman, A. Arda; Akkol, Bulut

    2016-06-01

    Remote sensing information has been extensively developed over the past few years including spatially distributed data for hydrological applications at high resolution. The implementation of these products in operational flow forecasting systems is still an active field of research, wherein data assimilation plays a vital role on the improvement of initial conditions of streamflow forecasts. We present a novel implementation of a variational method based on Moving Horizon Estimation (MHE), in application to the conceptual rainfall-runoff model HBV, to simultaneously assimilate remotely sensed snow covered area (SCA), snow water equivalent (SWE), soil moisture (SM) and in situ measurements of streamflow data using large assimilation windows of up to one year. This innovative application of the MHE approach allows to simultaneously update precipitation, temperature, soil moisture as well as upper and lower zones water storages of the conceptual model, within the assimilation window, without an explicit formulation of error covariance matrixes and it enables a highly flexible formulation of distance metrics for the agreement of simulated and observed variables. The framework is tested in two data-dense sites in Germany and one data-sparse environment in Turkey. Results show a potential improvement of the lead time performance of streamflow forecasts by using perfect time series of state variables generated by the simulation of the conceptual rainfall-runoff model itself. The framework is also tested using new operational data products from the Satellite Application Facility on Support to Operational Hydrology and Water Management (H-SAF) of EUMETSAT. This study is the first application of H-SAF products to hydrological forecasting systems and it verifies their added value. Results from assimilating H-SAF observations lead to a slight reduction of the streamflow forecast skill in all three cases compared to the assimilation of streamflow data only. On the other hand

  4. Genetic polymorphism of interleukin-6 influences susceptibility to HBV-related hepatocellular carcinoma in a male Chinese Han population.

    Science.gov (United States)

    Tang, Shengli; Yuan, Yufeng; He, Yueming; Pan, Dingyu; Zhang, Yongxi; Liu, Yuanyuan; Liu, Quanyan; Zhang, Zhonglin; Liu, Zhisu

    2014-04-01

    As a multifunctional cytokine, interleukin-6 (IL-6) plays a key role in chronic inflammation as well as tumor growth and progression of hepatitis B virus (HBV) infection. Recent studies have implicated that single nucleotide polymorphism (SNP) -572C>G (rs1800796) located within the promoter region of IL-6 gene was associated with susceptibility to several diseases. Here, a case-control study was undertaken to investigate the association between this polymorphism and HBV-related hepatocellular carcinoma (HCC) susceptibility in a Chinese Han population. A total of 900 patients with chronic HBV infection, including 505 HBV-related HCC patients and 395 HBV infected patients without HCC were enrolled, and rs1800796 polymorphism was genotyped by the TaqMan method and DNA sequencing technology. The results indicated no significant association between rs1800796 polymorphism and the risk of HBV-related HCC in all subjects; however, a significant difference was identified in male subjects. Under the dominant model, male subjects with the G allele (CG/GG) have higher susceptibility to HBV-related HCC than those with CC genotype after adjusting confounding factors (P=0.012, odds ratio [OR] 1.68, 95% confidence interval [95% CI] 1.15-2.42). Our results suggested that rs1800796 polymorphism of IL-6 gene was associated with susceptibility to HBV-related HCC in a male Chinese Han population.

  5. Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi

    Science.gov (United States)

    Liao, Xiwen; Han, Chuangye; Qin, Wei; Liu, Xiaoguang; Yu, Long; Lu, Sicong; Chen, Zhiwei; Zhu, Guangzhi; Su, Hao; Mo, Zengnan; Qin, Xue; Peng, Tao

    2016-01-01

    Objective: The genome-wide association approach was employed to explore the association between single nucleotide polymorphisms (SNPs) and TP53 expression in the HBV-related hepatocellular carcinoma (HCC) of Chinese patients in Guangxi. Methods: 403 HBV-related HCC patients were recruited into this study and classified according to the TP53 expression in the cancer by immunohistochemistry. DNA was extracted from the cancer and genotyped with the Human ExomeBeadChip 12v1-1 system; quality control and principal-component analysis (PCA) were applied for data analysis. Results: The Genome-wide association analysis indicated that rs2797992 with a P value of 4.35 × 10-5 locus in PLCE1 gene and rs6950826 with a P value of 2.2 × 10-3 locus in EGFR gene were associated with TP53 expression in the HCC. A allele of rs2797992 predicted a decreased risk for TP53 expression in HCC. In contrast, A allele of rs6950826 increased the risk for TP53 expression. There was no strong LD locus in the tested regions. PLCE1 and EGFR were associated with TP53 in pathway and at HCC mRNA level. Conclusion: rs2797992 of PLCE1 gene and rs6950826 of EGFR gene are associated with TP53 expression, but not with the prognosis of HBV-related HCC in HBV-related HCC of Chinese patients in Guangxi. PMID:27186304

  6. 乙型肝炎血清标志物和HBV-DNA载量相关性分析%Study on the correlation between serum markers of hepatitis B and HBV-DNA

    Institute of Scientific and Technical Information of China (English)

    罗慧琴; 王志刚; 李玲; 刘付芹

    2013-01-01

    目的 探讨乙肝血清标志物与病毒DNA水平之间的相关性.方法 采用实时荧光定量PCR对874例HBV感染者血清中HBV-DNA含量进行检测,同时运用ELISA法检测HBV血清标志物,并统计分析患者乙型肝炎血清标志物、病毒DNA之间的相关性及分布特点.结果 在受检的874例标本中,男性533例,阳性率58.16% (310/533);女性341例,阳性率50.44%(172/341),男性和女性阳性率比较差异有统计学意义(X2=5.01,P<0.05),男性和女性HBV-DNA水平差异无统计学意义(t =0.117,P=0.907).乙肝总阳性率和HBV-DNA水平均随年龄的增长呈下降趋势,不同年龄组间比较差异有统计学意义.同一年龄段的大三阳与小三阳、两头阳和三抗阳之间比较差异有统计学意义;其中男性和女性HBV-DNA水平随年龄增长均呈下降趋势,差异有统计学意义.≤20岁以下人群HBV-DNA阳性率最高达82.86%.结论 HBV-DNA阳性率和HBV-DNA水平都随年龄增长呈下降趋势,其中≤20岁年龄段HBV-DNA阳性率最高达82.86%;男性HBV-DNA的阳性率高于女性.%Objective To investigate the correlation between HBV serum markers and HBV DNA levels.Methods HBV-DNA and serum markers in 874 cases of HBV infected persons were detected by real-time fluorescence quantitative PCR and ELISA,respectively.SPSS 16.0 was used to analyze the correlation and distribution characteristics.Results In 874 cases,533 positive cases were male,the positive rate was 58.16% (310/533).341 positive cases were female,the positive rate was 50.44% (172/341).There was statistical difference (x2 =5.01,P <0.05) comparing male with female.But there was no statistical difference (t =0.117,P =0.907) in HBV-DNA level between male and female.The total positive rate and HBV-DNA level showed descending tendency with age,and there were statistical differences among different age groups.When comparing big 3 this world,small 3 this world,two head positive and three antibody positive

  7. Serum testosterone levels and androgen receptor CAG polymorphism correlate with hepatitis B virus (HBV-related acute liver failure in male HBV carriers.

    Directory of Open Access Journals (Sweden)

    Bao-Yan Xu

    Full Text Available BACKGROUND: Augmentation of androgen/androgen receptor (AR pathway may influence chronic hepatitis B (CHB more likely in males. AR activity is modulated by a polymorphic CAG repeat sequence in AR exon 1. This study aimed to investigate the relationship between serum testosterone levels, CAG repeat numbers and hepatitis B virus (HBV-related acute liver failure (ALF. METHODS: Three hundred and seventy eight male CHB patients with ALF and 441 asymptomatic HBV carriers (AsCs were recruited. AR CAG repeats numbers were analyzed. The serum testosterone levels of AsCs, ALFs and patients with hepatitis B flare groups, and sequential serum samples, were assessed quantitatively. RESULTS: The median CAG repeat (M-CAG frequency was significantly higher in ALF patients than AsCs (P<0.001. Patients with M-CAG alleles (P<0.001, OR 3.0, 95% CI 2.1-4.2 had the highest risk for ALF. Serum testosterone levels were significantly higher (P<0.001 at hepatitis flare point (8.2 ± 3.0 ng/mL than inactive phase (6.4 ± 2.0 ng/mL. CHB (8.30 ± 2.71 ng/mL, P = 7.6 × 10(-6 and ALF group (2.61 ± 1.83 ng/mL, P = 1.7 × 10(-17 had significantly different levels of testosterone in comparison with AsCs group (6.56 ± 2.36 ng/mL. The serum testosterone levels sharply decreased from hepatitis flare phase to liver failure phase, and tended to be normal at the recovery phase. Male AsCs with M-CAG alleles had significantly lower serum testosterone levels (P<0.05. CONCLUSIONS: There was a serum testosterone fluctuation during hepatitis B flare and HBV-related ALF, and the median CAG repeats in AR gene exon 1 were associated with lower serum testosterone levels in asymptomatic HBV carriers and an increased susceptibility to HBV-related ALF.

  8. DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic.

    Directory of Open Access Journals (Sweden)

    Ying Yin

    Full Text Available BACKGROUND: Typically, DNA immunization via the intramuscular route induces specific, Th1-dominant immune responses. However, plasmids expressing viral proteins fused to cytotoxic T lymphocyte antigen 4 (CTLA-4 primed Th2-biased responses and were able to induced effective protection against viral challenge in the woodchuck model. Thus, we addressed the question in the mouse model how the Th1/Th2 bias of primed immune responses by a DNA vaccine influences hepatitis B virus (HBV clearance. PRINCIPAL FINDINGS: Plasmids expressing HBV core protein (HBcAg or HBV e antigen and HBcAg fused to the extracellular domain of CTLA-4 (pCTLA-4-HBc, CD27, and full length CD40L were constructed. Immunizations of these DNA plasmids induced HBcAg-specific antibody and cytotoxic T-cell responses in mice, but with different characteristics regarding the titers and subtypes of specific antibodies and intensity of T-cell responses. The plasmid pHBc expressing HBcAg induced an IgG2a-dominant response while immunizations of pCTLA-4-HBc induced a balanced IgG1/IgG2a response. To assess the protective values of the immune responses of different characteristics, mice were pre-immunized with pCTLA-4-HBc and pHBc, and challenged by hydrodynamic injection (HI of pAAV/HBV1.2. HBV surface antigen (HBsAg and DNA in peripheral blood and HBcAg in liver tissue were cleared with significantly accelerated kinetics in both groups. The clearance of HBsAg was completed within 16 days in immunized mice while more than 50% of the control mice are still positive for HBsAg on day 22. Stronger HBcAg-specific T-cell responses were primed by pHBc correlating with a more rapid decline of HBcAg expression in liver tissue, while anti-HBs antibody response developed rapidly in the mice immunized with pCTLA-4-HBc, indicating that the Th1/Th2 bias of vaccine-primed immune responses influences the mode of viral clearance. CONCLUSION: Viral clearance could be efficiently achieved by Th1/Th2-balanced

  9. Anti-hepatitis B core antigen testing with detection and characterization of occult hepatitis B virus by an in-house nucleic acid testing among blood donors in Behrampur, Ganjam, Orissa in southeastern India: implications for transfusion

    Directory of Open Access Journals (Sweden)

    Panigrahi Rajesh

    2010-08-01

    Full Text Available Abstract Background Occult hepatitis B virus (HBV infection might transmit viremic units into the public blood supply if only hepatitis B surface antigen (HBsAg testing is used for donor screening. Our aim was to evaluate the prevalence of occult HBV infection among the HBsAg negative/antiHBc positive donations from a highly HIV prevalent region of India. Methods A total of 729 HBsAg negative donor units were included in this study. Surface gene and precore region were amplified by in house nucleic acid test (NAT for detection of occult HBV infection and surface gene was analyzed after direct sequencing. Results A total of 220 (30.1% HBsAg negative donors were antiHBc positive, of them 66 (30% were HBV DNA positive by NAT. HBV DNA positivity among 164 antiHBc only group, was 27.1% and among 40 antiHBs positive group was 30.0%. HBV/D (93.3% was predominant and prevalence of both HBV/C and HBV/A was 3.3%. Single or multiple amino acids substitutions were found in 95% samples. Conclusion Thus, a considerable number of HBV infected donors remain undiagnosed, if only HBsAg is used for screening. Addition of antiHBc testing for donor screening, although will lead to rejection of a large number of donor units, will definitely eliminate HBV infected donations and help in reducing HBV transmission with its potential consequences, especially among the immunocompromised population. The HBV genetic diversity found in this donor population are in accordance with other parts of India.

  10. Inhibition of Hepatitis B Virus Replication by Rheum palmatum L. Ethanol Extract in a Stable HBV-producing Cell

    Institute of Scientific and Technical Information of China (English)

    Yan SUN; Li-jun LI; Jing LI; Zhi LI

    2007-01-01

    Hepatitis B virus(HBV) infection is a severe health problem in the world.However,there is still not a satisfactory therapeutic strategy for the HBV infection.To search for new anti-HBV agents with higher efficacy and less side-effects,the inhibitory activities of traditional Chinese medicine Rheum palmatum L.ethanol extract(RPE) against HBV replication were investigated in this study.Quantitative real-time polymerase chain reaction(PCR) was employed to analyze the inhibitory activity of RPE against HBV-DNA replication in a stable HBV-producing cell line HepAD38; the expression levels of HBV surface antigen(HBsAg) and e antigen(HBeAg) were also determined by enzyme linked immunosorbent assay(ELISA) after RPE treatment.RPE could dose-dependently inhibit the production of HBV-DNA and HBsAg.The concentration of 50% inhibition(IC50) was calculated at 209.63,252.53 μg/mL,respectively.However,its inhibitory activity against HBeAg expression was slight even at high concentrations.RPE had a weak cytotoxic effect on HepAD38 cells(CC50 = 1 640 μg/mL) and the selectivity index(SI) was calculated at 7.82.Compared with two anthraquinone derivatives emodin and rhein,RPE showed higher ability of anti-HBV and weaker cytotoxicity.So Rheum palmatum L.might possess other functional agents which could effectively inhibit HBV-DNA replication and HBsAg expression.Further purification of the active agents,identification and modification of their structures to improve the efficacy and decrease the cytotoxicity are required.

  11. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

    OpenAIRE

    Cavenaugh, James S; Dorka Awi; Maimuna Mendy; Hill, Adrian V. S.; Hilton Whittle; McConkey, Samuel J.

    2011-01-01

    BACKGROUND: Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safety and efficacy of plasmid DNA (pSG2.HBs) vaccine, followed by recombinant modified vaccinia virus Ankara (MVA.HBs), encoding the surface antigen of HBV as therapy for chronic HBV. A secondary goal was to characterize the immune responses. METHODS: Firstly 32 HBV e antigen negative (eAg(-)) participants were randomly assigned to one of four groups: to receive vaccines alone, lamivud...

  12. 探讨乙型肝炎病毒携带产妇HBV-DNA水平对新生儿的影响

    Institute of Scientific and Technical Information of China (English)

    曹玲; 朱凡; 曾崇亮

    2014-01-01

    Objective To explore the effect on the newborn of maternal HBV-DNA levels in HBV carriers.So as to guide the treatment during pregnancy and breast feeding.Methods 120 cases of puerperas carried HBV were chosen from January 2012 to December 2012.The HBV-DNA levels in maternal serum,breast milk and neonatus serum were detected.And the results were an-alyzed comprehensively.Results The maternal serum HBV-DNA quantity of 64 cases were lower than 500 copies/mL.There was one case of breast milk HBV-DNA positive and one case of neonatal serum HBV-DNA positive.The maternal serum HBV-DNA quantity of 29 cases ranged from 500 copies/mL to <1.0×106 copies/mL,4 cases showed HBV-DNA positive in breast milk,and no one showed HBV-DNA positive in neonatal serum.The maternal serum HBV-DNA quantity of 27 cases were ≥1.0×106 cop-ies/mL,25 cases showed HBV-DNA positive in breast milk,and one case showed HBV-DNA positive in neonatal serum.ConclusionWhen maternal serum HBV-DNA quantity was 1.0×106 copies/mL,the HBV-DNA positive rate in breast milk increases sharp-ly,and breastfeeding should be prohibited.Maternal serum HBV-DNA concentration has little effect on intrauterine transmission.%目的:探讨乙型肝炎病毒携带产妇血清 HBV-DNA水平对乳汁和新生儿 HBV-DNA水平的影响,以此指导孕期处理和喂养方式。方法选择2012年1~12月的乙型肝炎病毒携带产妇120例,检测产妇血清、乳汁和新生儿血清中的 HBV-DNA水平,对结果进行综合分析。结果64例产妇血清 HBV-DNA<500 copies/mL,其乳汁 HBV-DNA 检出阳性为1例,新生儿血清 HBV-DNA 检出阳性1例;29例产妇血清 HBV-DNA水平为500 copies/mL至1.0×106 copies/mL,其中4例乳汁HBV-DNA检出阳性,新生儿血清 HBV-DNA检测均为阴性;27例产妇血清 HBV-DNA水平大于或等于1.0×106 copies/mL,其中25例乳汁 HBV-DNA阳性,1例新生儿血清 HBV-DNA检测阳性。结论产妇血清 HBV-DNA 水平大于或等于1.0

  13. Expression of HLA class Ⅰ and Ⅱ on peripheral blood lymphocytes in HBV infection

    Institute of Scientific and Technical Information of China (English)

    WANG Chuan-xin; WANG Jin-feng; LIU Min; ZOU Xiong; YU Xiu-ping; YANG Xiao-jing; ZHENG Gui-xi

    2006-01-01

    @@ Persistent hepatitis B virus (HBV) infection is the most important reason for chronic hepatitis B,hepatic cirrhosis, and hepatocellular carcinoma.1 T lymphocytes, including CD4+ and CD8+ T cells, are major composition of host cellular immunity.Furthermore, CD8+ cells play a primary role in host immune reaction of anti-tumor and anti-infection.

  14. Study on the risk factors related vertical transmission of HBV positive couples to their infant

    Institute of Scientific and Technical Information of China (English)

    张荣莲

    2013-01-01

    Objective To explore the risk factors and the rate of HBV vertical transmission from HBsAg-positive couple to their infant. Methods 46 families who had antenatal examination at Fujian Provincial Maternal and Child Health Hospital during August 2010 and November 2011 were

  15. Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV

    Institute of Scientific and Technical Information of China (English)

    Di-Peng Ou; Lian-Yue Yang; Geng-Wen Huang; Yi-Ming Tao; Xiang Ding; Zhi-Gang Chang

    2005-01-01

    AIM: To comprehend the risk factors of recurrence of hepatocellular carcinoma (HCC) and its relationship with the infection patterns of hepatitis B virus (HBV). METHODS: All materials of 270 cases of postoperative HCC were statistically analyzed by SPSS software. Recurrence and metastasis were classified into early (≤2 years) and late phase (>2 years). Risk factors for recurrence and metastasis after surgery in each group were analyzed.RESULTS: Out of 270 cases of HCC, 162 cases were followed up in which recurrence and metastasis occurred in 136 cases. There were a lot of risk factors related to recurrence and metastasis of HCC; risk factors contributing to early phase recurrence were serum AFP level, vascular invasion, incisal margin and operative transfusion, gross tumor classification and number of intrahepatic node to late phase recurrence. The HBV infective rate of recurrent HCC was 94.1%, in which "HBsAg, HBeAb, HBcAb" positive pattern reached 45.6%. The proportion of HBV infection in solitary large hepatocellular carcinoma (SLHCC) evidently decreased compared to nodular hepatocellular carcinoma (NHCC) (P<0.05).CONCLUSION: The early and late recurrence and metastasis after hepatectomy of HCC were associated with different risk factors. The early recurrence may be mediated by vascular invasion and remnant lesion, the late recurrence by tumor's clinical pathology propert, as multicentric carcinogenesis or intrahepatic carcinoma denovo. HBV replication takes a great role in this process. From this study, we found that SLHCC has more satisfactory neoplasm biological behavior than NHCC.

  16. Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine.

    Science.gov (United States)

    Tsai, Horng-Jyh

    2015-04-01

    Approximately 2 million new cancer cases are attributed to infectious agents each year worldwide. Vaccines for the hepatitis B virus (HBV), a risk factor of hepatocellular cancer, and human papillomavirus (HPV), a risk factor of cervical cancer, are considered major successes in clinical chemoprevention of cancer. In Taiwan, the first evidence of cancer prevention through vaccinations was provided by HBV vaccination data in infants. The Taiwanese HBV vaccination program has since become a model immunization schedule for newborns worldwide. Persistent infection with high-risk HPV is generally accepted as prerequisite for cervical cancer diagnosis; however, cervical cancer is a rare complication of HPV infections. This is due to the fact that such infections tend to be transient. The safety and efficacy of both available HPV quadrivalent vaccine and bivalent vaccine are not in doubt at the present time. Until a human cytomegalovirus (CMV) vaccine becomes available, simple hygienic practices, such as hand washing, can prevent CMV infection both before and during pregnancy. Each country should establish her official guidelines regarding which vaccines should be used to treat various conditions, the target population (i.e., universal or limited to a selected population), and the immunization schedules. After a vaccine is recommended, decisions regarding reimbursement by the public health care fund are evaluated. The guidelines become part of the immunization schedule, which is updated annually and published in the official bulletin. In conclusion, both HBV and HPV vaccines are considered major successes in the chemoprevention of cancer.

  17. Effect of vector-expressed siRNA on HBV replication in hepatoblastoma cells

    Institute of Scientific and Technical Information of China (English)

    Jun Liu; Ying Guo; Cai-Fang Xue; Ying-Hui Li; Yu-Xiao Huang; Jin Ding; Wei-Dong Gong; Ya Zhao

    2004-01-01

    AIM: To study the effect of siRNA expressed from DNA vector on HBV replication.METHODS: Human U6 promoter was amplified from genomic DNA and cloned into plasmid pUC18 to construct a mammalian siRNA expression vector pUC18U6. Then oligonucleotides coding for a short hairpin RNA against HBV were cloned into pUC18U6 to form pUC18U6HBVsir which was introduced into 2.2.15 cells by using liposome-mediated transfection.2.2.15 cells transfected by pUC18U6 and pUC18U6GFPsir which expressed siRNA against green fluorescent protein and mock-transfected 2.2.15 cells were used as controls.Concentration of HBsAg in the supernatant of the transfected cells was measured by using solid-phase radioimmunoassay.RESULTS: A mammalian siRNA expression vector pUC18U6was constructed successfully. Compared with controls,pUC18U6HBVsir which expressed siRNA against HBV decreased concentration of HBsAg significantly by 44%(P<0.05).CONCLUSION: HBV replication in 2.2.15 cells is inhibited by siRNA expressed from the DNA vector.

  18. 医学防治对乙肝病毒携带者子女HBV感染状况的影响%Effect of Medical Prevention on HBV Infection in Children of Hepatitis B Virus Carriers

    Institute of Scientific and Technical Information of China (English)

    姬国生; 姜孟华; 赵连文

    2015-01-01

    目的:探讨医学防治对于乙肝病毒携带者子女HBV感染状况的影响。方法收集2009年4月~2014年4月经医学防治(121人)和未经医学防治(122人)的患者,均对他们做乙肝五项指标定性检测。结果经过医学防治的乙肝病毒携带者子女HBV感染率低于未经过医学防治者,大部分经医学防治的HBV携带者子女产生了保护性抗体。结论乙肝病毒携带者经抗病毒治疗后,能降低其体内血液中的HBV-DNA含量,并且绝大多数能转阴;其子女出生后12 h内尽快接种乙肝疫苗、注射乙肝免疫球蛋白,可有效阻止母婴间的HBV感染。%Objective To investigate the effect of medical prevention on the HBV infection in children of HBV carriers.MethodsColected from April 2009 to April 2014 medical treatment(121)patients and without medical treatment(122)patients,and tested five indicators of hepatitis B virus.Results The rate of HBV infection in the children with hepatitis B virus carriers was significantly lower than that without medical treatment,and most of them had protective antibodies against HBV carriers. ConclusionHepatitis B virus carriers after antiviral therap,significantly reduced the HBV-DNA content in the blood,and most can be negative. The children within 12 hours after birth vaccinated the hepatitis B vaccine as soon as possible,and inject hepatitis B immunoglobulin protein,can effectively prevent mother to infant HBV infection.

  19. Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70

    Directory of Open Access Journals (Sweden)

    Bian Zhongqi

    2012-11-01

    Full Text Available Abstract Background Hepatitis B virus (HBV infection is a major health concern with more than two billion individuals currently infected worldwide. Because of the limited effectiveness of existing vaccines and drugs, development of novel antiviral strategies is urgently needed. Heat stress cognate 70 (Hsc70 is an ATP-binding protein of the heat stress protein 70 family. Hsc70 has been found to be required for HBV DNA replication. Here we report, for the first time, that combined siRNAs targeting viral gene and siHsc70 are highly effective in suppressing ongoing HBV expression and replication. Methods We constructed two plasmids (S1 and S2 expressing short hairpin RNAs (shRNAs targeting surface open reading frame of HBV(HBVS and one plasmid expressing shRNA targeting Hsc70 (siHsc70, and we used the EGFP-specific siRNA plasmid (siEGFP as we had previously described. First, we evaluated the gene-silencing efficacy of both shRNAs using an enhanced green fluorescent protein (EGFP reporter system and flow cytometry in HEK293 and T98G cells. Then, the antiviral potencies of HBV-specific siRNA (siHBV in combination with siHsc70 in HepG2.2.15 cells were investigated. Moreover, type I IFN and TNF-α induction were measured by quantitative real-time PCR and ELISA. Results Cotransfection of either S1 or S2 with an EGFP plasmid produced an 80%–90% reduction in EGFP signal relative to the control. This combinational RNAi effectively and specifically inhibited HBV protein, mRNA and HBV DNA, resulting in up to a 3.36 log10 reduction in HBV load in the HepG2.2.15 cell culture supernatants. The combined siRNAs were more potent than siHBV or siHsc70 used separately, and this approach can enhance potency in suppressing ongoing viral gene expression and replication in HepG2.2.15 cells while forestalling escape by mutant HBV. The antiviral synergy of siHBV used in combination with siHsc70 produced no cytotoxicity and induced no production of IFN-α, IFN-β and TNF

  20. [Requirement of standardizing anti-HBs assay methods in Japan for HBV infection-preventing strategy--discrepancy of anti-HBs measurements among three different kits widely used in Japan].

    Science.gov (United States)

    Ogata, Norio

    2006-09-01

    The strategy to eliminate hepatitis B virus (HBV) infection by administrating an HB vaccine is changing worldwide; however, this is not the case in Japan. An important concern about the HBV infection-preventing strategy in Japan may be that the assay methods for the antibody to hepatitis B surface antigen (anti-HBs) are not standardized. The minimum protective anti-HBs titer against HBV infection has been established as 10 mIU/ml by World Health Organization (WHO) -standardized assay methods worldwide, but that is still determined as a "positive" test result by the passive hemagglutination (PHA) method in Japan. We compared anti-HBs measurements in given samples among PHA(Mycell II, Institute of Immunology), chemiluminescent enzyme immunoassay (CLEIA) (Lumipulse, Fujirebio), and chemiluminescent immunoassay (CLIA) (Architect, Abbott), all of which are currently in wide use in Japan. First, anti-HBs measurements in serum from individuals who received a yeast-derived recombinant HB vaccine composed of the major surface protein of either subtype adr or subtype ayw were compared. The results clearly showed that in subtype adr-vaccinees CLIA underestimated the anti-HBs amount compared with CLEIA and PHA, but in ayw-vaccinees, the discordance in the measurements among the three kits was not prominent. Second, anti-HBs measurements in standard or calibration solutions of each assay kit were compared. Surprisingly, CLEIA showed higher measurements in all three kit-associated standard or calibration solutions than CLIA. Thus, the anti-HBs titer of 10 mIU/ml is difficult to introduce in Japan as the minimum protective level against HBV infection. Efforts to standardize anti-HBs assay methods are expected to share international evidence about the HBV infection-preventing strategy.

  1. Synergistic Action of Clonorchiasis,HBV Infection and Alcohol Consumption on Primary Hepatocellular Carcinoma

    Institute of Scientific and Technical Information of China (English)

    Shengkui Tan; Xiaoqiang Qiu; Hongping Yu; Xiaoyun Zeng; Zengming Xiao; Lequn Li; Qiuan Zhong

    2009-01-01

    OBJECTIVE It has been recognized that HBV infection and alcohol consumption are two important risk factors for primary hepatocellular carcinoma(HCC).Recently,the role of clonorchiasis as a risk factor for HCC is controversial.We aimed to investigate whether these factors increase the risk of HCC in Guangxi,China.METHODS A hospital-based,case-control study of HCC was conducted from July 2005 to July 2007.We enrolled 500consecutive patients with HCC as an experimental group and 500patients without tumor in liver as a control group.nle risk factors that the patients were exposed to were assessed.RESULTS Comparing the risks of developing the HCC,we found out the following results.The risk of developing HCC for the patients with clonorchiasis was 5 folds of that for the patients without clonorchiasis(OR=5.0;95%CI:3.1-8.1),and the risk for the patients with alcohol consumption was 3 folds of that for the patients without drinking alcohol(OR=3.4;95%CI:2.3-4.9),and similarly,the risk for the patients with HBV infection was 21 times of that for the patients without HBV infection (OR=20.6;95% CI:14.3-29.7).According to crossover analysis,there was significant interaction among clonorchiasis,HBV infection and alcohol consumption,with synergistic indices greater than 1.The etiologic fractions attributed to these interactions [EF(A x B)] are 0.7465,0.5789 and 0.5506,respectively.CoNCLUSION Clonorchiasis,HBV infection and heavy alcohol consumption are independent risk factors for developing HCC in our population in Guangxi,and as they can interact synergistically,the risk of developing HCC is increased.Data from this study may indicate new prevention strategies of developing HCC in hish-risk individuals.

  2. Blocking peptides against HBV: PreS1 protein selected from a phage display library

    Energy Technology Data Exchange (ETDEWEB)

    Wang, Wei; Liu, Yang; Zu, Xiangyang; Jin, Rui [State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071 (China); Xiao, Gengfu, E-mail: xiaogf@wh.iov.cn [State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071 (China)

    2011-09-09

    Highlights: {yields} Successfully selected specific PreS1-interacting peptides by using phage displayed library. {yields} Alignment of the positive phage clones revealed a consensus PreS1 binding motif. {yields} A highly enriched peptide named P7 had a strong binding ability for PreS1. {yields} P7 could block PreS1 attachment. -- Abstract: The PreS1 protein is present on the outermost part of the hepatitis B virus (HBV) surface and has been shown to have a pivotal function in viral infectivity and assembly. The development of reagents with high affinity and specificity for PreS1 is of great significance for early diagnosis and treatment of HBV infection. A phage display library of dodecapeptide was screened for interactions with purified PreS1 protein. Alignment of the positive phage clones revealed a putative consensus PreS1 binding motif of HX{sub n}HX{sub m}HP/R. Moreover, a peptide named P7 (KHMHWHPPALNT) was highly enriched and occurred with a surprisingly high frequency of 72%. A thermodynamic study revealed that P7 has a higher binding affinity to PreS1 than the other peptides. Furthermore, P7 was able to abrogate the binding of HBV virions to the PreS1 antibody, suggesting that P7 covers key functional sites on the native PreS1 protein. This newly isolated peptide may, therefore, be a new therapeutic candidate for the treatment of HBV. The consensus motif could be modified to deliver imaging, diagnostic, and therapeutic agents to tissues affected by HBV.

  3. TGF-β suppression of HBV RNA through AID-dependent recruitment of an RNA exosome complex.

    Directory of Open Access Journals (Sweden)

    Guoxin Liang

    2015-04-01

    Full Text Available Transforming growth factor (TGF-β inhibits hepatitis B virus (HBV replication although the intracellular effectors involved are not determined. Here, we report that reduction of HBV transcripts by TGF-β is dependent on AID expression, which significantly decreases both HBV transcripts and viral DNA, resulting in inhibition of viral replication. Immunoprecipitation reveals that AID physically associates with viral P protein that binds to specific virus RNA sequence called epsilon. AID also binds to an RNA degradation complex (RNA exosome proteins, indicating that AID, RNA exosome, and P protein form an RNP complex. Suppression of HBV transcripts by TGF-β was abrogated by depletion of either AID or RNA exosome components, suggesting that AID and the RNA exosome involve in TGF-β mediated suppression of HBV RNA. Moreover, AID-mediated HBV reduction does not occur when P protein is disrupted or when viral transcription is inhibited. These results suggest that induced expression of AID by TGF-β causes recruitment of the RNA exosome to viral RNP complex and the RNA exosome degrades HBV RNA in a transcription-coupled manner.

  4. Genomic and transcriptome profiling identified both human and HBV genetic variations and their interactions in Chinese hepatocellular carcinoma

    Directory of Open Access Journals (Sweden)

    Hua Dong

    2015-12-01

    Full Text Available Interaction between HBV and host genome integrations in hepatocellular carcinoma (HCC development is a complex process and the mechanism is still unclear. Here we described in details the quality controls and data mining of aCGH and transcriptome sequencing data on 50 HCC samples from the Chinese patients, published by Dong et al. (2015 (GEO#: GSE65486. In additional to the HBV-MLL4 integration discovered, we also investigated the genetic aberrations of HBV and host genes as well as their genetic interactions. We reported human genome copy number changes and frequent transcriptome variations (e.g. TP53, CTNNB1 mutation, especially MLL family mutations in this cohort of the patients. For HBV genotype C, we identified a novel linkage disequilibrium region covering HBV replication regulatory elements, including basal core promoter, DR1, epsilon and poly-A regions, which is associated with HBV core antigen over-expression and almost exclusive to HBV-MLL4 integration.

  5. The Role of the Innate Immune System of the Liver in the Control of HBV and HCV

    Institute of Scientific and Technical Information of China (English)

    Jun Wu; Ruth Br(o)ring; J(o)rg F. Schlaak

    2008-01-01

    Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infection are among the most frequent causes of chronic liver disease worldwide. As recent studies suggested that Toll like receptor (TLR)-based therapies may represent a promising approach in the treatment of HBV infection, we have studied the role of the local innate immune system of the liver as possible mediator of this effect. Murine non-parenchymal liver cells (NPC; Kupffer cells, KC; sinusoidal endothelial cells, LSEC) were isolated from C57/BL6 and stimulated by TLR 1-9 agonists. Supernatants were harvested and assayed for their antiviral activity against HBV in HBV-Met cells and HCV in the murine HCV replicon cell line MH1. Only supernatants from TLR 3 and -4 stimulated KC and TLR 3 stimulated LSEC were able to potently suppress HBV and HCV replication. By using neutralizing antibodies we could demonstrate that the TLR 3- but not the TLR 4 mediated effect is exclusively mediated through IFN-β. Our data indicate that TLR 3 and -4 mediated stimulation of NPC leads to production of IFN-β which can potently suppress HBV and HCV replication. This is of relevance for the local control of viral hepatitis infection by the innate immune system of the liver, the development of novel TLR-based therapeutic approaches and sheds new light on the viral crosstalk between HCV (TLR 3 stimulator) and HBV.

  6. Variations of HBV-DNA quantification and concentration of α-L-fucosidase and alpha fetal protein%HBV-DNA、AFU和AFP水平与肝损害的相关性

    Institute of Scientific and Technical Information of China (English)

    欧超伟; 陈绍鹏; 雷耀珍; 郝彦强

    2011-01-01

    目的 探讨HBV-DNA定量与α-L-岩藻糖苷酶(AFU)和甲胎蛋白(AFP)浓度变化的关系.方法 对373例慢性乙型肝炎患者血清进行HBV-DNA定量、AFU与AFP浓度检测,根据HBV-DNA水平分为3组:HBV-DNA 1×10copies/ml以下为阴性组;HBV-DNA 1×10~1×10copies/ml为低病毒量组;HBV-DNA 1×10~1×10copies/ml为高病毒量组进行分析.结果不同病毒量组的AFU、AFP浓度变化显示HBV-DNA低病毒量组和高病毒量组与正常对照组比较的差异则有统计学意义(P<0.05).AFU与AFP的阳性比例随病毒复制量的增加而升高.结论 对乙型肝炎病毒感染者,应定期进行血清HBV-DNA定量检测,评估病毒的复制状况,并同时检测AFU和AFP浓度,尽早发现肝组织的损害程度及演变过程,达到早期治疗的目的.%Objective To investigate the relationship between HBV-DNA quantification and concentration variation of α-L-fucosidase(AFU) and alpha fetal protein(AFP). Methods The levels of AFU,AFP and HBV-DNA in the serum of 373 chronic hepatitis B patients were determined. The 373 chronic hepatitis B patients were divided into 3 groups based the levels of HBV-DNA,that is the negative group(HBV-DNA <1×103 copies/ml(the low viral load group(HBV-DNA 1 ×104 ~1 ×105copies/ml); high viral load group (HBV-DNA 1×106~1×108copies/ml). Results The levels of AFU and AFP in low and high viral load groups were significantly different as compared with that of the norrmal control group (P<0.05).The positive rates of AFU and AFP increases along with the increase of virus replication. Conclusion HBV-DNA in the HBV carriers should be determined at regular intervals,the replication of HBV-DNA be assessed and the levels of AFU and AFP be simultaneously detected to diagnose the ealy liver lesions for early treatment.

  7. Species association of hepatitis B virus (HBV in non-human apes; evidence for recombination between gorilla and chimpanzee variants.

    Directory of Open Access Journals (Sweden)

    Sinéad Lyons

    Full Text Available Hepatitis B virus (HBV infections are widely distributed in humans, infecting approximately one third of the world's population. HBV variants have also been detected and genetically characterised from Old World apes; Gorilla gorilla (gorilla, Pan troglodytes (chimpanzee, Pongo pygmaeus (orang-utan, Nomascus nastusus and Hylobates pileatus (gibbons and from the New World monkey, Lagothrix lagotricha (woolly monkey. To investigate species-specificity and potential for cross species transmission of HBV between sympatric species of apes (such as gorillas and chimpanzees in Central Africa or between humans and chimpanzees or gorillas, variants of HBV infecting captive wild-born non-human primates were genetically characterised. 9 of 62 chimpanzees (11.3% and two from 11 gorillas (18% were HBV-infected (15% combined frequency, while other Old world monkey species were negative. Complete genome sequences were obtained from six of the infected chimpanzee and both gorillas; those from P. t .ellioti grouped with previously characterised variants from this subspecies. However, variants recovered from P. t. troglodytes HBV variants also grouped within this clade, indicative of transmission between sub-species, forming a paraphyletic clade. The two gorilla viruses were phylogenetically distinct from chimpanzee and human variants although one showed evidence for a recombination event with a P.t.e.-derived HBV variant in the partial X and core gene region. Both of these observations provide evidence for circulation of HBV between different species and sub-species of non-human primates, a conclusion that differs from the hypothesis if of strict host specificity of HBV genotypes.

  8. The prevalence of HBV infection in the cohort of IDPs of war against terrorism in Malakand Division of Northern Pakistan

    Directory of Open Access Journals (Sweden)

    Akbar Haji

    2011-06-01

    Full Text Available Abstract Background Hepatitis B is an important public health problem in the Pakistani population and is the major cause of chronic hepatitis, cirrhosis, fibrosis and hepatocellular carcinoma. High prevalence of HBV infections has been observed especially in areas of low economic status. In spite of effective immunization programs, no significant change has been observed in the epidemiology of HBV in the rural areas of Pakistan (~67.5% of the total population mainly due to lack of interest from government authorities and poor hygienic measures. The current study was aimed at estimating the prevalence and risk factors associated with HBV infection within internally displaced persons (IDPs due to war against terrorism in the Malakand Division of Northern Pakistan. Methods Blood samples from 950 IDPs suspected with HBV infection (including both males and females were collected and processed with commercial ELISA kits for HBsAg, Anti HBs, HBeAg, Anti HBe antibodies. The samples positive by ELISA were confirmed for HBV DNA by real-time PCR analysis. Results The overall prevalence of HBV observed was 21.05% of which 78.5% were males and 21.5% were females. Most confirmed HBV patients belong to the Malakand and Dir (lower district. High-risk of infection was found in the older subjects 29.13% (46-60 years, while a lower incidence (11.97% was observed in children aged Conclusion The present study, revealed for the first time a high degree of prevalence of HBV infection in rural areas of Northern Pakistan. The noticed prevalence is gender- and age-dependent that might be due to their high exposures to the common risk factors. To avoid the transmission of HBV infection proper awareness about the possible risk factors and extension of immunization to the rural areas are recommended.

  9. 1 018例孕妇血清HBV DNA荧光定量PCR检测分析

    Institute of Scientific and Technical Information of China (English)

    蔡筠; 金晴; 卢妙娟

    2005-01-01

    目的:探讨荧光定量PCR法检测乙肝病毒DNA与ELISA检测的乙肝病毒标志物之间的关系,拟在为乙肝病毒母婴传播的判断提供更为可靠的实验依据.方法:1 018例孕妇血清同时进行乙肝病毒标志物和HBV DNA的检测,按照不同的乙肝病毒标志物情况分组后,进行HBV DNA与乙肝病毒标志物之间的分析研究.结果:HBsAg、HBeAg、Anti-HBcAg阳性组和HBsAg、HBeAg组的HBV DNA阳性检出率分别为93.52%和100.00%,拷贝数大多数在5×105以上;HBsAg、Anti-HBeAg、Anti-HBcAg组的HBV DNA阳性检出率低于阴性检出率;HBsAg、Anti-HBcAg阳性组HBV DNA阳性检出率比单纯HBsAg组高:HBeAg和HBeAg、Anti-HBcAg组HBV DNA检出率仍较高,但拷贝数多数在5×105~5×102之间;Anti-HBsAg、AntiHBcAg阳性组及单纯Anti-HBcAg阳性组仍可检到HBV DNA;另有42例ELISA全阴性的仍有2例HBV DNA检出阳性,占4.76%.孕妇血清HBV DNA阳性检出率低于其他文献报道.结论:HBV DNA在各种乙肝病毒血清标志物模式中均可检出.乙肝病毒标志物中HBsAg和/或HBeAg阳性者HBV DNA拷贝数也较高,HBsAg及其抗体阳性者甚至全阴性者仍可检出HBV DNA.应将FQ-PCR的检测和ELISA检测结果结合来诊断患者的病况和是否有传染性.

  10. Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients

    Institute of Scientific and Technical Information of China (English)

    Etsuro Orito; Kei Fujiwara; Hiroshi Kanie; Tesshin Ban; Tomonori Yamada; Katsumi Hayashi

    2012-01-01

    AIM:To analysis the factors that predict the response to entecavir therapy in chronic hepatitis patients with hepatitis B virus (HBV) genotype C.METHODS:Fifty patients [hepatitis B e antigen (HBeAg)-negative:HBeAg-positive =26:24] with HBV genotype C,who received na(i)ve entecavir therapy for > 2 years,were analyzed.Patients who showed HBV DNA levels ≥3.0 log viral copies/mL after 2 years of entecavir therapy were designated as slow-responders,while those that showed < 3.0 log copies/mL were termed rapidresponders.Quantitative hepatitis B surface antigen (HBsAg) levels (qHBsAg) were determined by the Architect HBsAg QT immunoassay.Hepatitis B core-related antigen was detected by enzyme immunoassay.Pre-C and Core promoter mutations were determined using by polymerase chain reaction (PCR).Drug-resistance mutations were detected by the PCR-Invader method.RESULTS:At year 2,HBV DNA levels in all patients in the HBeAg-negative group were < 3.0 log copies/mL.In contrast,in the HBeAg-positive group,41.7% were slow-responders,while 58.3% were rapid-responders.No entecavir-resistant mutants were detected in the slow-responders.When the pretreatment factors were compared between the slow-and rapid-responders;the median qHBsAg in the slow-responders was 4.57log IU/mL,compared with 3.63 log IU/mL in the rapidresponders (P < 0.01).When the pretreatment factors predictive of HBV DNA-negative status at year 2 in all 50 patients were analyzed,HBeAg-negative status,low HBV DNA levels,and low qHBsAg levels were significant (P < 0.01).Multivariate analysis revealed that the low qHBsAg level was the most significant predictive factor (P =0.03).CONCLUSION:Quantitation of HBsAg could be a useful indicator to predict response to entecavir therapy.

  11. HBsAg阴性献血者输血HBV感染残余风险分析%Residual Risk of Transfusion-transmitted HBV Infection in HBsAg-negative Blood Donors

    Institute of Scientific and Technical Information of China (English)

    方昌志; 傅颖媛; 钱榕; 熊丽红

    2012-01-01

    目的 分析HBsAg ELISA法检测阴性献血者的输血HBV感染残余风险,评价其感染状况.方法 采用瑞士罗氏诊断公司的Cobas s201核酸检测平台对2011年1月1日至12月31日57 141人份2遍ELISA检测阴性标本进行HBV DNA/HCV RNA/HIV-1,-2 RNA三项联合核酸检测(Cobas TaqScreen MPX 试剂),检测模式为混样检测+拆分检测,即先进行6标本混样检测,再对检测阳性标本进行拆分检测;对127人份拆分检测阳性标本进行分项鉴别试验及乙型肝炎两对半检测.结果 1)2遍ELISA法共检测标本60 037人份,检出HBsAg阴性标本57 141人份;2)对57 141人份阴性标本进行HBV DNA/HCV RNA/HIV-1,-2 RNA三项联检,共检出127人份病毒核酸阳性标本;3)127人份病毒核酸阳性标本进行分项鉴别试验,共检出HBV DNA 阳性标本69人份,输血HBV残余风险为0.12%,其定量检测结果以<20 U·mL-1为主(51人份,占73.9%);4)69人份HBV DNA阳性标本进行乙型肝炎两对半检测,发现乙型肝炎可疑窗口期感染6人份(占8.7%),隐匿性感染 52人份(占75.4%).结论 HBsAg ELISA法检测阴性献血者的输血HBV感染残余风险依然存在,其感染状况多以隐匿性感染为主,将核酸检测纳入血液筛查常规模式,可降低输血残余风险,提高输血安全.%Objective To analyze the residual risk of transfusion-transmitted HBV infection by ELISA method in HBsAg-negative blood donors,and to assess the infection status. Methods TaqScreen MPX test was performed for the detection of HBV DNA/HCV RNA/HIV-1,-2 RNA on a Cobas s201 system (Swiss Roche Diagnosis Company) in 57 141 HBsAg-negative blood donations. The detection was repeated two times. The detection mode was a combination of 6-sample minipool and individual positive donation test. Then, subentry identification and HBV marker detection were conducted in the 127 positive individual donations. Results A total of 60 037 samples were detected by twice ELISA test and 57 141 of them were

  12. HBV父婴垂直传播水平与HBV-DNA载量的相关研究%A correlation analysis between the rate of vertical transmission of HBV and HBsAg-positive father to infant and the rate of neonatal cord blood HBV-DNA

    Institute of Scientific and Technical Information of China (English)

    张荣莲; 罗颖; 谢婧娴; 陈起燕; 成玲; 郭胜斌; 黄欣欣

    2010-01-01

    Objective To study the influence of HBV-DNA with different load levels of HBsAg-positive among fathers on the rate of neonatal cord blood HBV-DNA.Methods Using HBsAg and HBV-DNA as screening indicators for pregnant women and their husbands from an obstetric clinic.161 pregnant women whose HBsAg and HBV-DNA were negative,but HBsAg was positive among their husbands and their newborns,were selected.Blood samples from those pregnant women,their husbands and their newborns were collected to detect the related indicators.Using ELISA to detect hepatitis B virus markers(HBVM),and FQ-PCR to detect the levels of HBV-DNA load.According to neonatal cord blood HBV-DNA detection guideline,newborns with cord blood HBV-DNA positive were selected as cases,others as controls.Results(1)Result of the study showed that there was a dose-response relationship between paternal serum HBV-DNA load levels and neonatal cord blood HBV-DNA positive rates in newborns(trend χ~2=64.117,P=0.000).The rate of vertical transmission of HBV from HBsAg-positive father to infant in the paternal serum HBV-DNA>1.0×107 copies/ml group was significantly higher than HBV-DNA<1.0×107 copies/ml group(χ~2=71.539,P=0.000).(2)There was a positive rank correlation between semen positive HBeAg and vertical transmission of HBV from HBsAg-positive father to infant(χ~2=6.892,P=0.009).Conclusion There was a dose-response relationship between paternal serum HBV-DNA load levels and neonatal cord blood HBV-DNA positive in newborns.Paternal serum HBV-DNA≥1.0×107 copies/ml and with HBeAg positive status were risk factors of vertical transmission of HBV from HBsAg-positive father to infant.%目的 探讨HBsAg阳性父亲血HBV-DNA的不同载量水平对其新生儿发生HBV父婴垂直传播的影响.方法 对161例HBsAg阳性的父亲及其新生儿(母亲血清HBVM全阴性或仅HBsAb阳性及HBV-DNA均为阴性)HBV感染状况进行调查分析.采用ELISA检测HBVM,FQ-PCR法检测血清HBV DNA

  13. HBV携带产妇的血清及乳汁HBV-DNA载量的差异与母乳喂养安全性的研究%Load of HBV DNA in serum and breast milk of HBV carried mother and safety of breast-fed infants

    Institute of Scientific and Technical Information of China (English)

    马力; 王兆荃; 赵桂珍; 梁争论; 王心竹

    2007-01-01

    目的 探讨HBV携带产妇的血清、乳汁中HBV-DNA不同裁量与实施母乳喂养安全性的关系及对母婴传播阻断效果的影响.方法 应用荧光定量聚合酶链反应和酶免疫测定(EIA)技术对91例HBsAg、HBeAg双阳性产妇血清、乳汁及婴儿24月龄血标本进行HBV-DNA定量和HBVM检测.32例婴儿采用母乳喂养,59例采用人工喂养.对两种喂养方式的婴儿做3(T3)、9(T9)、12(T12)、24(T24)个月追踪检测观察.结果 HBsAg、HBeAg双阳性产妇的血清、乳汁中HBV-DNA阳性率为100%、49.45%(P<0.005),HBV-DNA平均含量(拷贝数/毫升的对数,(-x)±s)为(7.43±1.81)、(4.02±1.01);初乳HBV-DNA的检出率随母血HBV-DNA载量的增加而增加,两者呈正相关.母乳和人工两种方式喂养的婴儿HBV感染率为15.63%和13.56%,统计学处理X2=0.022,P>0.05差异无显著性;母乳喂养组抗体几何平均滴度(GMT)明显高于人工喂养组;发生HBV-DNA感染的13例婴儿T24血标本HBV-DNA载量为(3.24±0.23).结论 HBsAg、HBeAg双阳性产妇血清HBV-DNA载量大于109cps/mL的婴儿是母婴传播的高危易感人群.HBV感染的婴儿HBV-DNA水平较低,病毒载量<104cps/mL.乳汁HBV-DNA阳性率和病毒载量明显低于血清,HBV携带产妇的婴儿接受正规乙肝基因工程疫苗(Hbice)全程免疫或Hbice和HBIG(乙肝免疫球蛋白)的主、被动联合免疫后,母乳喂养不影响母婴传播阻断效果,母乳喂养有助于提高婴儿抗-HBs的GMT水平.%[Objective]To investigate the relationship between the load of HBV-DNA in serum and breast milk of pregnant women carrying HBV and the safety of breast-feeding and to explore the blocking effect on the mother-infant transmission of HBV.[Methods]Content of HBV-DNA and/or HBVM in serum and breast milk specimens of 91 pregnant women with positive HBsAg and HBeAg and in serum specimens of their 24 month old infants were detected by Real-time quantitative polymerase chain reaction(RQ-PCR)and/or EIA at

  14. Verification of the interaction between ASGPR and HBV preS1 protein%ASGPR 与 HBV preS1蛋白之间相互作用的验证

    Institute of Scientific and Technical Information of China (English)

    张曦; 刘小静; 陈云茹; 孔颖; 杨雪亮; 叶峰; 蔺淑梅

    2016-01-01

    目的:验证去唾液酸糖蛋白受体(asialoglycoprotein receptor,ASGPR)与乙肝病毒前 S1蛋白(HBV preS1蛋白)之间的相互作用,确认 ASGPR 作为乙肝病毒肝细胞膜受体在介导乙肝病毒感染的分子机制中的作用。方法分别用哺乳动物双杂交及体外免疫共沉淀技术验证 ASGPR 与 HBV preS1蛋白之间的相互作用,操作方法参照试剂盒说明书进行。结果哺乳动物双杂交实验结果提示,ASGPR 与 HBV preS1蛋白在细胞环境中具有相互作用;免疫共沉淀实验结果提示,ASGPR 与 HBV preS1蛋白在非细胞环境中具有相互作用。结论ASGPR 可能是介导 HBV 入侵的肝细胞膜受体之一。%Objective To verify the interaction between asialoglycoprotein receptor (ASGPR)and hepatitis B virus (HBV)preS1 protein in vivo and in vitro ,and identify ASGPR as a cell-surface receptor for HBV,which could elucidate the molecular mechanism of HBV infection.Methods The preS1-ASGPR interaction was examined in mammalian two-hybrid and coimmunoprecipitation system by strictly following the manufacturer’s instructions.Results ASGPR interacted specifically and directly with the preS1 domain of HBV in vivo and in vitro .Conclusion ASGPR may be a candidate receptor for HBV that mediates further step of HBV entry.

  15. ANALYSIS OF POINT MUTATION IN SITE 1896 OF HBV PRECORE AND ITS DETECTION IN THE TISSUES AND SERUM OF HCC PATIENTS

    Institute of Scientific and Technical Information of China (English)

    Wang Yuan; Liu Hu; Zhou Qing; Li Xu

    1999-01-01

    Aim The 3' -base specific polymerase chain reaction (3' - BS- PCR) method was established to investigate the relationship between the mutation of precore region of Hepatitis B virus (HBV) and the liver damage to the patients caused by HBV and the possibility of HBV precore gene integration in liver cells. Mdthods According to the DNA sequence of precore region of HBV, the method of 3' - BS- PCR is applied to analyze the point mutation site 1896 of HBV precore in 126 clinical serum specimens and 23 hepatocellular carcinoma (HCC) patients' tissues and serum whose trmors have been surgically excised and pathologically diagnosed. Rdsults The point mutation in site 1896 of HBV precore has been successfully rates of preore gene of HBV in the 23 patients' tissues and serum are 52.2 96 (12/23) and 30.4 96 (7/23) respectively. Conclusion The established method for HBV precore mutation analysis is simple and results can well repeated. It has provided a new approach to clinical HBV research and its relationship to liver damage. The results obtained suggested that HBV precore mutation exists in a wide range among serum and tissue of the patients infected by HBV and HCC patients, and the pre-c gene of HBV can not be detected in the serum of 21.8% of the HCC patients (tissue HBV precore gene positive). We may deduce that there may be the integration of HBV precore gence in the genome of liver cells, which may play an important role in the carcinogenesis of HCC.

  16. Seroprevalencia de VHB, VHC y VIH en donadores de sangre en Irapuato, México Seroprevalence of HBV, HCV and HIV in blood donors in Irapuato, Mexico

    Directory of Open Access Journals (Sweden)

    Miguel Angel Carreto-Vélez

    2003-01-01

    General Hospital No. 2 Family Medicine Unit, of the Mexican Social Security Institute in Irapuato, Mexico. MATERIAL AND METHODS: A cross-sectional descriptive study. Data was recorded on blood bank forms, and risk factors and illnesses were studied in the 7,056 blood donors at the General Hospital No. 2 Family Medicine Unit, of the Mexican Social Security Institute in Irapuato, Guanajuato, Mexico, over a period of two years (from July 1998 to June 2000. A sample of 4,010 donors was obtained, each of whom underwent serological tests for HBV, HCV and HIV, serotypes 1 and 2, using an enzymatic immunoassay of third generation in serum or human plasma; seroprevalence rate of seropositive donors was calculated and stratified by age and sex. RESULTS: The combined seroprevalence for HBV, HCV and HIV was 2.5% (101; HCV was 1.14% (46, HBV, 1.12% (45, and HIV, 0.24% (10. In males, HBV was 1.04% (33, HCV 1.07% (34, and HIV, 0.28% (9. In females, HBV was 1.42% (12, HCV was 1.42% (12, and HIV was 0.11% (1. Seropositive males had a 2.4 higher rate as compared to females. CONCLUSIONS: The seroprevalence of viral markers was greater than that reported in previous studies carried out in Mexico, which suggests that sexual transmission was the principal mechanism of infection; this reflects poor health education and the need to carefully select potential donors.

  17. Translational inactivation of RNA function: discrimination against a subset of genomic transcripts during HBV nucleocapsid assembly.

    Science.gov (United States)

    Nassal, M; Junker-Niepmann, M; Schaller, H

    1990-12-21

    Hepatitis B virus (HVB) is the prototype member of the hepadnaviridae, a family of small enveloped DNA viruses that replicate by reverse transcription. Assembly of replication-competent HBV nucleocapsids is based on specific interactions between the core protein, the product(s) of the P gene, and the RNA pregenome, which is marked for encapsidation by containing a sequence near its 5' end that acts in cis as an encapsidation signal. However, HBV produces several additional, almost identical, genomic transcripts that also bear the encapsidation sequence, but that are not encapsidated. The mechanism underlying this selection process has remained mysterious. Here we demonstrate that translating 80S ribosomes (but not scanning 40S ribosomal subunits) advancing into the encapsidation signal prevent its functioning. This finding reveals translational modulation of RNA function as a further regulatory mechanism employed by hepadnaviruses to utilize efficiently the restricted coding capacity of their extremely compact genome. PMID:2261646

  18. Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy

    Directory of Open Access Journals (Sweden)

    Laura Camoni

    2010-03-01

    Full Text Available We estimated the prevalence of HIV, HBV and HCV infections among injecting and non-injecting drug users treated within public drug-treatment centres in Italy to determine the correlates of infection. In the sample of 1330 drug users, the prevalence of HIV was 14.4% among drug injectors and 1.6% among non-injectors; the prevalence of HBV was 70.4% among injecting drug users and 22.8% among non-injectors and of HCV was 83.2% among injecting drug users and 22.0% among non-injectors. Old age, unemployment, and intravenous drug use were significantly correlated with each of the infections, as well as a longer history of injecting drug use. The results indicate that these infections continue to circulate among drug users, highlighting the need for monitoring of this group in Italy.

  19. Occult hepatitis B virus infection and cryptogenic chronic hepatitis in an area with intermediate prevalence of HBV infection

    Institute of Scientific and Technical Information of China (English)

    Mohammad Javad Kaviani; Behzad Behbahani; Mohammad Jafar Mosallaii; Fatemeh Sari-Aslani; Seyed Alireza Taghavi

    2006-01-01

    AIM: To assess the possible role of occult HBV infection in the pathogenesis of chronic hepatitis in Iranian patients.METHODS: After exclusion of autoimmune, metabolic and viral etiologies, 104 consecutive adult patients with histologic and biochemical features of chronic hepatitis and negative HBsAg were enrolled in the study.Qualitative PCR with a sensitivity of 150 × 103 copies/L,using two primers for Pre-S and core regions was applied to measure presence of HBV DNA in serum of the patients.RESULTS: All 104 patients completed the study.Qualitative HBV DNA was positive in two patients (1.9%).CONCLUSION: Occult HBV infection has negligible role in the pathogenesis of cryptogenic chronic hepatitis in Iranian patients.

  20. The Impact of Gender Differences in Attitudes and Beliefs Concerning HBV Vaccination and Screening in the Lao Community.

    Science.gov (United States)

    Akosionu, Odichinma; Virnig, Beth; Call, Kathleen T; Yuan, Jian-Min; Chanthanouvong, Sunny; Nguyen, Ruby H N

    2016-02-01

    Liver cancer incidence is increasing among Asian Americans. Laotians in the US have greater risk of liver cancer death compared to other Asian American groups. However, ethnicity is not the only disparity; Laotian men are at increased risk of liver cancer compared to Laotian women. Use of hepatitis B virus (HBV) vaccination and screening is low among Laotians. The impact of gender differences in attitudes and beliefs concerning HBV vaccination and screening is unknown. This secondary analysis of a cross-sectional community-based participatory research study. Although men were more likely to believe that infection with HBV is preventable, and treatable, causes liver cancer, and that healthy persons should be vaccinated, of those who thought people should get vaccinated, women were four times more likely to receive vaccine than men (adj. OR 4.0, CI 1.2-19). Understanding and addressing gender differences may increase HBV screening and vaccination uptake, thus reducing disparities within the Laotian community. PMID:25612922

  1. No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations

    Directory of Open Access Journals (Sweden)

    Sawai Hiromi

    2012-06-01

    Full Text Available Abstract Background A recent genome-wide association study (GWAS using chronic HBV (hepatitis B virus carriers with and without hepatocellular carcinoma (HCC in five independent Chinese populations found that one SNP (rs17401966 in KIF1B was associated with susceptibility to HCC. In the present study, a total of 580 HBV-derived HCC cases and 1351 individuals with chronic hepatitis B (CHB or asymptomatic carrier (ASC were used for replication studies in order to evaluate the reported association with HBV-derived HCC in other East Asian populations. Results We did not detect any associations between rs17401966 and HCC in the Japanese cohorts (replication 1: OR = 1.09, 95 % CI = 0.82-1.43; replication 2: OR = 0.79, 95 % CI = 0.54-1.15, in the Korean cohort (replication 3: OR = 0.95, 95 % CI = 0.66-1.36, or in the Hong Kong Chinese cohort (replication 4: OR = 1.17, 95 % CI = 0.79-1.75. Meta-analysis using these cohorts also did not show any associations with P = 0.97. Conclusions None of the replication cohorts showed associations between rs17401966 and HBV-derived HCC. This may be due to differences in the genetic diversity among the Japanese, Korean and Chinese populations. Other reasons could be the high complexity of multivariate interactions between the genomic information and the phenotype that is manifesting. A much wider range of investigations is needed in order to elucidate the differences in HCC susceptibility among these Asian populations.

  2. Seroprevalences of HBV, HCV and HIV among Children who examined Before Elective Surgery in Mardin province

    OpenAIRE

    Tekin A et al.

    2011-01-01

    Objectives: The aim of this study was to investigate the seroprevalence of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) among children who examined before elective surgery in Mardin province. Materials and Methods: Between 01 November 2008 and 30 April 2010, a total of 556 patients aged 0–16 years, who planned to be operated, were investigated for viral hepatitis seroprevalences in the Mardin Women and Pediatrics Hospital. Children’s blood samples w...

  3. Optimization of competitively differentiated polymerase chain reaction in detection of HBV basal core promoter mutation

    Institute of Scientific and Technical Information of China (English)

    Xiao-Mou Peng; Lin Gu; Xue-Juan Chen; Jian-Guo Li; Yang-Su Huang; Zhi-Liang Gao

    2005-01-01

    AIM: To improve competitively differentiated polymerase chain reaction (CD-PCR) in detection of HBV basal core promoter mutation.METHODS: Recombinant plasmid of double point mutation A1762T/G1764A in basal core promoter of HBV constructed by site-directed mutagenesis was used as mutant control.To reveal the deficiency mechanism of CD-PCR, relationship between the circle number of PCR and the increased speed of products of each competitive primer was comparatively studied. Diversified amount of dNTPs and mutual primer of the competitive primers were tried to optimize CDPCR. Optimized CD-PCR was evaluated by detecting A1762T/G1764A mutation in recombinant plasmids and clinical sera from patients with HBV infection. RESULTS: The deficiency mechanism of CD-PCR was that the products of mismatched competitive primer grew fast when the amplification of matched primer entered into plateau stage, which led to decrease in or disappearance of the difference in the amount of their products. This phenomenon could be eliminated by reducing dNTPs to10 μmol/L and mutual primer to about 100 nmol/L. Optimized CD-PCR could detect both mutant and wild strain indepe ndent of the amount of templates and the number of PCRcycles. Its detection limit was 103 copies/mL, about 50 copies/reaction. About 10% of mutant DNAs among wild type DNAs could be detected. A1762T/G1764A mutant was detected in 41.8% (51/122) of patients with HBV infection, but not detected in controls with negative HBsAg. CONCLUSION: Optimized CD-PCR can detect mutation independent of the amount of initial templates and the number of PCR cycles.

  4. Clinical and laboratory characteristics associated with dyslipidemia and liver steatosis in chronic HBV carriers

    Directory of Open Access Journals (Sweden)

    Angélica Luciana Nau

    2014-04-01

    Full Text Available Introduction Chronic hepatitis B virus (HBV infection and liver steatosis (LS are the most common causes of chronic liver disease, and their coexistence is frequently observed in clinical practice. Although metabolic syndrome is the main cause of LS, it has not been associated with HBV infection. The aims of this study were to describe the lipid profile and prevalence of LS among HBV carriers and to identify the characteristics associated with LS in this group. Methods This retrospective cross-sectional study included hepatitis B surface antigen (HBsAg-positive patients evaluated during 2011 and 2012. Results Of the 83 patients included, the mean age was 46.4±12.5 years, 53% were men, and 9.1% were hepatitis B e antigen (HBeAg -positive. These patients exhibited the following lipid profile: total cholesterol = 175.4±38.8mg/dL, low-density lipoprotein (LDL = 113.0±32.7mg/dL, and triglycerides = 91.1±45.2mg/dL. Their fasting glucose was 95.3±14.5g/dL, and fasting insulin was 6.1±5.9µIU/mL. Liver steatosis was observed on abdominal ultrasound in 11.3% of individuals. Factors associated with the presence of LS included higher levels of total cholesterol, prothrombin activity, fasting insulin, and body mass index (BMI as well as lower levels of aspartate aminotransferase (AST. Conclusions These findings suggest that LS in patients with chronic HBV appears to be a consequence of metabolic alterations and insulin action rather than of viral factors.

  5. 乙肝病毒携带孕妇检出病毒阳性年龄及疫苗接种调查%Investigation on detection age of positive HBV and vaccine inoculation of HBV - infected pregnant women

    Institute of Scientific and Technical Information of China (English)

    陈红; 任群

    2011-01-01

    目的:了解乙型肝炎病毒母婴和父婴传播中垂直传播和水平传播的比例和乙肝病毒携带孕妇乙肝疫苗接种情况.方法:对父母也为乙肝病毒携带者的乙型肝炎病毒携带孕妇的乙肝病毒检出年龄进行调查,并对乙肝病毒携带孕妇乙肝病毒检出前乙肝疫苗接种情况也进行了调查.结果:①165例被调查乙肝病毒携带孕妇中,否认在检出乙肝病毒阳性前家庭有乙肝病毒接触史72例,占43.64%.有非家庭乙肝病毒接触史11例,占6.67%.家庭中有乙肝病毒携带者76例,占46.06%,其中母亲为乙肝病毒携带者42例,占25.45%,父亲为乙肝病毒携带者21例,占12.73%,丈夫为乙肝病毒携带者13例,占7.88%.做过外科手术6例,占3.64%.②母亲为乙肝病毒携带者加父亲为乙肝病毒携带者63例中,4例1岁以前检出乙肝病毒阳性,占6.35%,1岁以后检出乙肝病毒阳性59例,占93.65%,差异有统计学意义(X2=96.032,P=0.000).其中6例7岁以前检出乙肝病毒阳性,占9.52%,其余57例均在7岁以后检出乙肝病毒阳性,占90.48%,经统计学处理,7岁以前与7岁以后检出乙肝病毒阳性差异仍有统计学意义(X2=76.222,P=0.000).③165例被调查乙肝病毒携带孕妇中有98例明确自己检出乙肝病毒阳性前是否接种过乙肝疫苗,占被调查乙肝病毒携带孕妇的59.39%.其中检出乙肝病毒阳性前接种过乙肝疫苗者39例,占39.80%,但均未在检出前3年内接种乙肝疫苗.未接种过乙肝疫苗者59例,占60.20%.结论:乙肝病毒母婴传播和父婴传播中水平传播多于垂直传播.全程接种乙肝疫苗后不可能终生免疫,乙肝病毒密切接触者需要定期检测乙肝保护性抗体定量,及时加强免疫.%Objective: To understand the ratio of vertical transmission and horizontal transmission in mother - to - fetus transmission and father - to - fetus transmission of hepatitis B virus ( HBV ) and the vaccine inoculation situation of HBV

  6. The Experimental Study on Treating Transgenic HBV Mice with Recombined IL-2-PreS DNA Vaccine

    Institute of Scientific and Technical Information of China (English)

    李建远; 王海燕; 沈肖方; 王学波; 靳绍华; 刘芙君; 刘运祥

    2004-01-01

    The aim of this study is to investigate the feasibility and mechanism of hIL-2-preS DNA vaccine as prevention and therapeutic approach against Hepatitis B. Eukaryon expression vector involving hIL-2 and preS gene was constructed with recombinant technique and transferred into normal BALB/c mice and HBV transgenic mice (Tg-Mice) respectively. Tnen a series of detection were performed: detection of anti-preS2, HBs antibody and HBsAg in BALB/c mice and Tg-mice with ELISA, quantification of HBV DNA copies in HBV Tg-mice serum with real-time PCR, determination of hepatitis degree with immunopathological HE staining and detection of liver function. Anti-preS1 can be detected at 4th , 6th and 10th week in inoculated BALB/c mice. Injection with gene gun gained an advantage over muscular and subcutaneous injection since it acquired just 1/10 inoculation quantity (10μg/mouse). Highest expression of IgG2a at 4th week suggested Thl-mediated immune response, which facilitated HBV cleaning. Of all inoculated HBV Tg-mice, 80% of them showed anfi-preS2, HBs antibody positive and HBV DNA decreased, and 20% showed negative for HBsAg. HE staining to hepatic tissue showed obvious infiltration of inflammatory cells, swelling and granular degeneration of hepatocytes. In our study, IL-2-preS DNA vaccine which can provoke the humoral and cellular immune response and break the immune tolerance supports the designation and construction of new vaccine against HBV and specific immune remedy for HBV continuous infection.

  7. Correlation study of serum markers and HBV-DNA levels in hepatitis B patients%乙型肝炎患者血清标志物与HBV-DNA含量的相关性研究

    Institute of Scientific and Technical Information of China (English)

    赵卫; 周盛杰

    2013-01-01

    Objective To investigate the correlation of serum markers and HBV-DNA levels in hepatitis B patients and its clinical significance. Methods Two hundred and fifty-eight hepatitis B patients was detected for serum markers by ELISA and HBV-DNA levels by quantitative fluorescent polymerase chain reaction (QF-PCR).The correlation between serum markers and HBV-DNA levels were investigated. Results In HBsAg+/HBeAg+ group and HBsAg+/ HBeAg+/anti-HBc+ group, the positive rate of HBV-DNA and the levels of HBV-DNA were the highest. For the five infection modes of HBsAg7anti-HBe7anti-HBc+, HBsAg+/HBc+, anti-HBs+/anti-HBe+/ anti-HBc+, anti-HBe+/anti-HBc+, an-ti-HBs+, the HBV-DNA positive rates were 62.96%, 52.94%, 37.50%, 27.27%, 4.35%, respectively. Conclusion There is a correlation between the positive rate of HBV-DNA and the serum markers in hepatitis B patients. The detection serum markers combined with the quantitative detection of HBV-DNA can accurately reflect the extent of virus replication and infection intensity, which is of great significance for the early diagnosis, treatment and prognosis of hepatitis B.%目的 探讨乙型肝炎患者血清标志物与HBV-DNA定量检测之间的关系及其临床意义.方法 选择258例经我院确诊的乙肝患者,采用酶联免疫吸附试验法检测患者体内血清标志物,采用荧光定量聚合酶链反应检测HBV-DNA含量,比较血清标志物与HBV-DNA检测量之间的关系.结果 HBsAg+/HBeAg+组与HBsAg+/HBeAg+/抗-HBc+组HBV-DNA阳性检出率与含量最高;HBsAg+/抗-HBe+/抗-HBc+、HBsAg+/HBc+、抗-HBs+抗HBe+/抗-HBc+、抗-HBe+/抗-HBc+、抗-HBs+5种感染模式下HBV-DNA阳性检测率分别为62.96%、52.94%、37.50%、27.27%、4.35%.结论 乙肝患者血清HBV-DNA阳性率与血清标志物存在相关性;同时进行血清标志物的检测与HBV-DNA定量检测能较准确直接地反应病毒复制程度及传染强度,对于早期诊断、治疗及预后判断具有指导意义.

  8. Tumor-infiltrating lymphocyte activity is enhanced in tumors with low IL-10 production in HBV-induced hepatocellular carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Shi, Yang, E-mail: yangshi_xz@126.com; Song, Qingwei; Hu, Dianhe; Zhuang, Xiaohu; Yu, Shengcai

    2015-05-22

    Hepatocellular carcinoma (HCC) is one of the most common cancers and can be induced by chronic HBV infection. The role of HBV-specific immune responses in mediating tumorigenesis and HCC prognosis is debated. The effect of intratumoral microenvironment on tumor-infiltrating lymphocytes (TILs) is also unclear. Here, we examined resected tumor tissue from 36 patients with HBV-induced HCC. We categorized study cohort based on ex vivo IL-10 secretion by tumor cells into high IL-10-secreting (Hi10) and low IL-10-secreting (Lo10) groups, and found that the Lo10 group was less sensitive to TLR ligand stimulation. TILs from the Lo10 group contained higher frequencies of HBV-specific IFN-g-producing cells and total IFN-g-producing cells, and possessed higher proliferative capacity. Moreover, the proliferative capacity of TILs from the Hi10 group was negatively correlated with IL-10 secretion from tumor cells. Together, our data demonstrated that low IL-10-producing capacity in HBV-induced HCC tumors is associated with enhanced TIL activity. - Highlights: • We examined intratumoral IL-10 production in HBV-induced HCC. • We grouped HCC tumors into Hi10 and Lo10 groups based on their IL-10 production. • Lo10 groups had better IFN-g response by TILs. • Lo10 groups had better TIL proliferative capacity. • Lo10 group tumor cells were refractory to TLR ligand stimulation.

  9. Correlation of HBV DNA contents in serum and saliva of patients with Hepatitis B%乙肝患者血清和唾液HBV DNA含量的相关性研究

    Institute of Scientific and Technical Information of China (English)

    李桂珍; 徐云芳; 刘娟; 江雪

    2011-01-01

    目的 探讨唾液是否为乙型肝炎病毒传播的途径之一,为乙型肝炎病毒经唾液传播提供临床依据。方法 采用时间分辨荧光免疫分析法检测免疫学指标,实时荧光定量PCR法检测乙肝患者血清、唾液HBVDNA含量。结果 119例乙肝患者血清、唾液HBV DNA的阳性率分别为91.6%(109例)、71.4% (85例)。乙肝患者唾液HBV DNA的阳性率与血清HBV DNA的阳性率之间差异有统计学意义(P<0.01),乙肝患者唾液HBV DNA含量与血清HHBV DNA含量呈显著正相关(r=0.83)。结论 乙型肝炎病毒可通过唾液传播。%Objective To investigate whether saliva is one of the important pathways for the transmission of hepatitis B virus (HBV), and to provide clinical evidences the spreading of HBV through saliva. Methods Immuno-logical indicators were determined with time-resolved fluoroimmunoassay (TR-FIA), and the contents of HBV DNA in serum and saliva were determined with real-time polymerase chain reaction (FQ-RT-PCR). Results In 119 cases of hepatitis B, the positive rate of HBV DNA in serum and saliva was 91.6% (n=109) and 71.4% (n=85), respectively, which showed a statistically significant difference (P<0.01). A positive correlation was found between the content of HBV DNA in serum and that in saliva (r=0.83). Conclusion This study provides clinical evidences for the transmission of HBV through saliva.

  10. Antihepatitis B Virus Activity of a Protein-Enriched Fraction from Housefly (Musca domestica in a Stable HBV-Producing Cell Line

    Directory of Open Access Journals (Sweden)

    Xuemei Lu

    2014-01-01

    Full Text Available Hepatitis B virus (HBV infection remains a major public health problem. Although several vaccines and therapeutic strategies are currently being implemented to combat HBV virus, effective antiviral therapy against HBV infection has not been fully developed. Alternative strategies and new drugs to combat this disease are urged. Insects and insect derivatives are a large and unexploited source of potentially useful compounds for modern medicine. In the present study, we investigated the first anti-HBV activity of a protein-enriched fraction (PE from the larvae of the housefly (Musca domestica in a stable HBV-producing cell line. HBsAg and HBeAg in the culture medium were measured by enzyme-linked immunosorbent assay. HBV-DNA was quantified by fluorescent quantification PCR. HBV core protein was assayed by immunofluorescent staining. Results indicate PE treatment inhibited both HBsAg, HBeAg secretion, and HBV-DNA replication. Furthermore, PE could also suppress HBV core protein expression. PE could be a potential candidate for the development of a novel and effective drug for the treatment of HBV infection.

  11. Antihepatitis B virus activity of a protein-enriched fraction from housefly (Musca domestica) in a stable HBV-producing cell line.

    Science.gov (United States)

    Lu, Xuemei; Jin, Xiaobao; Wang, Jie; Chu, Fujiang; Zhu, Jiayong

    2014-01-01

    Hepatitis B virus (HBV) infection remains a major public health problem. Although several vaccines and therapeutic strategies are currently being implemented to combat HBV virus, effective antiviral therapy against HBV infection has not been fully developed. Alternative strategies and new drugs to combat this disease are urged. Insects and insect derivatives are a large and unexploited source of potentially useful compounds for modern medicine. In the present study, we investigated the first anti-HBV activity of a protein-enriched fraction (PE) from the larvae of the housefly (Musca domestica) in a stable HBV-producing cell line. HBsAg and HBeAg in the culture medium were measured by enzyme-linked immunosorbent assay. HBV-DNA was quantified by fluorescent quantification PCR. HBV core protein was assayed by immunofluorescent staining. Results indicate PE treatment inhibited both HBsAg, HBeAg secretion, and HBV-DNA replication. Furthermore, PE could also suppress HBV core protein expression. PE could be a potential candidate for the development of a novel and effective drug for the treatment of HBV infection.

  12. 酵母双杂交系统筛选HBV PreS1相互作用蛋白%Screening the hepatitis B virus PreS1 associated proteins in yeast two-hybrid system

    Institute of Scientific and Technical Information of China (English)

    叶峰; 张曦; 邸莹; 王小清; 刘小静; 孔颖; 赵英仁; 陈天艳; 刘敏

    2012-01-01

    Objective To screen the interacted protein hepatitis B virus (HBV) PreSl with human hepatocytes from normal human liver cDNA library by sos-recruitment system (SRS) and explore the mechanism of HBV endocylosis. Methods PCR was performed to amplify the gene of HBV PreSl from the plasmid PCP10/ HBV ayw subtype containing the whole fragment of HBV;the PCR product was cloned into yeast expression plasmid pSos. and reconstituted plasmid was tested by auto-sequencing assay and named pSos- PreSl. The pSos-PreSl fusion protein expressed in the yeast cells was confirmed by Western blot after pSos- PreSl was transfected into the yeast cell cdc25.Self-activation of the bait protein was determined by cotransformation of pSos- PreSl and pMyr-Lamin C, and the cytoplasmic localization of the bait protein was verified by cotransformation of pSos- PreSl and pMyr SB. Yeast cells co-transfected with pSos- PreSl and the normal human liver cDNA library grew in selective nutrition and temperature. The true positive clones were submitted for sequencing. The results were submitted to the BLAST notebook of NCBI to seek homologous sequence. Results The yeast expression vector of HBV PreSl gene was constructed successfully and its expression in yeast was verified. The recombinant bait plasmid did not have self-activation and toxicity to yeast cdc25H cells. Furthermore, the cytoplasmic localization of the bait protein was verified correctly. After yeast cells were co-transfected with pSos-PreSl and the normal human liver cDNA library, 5 clones were positive and showed high homology with KCMF1, cyt C, vitamin D binding protein, Homo sapiens albumin (ALB) and Homo sapiens asialoglycoprotein receptor (ASGPR). Conclusion We obtained 5 proteins which may interact with HBV PreSl protein by SRS. This is helpful for exploring the mechanism of HBV endocytosis.%目的 利用Sos招募系统(SRS),构建含HBV PreS1基因的酵母双杂交诱饵载体,筛选人肝细胞与HBV PreS1蛋白相互作用的

  13. acute onset Pancreatitis in the third trimester of Pregnancy in HBV Carrier Women taking telbivudine for Blocking Mother-to-Infant transmission

    Institute of Scientific and Technical Information of China (English)

    Hao-feng Xiong; Jing-yuan Liu; Hao-dong Cai; Jun Cheng

    2014-01-01

    Acute pancreatitis in pregnancy (APIP) is rare and the reasons for APIP are biliary disease and congenital or acquired hypertriglyceridemia, which could occur during any trimester but more than 50% cases happened during the third trimester. In this report, one case of a young pregnant woman, a HBV carrier in her 37th week+5 d of gestation, was admitted to Emergency Department due to acute abdominal pain, vomiting and diarrhea. The patient was in antiretroviral treatment with telbivudine from 28 weeks of gestation to prevent mother-to-child transmission of HBV. Laboratory tests demonstrated hypertriglyceridemia, abdominal computed tomography scan revealed peripancreatic edema. Hyperlipidemic pancreatitits was primary diagnosed and the patient was admitted to the intensive care unit. Considering the possible role in the pathogenesis of pancreatitis, telbivudine was interrupted after birth giving. After supportive treatment, her condition gradually improved. Since it is the ifrst description of APIP during treatment with telbivudine, the association between pregnancy, hyperlipidemia, telbivudine and acute pancreatitis has been well investigated.

  14. 博尔泰力治疗100例慢性乙肝HBV-DNA的临床分析

    Institute of Scientific and Technical Information of China (English)

    张爱琴; 唐谦

    2003-01-01

    目的 分析总结国产新药博尔泰力(氧化苦参碱)抗慢性乙肝HBV-DNA的作用。方法 分治疗组和对照组各100例,疗程4个月,治疗前后两组均经荧光PCR检测HBV-DNA定量分析。结果 发现治疗组25例HBV-DNA转阴,26例HBV-DNA拷贝数明显下降,49例HBV-DNA无变化。结论 认为博尔泰力(氧化苦参碱)抗HBV-DNA确有一定疗效,与临床应用20年干扰素疗效略高,与近年使用的拉米夫定相比,无常期用药致HBV-DNA变异的报道。目前认为除干扰素、拉米夫定外,国产新药博尔泰力(氧化苦参碱)不失为抗乙肝病毒的疗效较好、费用较低的一种好药。其机理可能与氧化苦参碱抑制HBV-cccDNA有关,亦有可能通过激活机体非细胞损伤性消除HBV-DNA有关。治疗组约有三分之一的患者无效,可否与患者机体缺乏对氧化苦参碱的敏感性有关。目前认为博尔泰力(氧化苦参碱)抗乙肝HBV-DNA的靶位和机理不清,值得广泛研究。另外,博尔泰力(氧化苦参碱)如何通过调节免疫清除乙肝HVB-DNA的环节和机制,也值得深入研究。

  15. Recombination of IL18-HBV S Gene Vaccine to Resist Tumor and Hepatitis B%抗肿瘤和乙肝双效IL18-HBV S基因疫苗的构建

    Institute of Scientific and Technical Information of China (English)

    何淑雅; 薛志红; 任为; 刘映霞; 尹志华

    2001-01-01

    [Purpose] To find the combination function of 1L-18 and HBV S gene. [Method] 1L-18 cDNA was obtained by RT-PCR from human embryo liver tissue. And an eukaryote expression vector -pEGFP-N1/ IL-18 with a report gene which was expressing green fluorescene protein was constructed. Then the authors got the IL-18 cDNA by restriction enzyme and PCR. Because of its liverphagy and immunization, the authors used HBV S gene from an expression vector-pcDNA3.0/S and linked it with 1L-18 cDNA. [Result]This two genes were subcloned into an expression eukaryote vector-pIRES-EGFP and formed a new expression vector pIRES-EGFP-S-IL18 that would resist tumor and Hepatitis B.[Conclusion]The recombination of IL18-HBV S gene makes great progress in enhancing the immunity of HBV gene vaccine. It could play a basic role in resisted rumor and Hepatitis B.%[目的]探讨IL-18及乙肝病毒s基因(HBV s)的联合功效。[方法]从胎肝组织中抽提总RNA,RT-PCR扩增IL-18cDNA基因。从载体pcDNA3.0/S中限制性酶切获取HBV S基因,然后,将其与IL—18 cDNA一并亚克隆到真核表达质粒pIRES—EGFP中。[结果]构建了具有抗肿瘤及乙肝双重功效的IL18-HBV S乙肝基因疫苗。[结论]含有IL-18基因的HBv基因疫苗的构建为基因疫苗的功能和应用研究提供了基础。

  16. A Turbidity Test Based Centrifugal Microfluidics Diagnostic System for Simultaneous Detection of HBV, HCV, and CMV

    Directory of Open Access Journals (Sweden)

    Hung-Cheng Chang

    2015-01-01

    Full Text Available This paper presents a LAMP- (loop-mediated isothermal amplification- based lab-on-disk optical system that allows the simultaneous detection of hepatitis B virus, hepatitis C virus, and cytomegalovirus. The various flow stages are controlled in the proposed system using different balance among centrifugal pumping, Coriolis pumping, and the capillary force. We have implemented a servo system for positioning and speed control for the heating and centrifugal pumping. We have also successfully employed a polymer light-emitting diode section for turbidity detection. The easy-to-use one-click system can perform diagnostics in less than 1 hour.

  17. Prevalence of HBV-genotypes in immigrants affected by HBV-related chronic active hepatitis Prevalência dos genótipos do vírus da hepatite B em imigrantes na Itália com hepatite crônica ativa pelo vírus B

    Directory of Open Access Journals (Sweden)

    Emilio Palumbo

    2007-03-01

    Full Text Available BACKGROUND: The genetic heterogeneity of the HBV genome has been established and eight genotypes can be classified according to the criterion of >8% differences in the complete nucleotide sequence of the viral genome. AIMS: To evaluate the prevalence of HBV-infection in a population of immigrants and to determine in patients with detectable serum HBV-DNA the HBV-genotypes. METHODS: Between January 2005 and December 2005 a total of 556 immigrants were tested for HBsAg. In HBsAg positive patients the biochemical and virological activity of infection and the possible presence of co-infections (HCV, HDV, HIV were evaluated. In patients with detectable serum HBV DNA, the HBV-genotype was determined by INNOLiPA. RESULTS: Among the 556 subjects tested, 60 (10.7% resulted HBsAg positive. All were men, and 42 (70% come from Africa, 10 (16.6% from Asia and 9 (14.4% from East-Europe. 28/60 (46.6% patients presented normal ALT levels (RACIONAL: A heterogeneidade do genoma do vírus da hepatite B (VHB foi estabelecida e oito genótipos podem ser classificados de acordo com o critério de diferenças de percentagem maior ou igual a 8 na seqüência completa do nucleotídeo do genoma vira!. OBJETIVOS: Verificar a prevalência da infecção pelo vírus da hepatite B (VHB em uma população de imigrantes na Itália e determinar os genótipos do VHB em pacientes com níveis séricos detectáveis do VHB-DNA. MÉTODOS: Entre janeiro e dezembro de 2005, o total de 556 imigrantes foram testados para o HbsAg. Se positivos, a atividade bioquímica e viral da infecção e a possível presença de co-infecções (HVC, HVD e HIV foram examinadas. Nos pacientes positivos para o VHB-DNA, o genótipo do VHB foi determinado pelo método INNOLiPA. RESULTADOS: Entre os 556 pacientes, 60 (10,7% tinham HbsAg positivo. Todos eram do sexo masculino e 42 (70%, provenientes da África, 10 (16,6% da Ásia e 9 (14,4% do Leste Europeu. 28/60 (46,6% apresentaram níveis de ALT normais

  18. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.

    Science.gov (United States)

    Giray, Burcu Gurer; Emekdas, Gurol; Tezcan, Seda; Ulger, Mahmut; Serin, Mehmet Sami; Sezgin, Orhan; Altintas, Engin; Tiftik, Eyup Naci

    2014-07-01

    Recently, circulating miRNAs have been reported as promising biomarkers for various pathologic conditions including cancer. Certain microRNAs (miRNAs) have been shown early diagnostic potential for many types of cancer. The objective of this study was to investigate the potential of certain serum/plasma miRNAs as novel non-invasive biomarkers for early diagnosis of hepatitis B virus (HBV) related hepatocellular carcinoma (HCC). For this reason, the expression levels of 24 miRNA (let-7c, miR-92a-3p, 423-5p, 150-5p, 223-3p, 125b-5p, 342-3p, miR-206, 122-5p, 375, 223-5p, 10a-5p, 23b-5p, 99a-5p, 23a-5p, 10a-3p, 122-3p, 125b-1-3p, 23b-3p, 125b-2-3p, 23a-3p, 92a-1-5p, 92a-2-5p, 99a-3p) were analyzed in plasma of patients with chronic hepatitis B, HBV-positive cirrhosis and HBV-positive HCC and compared with control group samples. Totally 94 plasma samples; 28 control and 66 patient plasma (24 CHB, 22 HBV-positive cirrhosis, 20 HBV-positive HCC) and were included in this study. The expression levels of 24 miRNAs were detected for all control and patient group plasma samples by qRT-PCR using BioMark™ 96.96 Dynamic Array (Fluidigm Corporation) system. The expression levels of miR-125b-5p were detected 2.85 fold, 2.46 fold and 1.89 fold (p = 0.01513, p = 0.0009440, p = 0.0001446) up regulated in CHB, HBV-positive cirrhosis and HBV-positive HCC, respectively when compared versus control group individually by Mann-Whitney U test. The expression levels of miR-223-3p were detected 5.55 fold, 13.88 fold and 12.65 fold (p = 0.01513, p = 0.0009440, p = 0.0001446) down regulated in same comparisons. When all groups were compared versus control group by one-way ANOVA test, the expression levels of miR-223-3p were also found statistically significant (p < 0.05). Although not statistically significant, miR-125b-5p tended to be upregulated. (p = 0.07192). These results significantly imply that miR-125b-5p and miR223-3p could be used as novel non-invasive biomarkers of HBV-positive HCC

  19. Clinical study on safety and immunogenicity of therapeutic dual-plasmid HBV DNA vaccine mediated by in vivo electroporation

    Directory of Open Access Journals (Sweden)

    Hai-yan YANG

    2013-03-01

    Full Text Available Objective  To evaluate the safety and immunogenicity of the therapeutic dual-plasmid HBV DNA vaccine mediated by electroporation (EP in vivo against the hepatitis B virus in healthy adult volunteers. Methods The enrolled 30 healthy volunteers were randomly divided into three dosage groups (10 volunteers in each group, namely: high-dose (4mg, middle-dose (2mg and low-dose (1mg groups. Volunteers received four intramuscular injections of HBV DNA vaccine mediated by in vivo EP at the 0, 4th, 12th and 24th week. Each dose group was further divided into 2 sub-groups (5 persons/per group with different EP frequencies, i.e. 36 and 60 volt. The changes in response was determined by physical diagnosis (ECG, chest X-ray, type-B ultrasound, lab findings (blood and urine routine, blood biochemistry, prothrombin time, thyroid function, tumor biomarkers, immunological variables (IFN-γ, ANA, anti-dsDNA Ab, serological variables pertaining to HBV (HBsAg, HBcAb, HBeAg, HBeAb, HBV DNA and serum anti-HBs status in volunteers before and after receiving EP mediated HBV DNA vaccination. Results The dual-plasmid HBV DNA vaccination mediated by in vivo EP was well tolerated in all healthy volunteers with a stable life signs. It was found that EP-mediated immunization of the therapeutic DNA vaccine against hepatitis B virus had a specific and obvious anti-HBs humoral immune response in one volunteer (17.22mU/ml. Four repeated intramuscular injections of the vaccine did not show any significant adverse effects in the receptors. Although mild elevation of serum ALT and enlarged spleen were found in one individual, the abnormalities disappeared spontaneously at the end of the trial. Conclusions EP-mediated dual-plasmid HBV DNA vaccine is safe and well tolerated with certain degree of humoral immunogenicity.

  20. Anti-HBV effect of liposome-encapsulated matrine in vitro and in vivo

    Institute of Scientific and Technical Information of China (English)

    Chang-Qing Li; Yu-Tong Zhu; Feng-Xue Zhang; Lin-Chun Fu; Xiao-Hui Li; Yi Cheng; Xiang-Yang Li

    2005-01-01

    AIM: To study the anti-HBV effect of liposome-encapsulated matrine (Lip-M) in vitro and in vivo.METHODS: 2.2.15 cell line was cultured in vitro to observe the effect of Lip-M and matrine on the secretion of HBsAg and HBeAg. The toxicity of Lip-M and matrine to 2.2.15 cell line was also studied by MTT method. In in vivo study,drug treatment experiment was carried out on the 13th day after ducks were infected with duck hepatitis B virus (DHBV). The ducks were randomly divided into 4 groups with 5-6 ducks in each group. Lip-M and matrine were given to DHBV-infected ducks respectively by gastric perfusion. Four groups were observed: group of Lip-M (20 mg/kg), group of Lip-M (10 mg/kg), group of matrine (20 mg/kg) and group of blank model. The drug was given once daily for 20 d continuously, and normal saline was used as control. The blood was drawn from the posterior tibial vein of all ducks before treatment (T0), after the medication for 5 (T5), 10 (T10), 15 (T15), 20 (T20) d and withdrawl of the drug for 3 d (P3). The serum samples were separated and stored at -70 ℃, DHBV-DNA was detected by the dot-blot hybridization.RESULTS: After addition of Lip-M and matrine to 2.2.15cell line for eleven d, the median toxic concentration (TC50)of Lip-M and matrine was 7.29 mg/mL and 1.33 mg/mL respectively. The median concentration (IC50) of Lip-M to inhibit HBsAg and HBeAg expression was 0.078 mg/mL and 3.35 mg/mL respectively. The treatment index (TI)value of Lip-M for HBsAg and HBeAg was 93.46 and 2.17respectively, better than that of matrine. The DHBVinfected duck model treatment test showed that the duck serum DHBV-DNA levels were markedly reduced in the group of Lip-M (20 mg/kg) after treated by gastric perfusion for 10, 15 and 20 d (0.43±0.22 vs0.95±0.18,t= 4.70, P= 0.001<0.01.0.40±0.12 vs0.95±0.18, t= 6.34,P= 0.000<0.01. 0.22±0.10 vs 0.95±0.18, t= 8.30,P = 0.000<0.01), compared to the group of matrine (20 mg/kg) (0.43±0.22 vs0.79±0.19, t= 3.17, P= 0.01<0

  1. Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression

    Institute of Scientific and Technical Information of China (English)

    Rosa; Zampino; Adriana; Boemio; Aldo; Marrone; Luciano; Restivo; Maria; Chiara; Fascione; Riccardo; Nevola; Luigi; Elio; Adinolfi; Nicola; Coppola; Carmine; Minichini; Mario; Starace; Evangelista; Sagnelli; Grazia; Cirillo; Emanuele; Miraglia; del; Giudice; Maria; Stanzione; Emanuele; Durante-Mangoni; Giovanna; Salzillo

    2014-01-01

    AIM:To evaluate steatosis,insulin resistance(IR)and patatin-like phospholipase domain-containing 3(PNPLA3) and their relation to disease progression in hepatitis B and C viruses(HCV-HBV) coinfected patients.METHODS:Three hundred and thirty patients with biopsy proven chronic hepatitis were enrolled:66 had HBV-HCV,66 HBV and 198 HCV infection.Prevalence of steatosis,IR and PNPLA3 polymorphisms and their relation to anthropometric,biochemical,virological and histological parameters were evaluated.RESULTS:Prevalence of steatosis in group HBV-HCV was similar to that in HCV(47.0% vs 49.5%,respec-tively);group HBV showed the lowest steatosis(33.3%).Group HBV-HCV had a lesser degree of steatosis than HCV(P = 0.016),lower HCV RNA levels(P = 0.025) and lower prevalence and degree of IR(P = 0.01).PNPLA3 polymorphisms were associated with steatosis.Group HBV-HCV showed higher levels of liver fibrosis than group HCV(P = 0.001),but similar to that ob-served in HBV group.In HBV-HCV group,liver fibrosis was not associated with steatosis,IR or PNPLA3.HBV infection was the independent predictor of advanced liver fibrosis.CONCLUSION:HBV-HCV co-infected patients have lower degree of hepatic steatosis,IR and HCV RNA than HCV mono-infected;co-infected patients showed a more rapid liver fibrosis progression that seems to be due to the double infection and/or HBV dominance.

  2. Study on the hepatitis B serum markers and the correlation between serum and milk HBV-DNA in HBV-infectious pregnant women%乙肝病毒携带产妇血清标志物模式与血清及乳汁HBV-DNA相关性研究

    Institute of Scientific and Technical Information of China (English)

    朱珉之; 杭双熊; 申红玉

    2014-01-01

    目的:通过检测分析乙肝病毒携带产妇血清学标志物与血清、乳汁HBV-DNA阳性率的关系,以及产妇血清与乳汁中HBV-DNA含量之间的相关性,旨在指导母乳喂养。方法选取96例乙肝病毒携带产妇,将其分为大三阳组(54例)、小三阳组(25例)、HbsAg和HbeAg均阳性组(8例)及HbsAg和HbcAb均阳性组(9例)。另选取12例乙肝两对半全阴的产妇作为对照组。ELISA法检测乙肝病毒携带产妇乙肝免疫血清学标志物,实时荧光定量PCR法分别检测产妇血清与乳汁中HBV-DNA含量,并对所有检测指标进行相关性分析。结果大三阳组产妇血清和乳汁HBV-DNA阳性率明显高于其他三组(P0.05)。根据乙型肝炎血清学标志物HBeAg是否阳性将96例产妇分为HBeAg阳性组(62例)和HBeAg阴性组(34例),血清HBeAg阳性产妇的血清和乳汁中HBV-DNA阳性率均明显高于HBeAg阴性产妇,差异具有统计学意义(P0.05). The HBV-DNA positive rates in serum and milk in HBeAg positive groups were obvious-ly higher than that in HBeAg-negative group (P<0.01). However, HBV-DNA in serum and milk were also detected in part of the HBeAg-negative pregnancy women. The HBV-DNA content in serum had positive relation with HBV-DNA content in milk (r=0.891, P<0.05). Conclusion In HBV- infectious pregnant women, it is found that the HBV-DNA positive rate in milk was less than that in serum, and the content of HBV-DNA in milk was increased along with that increased in serum. Therefore, it is more reliable to determine the risk of hepatitis B virus transmission from mother to infant by quantitative measurement of HBV-DNA in serum and milk. It is helpful in interrupting HBV trans-mission, deciding the mode of breast-feeding, and guiding breast-feeding, so as to decrease the infectious rate of baby.

  3. YMDD variants of HBV DNA polymerase gene: Rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation

    Institute of Scientific and Technical Information of China (English)

    Fei Pei; Jun-Yu Ning; Jiang-Feng You; Jing-Pin Yang; Jie Zheng

    2005-01-01

    AIM: To look for a rapid low-cost technique for the detection of HBV variants.METHODS: Two patients who underwent orthotopic liver transplantation (OLT) for HBV infection were treated with lamivudine (100 mg daily) and HBV infection recurred in the grafted livers. The patients were monitored intensively for liver enzymes, hepatitis B surface antigen (HBsAg) and HBV DNA in serum. Liver biopsy was performed regularly. HBV DNA in a conserved polymerase domain (the YMDD locus) was amplified from serum of each patient by PCR and sequenced. HBV genotypes were analyzed by restriction fragment length polymorphism (RFLP) of the PCR products generated from a fragment of the polymerase gene.RESULTS: YMDD wild-type HBV was detected in one patient by PCR-RFLP and DNA sequencing 19 mo after OLT, and YIDD mutant-type HBV in the other patient, 16 mo after OLT.CONCLUSION: PCR-RFLP assay is an accurate and simple method for genotyping lamivudine-resistant HBV variants.

  4. Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative.

    Science.gov (United States)

    Geng, Lei; Lin, Bing-Yi; Shen, Tian; Guo, Hua; Ye, Yu-Fu; Zheng, Shu-Sen

    2016-06-01

    Anti-virus prophylactic therapy may be not necessary for the prevention of hepatitis B virus (HBV) recurrence after HBV-related liver transplantation (LT). However, studies on completely stopping the hepatitis B immune globulin (HBIG) and nucleos(t)ide analogs (NUC) after LT are few. The aim of the current study was to evaluate the safety of anti-virus prophylaxis withdrawal in liver recipients whose serum hepatitis B e antigen (HBeAg) and HBV DNA are negative. We analyzed 190 patients undergone LT for HBV-related liver disease from 2006 to 2012 and found that 10 patients completely stopped the HBIG and NUC due to poor compliance. These patients were liver biopsied and checked monthly with serum HBV markers, HBV DNA and liver function. Among the 10 patients, 9 did not show the signs of HBV recurrence after a mean follow-up of 51.6 months (range 20-73) after withdrawal of the HBIG and NUC. The average time from LT to the withdrawal of the anti-virus drug was 23.8 (13-42) months; one patient showed hepatitis B surface antigen-positive and detectable HBV DNA after stopping anti-virus drugs and this patient was successfully treated with entecavir. Our data suggested that complete withdrawal of anti-virus prophylaxis was safe and feasible for patients whose serum HBeAg and HBV DNA were negative at the time of LT.

  5. Phylogenetic analysis of complete genome sequences of hepatitis B virus from an Afro-Colombian community: presence of HBV F3/A1 recombinant strain

    Directory of Open Access Journals (Sweden)

    Alvarado-Mora Mónica V

    2012-10-01

    Full Text Available Abstract Background Hepatitis B virus (HBV infection is one of the most prevalent viral infections in humans and represents a serious public health problem. In Colombia, our group reported recently the presence of subgenotypes F3, A2 and genotype G in Bogotá. The aim of this study was to characterize the HBV genotypes circulating in Quibdó, the largest Afro-descendant community in Colombia. Sixty HBsAg-positive samples were studied. A fragment of 1306 bp (S/POL was amplified by nested PCR. Positive samples to S/POL fragment were submitted to PCR amplification of the HBV complete genome. Findings The distribution of HBV genotypes was: A1 (52.17%, E (39.13%, D3 (4.3% and F3/A1 (4.3%. An HBV recombinant strain subgenotype F3/A1 was found for the first time. Conclusions This study is the first analysis of complete HBV genome sequences from Afro-Colombian population. It was found an important presence of HBV/A1 and HBV/E genotypes. A new recombinant strain of HBV genotype F3/A1 was reported in this population. This fact may be correlated with the introduction of these genotypes in the times of slavery.

  6. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study

    DEFF Research Database (Denmark)

    Weber, Rainer; Sabin, Caroline; Reiss, Peter;

    2010-01-01

    Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals.......Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals....

  7. Composition of inflammatory infiltrate and its correlation with HBV/HCV antigen expression

    Institute of Scientific and Technical Information of China (English)

    Bozena Walewska-Zielecka; Kazimierz Madalinski; Joanna Jablonska; Paulina Godzik; Joanna Cielecka-Kuszyk; Bogumila Litwinska

    2008-01-01

    AIM: To study the composition of liver inflammatory infiltrate in biopsy material from patients chronically infected with hepatotropic viruses and to evaluate the correlation of inflammatory infiltrate with hepatitis B virus (HBV) and hepatitis C virus (HCV) viral antigen expression in chronic B and C hepatitis.METHODS: The phenotype of inflammatory cells was evaluated by the EnVision system, using a panel of monoclonal antibodies. HBV and HCV antigens were detected with the use of monoclonal anti-HBs, poly-clonal anti-HBc and anti-HCV antibodies, respectively.RESULTS: The cellular composition of liver inflammatory infiltrate was similar in the patients with B and C hepatitis: ~50%-60% of cells were T helper lymphooltes. Approximately 25% were T cytotoxic lymphocytes; B lymphocytes comprised 15% of inflammatory infiltrate; other cells, including NK, totalled 10%. Expression of HLA antigens paralleled inflammatory activity. Portal lymphadenoplasia was found more often in hepatitis C (54.5%) than in hepatitis B (30.6%). Expression of HB-cAg was found more often in chronic B hepatitis of moderate or severe activity. Overall inflammatory activity in HBV-infected cases did not correlate with the intensity of HBsAg expression in hepatooltes. Inflammatory infiltrates accompanied the focal expression of HCV anti-gens. A direct correlation between antigen expression and inflammatory reaction in situ was noted more often in hepatitis C than B.CONCLUSION: Irrespective of the etiology and activity of hepatitis, components of the inflammatory infiltrate in liver were similar. Overall inflammatory activity did not correlate with the expression of HBsAg and HCVAg; HBcAg expression, however, accompanied chronic hepatitis B of moderate and severe activity.

  8. Extraction of protoporphyrin disodium and its inhibitory effects on HBV-DNA

    Institute of Scientific and Technical Information of China (English)

    Chao-Pin Li; Li-Fa Xu; Qun-Hong Liu; Chao Zhang; Jian Wang; Yu-Xia Zhu

    2004-01-01

    AIM: To explore an ideal method for extracting protoporphyrin disodium (PPN) from unanticoagulated animal blood, and to study the inhibitory effects of PPN on HBV-DNA duplication and its cytotoxicity to 2.2.15 cell strain.METHODS: Protoporphyrin methyl ester and other intermediate products were prepared with protoheme separated from protein hydrolysates of coagulated animal blood, which were finally made into PPN and detected quantitatively with an ultraviolet fluorescent analyzer.Ten μg/ml, 20 μg/ml, 40 μg/ml, 80 μg/ml and 160 μg/ml of PPN-aqueous solution were added into culture medium for 2.2.15 cells respectively. Eight days later, the drug concentration in supernatant from the culture medium was detected when inhibition rate of HBeAg, cell Survival rate when inhibition rate of HBeAg was 50% (ID50), and when survival cells in experimental group were 50% of those in control group (CD50), and the therapeutic index (TI) was also detected. PPN with different concentration of 10 μg/ml,20 μg/ml, 40 μg/ml, 80 μg/ml and 160 μg/ml was respectively mixed and cultivated with HepG2 2.2.15 cell suspension,and then the inhibition of PPN against HBV-DNA was judged by PCR.RESULTS: The extract of henna crystal was identified to be PPN. When the concentrations of PPN were 160 μg/ml and 80 μg/ml, the inhibition rates of HBeAg were 89.8% and 82.4%, and the cell survival rates were 98.7% and 99.2%.CONCLUSION: It is suggested that PPN can be extracted from unanticoagulated animal blood. PPN can inhibit HBV-DNA expression and duplication ih vitro, and has no cytotoxicity to liver cells. Further study and application of PPN are warranted.

  9. Detection of HBV, PCNA and GST-π in hepatocellular carcinoma and chronic liver diseases

    Institute of Scientific and Technical Information of China (English)

    Li-Juan Shen; Hua-Xian Zhang; Zong-Ji Zhang; Jin-Yun Li; Ming-Qin Chen; Wei-Bo Yang; Run Huang

    2003-01-01

    AIM: To investigate the change of HBV DNA, PCNA and GST-π in chronic liver disease and hepatocellular carcinoma (HCC).METHODS: Hepatitis B surface antigen (HBsAg), proliferating cell nuclear antigen (PCNA) and glutathione S-transferases (GST-π) were detected by immunohistochemical staining and HBV DNA was detected by in situ hybridization (ISH) in formalin-fixed and paraffin-embedded sections with a total of 111 specimens of chronic hepatitis, liver cirrhosis,paratumorous tissue, HCC and normal liver tissue.RESULTS: The positive rates of HBsAg and HBVDNA were 62.5 %(15/24) and 75.0 %(12/16) in chronic hepatitis,64.0 %(16/25) and 83.3 %(15/18) in liver cirrhosis, 72.7 %(16/22) and 85.7 %(12/14) in the paratumorous tissu and 45.0 %(14/31) and 64.3 %(9/14) in HCC. The positive HBVDNA granules in chronic hepatitis, liver cirrhosis and the paratumorous tissue were more intense than that in HCC.The positive rates of PCNA and GST-π were 34.8 %(8/23)and 25.0 %(4/16) in chronic hepatitis, 73.7 %(14/19) and 17.6 %(3/17) in liver cirrhosis, 86.7 %(13/15) and 53.3 % (8/15) in the paratumorous tissue, 100 %(15/15) and 60.0 %(9/15) in HCC, respectively, and the positive rate of GST-πin the paratumorous tissue was significantly higher than that in the liver cirrhosis without tumor (P<0.05), but same as that in HCC(P>0.05).CONCLUSION: The HBV infection may increase expression of PCNA and GST-π. The paratumor cirrhosis may be a sequential lesion of precancerous cirrhosis around HCC.

  10. A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations

    Directory of Open Access Journals (Sweden)

    Schmit Jean-Claude

    2011-05-01

    . Conclusions Despite the existing national risk-reduction strategies implemented since 1993, high prevalence of HCV and HBV infections in injecting drug users is observed. Our study showed that implementing risk-prevention strategies, including immunisation remains difficult with PDUs. Improvement should be looked for by the provision of field healthcare structures providing tests with immediate results, advice, immunisation or treatment if appropriate.

  11. Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    Chiara Viola; Tarik Asselah; Didier Samuel; Fran(c)ois Durand; Hamza Boudjema; Dominique Vaila; Patrick Marcellin

    2006-01-01

    We described a 59-year-old male patient who underwent liver transplantation in 1989 for hepatocellular carcinoma (HCC) complicating hepatitis B virus (HBV) cirrhosis. In 2001 (12 years after liver transplantation), he developed a lung metastasis of HCC without intrahepatic recurrence and the resection was done. In July 2003, he was symptom free without any recurrence. HCCmetastasis can develop even after a very long time of liver transplantation. Many HCCs grow slowly, and the growth rate of recurrent tumors in patients receiving immunosuppressive therapy is significantly greater thanthat of those who do not receive immunosuppressive therapy.

  12. Characteristics of S gene mutation in patients with occult HBV infection

    Directory of Open Access Journals (Sweden)

    Jian-hong CHEN

    2015-04-01

    Full Text Available Objective To analyze characteristics of HBV S gene mutation in one patient with occult hepatitis B virus infection, who was positive for serum HBV DNA for long term, but negative for HBsAg in order to reveal the correlation between S gene mutation and development of OBI as well as the progression of the liver disease. Methods Four serum samples were collected at different time-points for the use of amplifying HBV S gene and performing cloning-sequencing. The representative S mutants were selected to construct recombinant vectors for phenotype analysis. Results Several S-gene mutational patterns were detected in the samples, including pre-S1 large fragment deletion, s126-127 "RPCMNCTI" insertion, sQ129N, s131-133 TSM→NST, and classical sG145R mutations. In sequential 4 samples, s131-133 TSM→NST mutation was detected in 0%, 26%, 59% and 74% of viral clones, respectively. The pre-S1 large fragment deletion was constantly found in the 4 serum samples, accounting for 26%, 17%, 15% and 21% of detected viral clones, respectively. Phenotypic analysis showed that sQ129N and s131-133 TSM → NST mutations reduced the affinity of the antibody to HBsAg and increased the secretion of virus particles. Compared with the wild-type strain, the replication capacity and surface antigen promoter Ⅱ (SPⅡ activity of large fragment-deleted (nt 3046-3177 deletion strain were decreased by 43.7% and 97.2%, respectively. In addition, sG145R-induced impairment to secretion capacity of viral particles was verified. Conclusions Clinical presentations of long-term OBI of this HBV-infected patient could be caused by multiple S-gene mutants. Some S-gene mutations influence viral phenotypic characteristics, which might closely be related to the progression of liver disease. DOI: 10.11855/j.issn.0577-7402.2015.03.02

  13. Khmer American Mothers’ Knowledge about HPV and HBV Infection and Their Perceptions of Parenting: My English Speaking Daughter Knows More

    Science.gov (United States)

    Lee, Haeok; Kiang, Peter; Tang, Shirely S.; Chea, Phala; Peou, Sonith; Semino-Asaro, Semira; Grigg-Saito, Dorcas C.

    2016-01-01

    SUMMARY Purpose The purpose of this study is to explore and describe Khmer mothers’ understanding of HBV and HPV prevention as well as their perception of parenting on health and health education of their daughters in the US. Methods The qualitative pilot study guided by the revised Network Episode Model and informed by ethnographic analysis and community-based purposive sampling method were used. Face-to-face audiotaped interviews with eight Khmer mothers were conducted by bilingual female middle-aged community health leaders who spoke Khmer. Results The findings revealed that Khmer mothers clearly lacked knowledge about HBV and HPV infection prevention and had difficulty understanding and educating their daughters about health behavior, especially on sex-related topics. The findings showed that histo-sociocultural factors are integrated with the individual factor, and these factors influenced the HBV and HPV knowledge and perspective of Khmer mothers’ parenting. Conclusion The study suggests that situation-specific conceptual and methodological approaches that take into account the uniqueness of the sociocultural context of CAs is a novel method for identifying factors that are significant in shaping the perception of Khmer mothers’ health education related to HBV and HPV prevention among their daughters. The communication between mother and daughter about sex and the risk involved in contracting HBV and HPV has been limited, partly because it is seen as a “taboo subject” and partly because mothers think that schools educate their children regarding sexuality and health. PMID:26160247

  14. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues

    Institute of Scientific and Technical Information of China (English)

    Zhuo-Lun Song; Yu-Jun Cui; Wei-Ping Zheng; Da-Hong Teng; Hong Zheng

    2012-01-01

    Nucleos(t)ide analogues (NA) are a breakthrough in the treatment and management of chronic hepatitis B.NA could suppress the replication of hepatitis B virus (HBV) and control the progression of the disease.However,drug resistance caused by their long-term use becomes a practical problem,which influences the long-term outcomes in patients.Liver transplantation is the only choice for patients with HBV-related end-stage liver disease.But,the recurrence of HBV after transplantation often caused by the development of drug resistance leads to unfavorable outcomes for the recipients.Recentiy,the multi-drug resistance (MDR) has become a common issue raised due to the development and clinical application of a variety of NA.This may complicate the antiviral therapy and bring poorly prognostic outcomes.Although clinical evidence has suggested that combination therapy with different NA could effectively reduce the viral load in patients with MDR,the advent of new antiviral agents with high potency and high genetic barrier to resistance brings hope to antiviral therapy.The future of HBV researches relies on how to prevent the MDR occurrence and develop reasonable and effective treatment strategies.This review focuses on the diagnostic and therapeutic progress in MDR caused by the anti-HBV NA and describes some new research progress in this field.

  15. Recombinant HBV vaccine enhances the rate of sustained virological response when early initiated after anti-HCV combination therapy.

    Science.gov (United States)

    Hanafy, Amr Shaaban; Farag, Alaa Ahmad; Hassanin, Hassan Mahmoud; Hassaneen, Ahmad Mahmoud

    2016-01-01

    The overall SVR rate for chronic hepatitis C genotype 4 using the Standard of care is 54.3%. HBV infection can be prevented by the administration of effective and safe vaccine. Evaluation of the vaccination-induced anti-HBs response rates in a cohort of HCV Egyptian patients after being exposed to antiviral combination therapy and the magnitude of its effect on the rate of SVR through its putative role in induction of crossed immunity. (A) 500 HCV patients who had completed the course of antiviral therapy and achieved ETR were retrospectively analyzed and received 20 μg of recombinant DNA vaccine for hepatitis B at time intervals (0, 1, and 4 months). The first dose of the vaccine was initiated one month post treatment. (B) Laboratory analysis: Included routine preliminary investigations to anti viral therapy and specific investigations as determination of anti-HBs antibodies 2 months following the third dose of vaccine. 433 patients showed protective response (86.6%), 67 patients were non-responders (13.4%) (P = 0.003). Adding HBV vaccine 1 month post-treatment increased SVR (400 patients, 80%) (χ(2)  = 40.3, P = 0.000). Diabetes affect response to HBV vaccine (P = 0.0001). Adding HBV vaccine to the post treatment care of patients with HCV after termination of antiviral therapy gain two benefits; protection from HBV and significant increase in rates of SVR. PMID:26147509

  16. Immunization with adenovirus LIGHT-engineered dendritic cells induces potent T cell responses and therapeutic immunity in HBV transgenic mice.

    Science.gov (United States)

    Jiang, Wenzheng; Chen, Ran; Kong, Xiaobo; Long, Fengying; Shi, Yaru

    2014-07-31

    LIGHT, a TNF superfamily member (TNFSF14), is a type II transmembrane protein expressed on activated T cells and immature dendritic cells (DCs). However, the expression of LIGHT on mature DCs is down-regulated. Recent studies demonstrated that LIGHT provides potent costimulatory activity for T cells, enhancing proliferation and the production of Th1 cytokines independently of the B7-CD28 pathway. Here, we evaluated the effectiveness of peptide-pulsed DC-mediated antiviral immunity in HBV transgenic mice and the immunoadjuvant effect of LIGHT. The bone marrow-derived DCs were modified in vitro with an adenovirus (Ad) vector expressing mouse LIGHT (Ad-LIGHT), the expression of costimulatory molecules was up-regulated and the secretion of cytokines IL-12 and IFN-γ increased. LIGHT-modified DCs enhanced allostimulation for T cells in mixed lymphocyte reaction (MLR). HBV peptide-pulsed DCs elicited HBV specific CD8+ T cell response and reduced the level of HBsAg and HBV DNA in sera of HBV transgenic mice. Importantly, LIGHT-modified DCs could induce stronger antiviral immunity. These results support the concept that genetic modification of DCs with a recombinant LIGHT adenovirus vector may be a useful strategy for antiviral immunotherapy. PMID:24951859

  17. Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line.

    Science.gov (United States)

    Cavallone, Daniela; Moriconi, Francesco; Colombatto, Piero; Oliveri, Filippo; Bonino, Ferruccio; Brunetto, Maurizia Rossana

    2013-04-01

    The Gunther's vector-free method (GM), using PCR-amplified full length HBV-DNA (fl-HBV-DNA), is currently the best in vitro HBV replication system despite the low intracellular HBV-DNA production. The replication efficiency and HBsAg secretion of 12 isolates from HBsAg/HBeAg positive sera by GM, Monomer-Linear-Sticky-Ends-DNA (MLSE) and Monomer-Circular-Closed (MCC) were compared in HuH7 cells. Eight of twelve genomes (67%) were replication competent by GM; however direct sequencing (DS) showed that more than 80% of input DNA was undigested in spite of SapI treatment. Replication Intermediates (RI) were detected earlier (24 vs. 48h) and in higher amounts (2.51±0.32 and 6.43±0.43 fold) by MCC than GM or MLSE. By MCC 10 of 12 genomes (83%) were replication competent and 7 produced high RI levels. RI and HBsAg kinetics correlated positively in MCC (R=0.696, p=0.017 overall; R=0.928, p=0.008), but not in GM (R=-0.437, p=0.179 overall; R=-0.395, p=0.439) in genotype D isolates. In conclusion, HBV-DNA circularization prior transfection improves in vitro viral replication and replication competent HBsAg production, mimicking better the in vivo conditions.

  18. HBV相关慢加亚急性肝衰竭患者中Th17细胞、Treg细胞的变化及其与肝功能和HBV-DNA载量间的研究%Change of Th17 cell, Treg cell in patients with HBV-associated acute-on-chronic liver failure and its relationship with liver function and HBV-DNA load

    Institute of Scientific and Technical Information of China (English)

    沈敏; 林明强; 冯奇桃; 吕友凯; 李永武

    2016-01-01

    目的:通过检测乙型肝炎病毒(HBV)相关慢加亚急性肝衰竭(HBV-ACLF)患者外周血中的Th17细胞、Treg细胞的水平,探讨Th17、Treg细胞在HBV-ACLF发病机制中的作用。方法流式细胞术检测22例HBV-ACLF患者、24例慢性乙型肝炎患者(CHB)以及20例健康对照者(HC)外周血Th17、Treg细胞的频率,荧光定量PCR法检测患者外周血HBV-DNA水平,同时分析Th17细胞、Treg细胞、Th17/Treg与谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TB)及HBV-DNA载量间的相关性。结果 HBV-ACLF组患者的Thl7细胞、Treg细胞、Th17/Treg较CHB组和HC组明显增高,CHB组又较HC组Th17细胞、Treg细胞、Th17/Treg升高,差异均有统计学意义(P0.05). Conclusion Th17 and Treg may be in a balanced state in healthy people, and such state might be broken in patients with CHB and HBV-ACLF, which indicates that Th17 and Treg are involved in the occurrence and development of CHB and HBV-AVLF. Th17 cell could be used as an immunological marker for determination of the liver damage degree in HBV-ACLF. Th17, Treg have no correlation with the load of HBV-DNA.

  19. Significant increase in HBV, HCV, HIV and syphilis infections among blood donors in West Bengal, Eastern India 2004-2005: Exploratory screening reveals high frequency of occult HBV infection

    Institute of Scientific and Technical Information of China (English)

    Prasun Bhattacharya; Partha Kumar Chandra; Sibnarayan Datta; Arup Banerjee; Subhashish Chakraborty; Krishnan Rajendran; Subir Kumar Basu; Sujit Kumar Bhattacharya; Runu Chakravarty

    2007-01-01

    AIM: To evaluate the prevalence of markers of hepatitis B virus (HBV) and hepatitis C virus (HCV) and human immunodeficiency virus (HIV) among blood donors in Kolkata, Eastern India for two consecutive years and to conduct a pilot study to explore the presence of HBV DNA among hepatitis B surface antigen (HBsAg) negative but anti-HBc positive blood donors.METHODS: Seroprevalence of HBsAg, anti-HCV and anti-HIV was studied among 113051 and 106695 voluntary blood donors screened in 2004 and 2005,respectively. Moreover, a pilot study on 1027 HBsAg negative donors was carried out for evaluating the presence of HBV DNA by PCR on HBsAg negative/antiHBc positive donors.RESJLTS: A statistically significant increase in the prevalence of HBV (1448 vs 1768, P < 0.001), HIV (262vs 374, P < 0.001), HCV (314 vs 372, P = 0.003) and syphilis (772 vs 853, P = 0.001) infections was noted among blood donors of Kolkata West Bengal in 2005 as compared to 2004. Moreover, the exploratory study on 1027 HBsAg negative donors revealed that 188 (18.3%) of them were anti-HBc positive out of which 21% were positive for HBV DNA.CONCLUSION: The findings of this study underscore the significantly increasing endemicity of hepatitis viruses, syphilis and HIV among the voluntary blood donors of our community. The pilot study indicates a high rate of prevalence of HBV DNA among HBsAg negative/anti-HBc positive donors and thus emphasizes the need for a more sensitive and stringent screening algorithm for blood donations.

  20. Prevalence of HBV and/or HDV markers using RIA in patients with chronic liver disease

    International Nuclear Information System (INIS)

    Sixty six with different chronic liver disease (CLD) were studied for the prevalence of HBV and/or HDV markers using radioimmunoassay. The total prevalence of HBV markers (i.e. when any of the markers is present) for chronic active hepatitis (CAH), post viral cirrhosis, chronic persistent hepatitis (CPH), cryptogenic cirrhosis, primary biliary cirrhosis (PBC), alcoholic cirrhosis, hepatocellular carcinoma (HCCA) and methyldopa induced chronic hepatitis were 6/13 (46.2%), 6/6 (100%), 7/9 (77.8%), 0/10, 0/2, 10/15 (66.7%), 7/10 (70%) and 0/1 respectively; whereas the total prevalence of anti-delta antibody was 0/13, 1/6 (16.7%), 3/9 (33.3%), 0/10 0/2, 0/15, 2/10 (20%) and 0/1 respectively, while the prevalence of anti-delta antibody for the control group was 4/102 (3.9%). Various patients with CLD, though they showed various viral markers yet they showed different pattern groups. 3 tabs

  1. Study the Three Extraction Methods for HBV DNA to Use in PCR

    Directory of Open Access Journals (Sweden)

    N. Sheikh

    2004-07-01

    Full Text Available Diagnosis of Hepatitis B is important because of the its high prevalence. Recently PCR method , has found greater interest among different diagnostic methods. Several reports emphasis on some false negative results in those laboratories using PCR. The aim of this study was to compare three different procedures for HBV DNA extraction. A total 30 serum samples received from Shariati hospital. Sera was taken from patients having chronic Hepatitis with HBs antigen positive and HBe antigen negative. The sensitivity of guanidium hydrochloride method for extracting the HBV DNA from serum were evaluated and compared with phenol–chloroform and boiling methods. Diagnostic PCR kit was obtained from Cynagene contained taq polymerase, reaction mixture, dNTP, and buffer for reaction. A 353 bp product were amplified by amplification program provided in used PCR protocol. The comparison of results indicated that procedure was successful for amplification of the designed products from Hepatitis B in sera. Number of positive results were 16,19,23 and number of negative result were 14,11,7 for the boiling, phenol-chloroform and guanidium-hydrochloride extraction methods respectively.PCR method is the fastest diagnosis method and the most accurate procedure to identify Hepatitis B. Guanidium hydrochloride method was the most successful procedure studied in this survey for viruses.

  2. STUDY OF VIRAL MARKERS (HIV, HBV, HCV IN A TERTIARY CARE HOSPITAL

    Directory of Open Access Journals (Sweden)

    Samatha

    2015-10-01

    Full Text Available BACKGROUND: Viral infections are global health problems, affecting millions. Studies show wide variations in the prevalence patterns of the Human Immuno deficiency, Hepatitis B and Hepatitis C Virus infections. Prevalence of these infections may vary not only from country to country but also in different regions of the same country . The present study was designed to find out the sero - prevalence of HBV, HCV, and HIV infections in patients attending a tertiary care hospital. METHODS: A prospective study was conducted for a period of one year from April 2014 to March 2015. A total of 4 276 patients were screened for Hepatitis B surface Antigen ( HBsAg, anti HCV antibodies and anti HIV antibodies. Patients with symptoms or signs of these viral infections and the patients for routine pre - surgical evaluation, referred by the clinicians were included in the study. Age, sex and serological result data was analysed for these patients. The results were analysed by Chi - square statistics. RESULTS: The sero - prevalence of HBsAg was 2.5%, anti HCV antibodies was 0.63%, anti HIV antibodies was 1.73% whereas, co - infection of HBsAg with HIV was seen in only three patients. CONCLUSION: In the present study, the sero - prevalence of Hepatitis B Virus (HBV was higher than HIV and HCV infections. As these viral infections are dangerous and cause morbidity an d mortality, population based awareness & screening programmes are recommended to limit the further spread.

  3. Detection of Mutations Resistant to Lamivudine or Adefovir in HBV and Its Management

    Institute of Scientific and Technical Information of China (English)

    De-xing Jia; Jing Feng; Ping Li; Xiu-ying Lun; Xian-jie Yu

    2013-01-01

    Objective Nucleos(t)ide analogues (NAs) naïve chronic hepatitis B(CHB) patients were given rescue combination therapy after drug resistance to lamivudine or adefovir. Evolution of HBV mutation patterns and its impact on antiviral effects were studied. Methods Total of 142 naïve CHB patients treated with lamivudine were randomly divided into two groups when lamivudine resistance occurred. One group was added with adefovir, the other was switched to entecavir and adefovir. Seventy-two naïve CHB patients treated with adefovir were randomly divided into two groups when adefovir resistance occurred. One group was added with lamivudine, the other was added with entecavir. HBV polymerase reverse transcriptase mutations associated with resistance were analyed before and after 48 weeks of rescue therapy, respectively. Results The mutation patterns of M204V/I, M204V+L180M were predominantly found in CHB patients after lamivudine resistance. Meanwhile, the entecavir resistance mutation patterns were also detected. Therefore, patients with lamivudine resistance could develop more diverse drug resistance mutations if they were switched to entecavir and adefovir. The mutation patterns of rtA181 were predominantly found in CHB patients after adefovir resistance and rescure therapy with add-on entecavir was more effective than with add-on lamivudine Conclusions Resistance mutation analysis chould help to choose NAs, reduce resistance and ehance antiviral effects.

  4. Variability in the precore and core promoter regions of HBV strains in Morocco: characterization and impact on liver disease progression.

    Directory of Open Access Journals (Sweden)

    Bouchra Kitab

    Full Text Available BACKGROUND: Hepatitis B virus (HBV is one of the most common human pathogens that cause aggressive hepatitis and advanced liver disease (AdLD, including liver cirrhosis and Hepatocellular Carcinoma. The persistence of active HBV replication and liver damage after the loss of hepatitis B e antigen (HBeAg has been frequently associated with mutations in the pre-core (pre-C and core promoter (CP regions of HBV genome that abolish or reduce HBeAg expression. The purpose of this study was to assess the prevalence of pre-C and CP mutations and their impact on the subsequent course of liver disease in Morocco. METHODS/PRINCIPAL FINDINGS: A cohort of 186 patients with HBeAg-negative chronic HBV infection was studied (81 inactive carriers, 69 with active chronic hepatitis, 36 with AdLD. Pre-C and CP mutations were analyzed by PCR-direct sequencing method. The pre-C stop codon G1896A mutation was the most frequent (83.9% and was associated with a lower risk of AdLD development (OR, 0.4; 95% CI, 0.15-1.04; p = 0.04. HBV-DNA levels in patients with G1896A were not significantly different from the other patients carrying wild-type strains (p = 0.84. CP mutations C1653T, T1753V, A1762T/G1764A, and C1766T/T1768A were associated with higher HBV-DNA level and increased liver disease severity. Multiple logistic regression analysis showed that older age (≥ 40 years, male sex, high viral load (>4.3 log(10 IU/mL and CP mutations C1653T, T1753V, A1762T/G1764A, and C1766T/T1768A were independent risk factors for AdLD development. Combination of these mutations was significantly associated with AdLD (OR, 7.52; 95% CI, 4.8-8; p<0.0001. CONCLUSIONS: This study shows for the first time the association of HBV viral load and CP mutations with the severity of liver disease in Moroccan HBV chronic carriers. The examination of CP mutations alone or in combination could be helpful for prediction of the clinical outcome.

  5. HBV-INFECTION DE NOVO AFTER ORTHOTOPIC LIVER TRANSPLANTATION: CLINICAL AND VIROLOGICAL CHARACTERISTICS, ASSESSMENT OF ANTIVIRUS THERAPY EFFECTIVENESS

    Directory of Open Access Journals (Sweden)

    O. I. Malomuzh

    2012-01-01

    Full Text Available We studied 11 cases of HBV-infection de novo in patients after orthotopic liver transplantation performed because of non-viral cirrhosis. Serum НBeAg, was revedled in all patients. In most cases clinical course of HBV-infection was benign. Treatment with entecavir was more effective than lamivudin, and brought to НBsAg elimination in 4 patients. Treatment with lamivudin led to descrease viral load in all patients and HBsAg elimination in one case. 

  6. Proifle, spectrum and signiifcance of hepatitis B virus genotypes in chronic HBV-infected patients in Yunnan, China

    Institute of Scientific and Technical Information of China (English)

    Jing You; Bao-Zhang Tang; Hutcha Sriplung; Virasakdi Chongsuvivatwong; Alan Geater; Lin Zhuang; Jun-Hua Huang; Hong-Ying Chen; Lan Yu

    2008-01-01

    BACKGROUND:There are signiifcant variations in the geographical distribution of hepatitis B virus (HBV) genotypes throughout the world, and some genotypes are associated with different clinical outcomes. Eight genotypes of human HBV (designated A-H) have been reported. The present study was designed to examine the distribution of HBV genotypes among patients at various stages of chronic type B liver disease in Yunnan Province, China, and to explore its signiifcance and the relationship of HBV genotype with gender and age, clinical spectrum of chronic HBV infection, and viral replicative activity. METHODS:Serum samples from 126 patients with chronic HBV infection from Yunnan Province, including 26 chronic asymptomatic HBV carriers (ASC), 61 patients with chronic hepatitis B (CHB) (21 mild, 30 moderate and 10 severe), 20 patients with chronic fulminant hepatic failure (CFHF), 12 patients with HBV-related liver cirrhosis (LC) and 7 patients with HBV-related hepatocellular carcinoma (HCC) were analyzed using reverse dot blot (RDB) methodology, which is based on the reverse hybridization principle for HBV genotyping. The relations of HBV genotype with gender and age, clinical patterns, and serological data of the patients were analyzed. RESULTS: In this series, genotypes A, B, C, and D were found. 38.1%patients (48/126) belonged to B, 54.8%(69/126) to C, 0.8%(1/126) to D, 1.6%(2/126) to a mixture of B and C, and 1.6%(2/126) to a mixture of A and C. 3.2%patients (4/126) had unknown genotypes. No other genotypes (E, F, G, and H) were found. Genotypes B and C were predominant. There was a statistically signiifcant difference in the distributions of genotypes C and B (χ2=7.04, P=0.008), and C was the dominant genotype in all patient categories. The rate of genotype B in the mild CHB group was signiifcantly higher than that in the moderate and severe groups (χ2=12.16, P=0.0001; χ2=11.98, P=0.001, respectively), the ASC group (χ2=5.46, P=0.02), the CFHF group (χ2

  7. Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection

    OpenAIRE

    Ling Li; Hie-Won Hann; Shaogui Wan; Hann, Richard S.; Chun Wang; Yinzhi Lai; Xishan Ye; Alison Evans; Ronald E Myers; Zhong Ye; Bingshan Li; Jinliang Xing; Hushan Yang

    2016-01-01

    Recent studies have demonstrated a potential link between circulating cell-free mitochondrial DNA (mtDNA) content and cancers. However, there is no study evaluating the association between circulating mtDNA as a non-invasive marker of hepatocellular carcinoma (HCC) risk. We conducted a nested case-control study to determine circulating mtDNA content in serum samples from 116 HBV-related HCC cases and 232 frequency-matched cancer-free HBV controls, and evaluate the retrospective association be...

  8. Improving testing for hepatitis B before treatment with rituximab

    Science.gov (United States)

    Jopson, Laura; Ng, Sarah; Lowery, Matthew; Harwood, Jayne; Waugh, Sheila; Valappil, Manoj; McPherson, Stuart

    2016-01-01

    Aims/Objectives/Background Individuals with current or previous infection with the hepatitis B virus (HBV) can experience viral reactivation when treated with immunosuppression. Rituximab, an anti-CD20 antibody used to treat many diseases, has potent immunosuppressant effects with a high risk of causing HBV reactivation. Reactivation can range from elevated liver enzymes to acute severe hepatitis with liver failure and a significant mortality risk. HBV screening and appropriate use of prophylactic antiviral therapy can prevent reactivation. This work describes the introduction of a local policy for HBV testing in patients before rituximab treatment and assesses its impact. Methods and Results A baseline review (before policy introduction) of 90 patients showed that only 21 (23%) had hepatitis B surface antigen (HBsAg) and 17 (19%) had hepatitis B core antibody (anti-HBcAb) tested before receiving rituximab. Following introduction of the policy (on the basis of international guidelines), improved laboratory reporting protocols and targeted education sessions, two further reviews of HBV testing rates among patients being initiated onto rituximab were performed. There was a marked increase in pre-rituximab testing for HBsAg from 23 to 79% and for anti-HBcAb from 19 to 78%. Throughout the study period, a total of one (0.8%) HBsAg-positive and six (4.7%) anti-HBcAb-positive patients were identified. Conclusions This work clearly indicates that simple strategies can markedly improve appropriate HBV screening. In our cohort, 6% (of whom only 43% had recognized HBV risk factors) required antiviral prophylaxis, which emphasizes the importance of universal screening before rituximab. Reinforcement of the guidelines and ongoing education is needed to further increase testing rates. PMID:27388147

  9. The Knowledge, Attitude and Practices regarding HBV Infection of Married Women in the Reproductive Age Group living in Cantonment Area, Sunjawan, Jammu

    Directory of Open Access Journals (Sweden)

    Rashmi Sharma, C.L. Sharma, Ruchi Khajuria

    2004-07-01

    Full Text Available The present study was conducted to know the knowledge, attitude and practices of 300 marriedwomen in the reproductive age group living in the cantonment area Sunjawan, Jammu regardingHBV infection. Only 20% of the women were found aware of the mode of transmission of HBV.However, 50% of the women were having the misconceptions regarding mode of transmission ofHBV. 4% of women, 30% of children up to 5 years and 15% of children above 5 years were fullyimmunized with hepatitis B vaccine. 80% of children up to 5 years and 75% of children above 5years were fully immunized as per universal immunization programme. Hence, the results of thestudy clearly indicated the low immunization rate with vaccine against HBV than that under universalimmunization programme and further potentiated the need for implementation of therecommendations in 9th five year plan of India regarding introduction of immunization againstHBV in universal immunization programme at the earliest .

  10. MOLECULAR EPIDEMIOLOGY FEATURES OF HBV/HDV CO-INFECTION IN KYRGYZSTAN

    Directory of Open Access Journals (Sweden)

    A. V. Semenov

    2016-01-01

    Full Text Available One of the most serious health problems in the world are hepatotropic viruses that cause chronic liver disease. Hepatitis B virus is distributed globally; around 5% of the carriers are also infected with hepatitis delta virus. Co-infection or superinfection of hepatitis viruses B and D significantly associated with a much more severe liver disease, compared with infection only hepatitis B virus. However, examination of hepatitis virus B carriers for the presence of hepatitis D virus in most regions of the world is not mandatory. It should be noted that the complete genotype mapping of viruses hepatitis B and D isolated on the territory of the CIS and the countries of the former Soviet Union, there is not yet, despite the constantly ongoing works devoted genotyping hepatotropic virus in the territory of the Russian Federation and neighboring countries. Due to the fact that one of the prospective ways of spreading viruses is the “labor migration” the inhabitants of Central Asia in other countries, including the Russian Federation, there is a need to pay attention to the situation of viral hepatitis in the region. The aim of our study was to estimate the prevalence of genetic variants and characteristics of molecular epidemiology of chronic viral hepatitis co-infection B + D in Kyrgyzstan. The study involved 30 plasma samples from patients with chronic viral hepatitis B and D from different regions of Kyrgyzstan. Based on the phylogenetic analysis of the isolates showed that among patients examined HBV identified only D genotype. Based on the phylogenetic analysis of the isolates indicated that among the examined patients with chronic viral hepatitis B revealed only genotype D. It is shown prevalence of HBV subtype D1 (73.34% compared to the HBV subtype D2 (3.33% and D3 (23.33%. Revealed HDV genotype I with highly variable region of the gene encoding the delta antigen. The high similarity of some isolates with strains specific to neighboring

  11. 复制型HBV转基因小鼠的建立与应用%Establislunent and use of HBV- replication transgenic mice

    Institute of Scientific and Technical Information of China (English)

    孔祥平; 刘光泽; 易学瑞

    2011-01-01

    尽管有了有效的疫苗,但乙肝病毒(HBV)感染依然是全球性公共卫生问题,在我国形势尤为严峻.由于HBV的自然宿主仅限于人和黑猩猩,现有的模型都有不同的缺陷,因此关于其生物学及治疗方法 研究的诸多问题依然没有解决.复制型HBV转基因小鼠模型的建立,极大地提高了我们对HBV生活史、免疫生物学和肝脏病变的免疫发病机制的认识.本文简要介绍国际上由Francis V.Chisari实验室和国内由本实验室建立的复制型HBV转基因小鼠,以及利用该模型开展抗病毒药物和乙肝发病机制的研究工作.%Despite the existence of a preventive vaccinet hepatitis B virus (HBV) infection is still a major worldwide health problem, especially in China. As HBV naturally Despite of the existence of a preventive vaccine, hepatitis B virus CHBV) infection is still a major worldwide healthy problem, especially in China. As HBV naturally infects only human and chimpanzees, many issues pertaining to the biology and the therapeutic of HBV infection remain unresolved due to the limitation of the establishment of a HBV model. However, the establishment of HBV-replication transgenic mice has greatly improved our understanding of life cycle, immunobiology and pathogensis of HBV. The establishment of HBV transgenic mice and its use in assessing the antiviral potential of pharmacological agents and HBV immunopathogenesis are herewith briefly described in the present paper.

  12. Association of Mutations in the Basal Core Promoter and Pre-core Regions of the Hepatitis B Viral Genome and Longitudinal Changes in HBV Level in HBeAg Negative Individuals: Results From a Cohort Study in Northern Iran

    OpenAIRE

    Besharat, Sima; Poustchi, Hossein; Mohamadkhani, Ashraf; Katoonizadeh, Aezam; Moradi, Abdolvahab; Roshandel, Gholamreza; Freedman, Neal David; Malekzadeh, Reza

    2015-01-01

    Background: Although certain HBV mutations are known to affect the expression of Hepatitis e antigen, their association with HBV viral level or clinical outcomes is less clear. Objectives: We evaluated associations between different mutations in the Basal Core promoter (BCP) and Pre-core (PC) regions of HBV genome and subsequent changes in HBV viral DNA level over seven years in a population of untreated HBeAg negative chronic hepatitis B (CHB) participants in Northeast of Iran. Materials and...

  13. Determination of HBV Genotypes among Hbs Ag Positive Blood Donors in Tehran, Iran Using PCR-RFLP

    Directory of Open Access Journals (Sweden)

    S Milani

    2009-03-01

    Full Text Available Background: Hepatitis B virus (HBV is one of the major causative agents of acute and chronic liver disease worldwide and is believed to be responsible for a million deaths annually. On the basis of a comparison of complete genomic se­quences, HBV has been classified into eight genotypes A-H which show a geographical distribution. Some genotypes are associ­ated with different clinical outcomes. Identification of HBV genotypes is important to begin and follow up the treat­ment."nMethods: In this cross-sectional study, the serum samples of blood donors were collected from Tehran Blood Transfusion Cen­ters in period during "2005-2006". Sera of 55 blood donors who were positive for hepatitis B surface antigen were se­lected. DNA was extracted using commercial kit and the S gene sequence was amplified by nested-PCR. PCR products were then analyzed for restriction enzymes that would be genotype specific."nResults: Genotype D was found the only type in all HBV DNA positive serum samples, in Tehran."nConclusion: Genotype D is dominant among Tehran's blood donors, which is consistent with Iran and the Middle East domi­nant genotype.  

  14. DNA immunization with fusion genes containing HCV core region and HBV core region

    Institute of Scientific and Technical Information of China (English)

    杨莉; 刘晶; 孔玉英; 汪垣; 李光地

    1999-01-01

    The eucaryotic expression plasmids were constructed to express the complete (HCc191) or the truncated (HCc69 and HCc40) HCV core genes, solely or fused with the HBV core gene (HBc144). These constructions were transiently expressed in COS cells under the control of the CMV promoter. The antigenicity of HBc and HCc could be detected in the expression products by ELISA and Western blot. The mice immunized with these expression plasmids efficiently produced the anti-HCc antibodies, and also anti-HBc antibodies when the plasmids contained the fusion genes. In addition, the antibodies induced by the fusion genes were more persistent than those induced by the non-fusion HCV core genes. These indicate that the fusion of HCc genes to HBc gene is in favor of the immunogenicity of HCc, while the immunogenicity of HBc is not affected.

  15. 献血人群血清anti-HBC和HBV DNA检测的意义

    Institute of Scientific and Technical Information of China (English)

    朱紫苗; 谢步飞

    2014-01-01

    目的 探讨无偿献血者乙型肝炎病毒核心抗体与隐匿性感染的关系.方法 收集无偿献血者样本9 100份,采用ELISA法进行HBsAg和anti-HBC血清学筛查,对anti-HBC阳性血清PCR检测乙肝病毒核酸.结果 911份(10.01%)标本为anti-HBC阳性,其中820份(90.01%)HBsAg阴性,34例血清HBV DNA阳性.结论 常规检测对于献血者筛查具有重要意义.

  16. HBV cccDNA 检测的研究进展

    Institute of Scientific and Technical Information of China (English)

    陆晖; 江建宁

    2008-01-01

    @@ 自1965年Blumberg发现澳大利亚抗原(HBsAg)以来,病毒性乙型肝炎(viral hepatitis B)有了划时代的研究进展.病毒性乙型肝炎主要流行于亚洲、非洲、南部欧洲和拉丁美洲.全世界约20亿人有既往或持续感染HBV,慢性HBV感染者达3~3.5亿,其中15%~25%最终死于肝衰竭、肝硬化或肝癌,年病死人数约100万;男女性病人的病死率分别约50%和15%.

  17. The hydrological response of the Ourthe catchment to climate change as modelled by the HBV model

    Directory of Open Access Journals (Sweden)

    T. L. A. Driessen

    2009-11-01

    Full Text Available The Meuse is an important river in western Europe, and almost exclusively rain-fed. Projected changes in precipitation characteristics due to climate change, therefore, are expected to have a considerable effect on the hydrological regime of the river Meuse. We focus on an important tributary of the Meuse, the Ourthe, measuring about 1600 km2. The well-known hydrological model HBV is forced with three high-resolution (0.088° regional climate scenarios, each based on one of three different IPCC CO2 emission scenarios: A1B, A2 and B1. To represent the current climate, a reference model run at the same resolution is used. Prior to running the hydrological model, the biases in the climate model output are investigated and corrected for. Different approaches to correct the distributed climate model output using single-site observations are compared. Correcting the spatially averaged temperature and precipitation is found to give the best results, but still large differences exist between observations and simulations. The bias corrected data are then used to force HBV. Results indicate a small increase in overall discharge for especially the B1 scenario during the beginning of the 21st century. Towards the end of the century, all scenarios show a decrease in summer discharge, partially because of the diminished buffering effect by the snow pack, and an increased discharge in winter. It should be stressed, however, that we used results from only one GCM (the only one available at such a high resolution. It would be interesting to repeat the analysis with multiple models.

  18. 基于磁性纳米探针的乙肝前 S1抗原的快速磁性免疫层析方法的建立%Establishment of HBV rapid magnetic immunochromatographic method based on magnetic nanoprobe for Pre-S1 antigen

    Institute of Scientific and Technical Information of China (English)

    徐晓巍; 崔正权; 卢瑛; 贾鑫明; 王祎龙

    2016-01-01

    为了建立快速灵敏的乙肝磁性免疫层析检测方法,选用前S1抗原作为乙肝检测标志物,将前S1抗原的特异性单抗偶联到磁珠表面,制备了乙肝的特异性磁性纳米探针,并以此探针作为检测标记物制备了乙肝的磁性试纸条。采用乙肝临床血样,对所构建磁性试纸条的检测灵敏度、稳定性和重现性等检测性能进行了评价,并和市售的乙肝ELISA试剂盒进行了对比分析。与ELISA试剂盒的对比结果显示,研究所建立的乙肝磁性试纸条灵敏度较ELISA法高2倍,具有较好的稳定性(25℃可保存半年)和重现性;这两种方法对441份临床血样的检测结果一致性高达97%。研究可为今后乙肝的床边早期诊断产品开发提供技术支撑。%To establish a rapid and sensitive detection method for HBV in serum samples of people , in this study, PreS1 antigen was selected as markers for HBV detection .Specific antibody against PreS 1 was coupled onto the surface of magnetic beads to prepare mag-netic nanoprobe .HBV magnetic test strip labeled by magnetic nanoprobe was constructed .HBV clinical serum samples were used as detection samples .The detection performance of magnetic test strip including sensitivity , stability and repeatability was performed .The developed magnetic test strip was compared with commercially ELISA kit of HBV .Comparison results showed that the sensitivity of our test strip was two folds higher than ELISA method .Good stability ( can save half a year in 25 ℃) and reproducibility was assessed for the magnetic test strip .The consistency of these two methods was as high as 97%( n=441 ) .Our study can provide technological sup-port of point of care products for early diagnosis of HBV .

  19. PCR-Based Molecular Diagnosis of Hepatitis Virus (HBV and HDV) in HCV Infected Patients and Their Biochemical Study

    Science.gov (United States)

    Anwar, Muhammad Ayaz; Raheel, Ummar; Badshah, Yasmeen; Akhtar, Hashaam; Tamanna, Kosar; Tahir, Muhammad; Sadaf Zaidi, Najam us Sahar

    2016-01-01

    Seroprevalence of HCV indicates that HCV is found in more than 10% of HBV- or HDV-infected patients worldwide leading to liver disease. Here we show HBV and HDV coinfection association with HCV infected Pakistani patients, study of disease severity, and possible interpretation of associated risk factors in coinfected patients. A total of 730 liver diseased patients were included, out of which 501 were found positive for HCV infection via PCR. 5.1% of patients were coinfected with HBV while 1% were coinfected with HBV and HDV both. LFTs were significantly altered in dually and triply infected patients as compared to single HCV infection. Mean bilirubin, AST, and ALT levels were highest (3.25 mg/dL, 174 IU/L, and 348 IU/L) in patients with triple infection while dual infection LFTs (1.6 mg/dL, 61 IU/L, and 74 IU/L) were not high as in single infection (1.9 mg/dL, 76 IU/L, and 91 IU/L). The most prominent risk factor in case of single (22%) and dual infection (27%) group was “reuse of syringes” while in triple infection it was “intravenous drug users” (60%). It is concluded that HBV and HDV coinfections are strongly associated with HCV infected Pakistani patients and in case of severe liver disease the possibility of double and triple coinfection should be kept in consideration. PMID:27366331

  20. Kinetics of serum HBsAg in Chinese patients with chronic HBV infection with long-term adefovir dipivoxil treatment

    Institute of Scientific and Technical Information of China (English)

    Li Minran; Xi Hongli; Wang Qinhuan; Hou Fengqin; Huo Na; Zhang Xiaxia; Li Fang

    2014-01-01

    Background Knowledge on Hepatitis B surface antigen (HBsAg) kinetics in chronic hepatitis B (CHB) patients with longterm adefovir dipivoxil (ADV) treatment is limited.The aims of this study were to investigate HBsAg kinetics in patients with chronic hepatitis B virus (HBV) infection treated with long-term ADV and to evaluate different characteristics between patients with and without HBsAg loss.Methods We retrospectively evaluated HBsAg kinetics in 24 Chinese patients with chronic HBV infection who achieved continuous virologic suppression during ADV therapy.HBV genotype was determined at baseline.Liver biochemistry,hepatitis B e antigen status,serum HBV DNA,and HBsAg levels were measured at baseline,6 months,and once every year thereafter.Results Of these 24 patients,3,1,and 20 patients were followed up for 3,5,and 6 years,respectively.Baseline serum HBsAg level had a moderate correlation with baseline HBV DNA level (r=0.52,P=0.01).The median rate of HBsAg reduction during the therapy period was 0.08 Ig IU·ml-1·y-1.Baseline serum HBsAg level was significantly higher than other time points (P ranges from 0.046 to 0.002).The HBsAg reduction rate during the first year was similar to that in other years (P>0.05).The HBsAg reduction rate during the first year in patients with eventual HBsAg loss was significantly faster than that in patients without HBsAg loss (P=0.005).Conclusions Serum HBsAg levels in Chinese CHB patients receiving long-term ADV demonstrated a gradual reduction.Patients with eventual HBsAg loss had a significantly faster HBsAg reduction rate during the first year than those without HBsAg loss.

  1. COOH-terminal deletion of HBx gene is a frequent event in HBV-associated hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    Xiao-Hong Liu; Jing Lin; Shu-Hui Zhang; Shun-Min Zhang; Mark A Feitelson; Heng-Jun Gao; Ming-Hua Zhu

    2008-01-01

    AIM:To investigate the hepatitis B virus (HBV) x gene (HBx) state in the tissues of HBV-related hepatocellular carcinoma (HCC) in Chinese patients and whether there were particular HBx mutations.METHODS:HBx gene was amplified and direct sequencing was used in genomic DNA samples from 20HCC and corresponding non-cancerous liver tissues from HBsAg-positive patients.HBV DNA integration and HBx deleted mutation were validated in 45 HCC patients at different stages by Southern blot analysis and polymerase chain reaction methods.RESULTS:The frequencies of HBx point mutations were significantly lower in HCC than their corresponding non-cancerous liver tissues (11/19 vs 18/19,P = 0.019).In contrast,deletions in HBx gene were significantly higher in HCC than their non-cancerous liver tissues (16/19 vs 4/19,P<0.001).The deletion of HBx COOH-terminal was detected in 14 HCC tissues.A specific integration of HBx at 17p13 locus was also found in 8 of 16 HCC,and all of them also exhibited full-length HBx deletions.Integrated or integrated coexistence with replicated pattern was obtained in 45.5% (20145)-56.8% (25145)tumors and 40.9% (18/45)-52.3% (23/45) non-tumor tissues.CONCLUSION:HBx deletion,especially the COOH-terminal deletion of HBx is a frequent event in HBV-associated HCC tissues in China.HBV integration had also taken place in partial HCC tissues.This supporting the hypothesis that deletion and probably integrated forms of the HBx gene may be implicated in liver carcinogenesis.

  2. Association of CMV, HBV, or HCV co-infection with vaccine response in adults with well-controlled HIV infection.

    Science.gov (United States)

    Troy, S B; Rossheim, A E B; Siik, J; Cunningham, T D; Kerry, J A

    2016-05-01

    Even after CD4 count recovery on antiretroviral therapy, HIV infection is associated with decreased response to most vaccines compared to the general population. Chronic infections with viruses such as cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis C virus (HCV), which are more prevalent in HIV-infected populations, have been linked to immune dysfunction and decreased vaccine response in the general population. However, whether co-infection with these other viruses contributes to the decreased vaccine response seen in adults with well-controlled HIV infection is unknown. We conducted a secondary analysis of data and serum from adults with well-controlled HIV infection from an inactivated polio vaccine trial (224 subjects) and a pneumococcal conjugate vaccine study (128 subjects). We evaluated the association of CMV, HBV, or HCV co-infection with post-vaccination antibody levels using both univariate and multivariate analyses, controlling for factors such as age, race, CD4 count, comorbidities, smoking status, and baseline antibody levels. Ninety-three percent, 7%, and 14% of subjects were co-infected with CMV, HBV, and HCV respectively. On both univariate and multivariate analysis, neither CMV nor HCV co-infection were significantly associated with post-vaccination antibody levels to either vaccine. HBV co-infection was significantly associated with post-vaccination antibody concentrations for pneumococcal serotype 7F on univariate analysis and 6A on multivariate analysis, but the association was with higher antibody concentrations. In conclusion, co-infection with CMV, HBV, or HCV does not appear to contribute to the decreased vaccine response seen in adults with well-controlled HIV infection. PMID:26751638

  3. A new multiparameter integrated MELD model for prognosis of HBV-related acute-on-chronic liver failure.

    Science.gov (United States)

    Luo, Yue; Xu, Yun; Li, Mingming; Xie, Ya; Gong, Guozhong

    2016-08-01

    Hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF) is one of the most deadly diseases. Many models have been proposed to evaluate the prognosis of it. However, these models are still controversial. In this study, we aimed to incorporate some characters into model for end-stage liver disease (MELD) to establish a new reliable and feasible model for the prognosis of HBV-ACLF.A total of 530 HBV-ACLF patients who had received antiviral therapy were enrolled into a retrospective study and divided into the training cohort (300) and validation cohort (230). Logistic regression analysis was used to establish a model to predict the 3-month mortality from the patients in the training cohort, and then, the new model was evaluated in the validation cohort.Except for MELD score, 4 other independent factors, namely degree of hepatic encephalopathy (HE), alpha-fetoprotein (AFP), white blood cell (WBC) count, and age, were important for the new model called HBV-ACLF MELD (HAM) model: R = 0.174 × MELD + 1.106 × HE - (0.003 × AFP) + (0.237 × WBC) + (0.103 × Age) - 11.388. The areas under receiver-operating characteristic curve of HAM in the training and validation cohort were 0.894 and 0.868, respectively, which were significantly higher than those of other 7 models. With the best cut-off value of -1.191, HAM achieved higher sensitivity and negative predictive value.We developed a new model that has a great prognostic value of the 3-month mortality of patients with HBV-ACLF. PMID:27559979

  4. Association Between IL-10 Gene Promoter Polymorphisms (-592 A/C, -819 T/C, -1082 A/G) and Susceptibility to HBV Infection in an Iranian Population

    Science.gov (United States)

    Moudi, Bita; Heidari, Zahra; Mahmoudzadeh-Sagheb, Hamidreza; Hashemi, Mohammad; Metanat, Malihe; Khosravi, Soheila; Farrokh, Parisa

    2016-01-01

    Background IL-10 can play a vital role in immune response against HBV. Three biallelic SNPs from the transcription start site control the transcription of the IL-10 gene. An association between susceptibility to HBV and IL-10 polymorphisms has been suggested in patients with HBV infection. Objectives The present study was designed to study the association between polymorphisms in interleukin-10 (-1082 A/G, -819 T/C and -592 A/C) promoter gene and chronic hepatitis B virus (HBV) infection. Patients and Methods 221 chronically infected patients and 200 healthy control subjects were enrolled in the study. Three biallelic (-1082 A/G, -819 T/C and -592 A/C) polymorphisms in the IL-10 promoter gene were determined by PCR-RFLP method. Results Persistent HBV infection was associated with IL-10-1082 AG (P = 0.001) and GG (P = 0.004) genotypes and G (P = 0.000) allele. IL-10-819 T/C and -592 A/C genotype and allele frequencies did not show any correlation with the risk of chronic hepatitis B infection. Conclusions These results suggest that polymorphisms in interleukin-10 gene promoter influence clinical outcome of HBV infection and susceptibility to HBV infection. PMID:27148384

  5. Towards the complete eradication of mother-to-child HIV/HBV coinfection at Saint Camille Medical Centre in Burkina Faso, Africa

    Directory of Open Access Journals (Sweden)

    Denise Ilboudo

    2010-06-01

    Full Text Available The coinfection of HIV and hepatitis B virus (HBV and their vertical transmission constitute a public health problem in sub-Saharan countries of Africa. The objectives of this research are: i identify the pregnant women that are coinfected by HIV and HBV at Saint Camille Medical Centre; ii use three antiretroviral drugs (zidovudine, nevirapine and lamivudine to interrupt the vertical transmission of HIV and HBV from infected mothers; and iii use the PCR technique to diagnose children who are vertically infected by these viruses in order to offer them an early medical assistance. At Saint Camille Medical Centre, 115 pregnant women, aged from 19 to 41 years, were diagnosed as HIV-positive and, among them, 14 coinfected with HBV. They had at least 32 weeks of amenorrhoea and all of them received the HAART, which contained lamivudine. Two to six months after childbirth, the babies underwent PCR diagnosis for HIV and HBV. The results revealed that, among these mothers, 64.4% were housewives, 36.5% were illiterates, and only 1.7% had a university degree. The rate of vertical transmission of HIV and HBV was 0.0% (0/115 and 21.4% (3/14, respectively. The 3 mothers who transmitted the HBV to their children had all HBsAg, HbeAg, and HBV DNA positive. An antiretroviral therapy that in addition to zidovudine and nevirapine includes lamivudine could, as in the present study, block or reduce the vertical transmission in HIV positive pregnant women who are coinfected with HBV.

  6. Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative

    Institute of Scientific and Technical Information of China (English)

    Lei Geng; Bing-Yi Lin; Tian Shen; Hua Guo; Yu-Fu Ye; Shu-Sen Zheng

    2015-01-01

    Anti-virus prophylactic therapy may be not nec-essary for the prevention of hepatitis B virus (HBV) recur-rence after HBV-related liver transplantation (LT). However, studies on completely stopping the hepatitis B immune globu-lin (HBIG) and nucleos(t)ide analogs (NUC) after LT are few. The aim of the current study was to evaluate the safety of anti-virus prophylaxis withdrawal in liver recipients whose serum hepatitis Be antigen (HBeAg) and HBV DNA are negative. We analyzed 190 patients undergone LT for HBV-related liver dis-ease from 2006 to 2012 and found that 10 patients completely stopped the HBIG and NUC due to poor compliance. These patients were liver biopsied and checked monthly with serum HBV markers, HBV DNA and liver function. Among the 10 patients, 9 did not show the signs of HBV recurrence after a mean follow-up of 51.6 months (range 20-73) after with-drawal of the HBIG and NUC. The average time from LT to the withdrawal of the anti-virus drug was 23.8 (13-42) months;one patient showed hepatitis B surface antigen-positive and detectable HBV DNA after stopping anti-virus drugs and this patient was successfully treated with entecavir. Our data sug-gested that complete withdrawal of anti-virus prophylaxis was safe and feasible for patients whose serum HBeAg and HBV DNA were negative at the time of LT.

  7. Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative

    Institute of Scientific and Technical Information of China (English)

    Lei Geng; Bing-Yi Lin; Tian Shen; Hua Guo; Yu-Fu Ye; Shu-Sen Zheng

    2016-01-01

    Anti-virus prophylactic therapy may be not nec-essary for the prevention of hepatitis B virus (HBV) recur-rence after HBV-related liver transplantation (LT). However, studies on completely stopping the hepatitis B immune globu-lin (HBIG) and nucleos(t)ide analogs (NUC) after LT are few. The aim of the current study was to evaluate the safety of anti-virus prophylaxis withdrawal in liver recipients whose serum hepatitis Be antigen (HBeAg) and HBV DNA are negative. We analyzed 190 patients undergone LT for HBV-related liver dis-ease from 2006 to 2012 and found that 10 patients completely stopped the HBIG and NUC due to poor compliance. These patients were liver biopsied and checked monthly with serum HBV markers, HBV DNA and liver function. Among the 10 patients, 9 did not show the signs of HBV recurrence after a mean follow-up of 51.6 months (range 20-73) after with-drawal of the HBIG and NUC. The average time from LT to the withdrawal of the anti-virus drug was 23.8 (13-42) months;one patient showed hepatitis B surface antigen-positive and detectable HBV DNA after stopping anti-virus drugs and this patient was successfully treated with entecavir. Our data sug-gested that complete withdrawal of anti-virus prophylaxis was safe and feasible for patients whose serum HBeAg and HBV DNA were negative at the time of LT.

  8. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule

    Directory of Open Access Journals (Sweden)

    Collard Alix

    2010-10-01

    Full Text Available Abstract Background Combination vaccines improve coverage, compliance and effectively introduce new antigens to mass vaccination programmes. This was a phase III, observer-blind, randomized study of GSK Biologicals diphtheria-tetanus-whole cell pertussis vaccine combined with hepatitis B and Haemophilus influenzae type b vaccines, containing a reduced amount of polyribosyl-ribitol-phosphate (PRP and a DTPw component manufactured at a different site (DTPw-HBV/Hib2.5 [Kft]. The primary aim of this study was to demonstrate that DTPw-HBV/Hib2.5 [Kft] was not inferior to the licensed DTPw-HBV/Hib (Tritanrix(tm-HepB/Hiberix(tm vaccine or the DTPw-HBV/Hib2.5 vaccine, also containing a reduced amount of PRP, with respect to the immune response to the PRP antigen, when administered to healthy infants, according to the Expanded Programme for Immunization (EPI schedule at 6, 10 and 14 weeks of age. Methods 299 healthy infants were randomised to receive either DTPw-HBV/Hib2.5 [Kft] DTPw-HBV/Hib2.5 or DTPw-HBV/Hib according to the 6-10-14 week EPI schedule. Blood samples were analysed prior to the first dose of study vaccine and one month after the third vaccine dose for the analysis of immune responses. Solicited local and general symptoms such as pain, redness and swelling at the injection site and drowsiness and fever, unsolicited symptoms (defined as any additional adverse event and serious adverse events (SAEs were recorded up to 20 weeks of age. Results One month after the third vaccine dose, 100% of subjects receiving DTPw-HBV/Hib2.5 [Kft] or DTPw-HBV/Hib and 98.8% of subjects receiving DTPw-HBV/Hib2.5 vaccine had seroprotective levels of anti-PRP antibodies (defined as anti-PRP antibody concentration ≥0.15 μg/ml. Seroprotective antibody concentrations were attained in over 98.9% of subjects for diphtheria, tetanus and hepatitis B. The vaccine response rate to pertussis antigen was at least 97.8% in each group. Overall, the DTPw-HBV/Hib2.5 [Kft

  9. 河北省HIV-1感染者中HCV和HBV合并感染状况调查%Study on HCV and HBV co-infection among HIV-1 infected people in Hebei Province

    Institute of Scientific and Technical Information of China (English)

    赵翠英; 李巧敏; 赵宏儒; 路新利; 白广义; 李岩; 王莹莹; 王伟

    2012-01-01

    Objective To study the ratios of HCV and HBV co-infection among HIV-1 infected people in Hebei Province. Method Peripheral blood was collected for testing HCV antibody and HBsAg in HIV-1 infected individuals. Results Of the 147 HIV-1 infected individuals receiving blood tests, 17. 7% (26/147) were infected with HCV, 15. 0% (22/147) were infected with HBV,and 3. 4%(5/147) were co-infected with HCV/HBV. The statistical a-nalysis showed a significant difference in the ratios of HCV co-infection among individuals who were infected with HIV through different routes(P<0. 001). The ratios of HCV co-infection were 100. 0%(6/6)in injecting drug users. In those infected via blood transmission and sexual behaviors,the ratios of HCV co-infection were 73. 3%(11/ 15) and 6. 3%(7/lll)respectively. HIV infected females had a higher ratio of HCV co-infection than males (P = 0. 002). Statistically significant difference was found in ratio of HCV co-infection among individuals with various educational backgrounds (P<0. 01). HIV infected individuals with lower education had higher HCV co-infection rati-o. Statistically significant difference was also observed in ratio of HCV co-infection among HIV infected individuals of different ages (P<0. 05). HIV infected individuals of lowe_r age had higher HBV co-infection ratio.' Conclusion There are higher ratios of HCV and HBV co-infection in HIV-1 infected individuals.%目的 了解河北省艾滋病病毒Ⅰ型(HIV-1)感染者中,丙型肝炎病毒(HCV)、乙型肝炎(乙肝)病毒(HBV)的感染状况.方法 采集了HIV-1感染者的抗凝全血样品,进行了HCV抗体和乙肝病毒表面抗原(HBsAg)的检测.结果 147例HIV-1感染者中,HCV感染率为17.7%(26/147),HBV感染率为15.0%(22/147),HCV/HBV混合感染率为3.4%(5/147).在HIV-1感染者中,HCV的感染率在注射吸毒感染者中为100%(6/6),血液途径感染者中为73.3%(11/15),性感染者中为6.3%(7/111),不同感染途径间

  10. PIN1 genetic polymorphisms and the susceptibility of HBV-related hepatocellular carcinoma in a Guangxi population.

    Science.gov (United States)

    Huang, Li; Mo, Zhuning; Lao, Xianjun; Zhang, Xiaolian; Liu, Yanqiong; Sui, Jingzhe; Qin, Xue; Li, Shan

    2016-05-01

    Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (PIN1) plays a critical role in different signaling pathways, cell cycle progression and proliferation, and gene expression, and it has been found to overexpress in many tumor tissues. Recently, researchers have found that PIN1 gene polymorphisms may alter the function of protein and be associated with the risk of cancer. The present study analyzed three common polymorphisms in promoter regions (rs2233678 and rs2233679) and in exon2 (rs2233682) of the PIN1 gene in 254 patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and 235 healthy controls in a Guangxi study population to determine whether any relationship exists between the polymorphisms and the risk of HBV-related HCC. The results revealed that the rs2233679 TT genotype was associated with increased risk of HCC with HBV infection [odds ratio (OR) = 2.04, 95 % confidence interval (95 % CI) = 1.13-3.69, p = 0.019]. This association was stronger in men than in women (OR = 2.17, 95 % CI = 1.09-4.34, p = 0.028) as well as in men 50 years of age and older (OR = 3.91, 95 % CI = 1.29-11.80, p = 0.016); moreover, for alcohol drinkers, being a carrier of the PIN1 rs2233679 CT genotype had a moderately increased risk of HCC (OR = 3.98, 95 % CI = 1.02-15.57, p = 0.047). In contrast, people carrying the rs2233682 GA genotype and A alleles were 0.23 times more likely to develop HCC (OR = 0.23, 95 % CI = 0.06-0.87, p = 0.031 and OR = 0.23, 95 % CI = 0.06-0.87, p = 0.030). No such associations were found in the PIN1 rs2233678 polymorphisms between the HBV-related HCC cases and the controls. In addition, the haplotype GCA was found to be a high protection factor for HCC with HBV infection (OR = 0.14, 95 % CI = 0.03-0.62, p = 0.003). In conclusion, this study's findings suggest that the PIN1 rs2233679 TT genotype, the rs2233682GA genotype, and A alleles

  11. DETECTTON OF HVB DNA IN MONONUCLEAR CELLS IN PERIPHERAL BLOOD OF HEPATITIS B PATIENTS BY PCR ASSAY%PCR法检测慢性乙肝患者外周血单个核细胞中HBV-DNA

    Institute of Scientific and Technical Information of China (English)

    黄敦武; 武英; 刘碧坚

    2002-01-01

    目的:了解慢性乙型肝炎患者外周血单个核细胞(PBMCa)HBV的感染情况及其与血清HBV的关系.方法:采用聚合酶链反应(PCR)检测55例慢性乙型肝炎患者PBMCs和血清中HBV.结果:PBMCs HBV-DNA检出率为69%(38例/55例).血清HBV-DNA检出率为36%(20例/55例),PBMCs HBV-DNA与血清HBV-DNA无一致性,P<0.05,PCR法检测慢性乙型肝炎患者HBV-DNA、PBMCs检出率优于血清检出率,P<0.05.结论:在慢性乙型肝炎患者中,PBMCs存在HBV-DNA.

  12. Simultaneous detection of HBV-DNA concentration and its melting temperature by improved fluorescent quantitative PCR%改良荧光定量PCR同步检测HBV-DNA含量及其熔解温度

    Institute of Scientific and Technical Information of China (English)

    赵友云; 高应林; 王春香; 乐惠荣

    2007-01-01

    目的 通过改进荧光定量聚合酶链反应(FQ-PCR)的单荧光标记,建立灵敏、特异的HBV-DNA含量及其熔解温度(Tm)的同步检测方法.方法 根据荧光标记物质的不同,将FQ-PCR分为TaqMan+SYBR Green I双标记(T+S组)、TaqMan探针单标记(T组)和SYBR Green I染料单标记(S组)三种,同时检测HBV-DNA已知浓度为108.48、105.70、103.70和<1×103.00(copies/ml)的血清中HBV-DNA含量及Tm,每组FQ-PCR检测每份血清时1次做5个平行管.结果 T+S组检测的HBV-DNA阳性血清均为阳性,其平均含量为108.55±0.32、105.79±0.29、103.81±0.30,与T组的108.49±0.31、105.69±0.30、103.72±0.25copies/ml对应浓度值取10对数比较,无统计学意义(t=0.31、0.54和0.27,P>0.05);与S组的108.41±0.35、105.21±0.34和103.26±0.26 copies/ml(不含未检出的两次血清)比较,除高浓度外,中低浓度有统计学意义(t=2.90和2.62,P<0.05).T+S组和S组阳性血清均出现明显熔解曲线,Tm分别为71.8℃、72℃和79.8℃,阴性血清未出现扩增曲线和Tm值.T+S组、T组和S组的灵敏度分别为102.70、102.70和103.00copies/ml.结论 改良的SYBR Green I和TaqMan探针双标记的FQ-PCR检测HBV-DNA时,兼有TaqMan探针标记FQ-PCR的灵敏度高、特异性强和SYBR Green I标记FQ-PCR的Tm分析的优点,能达到同步检测HBV-DNA含量及其Tm的目的 ,为HBV-DNA含量及其多态性分析,尤其是为HBV-DNA含量及其基因分型同步检测提供了新思路.

  13. Test

    DEFF Research Database (Denmark)

    Bendixen, Carsten

    2014-01-01

    Bidrag med en kortfattet, introducerende, perspektiverende og begrebsafklarende fremstilling af begrebet test i det pædagogiske univers.......Bidrag med en kortfattet, introducerende, perspektiverende og begrebsafklarende fremstilling af begrebet test i det pædagogiske univers....

  14. Coinfecciones por HBV y HCV en pacientes HIV positivos en la "era HAART": nuevos desafíos Hbv and hcv co-infections in hiv positive patients in the "HAART era": new challenges

    Directory of Open Access Journals (Sweden)

    Natalia L. Laufer

    2007-02-01

    Full Text Available Las coinfecciones con virus de la hepatitis C (HCV y/o virus de la hepatitis B (HBV en pacientes infectados por el virus de la inmunodeficiencia humana (HIV son un hallazgo frecuente en virtud de las similares vías de transmisión que estos agentes presentan (sexual, parenteral y vertical. Desde el advenimiento del tratamiento antirretroviral de alta eficiencia (TARV se evidenció una marcada disminución en la morbi-mortalidad de los pacientes; sin embargo, ante la prolongación de su sobrevida, las complicaciones crónicas debidas a las coinfecciones con estos virus hepatotropos han cobrado importancia, convirtiéndose la enfermedad hepática en una de las primeras causas de morbi-mortalidad de los pacientes HIV positivos en los países desarrollados. Se disponen en la actualidad de nuevas terapias y métodos de diagnóstico y seguimiento para HBV y HCV, lo cual permite un mejor control de ambas coinfecciones.Co-infections with HIV and HCV/HBV are frequently found due to the similar routes of transmission (sexual, parenteral and vertical. Since the introduction of highly active antiretroviral therapy (HAART there has been a notably decrease in patients morbidity and mortality, nevertheless with the prolonged survival, many of these patients are at risk of developing chronic complication, secondary to the infection of hepatotropic viruses. End stage liver disease is one of the main causes of morbid-mortality among HIV patients in developed countries. Nowadays there are new available therapies, diagnostic and follow up techniques for HBV and HCV, what provides a better control of both co-infections.

  15. The ``Nordic`` HBV model. Description and documentation of the model version developed for the project Climate Change and Energy Production

    Energy Technology Data Exchange (ETDEWEB)

    Saelthun, N.R.

    1996-12-31

    The model described in this report is a version of the HBV model developed for the project Climate Change and Energy Production. This was a Nordic project aimed at evaluating the impacts of the Scandinavian countries including Greenland with emphasis on hydropower production. The model incorporates many of the features found in individual versions of the HBV model in use in the Nordic countries, and some new ones. It has catchment subdivision in altitude intervals, a simple vegetation parametrization including interception, temperature based evapotranspiration calculation, lake evaporation, lake routing, glacier mass balance simulation, special functions for climate change simulations etc. The user interface is very basic, and the model is primarily intended for research and educational purposes. Commercial versions of the model should be used for operational implementations. 5 refs., 4 figs., 1 tab.

  16. Selection of affinity-improved neutralizing human scFv against HBV PreS1 from CDR3 VH/VL mutant library.

    Science.gov (United States)

    Chen, YanMin; Bai, Yin; Guo, XiaoChen; Wang, WenFei; Zheng, Qi; Wang, FuXiang; Sun, Dejun; Li, DeShan; Ren, GuiPing; Yin, JieChao

    2016-07-01

    A CDR3 mutant library was constructed from a previously isolated anti-HBV neutralizing Homo sapiens scFv-31 template by random mutant primers PCR. Then the library was displayed on the inner membrane surface in Escherichia coli periplasmic space. Seven scFv clones were isolated from the mutant library through three rounds of screening by flow cytometry. Competition ELISA assay indicates that isolated scFv fragments show more efficient binding ability to HBV PreS1 compared with parental scFv-31. HBV neutralization assay indicated that two clones (scFv-3 and 59) show higher neutralizing activity by blocking the HBV infection to Chang liver cells. Our method provides a new strategy for rapid screening of mutant antibody library for affinity-enhanced scFv clones and the neutralizing scFvs obtained from this study provide a potential alternative of Hepatitis B immune globulin.

  17. Selection of affinity-improved neutralizing human scFv against HBV PreS1 from CDR3 VH/VL mutant library.

    Science.gov (United States)

    Chen, YanMin; Bai, Yin; Guo, XiaoChen; Wang, WenFei; Zheng, Qi; Wang, FuXiang; Sun, Dejun; Li, DeShan; Ren, GuiPing; Yin, JieChao

    2016-07-01

    A CDR3 mutant library was constructed from a previously isolated anti-HBV neutralizing Homo sapiens scFv-31 template by random mutant primers PCR. Then the library was displayed on the inner membrane surface in Escherichia coli periplasmic space. Seven scFv clones were isolated from the mutant library through three rounds of screening by flow cytometry. Competition ELISA assay indicates that isolated scFv fragments show more efficient binding ability to HBV PreS1 compared with parental scFv-31. HBV neutralization assay indicated that two clones (scFv-3 and 59) show higher neutralizing activity by blocking the HBV infection to Chang liver cells. Our method provides a new strategy for rapid screening of mutant antibody library for affinity-enhanced scFv clones and the neutralizing scFvs obtained from this study provide a potential alternative of Hepatitis B immune globulin. PMID:27255707

  18. The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation.

    Science.gov (United States)

    Sun, Hai-Hua; Zhou, Dong-Fang; Zhou, Jun-Ying

    2016-01-01

    Chronic hepatitis B virus (HBV) infection is the result of an inadequate immune response towards the virus. Dendritic cells (DCs), as the most efficient professional antigen-presenting cells (APCs), possess the strongest antigen presenting the effect in the body and can stimulate the initial T cell activation and proliferation. DCs of patients with chronic HBV infection are impaired, resulting in more tolerogenic rather than immunogenic responses, which may contribute to viral persistence. Recently, numerous methods have been developed to induce DCs maturation. To date, recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) combined with interleukin-4 (rhIL-4) has been a classic culture combination to DCs. The recently classified type III interferon group interferon-λ (IFN-λ) displays antiviral, antitumor, and immunoregulatory activity. In our laboratory, we demonstrate that IFN-λ1 combined with rhGM-CSF and rhIL-4 can significantly increase the expression of DC surface molecules and the secretion of interleukin-12 (IL-12) and interferon-γ (IFN-γ) in patients with chronic hepatitis B infection. In this review, we emphasize on the role of DCs in the immunopathogenesis of chronic HBV infection. Importantly, we systematic review that the latest update in the current status of knowledge on the methods of inducing DCs maturation in anti-HBV immunity. What's more, we conclude that IFN-λ1 combined with GM-CSF and IL-4 can induce DCs maturation, which could become a possibility to be applied to the autologus dendritic cell vaccine to treat chronic hepatitis B. PMID:26104380

  19. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: A national multicenter study

    OpenAIRE

    Asare Isaac; Adu-Gyamfi Clement; Boamah Isaac; Ampofo William K; Gbagbo Foster; Armah Henry B; Adjei Andrew A; Hesse Ian FA; Mensah George

    2008-01-01

    Abstract Background Prisons are known to be high-risk environments for the spread of bloodborne and sexually transmitted infections. Prison officers are considered to have an intermittent exposure potential to bloodborne infectious diseases on the job, however there has been no studies on the prevalence of these infections in prison officers in Ghana. Methods A national multicenter cross-sectional study was undertaken on correlates of human immunodeficiency virus (HIV), hepatitis B virus (HBV...

  20. Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling, docking and dynamics simulation studies

    OpenAIRE

    Li, Jing; Du, Yun; Liu, Xian; Shen, Qian-cheng; Huang, Ai-Long; Zheng, Ming-Yue; Luo, Xiao-Min; Jiang, Hua-liang

    2012-01-01

    Aim: To investigate the molecular mechanisms underlying the influence of DNA polymerase from different genotypes of hepatitis B virus (HBV) on the binding affinity of adefovir (ADV). Methods: Computational approaches, including homology modeling, docking, MD simulation and MM/PBSA free energy analyses were used. Results: Sequence analyses revealed that residue 238 near the binding pocket was not only a polymorphic site but also a genotype-specific site (His238 in genotype B; Asn238 in genotyp...

  1. Occult HBV infection status among chronic hepatitis C and hemodialysis patients in Northeastern Egypt: regional and national overview

    Directory of Open Access Journals (Sweden)

    Mohamed Mandour

    2015-06-01

    Full Text Available INTRODUCTION: Occult hepatitis B infection (OBI is considered to be one of the major risks for patients suffering from end-stage renal disease (ESRD on regular hemodialysis (HD and patients with chronic hepatitis C virus (HCV infection. This study compared the prevalence of OBI among these two high-risk groups in the Suez Canal region, Northeastern Egypt, to obtain a better national overview of the magnitude of OBI in this region. METHODS: Serum samples were collected from 165 HD patients and 210 chronic HCV-infected patients. Anti-HCV antibody, hepatitis B surface antigen (HBsAg, total hepatitis B core (anti-HBc antibody, and hepatitis B surface antibody (anti-HBs were detected by enzyme-linked immunosorbent assay (ELISA. HCV RNA was detected using a quantitative real-time RT-PCR assay, and HBV was detected using a nested PCR. RESULTS: All patients were negative for HBsAg. A total of 49.1% and 25.2% of the patients in the HD and HCV groups, respectively, were anti-HBc-positive. In addition, more anti-HBs-positive patients were detected in the HD group compared to the HCV group (52.1% and 11.4%, respectively. Three cases were positive for HBV DNA in the HD group, while eighteen positive cases were detected in the HCV group. Both study groups showed significant differences in serum alanine aminotransferase (ALT and aspartate aminotransferase (AST level as well as anti-HBc, anti-HBs and HBV-DNA positivity. CONCLUSIONS: OBI was more prevalent among chronic HCV patients than HD patients in the Suez Canal region, Egypt, with rates of 8.5% and 1.8%, respectively. However, more precise assessment of this infection requires regular patient follow-up using HBV DNA detection methods.

  2. Therapeutic potential of peripheral blood stem cell transplantation in one cirrhotic patient caused by HBV combined with HCV

    OpenAIRE

    Fan, Daiming; Han, Huohong; Han, Ying; He, Yuang-long; Liu, Jingmei; Wang, Jianhong; Yan, Li; Zhou, Xinmin

    2008-01-01

    Stem cell based therapy was very attractive in decompensated liver cirrhosis currently. The possible mechanism might be due to its potential to help tissue regeneration with minimally invasive procedures. Here we report the case of a 44-year-old man, infected by hepatitis B virus (HBV) combined with hepatitis C virus (HCV) for longer than 10 years, who eventually developed decompensated liver cirrhosis. After being infused with mobilized peripheral blood stem cells, the patient showed signifi...

  3. Influence of supplementary immunization activities for adults dynamics of chronic disease HBV-infection and its outcomes

    Directory of Open Access Journals (Sweden)

    S. V. Baramzina

    2014-01-01

    Full Text Available Purpose: to evaluate the effect of additional vaccination of adult HBV- infection years 2007–2010 on the incidence of chronic hepatitis B and its outcomes on the example of the Kirov region.Materials and Methods: the evaluation of epidemiological features process in patients with chronic HBV infection in adults, depending on the vaccination carried out on the basis of official data Rospotrebnadzora in Russia and Kirov region on incidence of infectious disease for the period 1999–2012. Diagnosis of chronic hepatitis B was based on clinical and biochemical, instrumental, virological data. Structure outcomes of chronic hepatitis B was studied in 295 patients aged 18–75 years who were hospitalized in the department of viral hepatitis Kirov infectious diseases hospital in 2006–2010.Results: In the Kirov region tended to decrease the incidence of chronic hepatitis B in adults. Additional adult vaccination against hepatitis B has not led to the expected significant decrease of the number of patients with chronic forms. One reason for this is the low (20,3–64% of the adult population immunization coverage. Chronic HBV- monoinfected was observed in 17.1% , cirrhosis in the outcome of chronic hepatitis B in 5,4% of cases, in hospital mortality from complications of HBV- cirrhosis was 0,7%. Association virus C and D have increased the total cohort, compared to a mono- infection by 3,8% and 0,5% lethality.Conclusion: Additional adult vaccination against hepatitis B in the area has led to a slight decrease in the overall incidence of chronic hepatitis B, but has not reduced the incidence of adverse events – cirrhosis and liver- mediated lethality.

  4. Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection.

    Science.gov (United States)

    Li, Ling; Hann, Hie-Won; Wan, Shaogui; Hann, Richard S; Wang, Chun; Lai, Yinzhi; Ye, Xishan; Evans, Alison; Myers, Ronald E; Ye, Zhong; Li, Bingshan; Xing, Jinliang; Yang, Hushan

    2016-01-01

    Recent studies have demonstrated a potential link between circulating cell-free mitochondrial DNA (mtDNA) content and cancers. However, there is no study evaluating the association between circulating mtDNA as a non-invasive marker of hepatocellular carcinoma (HCC) risk. We conducted a nested case-control study to determine circulating mtDNA content in serum samples from 116 HBV-related HCC cases and 232 frequency-matched cancer-free HBV controls, and evaluate the retrospective association between mtDNA content and HCC risk using logistic regression and their temporal relationship using a mixed effects model. HCC cases had significantly lower circulating mtDNA content than controls (1.06 versus 2.47, P = 1.7 × 10(-5)). Compared to HBV patients with higher mtDNA content, those with lower mtDNA content had a significantly increased risk of HCC with an odds ratio (OR) of 2.19 (95% confidence interval [CI] 1.28-3.72, P = 0.004). Quartile analyses revealed a significant dose-dependent effect (Ptrend = 0.001) for this association. In a pilot longitudinal sub-cohort of 14 matched cases-control pairs, we observed a trend of dramatically decreased mtDNA content in cases and slightly decreased mtDNA content in controls, with a significant interaction of case-control status with time (Pinteraction = 0.049). Our findings suggest that circulating mtDNA is a potential novel non-invasive biomarker of HCC risk in HBV patients. PMID:27063412

  5. Modeling and simulating dynamics of anti-HBV infection combination therapy%抗HBV感染组合治疗动力学建模及模拟

    Institute of Scientific and Technical Information of China (English)

    陈晓; 闵乐泉; 郑宇; 叶永安

    2012-01-01

    Evidences show that Traditional Chinese Medicines(TCM) plus Nucleoside Analogues(NA) anti-Hepatitis B Virus(HBV) infection therapy may not only suppress chronic HBV patients' serum HBV DNA level but also regulate patients' specific immune functions, which clear HBV directly and almost do not damage patients' hepato-cytes. This paper introduces a differential equation model with five state variables to describe the dynamics of TCM+NA anti-HBV infection therapy. It has been proved that if a basic virus reproductive number Ro < 1, then the infection free solution is globally attractive. This result suggests that if an anti-virus infection therapy makes an HBV infected patient' s i?0 < 1, then the patient will eventually recover even if the patient' s serum HBV DNA has very high level. As an application, this model is used to simulate the dynamics of TCM+NA anti-HBV infection personalized combination therapy. Numerical simulations and analysis suggest that the TCM+NA combination therapies are able to activate patients' abilities of cytokine-mediated noncytolytic HBV clearance.%证据显示,传统中药(TCM)加核苷类似物(NA)抗乙型肝炎病毒(HBV)感染治疗可能不仅压制患者血清HBV DNA水平,而且还能激活患者的特殊免疫功能直接清除HBV而几乎不损伤患者的肝细胞.提出一个具有5个变量的微分方程模型来描述TCM+NA抗HBV感染治疗动力学.证明当新模型的基本病毒复制数R0<1时,病毒清除平衡点全局吸引.这意指如果抗病毒感染治疗使得患者的R0<1,则即使患者的血清HBVDNA水平非常高也将最终痊愈.作为应用,运用新模型模拟TCM+NA抗HBV感染个性化组合治疗的动力学.数值模拟和分析说明TCM+NA组合治疗能够激活病人细胞因子介导的非细胞毒性HBV清除能力.

  6. 慢性乙型肝炎患者血清HBV DNA与e抗原含量的关系

    Institute of Scientific and Technical Information of China (English)

    马兰

    2010-01-01

    目的 探讨慢性乙型肝炎(简称乙肝)患者血清乙肝病毒脱氧核糖核酸(HBV DNA)含量与e抗生素原含量的关系.方法 采用定量聚合酶链反应(PCR)和美国Abbott微粒子酶免疫荧光法(MEIA)检测330例慢性乙肝患者血清HBV DNA含量和乙肝病毒标志物(HBV-M)含量.结果 乙肝e抗原(HBeAg)(+)/乙肝e抗体(抗-HBe)(-)血清180例,HBV DNA平均含量为(6.23±2.51)copy/mL,HBeAg平均含量为(1 311.8±1 035.2)peiu/mL;HBeAg(+)/抗-HBe(+)血清62例,HBV DNA平均含量为(5.06±1.32)copy/mL,HBeAg平均含量为(5.2±2.1)peiu/mL;HBeAg(-)/抗-HBe(+)血清88例,HBV DNA平均含量为(4.18±1.14)copy/mL,HBeAg平均含量为(0.02±0.01)peiu/mL.任意两组间比较,差异均有统计学意义.轻度慢性乙肝患者血清160例,HBVDNA平均含量为(6.41±2.32)copy/mL;中度慢性乙肝患者血清138例,HBV DNA平均含量为(5.32±1.44)cop-y/mL;重度慢性乙肝血清32例,HBV DNA平均含量为(4.24±1.12)copy/mL.轻、重度组间差异均有统计学意义.结论 血清HBeAg阳性组HBV DNA含量明显高于e系统双阳性组及e抗原阴性组(P<0.05),HBV DNA含量与HBeAg含量具有相关性.慢性乙肝随病变程度的加重,HBV DNA平均拷贝数下降.

  7. DNA聚合酶链反应血清直接法测定HBV DNA

    Institute of Scientific and Technical Information of China (English)

    陈渊卿; 严根宝; 等

    1990-01-01

    应用pADR1-HBc区的一对DNA引物,A和B(A:459-482,B:1039=1061),首次建立了微量血清DNA聚合酶链反应(polymerase chain,reaction PCR)直接法,用常规琼脂糖凝胶电泳HBV一DNA。经双盲法测定182份血清HVB DNA,同时以HBVDNA标准样品(PBR322-HBV DNA)为模板,模拟血清直接法进行PCR测定。结果表明,该方法灵敏可靠,受检血清中仅含10fgHBVDNA时即可检出,较正向和逆向HBVDNA斑点杂交试验检测的灵敏度至少高100倍。本方法毋须从血清中提DNA,反应后仅需作常规的DNA琼脂糖电泳,观察619bpHBVDNA特异区带,以判定其结果。从而简化了方法,提高了检测的灵敏度,为推广临床应用,奠定了基础。

  8. Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection

    Institute of Scientific and Technical Information of China (English)

    Kazumoto Murata; Kazushi Sugimoto; Katsuya Shiraki; Takeshi Nakano

    2005-01-01

    AIM: To determine the predictive factors forhepatocellular carcinoma (HCC) development in patientsafter spontaneous or therapeutic HBeAg seroconversion.METHODS: In 48 patients who seroconverted to anti-HBe positive during follow-up, the background factors forHCC development were analyzed.RESULTS: HCC was developed in six patients duringfollow-up (average follow-up after HBeAg seroconversion:10.9±5.4 years). The incidence of HCC evaluated byKaplan-Meier analysis was significantly higher in patientswith abnormal aspartate aminotransferase (AST>40 IU/L) level, lower platelet counts (PLT<10×104/μL),lower albumin level (Alb<30 g/L), positive HBV-DNA or older age at seroconversion (>40 years). However, lower platelet count was the only predictive factor for HCC development shown by multivariate proportional-hazard analysis.CONCLUSION: Active hepatitis or advanced hepatitis at HBeAg seroconversion or progressive hepatitis even after HBeAg seroconversion would be the risk factors for HCC development. These predictive factors should be taken into account in determining the frequency of biochemical study or imaging studies for HCC surveillance.

  9. HBV X PROTEIN (HBX) INTERACTS WITH GENERAL TRANSCRIPTION FACTOR TFIIB BOTH IN VITRO AND IN VIVO

    Institute of Scientific and Technical Information of China (English)

    1999-01-01

    Objective.In order to demonstrate the binding of HBV X protein (HBX) with the general transcription factor TFIIB.Methods.In vitro glutathion S-transferase (GST)resin Pull-Down assay and Far-Western Blotting assay, in vivo Co-immunoprecipition assay were used.Results.The X199(51-99)domain of HBX is reponsible for HBX binding to TFIIB.While the d10 domain (125-295)of TFIIB is required for TFIIB binding to HBX.When the two basic amino acids(K) at position 178 and 189 of TFIIB were substituted by neutral amino acids(L),the binding of TFIIBK178L and K189L to HBX was siginificantly reduced. When the the basic amino acids were substituted by the acidic amino acids(E),the binding of TFIIB K178E and K189E to HBX were almost lost.In vitro results of HBX binding to TFIIB were further confirmed by in vivo co-immunoprecipitation assay.Our results also indicated that the Woodchuck hepatitis virus X protein (WHX)interacts with TFIIB.Conclusion.These results suggested that the communication between HBX and general transcription factor TFIIB is one of the mechanisms which account for its transcriptional transactivation.

  10. The correlation study of HBV serological index in neonate's venus, cord blood and mother's venus blood%新生儿静脉血与脐带血及孕妇静脉血HBV病原学标记物相关性研究

    Institute of Scientific and Technical Information of China (English)

    易为; 张禄雪; 胡玉红; 李明慧; 郝红晓; 王士俊; 姜秀娟; 张书凤; 宋淑静

    2013-01-01

    Objective In this study,we discussed the consistency and correlation of HBV serological indexes between neonates' venous blood and cord blood whose mothers had chronical HBV infection,as well as the correlation of thoses indexes with the mothers'.Method Chronically HBV infected mothers who were postive of both HBsAg and HBeAg and also had a HBV DNA virus load above 105copies/ml and their infants were enrolled.The mothers' venous blood were collected before delivery.The neonates' cord blood were collected at birth after removal of contaminants and disinfected with alcohol on the cord's surface,and the venous blood were collected before hepatitis B virus immune globin(HBIG) and hepatitis B vaccine were given.The levels of HBsAg,anti-HBs,HBeAg and anti-HBeAg were tested with Abbott microparticle chemiluminescence method (Abbott Laboratories,Abbott Architac i2000).HBV DNA quantification were tested by COBAS TagMan real-time PCR Assay.Results 383 mothers and their infants were enrolled.The positive rates of HBsAg in cord blood and venous blood were 61.2% and 63.9%.The positive rates of HBeAg level in cord blood and venous blood were 83.2% and 83.5%.The positive rates of HBV DNA level in cord blood and venous blood were 56.0% and 59.4%.The state of HBsAg,HBeAg and HBV DNA in cord blood and venous blood were consistency,and significant correlation was observed in their levels with correlation coefficients of 0.766,0.857,and 0.692,respectively (P < 0.000).Significant correlation of the HBeAg levels were observed between mothers' venous blood and neonates' venous blood,as well as neonates' cord blood with correlation coefficients of 0.362 and 0.352 (P < 0.000).However,there was no significant correlation of HBsAg levels between them (r =0.023,P =0.785 ; r =0.04,P =0.604).Conclusions The HBV serological index of neonate's cord blood could reflect the HBV serological indexes in venous blood because of the good correlation and consistency between them.%目的

  11. Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study

    International Nuclear Information System (INIS)

    There has been limited study on the effect of infection with different hepatitis C virus (HCV) genotypes on the risk of hepatocellular carcinoma (HCC) in hepatitis B virus (HBV) endemic regions of Asia. Hazard ratios of HCC development were estimated for HBV and HCV co-infected subjects among a community-based prospective cohort. HCV genotype was determined in HCV RNA-positive samples. Incident HCC cases were identified through linkage to the cancer registry. HCC incidence was 79 per 100,000 person-years in the study population (50 incident cases among 6,694 individuals within 63,170 person-years with an average of 9.4 years of follow-up); seroprevalence of HBsAg and anti-HCV was 5.2% and 5.6%. Adjusted hazard ratios of HCC by HBsAg positivity and anti-HCV positivity were 13.3 (CI: 7.3-24.4) and 6.7 (CI: 3.6-12.6). HRs of HBV and HCV monoinfection, and HBV/HCV coinfection were 17.1 (CI: 8.4-34.8), 10.4 (CI: 4.9-22.1) and 115.0 (CI: 32.5-407.3). Multiplicative synergistic effect of HBV/HCV coinfection on HCC risk was also observed (synergy index: 4.5, CI: 1.3-15.5). Infection with HCV genotype 1 (HR: 29.7, CI: 13.6-46.8) and mixed infection with genotype 1 and 2 (HR: 68.7, CI: 16.4-288.4) significantly elevated HCC risk, much higher than HBV infection. The effect of differences in HCV genotype and the multiplicative synergistic effect of HBV/HCV coinfection on HCC risk shown in the present study underline the need for comprehensive identification of hepatitis infection status in order to prevent and control HCC in this HBV endemic area

  12. Combining serum cystatin C with total bilirubin improves short-term mortality prediction in patients with HBV-related acute-on-chronic liver failure.

    Directory of Open Access Journals (Sweden)

    Zhihong Wan

    Full Text Available BACKGROUND & AIMS: HBV-related acute-on-chronic liver failure (HBV-ACLF is a severe liver disease which results in a high mortality in China. To early predict the prognosis of the patients may prevent the complications and improve the survival. This study was aimed to develop a new prognostic index to estimate the survival related to HBV-ACLF. METHODS: Consecutive patients with HBV-ACLF were included in a prospective observational study. Serum Cystatin C concentrations were measured by using the particle-enhanced immunonephelometry assay. All of the patients were followed for at least 3 months. Cox regression analysis was carried out to identify which factors were predictive of mortality. The area under the receiver operating characteristic curve (AUC was used to evaluate the efficacy of the variates for early predicting mortality. RESULTS: Seventy-two patients with HBV-ACLF were recruited between January 2012 and January 2013. Thirty patients died (41.7% during 3-months followed up. Cox multivariate regression analysis identified serum cystatin C (CysC and total bilirubin (TBil were independent factors significantly (P < 0.01 associated with survival. Our results further showed that new prognostic index (PI combining serum CysC with TBil was a good indicator for predicting the mortality of patients with HBV-ACLF. Specifically, the PI had a higher accuracy than the CTP, MELD, or MELD-Na scoring for early prediction short-term survival of HBV-ACLF patients with normal levels of serum creatinine (Cr. The survival rate in low risk group (PI < 3.91 was 94.3%, which was markedly higher than those in the high-risk group (PI ≥ 3.91 (17.4%, P < 0.001. CONCLUSION: We developed a new prognostic index combining serum CysC with TBil which early predicted the short-term mortality of HBV-ACLF patients.

  13. Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(tide resistance in treatment-naive patients with Chronic Hepatitis B in Central China

    Directory of Open Access Journals (Sweden)

    Youyun Zhao

    2016-04-01

    Full Text Available Abstract Objective There are a lot of disagreements in the studies on hepatitis B virus (HBV DNA polymerase mutation rate associated with nucleos(tide analogues (NAs in treatment-naive chronic hepatitis B (CHB patients. This is the first study aimed to investigate the prevalence of spontaneous HBV resistance mutations in Central China. Methods This study included treatment-naive patients with CHB from June 2012 to May 2015 receiving care at the Institute of Liver Disease in Central China. All patients completed a questionnaire covering different aspects, such as family medical history, course of liver disease, medication history, alcohol use, among others. Mutations in HBV DNA polymerase associated with NAs resistance were detected using INNO-LiPA assay. Results 269 patients were infected with HBV genotype B (81.4%, C (17.9%, and both B and C (0.7%. Mutations in HBV DNA polymerase were detected in 24 patients (8.9% including rtM204I/V (n = 6, rtN236T (n = 5, rtM250V (n = 2, rtL180M (n = 2, rtT184G (n = 1, rtM207I (n = 1, rtS202I (n = 1, rtM204V/I & rtL180M (n = 5, and rtM204I & rtM250V (n = 1. Conclusion Spontaneous HBV resistance mutations in HBV DNA polymerase were found in treatment-naive patients with CHB in Central China. These findings suggest that we should analyze HBV DNA polymerase resistance mutation associated with NAs before giving antiviral therapy such as lamivudine (LAM, adefovir (ADV, and telbivudine (LdT.

  14. Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling,docking and dynamics simulation studies

    Institute of Scientific and Technical Information of China (English)

    Jing LI; Yun DU; Xian LIU; Qian-cheng SHEN; Ai-long HUANG; Ming-yue ZHENG; Xiao-min LUO; Hua-liang JIANG

    2013-01-01

    Aim: To investigate the molecular mechanisms underlying the influence of DNA polymerase from different genotypes of hepatitis B virus (HBV) on the binding affinity of adefovir (ADV).Methods: Computational approaches,including homology modeling,docking,MD simulation and MM/PBSA free energy analyses were used.Results: Sequence analyses revealed that residue 238 near the binding pocket was not only a polymorphic site but also a genotypespecific site (His238 in genotype B; Asn238 in genotype C).The calculated binding free-energy supported the hypothesis that the polymerase from HBV genotype C was more sensitive to ADV than that from genotype B.By using MD simulation trajectory analysis,binding free energy decomposition and alanine scanning,some energy variation in the residues around the binding pocket was observed.Both the alanine mutations at residues 236 and 238 led to an increase of the energy difference between genotypes C and B (△△Gc-B),suggesting that these residues contributed to the genotype-associated antiviral variability with regard to the interaction with ADV.Conclusion: The results support the hypothesis that the HBV genotype C polymerase is more sensitive to ADV than that from genotype B.Moreover,residue N236 and the polymorphic site 238 play important roles in contributing to the higher sensitivity of genotype C over B in the interaction with ADV.

  15. A unique seroepidemiological pattern of HBV, HCV and HTLV-I in Nenets and Komi in northwestern Russia.

    Science.gov (United States)

    Dobrodeeva, Liliya K; Kornienko, Elena B; Petrenya, Nataliya N; Lutfalieva, Gulnara T; Schegoleva, Lyubov S; Demeneva, Ludmila V; Duberman, Boris L; Tkachev, Anatolij V; Chiba, Hitoshi; Senoo, Haruki; Ito, Keiko; Mizoguchi, Emi; Yoshida, Shigeru; Tajima, Kazuo

    2005-01-01

    An epidemiological study of hepatitis viruses type B (HBV) and type C (HCV) and human T-cell leukemia virus type I (HTLV-I) was carried out among 105 residents (male:female=19:86) regarded as Nenets partly mixed with Komi, in the region of Krasnoe, the Nenets Autonomous District of the Arkhangelsk Region, in northwestern Russia in 2004. Blood was drawn from apparently healthy volunteers at ages of 41.6+/-16.5 (range 14-85) years. HBsAg, HBsAb, HBcAb, HBeAb and HCV Ab were measured by microparticle enzyme-immunoassay, and HTLV-I Ab was measured by particle agglutination. Prevalences of HBsAg(+), HBsAb(+), HBcAb(+) and HBeAb(+) were 0.0%, 29.5.%, 20.0% and 7.6%, respectively. The overall HBV infection rate (positive HBsAb or HBcAb) was 34.3%, while no positive HCV or HTLV-I Abs could be detected. A serological subgroup with positive HBsAb and negative HBcAb, consisting of 15(14.3%) females, contrasted sharply to other serological subgroups in sex, age, parent's ethnicity, positive HBeAb rate, and HBcAb inhibition%. We conclude that HBV is prevalent with unique serological patterns among the Nenets, while HCV and HTLV-I infections are negligible.

  16. Pokemon siRNA Delivery Mediated by RGD-Modified HBV Core Protein Suppressed the Growth of Hepatocellular Carcinoma.

    Science.gov (United States)

    Kong, Jing; Liu, Xiaoping; Jia, Jianbo; Wu, Jinsheng; Wu, Ning; Chen, Jun; Fang, Fang

    2015-10-01

    Hepatocellular carcinoma (HCC) is a deadly human malignant tumor that is among the most common cancers in the world, especially in Asia. Hepatitis B virus (HBV) infection has been well established as a high risk factor for hepatic malignance. Studies have shown that Pokemon is a master oncogene for HCC growth, suggesting it as an ideal therapeutic target. However, efficient delivery system is still lacking for Pokemon targeting treatment. In this study, we used core proteins of HBV, which is modified with RGD peptides, to construct a biomimetic vector for the delivery of Pokemon siRNAs (namely, RGD-HBc-Pokemon siRNA). Quantitative PCR and Western blot assays revealed that RGD-HBc-Pokemon siRNA possessed the highest efficiency of Pokemon suppression in HCC cells. In vitro experiments further indicated that RGD-HBc-Pokemon-siRNA exerted a higher tumor suppressor activity on HCC cell lines, evidenced by reduced proliferation and attenuated invasiveness, than Pokemon-siRNA or RGD-HBc alone. Finally, animal studies demonstrated that RGD-HBc-Pokemon siRNA suppressed the growth of HCC xenografts in mice by a greater extent than Pokemon-siRNA or RGD-HBc alone. Based on the above results, Pokemon siRNA delivery mediated by RGD-modified HBV core protein was shown to be an effective strategy of HCC gene therapy. PMID:26356810

  17. The recombined cccDNA produced using minicircle technology mimicked HBV genome in structure and function closely.

    Science.gov (United States)

    Guo, Xiaoyan; Chen, Ping; Hou, Xiaohu; Xu, Wenjuan; Wang, Dan; Wang, Tian-Yan; Zhang, Liping; Zheng, Gang; Gao, Zhi-Liang; He, Cheng-Yi; Zhou, Boping; Chen, Zhi-Ying

    2016-01-01

    HBV covalently closed circular DNA (cccDNA) is drug-resistant and responsible for viral persistence. To facilitate the development of anti-cccDNA drugs, we developed a minicircle DNA vector (MC)-based technology to produce large quantity of recombined cccDNA (rcccDNA) resembling closely to its wild-type counterpart both in structure and function. The rcccDNA differed to the wild-type cccDNA (wtcccDNA) only in that it carried an extra 36-bp DNA recombinant product attR upstream of the preC/C gene. Using a procedure similar to standard plasmid production, milligrams of rcccDNA can be generated in common laboratories conveniently. The rcccDNA demonstrated many essential biological features of wtcccDNA, including: (1) undergoing nucleation upon nucleus entry; (2) serving as template for production of all HBV RNAs and proteins; (3) deriving virions capable of infecting tree shrew, and subsequently producing viral mRNAs, proteins, rcccDNA and infectious virions. As an example to develop anti-cccDNA drugs, we used the Crispr/Cas9 system to provide clear-cut evidence that rcccDNA was cleaved by this DNA editing tool in vitro. In summary, we have developed a convenient technology to produce large quantity of rcccDNA as a surrogate of wtcccDNA for investigating HBV biology and developing treatment to eradicate this most wide-spreading virus. PMID:27174254

  18. Protective immune barrier against hepatitis B is needed in individuals born before infant HBV vaccination program in China.

    Science.gov (United States)

    Yang, Shigui; Yu, Chengbo; Chen, Ping; Deng, Min; Cao, Qing; Li, Yiping; Ren, Jingjing; Xu, Kaijin; Yao, Jun; Xie, Tiansheng; Wang, Chencheng; Cui, Yuanxia; Ding, Cheng; Tian, Guo; Wang, Bing; Zhang, Xiaoyan; Ruan, Bing; Li, Lanjuan

    2015-01-01

    The hepatitis B prevalence rate in adults is still at a high to intermediate level in China. Our purpose was to explore the incidence rate and protective immune barrier against hepatitis B in adults in China. A sample of 317961 participants was multi-screened for hepatitis B surface antigens (HBsAg) in a large-scale cohort of the National Hepatitis B Demonstration Project. A total of 5401 persons were newly-infected, representing an incidence rate of 0.81 (95% CI: 0.77-0.85) per 100 person-years after adjusted by gender and age. History of acquired immune deficiency syndrome, birth prior to 1992, coastal residence, family history of HBV, and migrant worker status were significantly associated with higher incidence, while HBV vaccination and greater exercise with lower incidence. The hepatitis B surface antibody (HBsAb) positive rate was negatively correlated with the incidence rate of hepatitis B (r = -0.826). Linear fitting yielded an incidence rate of 1.23 plus 0.02 multiplied by HBsAb positive rate. The study firstly identified the HBsAg incidence rate, which was reduced to 0.1 per 100 person-years after vaccination coverage of about 64%. The protective immune barrier against hepatitis B needs to be established in individuals born prior to the advent of infant HBV vaccination. PMID:26655735

  19. Comparison of the influence of different nucleic acid extraction methods on HBV DNA detection using quantitative fluorescence-PCR%不同核酸提取方法在HBV DNA荧光定量检测中的比较

    Institute of Scientific and Technical Information of China (English)

    李成德; 黄晓佳; 陈雄毅

    2010-01-01

    目的 研究不同核酸提取方法在HBV DNA荧光定量检测中的提取效率、重复性、抗干扰性及对扩增试剂的兼容能力.方法 运用两种具有不同启动温度的Taq酶的扩增试剂分别扩增经一步法、煮沸法和磁珠法提取HBV DNA强阳性血清的模板,比较不同提取方法对扩增试剂的兼容能力.采用3种方法提取3份HBV DNA含量不同的标本各10次,进行扩增,比较不同方法的提取效率和重复性;对HBV DNA阳性标本用HBV DNA阴性的黄疸血清和溶血液进行10倍稀释后分别用前述方法提取进行干扰试验.结果 3种提取方法中,磁珠法和煮沸法提取的模板对两种扩增试剂具有良好的兼容性;重复性比较以一步法最佳,磁珠法次之,煮沸法较差;提取效率比较以磁珠法最理想,一步法次之,煮沸法最差;对黄疸和溶血的抗干扰能力以磁珠法最佳,溶血对煮沸法有一定影响,在无5-羧基-X-罗丹明(5-ROX)校正的情况下,黄疸对一步法影响较大,有5-ROX校正系统分析则可以消除这种影响.结论 磁珠法具有良好的重复性和提取效率,对黄疸和溶血有较强抗干扰能力,对扩增试剂的兼容性好,是一种理想的核酸提取方法;相对而言,一步法快捷且重复性更佳.

  20. Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24

    Directory of Open Access Journals (Sweden)

    Hsu Chao Wei

    2012-12-01

    Full Text Available Abstract Background The aims of this study were to compare results from a Taiwanese sub-study of the GLOBE 2303 telbivudine study and evaluate the HBV DNA kinetics. Methods Forty-one Taiwanese patients were treated for an additional 2 years with telbivudine. Efficacy endpoints were the same as the GLOBE study. The correlations of reductions in HBV DNA levels at Week 24 were evaluated. Results All 7 HBeAg-positive patients with undetectable HBV DNA levels at Week 24 sustained this response at Year 4 with rates of ALT normalization 71%, HBeAg seroconversion 57%, and cumulative resistance 0%. Out of 16 HBeAg-negative patients with undetectable HBV DNA levels at Week 24, 11 (78% sustained this response at Year 4 with rates of ALT normalization 83% and cumulative resistance 8.7%. There were significant correlations between reductions of DNA of ≥5 log10 copies/mL at Week 24 with maintained PCR negativity at Years 2–4 and a lack of resistance at Year 2. Conclusions Long-term telbivudine efficacy in Taiwanese patients was comparable to the GLOBE 2303 study. A reduction in HBV DNA levels by ≥5 log10 copies/mL at Week 24 represented the optimal cut-off point, which may predict favourable outcomes in patients with high baseline HBV DNA levels. Trial registration ClinicalTrials.gov Identifier: NCT00142298 (http://clinicaltrials.gov/.

  1. Study on the risk factors related vertical transmission of HBV positive couples to their infant%父母双方乙型肝炎病毒感染垂直传播的危险因素研究

    Institute of Scientific and Technical Information of China (English)

    张荣莲; 王梅颖; 陈起燕; 修晓燕; 任坤海; 邱丽茵; 黄欣欣

    2012-01-01

    Objective To explore the risk factors and the rate of HBV vertical transmission from HBsAg-positive couple to their infant.Methods 46 families who had antenatal examination at Fujian Provincial Maternal and Child Health Hospital during August 2010 and November 2011 were chosen as research object.Cord blood was sampled after delivery for HBVM and HBV-DNA quantification.Those with HBV-DNA load ≥5 × 102 copies/ml were involved in the case group while those having <5 × 102 copies/ml were chosen as controls.Results The average positive rate of neonatal cord blood HBV-DNA was 45.7% (21/46),while the positive rates of cord blood HBsAg and HBeAg were 34.8%(16/46) and 23.9% (11/46) respectively.The positive rates of maternal serum HBV-DNA and paternal serum HBV-DNA were 52.2% (24/46) and 69.6% (32/46) respectively,with the positive rate of couple serum HBeAg as 39.1% (18/46) and 32.6%(15/46) respectively.Results from univariate analysis showed that hepatitis B surface markers,serum HBeAg-positive,serum HBV-DNA positive,and serum HBV-DNA load of the couples were risk factors to the HBV vertical transmission(x2=8.731,8.414,8.932,9.663,10.823,3.962,13.638,36.501 ;P<0.05).Data from the multivariate analysis showed that maternal serum HBV-DNA positive and paternal serum HBV-DNA load were risk factors to the HBV vertical transmission [OR= 17.6 (1.3-238.4) ;OR = 3.5 (1.6-7.6)].Serum HBV-DNA loads of the couples were positively correlated with the cord blood HBV-DNA load,while the load levels of the couple' s serum HBV-DNA were higher than cord blood HBV-DNA.There appeared dose-response relationship between couple' s serum HBV-DNA load level and the cord blood HBV-DNA load level.Results from the analysis of ROC curve showed that both maternal serum HBV-DNA load level (103 copies/ml) and paternal serum HBV-DNA load level (104 copies/ml) were demarcation points to better forecast the occurrence of vertical transmission of HBV,because there showed higher

  2. 不同程度慢性乙型肝炎血脂与HBV DNA关系研究%Relationship between blood lipid levels and HBV-DNA in patients with different stages of chronic hepatitis B

    Institute of Scientific and Technical Information of China (English)

    颜华东; 高国生; 祝成亮; 盛吉芳

    2013-01-01

    目的 探讨慢性乙型肝炎患者不同血脂指标的表达水平及其与病情轻重和HBV DNA的关系.方法 收集2011年1月至2012年10月宁波市第二医院142例慢性乙型病毒性肝炎患者以及44名健康献血员血清,检测总胆固醇(TCHO)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A1(ApoAl)、载脂蛋白B(ApoB)、载脂蛋白E(ApoE)、脂蛋白a及HBV DNA,对检测结果进行统计学分析.结果 不同病情及不同HBVDNA栽量慢性乙型肝炎患者ApoE水平均显著高于正常对照组(P均<0.05);而其他各血脂指标均低于正常对照组(P均<0.05).ApoE含量与病情轻重呈正相关,而T-CHO、HDL-C、ApoA1则呈负相关.HDL-C、ApoA1含量与HBV DNA载量呈正相关,而T-CHO、LDL-C、ApoB、ApoE则呈负相关.结论 慢性乙型肝炎患者血脂水平受肝脏合成功能以及HBV本身等多种因素的影响.%Objective To investigate the correlations of dislipidemia with disease stages and HBV-DNA in patients with chronic hepatitis B (CHB). Methods Serum samples were collected from 142 CHB patients and 44 healthy controls at Ningbo Second Hospital from January 2011 to October 2012, and the levels of TCHO, HDL-C, LDL-C, ApoAl, ApoB, ApoE, lipo and HBV-DNA were detected. The detected data were statistically analyzed. Results Regardless of disease stages and viral loads, the serum ApoE level was higher in CHB patients than that in the healthy controls ( P < 0. 05 ) , while the levels of other indicators were lower (P < 0. 05 ). The serum ApoE concentration was correlated positively with disease progression, but the levels of T-CHO, HDL-C, and ApoAl were correlated negatively with disease stages. The serum ApoAl concentration was correlated positively with HBV-DNA,but the levels of T-CHO,LDL-C, ApoB and ApoE were correlated negatively with the viral loads. Conclusion Dislipidemia is affected multiple factors such as liver synthesis function and HBV-DNA in CHB

  3. 肝细胞癌患者石蜡包埋肝组织HBV ccc DNA的检测%Detection of HBV ccc DNA in FFPE liver tissues of patients with hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    胡双烨; 苏何玲; 侯俊; 钟彦伟; 徐晨; 赵雨来; 李智彬; 徐东平; 刘永明; 杨媛; 赵景民; 成军

    2013-01-01

    目的 检测肝细胞癌患者肝组织中乙型肝炎病毒共价闭合环状DNA(HBV ccc DNA),探讨其在肝细胞癌发生、发展中的意义.方法 选取20例肝细胞癌患者的癌及癌旁组织,经10%福尔马林固定、石蜡包埋、连续切片,采用0.05%多聚赖氨酸进行处理.经不降解质粒的ATP依赖的DNA酶(PSAD酶)消化后,应用原位滚环扩增(in situ RCA)结合原位跨缺口PCR扩增技术检测肝组织中ccc DNA的表达.结果 20例肝癌患者标本中有17例检测到HBV ccc DNA阳性信号,为蓝色或紫蓝色并呈团块状,定位于细胞核.肝癌患者癌及癌旁组织HBV ccc DNA阳性率分别为10%(2/20)和85%(17/20),差异具有显著统计学意义(P < 0.01).结论 肝细胞癌患者癌旁组织病毒复制水平高于癌组织.%Objective To detect the intrahepatic covalently closed circular DNA (ccc DNA) in patients with HBV-related hepatocellular carcinoma (HCC) and to investigate its significance in progression of HCC. Methods The paired tumor and adjacent non-tumor tissues of 20 cases with HCC were selected, respectively. The samples were fixed by 10% formaldehyde, paraffin imbedded and treated with 0.05% poly-L-Lysine. The liver tissue sections were treated by plasmid-safe ATP-dependent DNase (PSAD) and the expression of intrahepatic ccc DNA was detected by in situ rolling circle amplification (RCA) combined with in situ polymerase chain reaction (PCR) targeting the gap region. Results HBV ccc DNA was expressed in 17 of 20 subjects and located in the nuclear compartment with clustering, staining blue or blue-violet. The positive rate of HBV ccc DNA in HCC and their adjacent tissues were 10% (2/20) and 85% (17/20), respectively, with significant difference (P < 0.01). Conclusion The level of HBV replication in the tumor-adjacent tissues was higher than that of the tumor tissues of patients with HCC.

  4. Interleukin-22 as a molecular adjuvant facilitates IL-17-producing CD8+ T cell responses against a HBV DNA vaccine in mice.

    Science.gov (United States)

    Wu, Bing; Zou, Qiang; Hu, Yanxin; Wang, Bin

    2013-10-01

    Interleukin-22 (IL-22) is mainly produced by activated Th1 cells, Th17 cells and NK cells and promotes anti-microbial defense, pro-inflammatory and tissue remodeling responses. However, its potential use as a vaccine adjuvant has not been tested. In this study, we tested if a DNA construct expressing IL-22 (pVAX-IL-22) could be used as a molecular adjuvant to enhance host immune responses induced by HBV DNA vaccination (pcD-S2). After immunizing mice with pcD-S2 combined with pVAX-IL-22, we didn't find enhancement of HBsAg-specific antibody responses in comparison to mice immunized with pcD-S2 alone. However, there was an enhancement of the level of IL-17 expression in antigen specific CD8(+) cytotoxic T lymphocytes (Tc17). By using CD8 T-cell knockout (KO) and IL-17 KO mice, Tc17 cells were found to be a dominant population driving cytotoxicity. Importantly, there was a correlation between pVAX-IL-22 enhancement of T lymphocytes and a reduction of HBsAg-positive hepatocytes in HBsAg transgenic mice. These results demonstrate that IL-22 might be used as an effective adjuvant to enhance cellular immune responses during HBsAg DNA vaccination since it can induce Tc17 cells to break tolerance in HBsAg transgenic mice. PMID:23941891

  5. Relationship between the monocyte proportion in peripheral blood and the extent of liver lesion in patients infected with HBV

    Directory of Open Access Journals (Sweden)

    Da-gang WANG

    2012-08-01

    Full Text Available Objective To discuss the relationship between the monocyte proportion in peripheral blood and the extent of liver lesions in HBV patients. Methods The clinical data of HBV patients, which were definitely diagnosed from 2010 to 2011 in our hospital, were studied, including 197 cases with mild or moderate hepatitis (hepatitis group and 248 cases of cirrhosis (cirrhosis group. The data of 269 healthy people concurrently coming for physical examination served as control (control group. The peripheral blood were analyzed by Sysmex XE-2100 hematology analyzer. The real-time PCR was employed to quantitatively detect the HBV DNA in serum; ELISA was performed to determine the liver fibrosis indicators, including hyaluronic acid (HA, laminin (LN, type Ⅳcollegen (IV. C and type Ⅲprecollegen (PCⅢ. Liver biopsy was done in 390 patients, and the extents of liver inflammation (G0-G4 and hepatic fibrosis (S0-S4 were evaluated according to the “Program of Viral Hepatitis Prevention and Control”issued by Chinese Medical Association in 2000. Results The peripheral blood analysis revealed that the monocyte proportion were significantly higher in hepatitis group and cirrhosis group (8.93%±3.05% and 9.85%±3.61% than in control group (8.16%±1.88%, P < 0.01, and also in cirrhosis group than in hepatitis group (P < 0.01. The result of real-time PCR showed that the monocyte proportion was significantly higher in 239 patients with HBV DNA≥100U/ml (8.61%±2.83% than that in the 206 patients with HBV DNA < 100U/ml (8.12%±2.53%, P < 0.05. The ELISA results indicated that the levels of liver fibrosis indicators (HA, LN, IV.C, PCⅢ were significantly higher in cirrhosis group than in hepatitis group, and moreover, in the same group the higher of those indicators, the higher of monocyte proportion. The results of liver biopsy in 390 patients showed that the monocyte proportion significantly elevated along with aggravation of liver inflammation and fibrosis (P

  6. HBV BCP区1762/1764和1896突变位点检测新技术研究%The Study on Mutation Locus Detection Technology of the HBV BCP Double Muta-tions with 1762/1764 and Precore Mutation with 1896

    Institute of Scientific and Technical Information of China (English)

    王泽; 唐景峰

    2014-01-01

    Objective:To establish a new method( MAMA-PCR)for the detection of mutations at 1762/1764 and 1896 in the BCP region and precore region of HBV using mismatch amplification and Fluorescent PCR and to evaluate this method with clinical samples. Method:a)Evaluate the parameters of the MAMA-PCR mutation detection method:to analyze the stability of reagents by reactions with three repeats using the wild-type and mutant reference as a template;to test the detection efficiency of the HBV hybrid infection using mutant and wild-type references with different mixing ratio. b)Compare the MAMA-PCR method with sequencing and commercialized mutation detection kits and evaluate the MAMA-PCR method. Results:Three tests of MAMA-PCR had good repeatability with a CV value of less than 5% and HBV infection samples which contained 1% mutation could be stably detected. In 132 HBV samples,sequencing meth-od identified 67 with 1762/1764 mutations,mutation detection kit identified 69,and MAMA-PCR identified 69. The detection rates were 50. 8%,52. 3%,and 52. 3%,respectively. Sequencing method identified 39 samples with 1896 mutation,mutation detection kit identified 41,and MAMA-PCR identified 42. The detection rates were 29. 5%, 31. 1%,and 31. 8%,respectively. Conclusions:The MAMA-PCR method is very stable. The mutation detection rate of MAMA-PCR is almost the same as commercialized kits,and is higher than sequencing. This new technology( MAMA-PCR)can be used in the fast detection of HBV BCP 1762/1764 double mutations and precore 1896 mutation in clinical samples.%目的:利用错配扩增和荧光PCR原理,建立一种针对HBV BCP区1762/1764和前C区1896突变位点的新型检测方法---错配扩增突变分析PCR法( MAMA-PCR),并对该方法进行临床评价。方法:a)MAMA-PCR突变检测方法性能评估:以野生和突变性阳性参考品作为模板检测3次,分析该方法稳定性;将突变型和野生型质控品梯度比例混合,分析该方法

  7. Relationship Between HBV-DNA and Pre S1 Antigen in Patients with HBsAg, Anti-HBe and Anti-HBc Positive Hepatitis B%乙型肝炎“小三阳”患者HBV-DNA定量检测与前S1抗原的关系

    Institute of Scientific and Technical Information of China (English)

    石万元; 阚秉辉; 刘克芹; 尹卫东

    2013-01-01

    目的 探讨“小三阳”患者HBV-DNA含量与前S1抗原的关系.方法 收集乙型肝炎“小三阳”患者血清152例,用ELISA方法检测前S1抗原,用实时荧光定量PCR(FQ-PCR)方法检测HBV-DNA.结果 前S1与HBV-DNA同时阳性者74例,二者同时阴性者34例,符合率为71.1%.前S1阳性、HBV-DNA阴性者为30例,HBV-DNA阳性而前S1阴性者为14例.即“小三阳”患者中前S1的检出率为68.4%,HBV-DNA的检出率为57.9%,并且拷贝数高低有差别.结论 “小三阳”患者体内也存在着不同程度的病毒复制.前S1的检测不能代替HBV-DNA,只能作为其补充指标.对于“小三阳”患者,同时检测HBV-DNA定量有助于判断病毒在体内是否复制.%Objective To investigate the relationship between HBV-DNA with pre S1 antigen in patients with HBsAg,Anti-HBe and Anti-HBc positive hepatitis B.Methods The serum express of pre S1 antigen and HBV-DNA in 152 patients with HBsAg,Anti-HBe and Anti-HBc positive hepatitis B were detected by ELISA and PCR(FQ-PCR) respectively.Results 74 cases of samples were both pre S1 and HBV-DNA positive,while 34 cases were found Pre S1 and HBV-DNA negative.The positive coincidence rate between Pre S1 and HBV-DNA was 71.1%.There were 30 cases with pre S1 positive and HBV-DNA negative,while 14 cases had HBV-DNA positive and pre S1 negative.The detection rate of pre S1 and HBV-DNA in patients with HBsAg,Anti-HBe and Anti-HBc positive hepatitis B were 68.4% and 57.9%,respectively.Conclusion There are virus replications of different degrees in patients with HBsAg,Anti-HBe and Anti-HBc positive hepatitis B.The detection of Pre S1 can not replace HBV-DNA detection,and it could be only used as a supplementary index.The HBV-DNA quantitative detection could facilitate to judge whether virus in-vivo replicate or not.

  8. THE DETECTION OF ANTI-HBs,ANTI-HBc,AND HBV-DNA OF 2 274 BLOOD DONORS WITH HBsAg NEGATIVE%2 274名HBsAg阴性献血员抗-HBs、抗-HBc、HBV-DNA检测结果分析

    Institute of Scientific and Technical Information of China (English)

    许顺姬

    2007-01-01

    [目的]检测2 274名HBsAg阴性献血员血清抗-HBs、抗-HBc、HBV-DNA,探讨献血员筛查中检测抗-HBs、抗-HBc的必要性.[方法]对2 274名HBsAg阴性献血员血清ELISA法检测抗-HBs、抗-HBc,用PCR法检测HBV-DNA.[结果]检测者2 274名中①抗-HBs阳性/抗-HBc阴性59.3%,HBV-DNA阳性率0.2%;②抗-HBs阴性/抗-HBc阴性17.4%,HBV-DNA阳性率0.3%;③抗-HBs阴性/抗-HBc阳性1.4%,HBV-DNA阳性率6.3%:④抗HBs阳性/抗-HBc阳性21.9%,HBV-DNA阳性率0.2%.[结论]抗-HBs阴性/抗-HBc阳性群体中HBV-DNA阳性率最高(6.3%),提示献血员筛查中检测抗-HBs、抗-HBc,可以降低通过输血途径的感染率.

  9. Construction of exogenous multiple epitopes of helper T lymphocytes and DNA immunization of its chimeric plasmid with HBV pre-S2/S gene

    Institute of Scientific and Technical Information of China (English)

    Wen-Jun Gao; Xiao-Mou Peng; Dong-Ying Xie; Qi-Feng Xie; Zhi-Liang Gao; Ji-Lu Yao

    2004-01-01

    AIM: To design and construct an exogenous multiple epitope of helper T lymphocytes (HTL), and to evaluate its effect on anti-HBs response through DNA immunization.METHODS: Artificial HTL epitope, PADRE and four other HTL epitopes from different proteins were linked together using splicing by overlap extension to generate exogenous multiple epitopes of HTL, MTE5. pcMTE5 and pcHB weregenerated by cloning MTE5 and fragments of HBV pre-S2/S gene into mammalian expression plasmid pcDNA3. Four chimeric plasmids were constructed by cloning MTE5 into the region of pre-S2 gene (Bam HI), 5′ terminal of S gene (HincⅡ, Xba Ⅰ) and 3′ terminal of S gene (Acc Ⅰ) of pcHB respectively. BALB/c mice were used in DNA immunization of the recombinant plasmids. Anti-HBs was detected using Abbott IMx AUSAB test kits.RESULTS: The sequences of MTE5 and the 6 constructs of recombinant plasmids were confirmed to be correct by DNA sequencing. The anti-HBs response of the coinoculation of pcHB and pcMTE5 was much higher than that of the inoculation of pcHB only (136.7±69.1 mIU/mL vs 27.6±17.3 mIU/mL, P<0.01, t = -6.56). Among the 4 chimeric plasmids, only the plasmid in which MTE5 was inserted into the pre-S2 region had good anti-HBs response (57.54±7.68 mIU/mL), and had no significant difference compared with those of pcHB and the co-inoculation of pcHB and pcMTE5.CONCLUSION: Exogenous multiple epitopes of HTL had immune enhancement when they were co-inoculated with pre-S2/S gene or inoculated in the chimeric form at a proper site of pre-S2/S gene of HBV. It might suggest that it was possible to improve hepatitis B vaccine using exogenous multiple epitopes of HTL. The antibody responses were very low using DNA immunization in the study. Thus, the immune enhancement effect of exogenous multiple epitopes of HTL has to be confirmed and the effect on overcoming the drawback of the polymorphism of HLA Ⅱ antigens should also be evaluated after these chimeric plasmids are expressed

  10. Incidence of HBV, HCV and syphilis co-infections among 194 HIV-infected pregnant women%194例HIV阳性孕妇HBV HCV及梅毒合并感染状况分析

    Institute of Scientific and Technical Information of China (English)

    于兰; 桂秀枝; 蒙秀宁; 班子淇; 鲁鸿艳; 李文英; 张福杰

    2011-01-01

    目的 了解广西艾滋病病毒(HIV)阳性孕妇合并感染乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)、梅毒状况,为医疗部门及相关部门采取有效的措施,实施母婴阻断、提高人口素质提供科学的依据.方法 对广西贺州、柳州、南宁和横县发现的194名HIV阳性孕妇的HBV、HCV及梅毒合并感染状况进行检测分析.结果 在调查的194名HIV阳性孕妇中,HIV/HCV、HIV/HBV和HIV/梅毒合并感染率分别为14.14%、9.42%和5.24%.2.62%和1.05%的妇女分别有HIV/HBV/HCV和HIV/HCV/梅毒混合感染,吸毒是HIV/HCV合并感染的危险因素,HIV/HBV合并感染存在地区差异.结论 研究地区HIV阳性孕妇的HBV、HCV及梅毒感染率显著高于普通孕妇,应早期发现并采取有效的干预措施以预防母婴垂直传播.%Objective To learn about the incidence of HBV, HCV and syphilis co-infections among pregnant women infected with HIV in Guangxi so as to provide scientific evidences for adopting effective interventions to interrupt MTCT and improve quality of the population. Methods The data collected from 194 HIV positive pregnant women in Hezhou, Liuzhou and Nanning cities and Heng county of Guangxi were analyzed. Results Among the 194 HIV-infected pregnant women, the co-infection rates of HIV/HCV, HIV/HBV and HIV/syphilis were 14. 14%, 9. 42% and 5. 24% , respectively; 2. 62% and 1. 05% of the women had co-infections of HIV/HBV/HCV and HIV/ HCV/ syphilis, respectively. Drug use was the risk factor for HIV/HCV co-infection and the co-infection of HIV/ HCB had regional variations. Conclusion The incidence of HBV, HCV and syphilis co-infections in HIV-infected pregnant women are obviously higher than in general pregnant women in the areas under study. It is urgent to detect HIV positive pregnant women at an early stage and take effective interventions for the prevention of vertical mother to child transmission.

  11. 实时定量RT-PCR对乙型肝炎病毒全长RNA(fRNA)的定量检测%Validation of a Simple Real-time RT-PCR for Detection and Quantization of HBV fRNA

    Institute of Scientific and Technical Information of China (English)

    张佳瑞; 巩丽; 朱少君; 韩秀娟; 姚丽; 王姝妹; 李艳红; 张伟

    2015-01-01

    Objective:To establish a simple assay for the detection and quantization of full-length RNA (fRNA) terminating at polyadenilation site in sera of chronic hepatitis B (CHB) patients.Methods:fRNA were assayed via TaqMan real-time RT/PCR using anchored oligo-dT primers in sera of 53 treatment-naive CHB patients and 22 HBsAg-negative healthy controls.Results were analyzed by comparation ofHBV DNA with HBcrAg and HBeAg.Results:The fRNA assay had a lower limit of detection and quantization at 2.3 log copies/ml,and a correlation coefficient of 0.99 (P<0.0001).fRNA was detected in 29 of 53 (54.7%) of the CHB patients as compared to non of 22 controls (Specificity).fRNA was detected in all 27 HBeAg-positive and/or high HBV DNA levels CHB patients as compared to 2 of 26 (7.7%) HBeAg-negative and low HBV DNA levels CHB patients (P<0.0001).fRNA levels were higher in HBeAg-positive than in HBeAg-negative samples (5.0± 0.3 vs.2.9± 0.4 log copies/ml,P<0.001).Significant correlation was found between fRNA and HBV DNA/HBcrAg (r=0.905 and 0.881,respectively,P<0.0001).The effective items on fRNA levels,in descending order,were:HBV DNA,HBcrAg by means of Hayashi's quantification method type Ⅰ (Multiple correlation efficient=0.939).Conclusion:The simple real-time RT/PCR for detection and quantization of fRNA was suitable for routine clinical test in assessing HBV replication status the same as HBV DNA and HBeAg in CHB patients.%目的:建立一种简便的定量检测慢性乙型肝炎患者血清中终止于聚腺苷酸化位点的乙型肝炎病毒全长RNA(fRNA)的方法.方法:选取53例未治疗的乙型肝炎患者及22例HBsAg阴性的健康者为研究对象,使用锚定oligo-dT的引物对其血清中fRNA进行实时定量反转录PCR检测,统计分析其与HBV DNA、HBcrAg和HBeAg的相关性.结果:对fRNA进行实时荧光定量RT-PCR检测的下线为2.3 log copies/ml,标准曲线的相关系数为0.99(P<0.0001).53例乙型肝炎患者中,29例(54.7

  12. Tissue donation and virus safety: more nucleic acid amplification testing is needed.

    Science.gov (United States)

    Pruss, A; Caspari, G; Krüger, D H; Blümel, J; Nübling, C M; Gürtler, L; Gerlich, W H

    2010-10-01

    In tissue and organ transplantation, it is of great importance to avoid the transmission of blood-borne viruses to the recipient. While serologic testing for anti-human immunodeficiency virus (HIV)-1 and -2, anti-hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), anti-hepatitis B core antigen (HBc), and Treponema pallidum infection is mandatory, there is until now in most countries no explicit demand for nucleic acid amplification testing (NAT) to detect HIV, hepatitis B virus (HBV), and HCV infection. After a review of reports in the literature on viral transmission events, tissue-specific issues, and manufacturing and inactivation procedures, we evaluated the significance of HIV, HCV, and HBV detection using NAT  in  donors of various types of tissues and compared our results with the experiences of blood banking organizations. There is a significant risk of HIV, HCV, and HBV transmission by musculoskeletal tissues because of their high blood content and the high donor-recipient ratio. If no effective virus inactivation procedure for musculoskeletal tissue is applied, donors should be screened using NAT  for  HIV, HCV, and HBV. Serologically screened cardiovascular tissue carries a very low risk of HIV, HCV, or HBV transmission. Nevertheless, because effective virus inactivation is impossible (retention of tissue morphology) and the donor-recipient ratio may be as high as 1:10, we concluded that NAT  should be performed for HIV, HCV, and HBV as an additional safety measure. Although cornea allografts carry the lowest risk of transmitting HIV, HCV, and HBV  owing to corneal physiology, morphology, and the epidemiology of corneal diseases, NAT  for  HCV should still be performed. If the NAT  screening of a donor for HIV, HCV, and HBV is negative, quarantine storage of the donor tissue seems dispensable. In view of numerous synergistic effects with transfusion medicine, it would be advantageous for tissue banks to cooperate with blood

  13. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life

    Directory of Open Access Journals (Sweden)

    Van Der Meeren Olivier

    2010-01-01

    Full Text Available Abstract Background Few studies have assessed long term persisting immunity against hepatitis B virus (HBV in children vaccinated during infancy with combined vaccines containing recombinant HBV surface antigen (HBs. We assessed antibody persistence and immune memory in children 4-5 years of age, previously vaccinated with four doses of combined hexavalent DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™. Methods Immune memory was assessed in 301 children through administration of a challenge dose of monovalent HBV vaccine. Results At 4-5 years of age, 85.3% of subjects had persisting anti-HBs antibody concentrations ≥ 10 mIU/mL, rising to 98.6% after the HBV challenge dose. All but 12 subjects (95.8% achieved post-challenge anti-HBs concentrations ≥ 100 mIU/mL. The post-challenge anti-HBs GMC rose by 100-fold compared to pre-challenge concentrations. An anamnestic response to the HBV vaccine challenge was observed in 96.8% of subjects, including 17/21 (81.0% of children with initially undetectable antibodies ( Conclusion The combined DTPa-HBV-IPV/Hib vaccine induced lasting immune memory against hepatitis B. Long term protection afforded by DTPa-HBV-IPV/Hib is likely to be similar to that observed following priming with monovalent HBV vaccines. Trial registration http://www.clinicaltrials.gov 106789 NCT00411697

  14. PRODUCTION IN PICHIA PASTORIS AND CHARACTERIZATION OF GENETIC ENGINEERED CHIMERIC HBV/HEV VIRUS-LIKE PARTICLES

    Institute of Scientific and Technical Information of China (English)

    Hong-zhao Li; Hong-ying Gang; Qiang-ming Sun; Xiao Liu; Yan-bing Ma; Mao-sheng Sun; Chang-bai Dai

    2004-01-01

    Objective To investigate the presentation of a neutralization epitope-containing peptide antigen of hepatitis E virus (HEV)on chimeric virus-like particles (VLPs) of hepatitis B surface antigen (HBsAg).Methods The gene fragment corresponding to amino acids (aa) 551-607 (HEnAg) of HEV capsid protein, which contains the only neutralization epitope identified to date, was fused via a synthetic glycine linker in frame with the gene of HBsAg.The resulted fusion gene was then integrated through transformation into the genome of Pichiapastoris under the control of a methanol-induced alcohol oxidase 1 (A OX 1) promoter and expressed intracellularly. The expression products in the soluble cell extracts were characterized by Western blot, ELISA, CsCl density gradient analysis, and electron microscopic visualization.Results The novel fusion protein incorporating HBsAg and the neutralization epitope-containing HEnAg was expressed successfully in Pichiapastoris with an expected molecular weight of approximately 32 kD. It was found to possess the ability to assemble into chimeric HBV/HEV VLPs with immunological, physical and morphological characteristics akin to HBsAg particles. Not only did the chimeric VLPs show high activity levels in a HBsAg particle-specific ELISA but they were also strongly immunoreactive with hepatitis E (HE) positive human serum in a HEV specific ELISA, indicating that HEnAg peptide fragments were exposed on VLP surfaces and would be expected to be readily accessible by cells and molecules of the immune system. Similarity between chimeric VLPs to highly immunogenic HBsAg particles may confer good immunogenicity on surface-displayed HEnAg.Conclusion The chimeric HBV/HEV VLPs produced in this study may have potential to be a recombinant HBV/HEV bivalent vaccine candidate.

  15. Risk of Severe Acute Exacerbation of Chronic HBV Infection Cancer Patients Who Underwent Chemotherapy and Did Not Receive Anti-Viral Prophylaxis.

    Directory of Open Access Journals (Sweden)

    Chih-An Shih

    Full Text Available Reactivation of HBV replication with an increase in serum HBV DNA and alanine aminotransferase (ALT activity has been reported in 20-50% of hepatitis B carriers undergoing cytotoxic chemotherapy for cancer treatment. Manifestation of HBV reactivation ranges from asymptomatic self-limiting hepatitis to severe progressive hepatic failure and fatal consequences.To investigate the risk of severe acute exacerbation of chronic HBV infection in HBsAg-positive cancer patients with solid tumors or hematological malignancies who underwent chemotherapy without antiviral prophylaxis.A retrospective review of charts was conducted for HBsAg-positive cancer patients in our institution who underwent chemotherapy and did not receive anti-viral prophylaxis between the periods of July 2007 to January 2013. We investigate the incidence of severe acute exacerbation of chronic HBV infection if these patients with a variety of solid tumors and hematological malignancies.A total of 156 patients (hematological malignancies: 16; solid tumors: 140 were included. The incidence of severe acute HBV exacerbation in the patients with hematological malignancy was higher than that in solid tumors (25.0% [4/16] vs 4.3% [6/140]; P = 0.005. Additionally, patients receiving rituximab-based chemotherapy had higher acute exacerbation rate than those with non-rituximab-based chemotherapy (40.0% vs 4.1%, P = 0.001. Among the patients with solid tumors, the incidences of severe acute exacerbation of chronic HBV in hepatocellular carcinoma, colorectal cancer, lung cancer, breast cancer, gynecological cancer, urological tract cancer, head/neck cancer and other solid malignancies were 2.3%, 4.0%, 7.1%, 9.0%, 16.7%, 6.7%, 0% and 0%, respectively.Severe acute exacerbation of chronic HBV infection may occur in HBsAg-positive patients with a variety of solid tumors who received chemotherapy without adequate anti-viral prophylaxis. Hematological malignancy and rituximab-based chemotherapy are

  16. Depletion of CD25+CD4+T cells (Tregs) enhances the HBV-specific CD8+ T cell response primed by DNA immunization

    Institute of Scientific and Technical Information of China (English)

    Yoshihiro Furuichi; Hirotake Tokuyama; Satoshi Ueha; Makoto Kurachi; Fuminori Moriyasu; Kazuhiro Kakimi

    2005-01-01

    AIM: Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8+ T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25+CD4+ regulatory T (Treg) cells might be involved in a inhibition of CD8+T cell priming or in the modulation of the magnitude of the'peak' antiviral CD8+ T cell response primed by DNA immunization. METHODS: B10.D2 mice were immunized once with plasmid pCMV-S. Mice received 500 μg of anti-CD25 mAb injected intraperitoneally 3 d before DNA immunization to deplete CD25+ cells. Induction of HBV-specific CD8+ T ceils in peripheral blood mononuclear cells (PBMCs) was measured by S28-39 peptide loaded DimerX staining and their function was analyzed by intracellular IFN-γ staining.RESULTS: DNA immunization induced HBV-specific CD8+ T cells. At the peak T cell response (d 10), 7.1±2.0% of CD8+ T cells were HBV-specific after DNA immunization, whereas 12.7±3.2% of CD8+ T cells were HBV-specific in Treg-depleted mice, suggesting that DNA immunization induced more antigen-specific CD8+ T cells in the absence of CD25+ Treg cells (n = 6, P<0.05). Similarly, fewer HBVspecific memory T cells were detected in the presence of these cells (1.3±0.4%) in comparison to Treg-depleted mice (2.6±0.9%) on d 30 after DNA immunization (n = 6, P<0.01). Both IFN-γ production and the avidity of the HBV-specific CD8+ T cell response to antigen were higher in HBV-specific CD8+ T cells induced in the absence of Treg cells.CONCLUSION: CD25+ Treg cells suppress priming and/or expansion of antigen-specific CD8+ T cells during DNA immunization and the peak CD8+ T cell response is enhanced by depleting this cell population. Furthermore, Treg cells appear to be involved in the contraction phase of the CD8+ T ceil response and may affect the quality of memory T cell pools. The elimination of Treg

  17. New Susceptibility and Resistance HLA-DP Alleles to HBV-Related Diseases Identified by a Trans-Ethnic Association Study in Asia

    Science.gov (United States)

    Kashiwase, Koichi; Minami, Mutsuhiko; Sugiyama, Masaya; Seto, Wai-Kay; Yuen, Man-Fung; Posuwan, Nawarat; Poovorawan, Yong; Ahn, Sang Hoon; Han, Kwang-Hyub; Matsuura, Kentaro; Tanaka, Yasuhito; Kurosaki, Masayuki; Asahina, Yasuhiro; Izumi, Namiki; Kang, Jong-Hon; Hige, Shuhei; Ide, Tatsuya; Yamamoto, Kazuhide; Sakaida, Isao; Murawaki, Yoshikazu; Itoh, Yoshito; Tamori, Akihiro; Orito, Etsuro; Hiasa, Yoichi; Honda, Masao; Kaneko, Shuichi; Mita, Eiji; Suzuki, Kazuyuki; Hino, Keisuke; Tanaka, Eiji; Mochida, Satoshi; Watanabe, Masaaki; Eguchi, Yuichiro; Masaki, Naohiko; Murata, Kazumoto; Korenaga, Masaaki; Mawatari, Yoriko; Ohashi, Jun; Kawashima, Minae; Tokunaga, Katsushi; Mizokami, Masashi

    2014-01-01

    Previous studies have revealed the association between SNPs located on human leukocyte antigen (HLA) class II genes, including HLA-DP and HLA-DQ, and chronic hepatitis B virus (HBV) infection, mainly in Asian populations. HLA-DP alleles or haplotypes associated with chronic HBV infection or disease progression have not been fully identified in Asian populations. We performed trans-ethnic association analyses of HLA-DPA1, HLA-DPB1 alleles and haplotypes with hepatitis B virus infection and disease progression among Asian populations comprising Japanese, Korean, Hong Kong, and Thai subjects. To assess the association between HLA-DP and chronic HBV infection and disease progression, we conducted high-resolution (4-digit) HLA-DPA1 and HLA-DPB1 genotyping in a total of 3,167 samples, including HBV patients, HBV-resolved individuals and healthy controls. Trans-ethnic association analyses among Asian populations identified a new risk allele HLA-DPB1*09∶01 (P = 1.36×10−6; OR = 1.97; 95% CI, 1.50–2.59) and a new protective allele DPB1*02∶01 (P = 5.22×10−6; OR = 0.68; 95% CI, 0.58–0.81) to chronic HBV infection, in addition to the previously reported alleles. Moreover, DPB1*02∶01 was also associated with a decreased risk of disease progression in chronic HBV patients among Asian populations (P = 1.55×10−7; OR = 0.50; 95% CI, 0.39–0.65). Trans-ethnic association analyses identified Asian-specific associations of HLA-DP alleles and haplotypes with HBV infection or disease progression. The present findings will serve as a base for future functional studies of HLA-DP molecules in order to understand the pathogenesis of HBV infection and the development of hepatocellular carcinoma. PMID:24520320

  18. 隐匿性乙型肝炎病毒感染可通过密切接触传播%Occult HBV infection may be transmitted through close contact

    Institute of Scientific and Technical Information of China (English)

    胡莉萍; 方钟燎; 刘德平; 陈钦艳; Tim J. Harrison; 何翔; 王学燕; 李海; 谭超; 杨庆利

    2016-01-01

    Objective To search for the infectious source of hepatitis B virus from a child, who had received the standard vaccination regimen at birth and produced protective antibody. Methods Serum samples were obtained from a child and his parents. Sera were tested for HBV serological markers and viral loads. HBV DNA was extracted using phenol-chloroform .The surface gene of HBV was amplified by nested PCR and the amplicons were cloned and sequenced. Phylogenetic analysis was carried out using Mega 5.0 and Bioedit 7.0. Results Both parents had occult infections. Twelve, eleven and nine clones, from the father, mother and son, respectively, were sequenced. Serotypes adrq +, ayw1, ayw,ayr and genotype B, subgenotype C2, a recombinant B/C were identified in the father. Serotypes ayw1, adw2, adwq+ and genotype B, subgenotype C5 ,two recombinants B/C、a recombinant C/G were identified in the mother. The adrq + was the only serotype in son. Subgenotype C2 was the only genotype identified in son. A phylogenetic tree showed that all of the child’s sequences and most of the father’s sequences clustered together. However, none of mother’s sequences clustered with those of the child. The surface antigens gene from the child and his father had the same amino acid substitution patterns (T118K, T123N and G145A). Conclusions The father was the source of the son’s HBV infection, suggesting that occult HBV infection may be transmitted through close contact.%目的探索一名出生时乙肝疫苗免疫成功后仍感染乙肝病毒的小孩的感染来源。方法采集小孩及其父母的血标本进行HBV 血清学标志物和病毒载量检测,使用酚氯仿法提取HBV DNA,PCR扩增HBV S基因,将扩增产物进行克隆并测序,利用Mega 5.0和Bioedit 7.0对测序结果进行分析。结果父亲和母亲均为隐匿性乙型肝炎病毒感染,父亲、母亲、儿子的 PCR 产物分别获得12、11和9个克隆株。父亲克隆株的血清型为 adrq+,ayw1

  19. Monitoring lamivudine therapy in HBV-infected patients by the quantity and structures of circulating viral nucleic acids

    Institute of Scientific and Technical Information of China (English)

    ZHANG Wei(张伟); Hans Jorg Hacker; Maria Mildenberger; Claus H.Schroder; SU Qin(苏勤)

    2003-01-01

    To monitor the progression of lamivudine therapy by demonstrating HBV DNAs and RNAs in the serum of a chronically infected patient.Viral nucleic acids were extracted from serum samples taken during a 14-week treatment period and analyzed via competitive PCR and RT/PCR.The dynamic changes n the amount as well as in the structures can monitor therapy process very well.Our study indicated the level of polyadenylated viral RNA can be a marker for expression in general,and the appearance of replicative intermediates as a mirror of the mode of action of an antiviral drug.

  20. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation

    Institute of Scientific and Technical Information of China (English)

    Tadeusz Wojciech Lapinski; Robert Flisiak; Jerzy Jaroszewicz; Ma3gorzata Michalewicz; Oksana Kowalczuk

    2005-01-01

    AIM: To analyze the effectiveness and safety of lamivudine treatment in patients with chronic HBV infection undergoing hemodialysis or after kidney transplantation, and to study the frequency of tyrosine - methionine - aspartate - aspartate (YMDD) mutation occurrence after lamivudine treatment.METHODS: We analyzed 91 patients with chronic hepatitis B, among whom, 16 patients underwent hemodialysis, 7patients had kidney transplantation and 68 patients had normal function of kidney. The hemodialysis patients were treated by lamivudine 300 mg/wk. Patients after kidney transplantation and patients with normal function of kidney were treated with lamivudine 100 mg/d. Therapy lasted for 12 mo. HBV-DNA, HBsAg, HBeAg and anti-HBe, and antiHCV antibodies were assessed in sera of patients. The analysis was performed before and 6 mo after the end of lamivudine treatment. Before, during and after the lamivudine therapy,the number of erythrocytes, leukocytes, platelets and hemoglobin concentration, ALT and AST activity, as well as bilirubin, urea and creatinine concentrations were analyzed in sera from patients.RESULTS: After the 12-mo lamivudine treatment, elimination of HBV - DNA was observed in 56% patients undergoing hemodialysis and in 53% patients with normal kidney function. Only 1 from 7 (14%) kidney-transplanted patients eliminated HBV-DNA. Furthermore, HBeAg elimination was observed in 36% hemodialysis patients, in 51% patients with normal function of kidneys and in 43% kidneytransplanted patients. Among the patients undergoing dialysis, no YMDD mutation was found after 12 mo of therapy, while it was detected in 9 patients (13%) with normal function of kidney and in 2 kidney-transplanted patients (29%, P<0.006). We did not observe significant side effects of lamivudine treatment in studied patients.CONCLUSION: Effectiveness of lamivudine therapy in dialysis patients is comparable with that in patients withnormal function of kidney. Lamivudine treatment is well

  1. The recombined cccDNA produced using minicircle technology mimicked HBV genome in structure and function closely

    OpenAIRE

    Xiaoyan Guo; Ping Chen; Xiaohu Hou; Wenjuan Xu; Dan Wang; Tian-yan Wang; Liping Zhang; Gang Zheng; Zhi-liang Gao; Cheng-Yi He; Boping Zhou; Zhi-Ying Chen

    2016-01-01

    HBV covalently closed circular DNA (cccDNA) is drug-resistant and responsible for viral persistence. To facilitate the development of anti-cccDNA drugs, we developed a minicircle DNA vector (MC)-based technology to produce large quantity of recombined cccDNA (rcccDNA) resembling closely to its wild-type counterpart both in structure and function. The rcccDNA differed to the wild-type cccDNA (wtcccDNA) only in that it carried an extra 36-bp DNA recombinant product attR upstream of the preC/C g...

  2. Seroprevalence of HIV, HBV, HCV and Syphilis in Blood Donors in Saurashtra Region of Gujarat: Declining Trends Over a Period of 3½ Years

    Directory of Open Access Journals (Sweden)

    Dhruva Gauravi A

    2012-04-01

    Full Text Available Background: Transfusion of blood and blood products is a life saving intervention and benefits innumerous patients worldwide. At the same time it could be an ominous mode of infection transmission to recipients. In 15 percent of total patients infected with HIV, blood transfusion has been the responsible mechanism of transmission. Methods: In this study, we aimed to access the prevalence and trend of HIV, HBV, HCV and Syphilis over the last 3½ years (January 2008 to June 2011 among the blood donors who came to donate blood at Blood Bank, P.D.U. Medical College & Hospital, Rajkot as well as in various blood donation camps organized by the same blood bank. Results: From the total of 30,178 blood donors, 711 (2.35% had serological evidence of infection with at least one pathogen, either of HIV, HBV, HCV or Syphilis. These included 131 (0.43% with HIV, 293 (0.97% with HBV, 124 (0.41% with HCV and 94 (0.31% with Syphilis. Moreover, significantly declining trends of HIV, HBV and Syphilis was observed over the study period. Conclusion: A substantial percentage of blood donors harbor HIV, HBV, HCV and Syphilis infections. Strict selection of blood donors and comprehensive screening of donors’ blood using standard methods are highly recommended to ensure the safety of blood for recipient.

  3. Evaluating the performance of remotely sensed and reanalysed precipitation data over West Africa using HBV light

    Science.gov (United States)

    Jütten, Thomas; Jackisch, Dominik; Diekkrüger, Bernd; Kusche, Jürgen; Eicker, Annette; Springer, Anne

    2016-04-01

    Water is one of the most crucial natural resources in West Africa, where the livelihoods of large parts of the population rely heavily on rain-fed agriculture. Therefore, the modelling of the water balance is an important tool to aid in water resource management. Precipitation is one of most important atmospheric drivers of hydrological models. However, ground-based observation networks are sparse in Western Africa and a further decline in station numbers due to a variety of reasons such as the deterioration of stations or political unrest has been observed in recent years. In ungauged river basins, or basins with insufficiently available precipitation data, several studies have shown that remotely sensed or reanalysed precipitation data may be used to compliment or replace missing information. However, the uncertainties of these datasets over Western Africa are not well examined and a need for further studies is apparent. For validation purposes, precipitation datasets are traditionally compared to in-situ ground measurements. This is not possible in ungauged basins. A new approach to assess the quality of satellite and reanalysis data which is gaining popularity among researchers compares different precipitation datasets using hydrological models. In this so-called hydrological evaluation, ground-truth data is no longer necessary in order to validate a product. The chosen model is calibrated for different precipitation products and the simulated streamflow generated for each product is compared to the measured streamflow. Multiple state of the art satellite and reanalysis precipitation datasets with various spatial resolutions were used in this study, namely: CFSR (0.3125°), CHIRPS (0.05°), CMORPH (0.25°), PERSIANN (0.25°), RFE 2.0 (0.1°), TAMSAT (0.0375°), TRMM 3B42 v7 (0.25°) and TRMM 3B42RT (real time) (0.25°). These datasets were evaluated at the regional as well as local scale using the HBV light conceptual hydrological model for several basins

  4. Cost-Effectiveness of Testing Hepatitis B–Positive Pregnant Women for Hepatitis B e Antigen or Viral Load

    Science.gov (United States)

    Fan, Lin; Owusu-Edusei, Kwame; Schillie, Sarah F.; Murphy, Trudy V.

    2015-01-01

    OBJECTIVE To estimate the cost-effectiveness of testing pregnant women with hepatitis B (hepatitis B surface antigen [HBsAg]-positive) for hepatitis B e antigen (HBeAg) or hepatitis B virus (HBV) DNA, and administering maternal antiviral prophylaxis if indicated, to decrease breakthrough perinatal HBV transmission from the U.S. health care perspective. METHODS A Markov decision model was constructed for a 2010 birth cohort of 4 million neonates to estimate the cost-effectiveness of two strategies: testing HBsAg-positive pregnant women for 1) HBeAg or 2) HBV load. Maternal antiviral prophylaxis is given from 28 weeks of gestation through 4 weeks postpartum when HBeAg is positive or HBV load is high (108 copies/mL or greater). These strategies were compared with the current recommendation. All neonates born to HBsAg-positive women received recommended active-passive immunoprophylaxis. Effects were measured in quality-adjusted life-years (QALYs) and all costs were in 2010 U.S. dollars. RESULTS The HBeAg testing strategy saved $3.3 million and 3,080 QALYs and prevented 486 chronic HBV infections compared with the current recommendation. The HBV load testing strategy cost $3 million more than current recommendation, saved 2,080 QALYs, and prevented 324 chronic infections with an incremental cost-effectiveness ratio of $1,583 per QALY saved compared with the current recommendations. The results remained robust over a wide range of assumptions. CONCLUSION Testing HBsAg-positive pregnant women for HBeAg or HBV load followed by maternal antiviral prophylaxis if HBeAg-positive or high viral load to reduce perinatal hepatitis B transmission in the United States is cost-effective. PMID:24785842

  5. 乙型肝炎病毒基因型的研究%Research on the Gene Type of HBV

    Institute of Scientific and Technical Information of China (English)

    廖可育; 彭志高; 侯宏锦; 熊昌本; 罗玲; 梁华; 周海峰; 白熠; 熊玉珍

    2003-01-01

    目的:研究常德市乙型肝炎病毒(HBV)基因型的分布状况.方法:随机选择2737例高考生检测HBV血清标志物.随机选择其中的HBsAg阳性携带者65例,HBsAg阴性者10例.随机选择慢性乙型肝炎患者5例.应用FQ-PCR方法检测血清HVB DNA含量.采用PCR荧光分子信标检测技术进行血清HBVA~F6种基因分型.结果:43例HBV DNA定量阳性血清中B、D混合型占51.2%(22例),B型占27.9%(12)例,C型占9.3%(4例),C、D混合型占4.7%(2例),B、C混合型占2.3%(1例),未分型者2例,来发现A型、单纯D型、E型和F型.结论:湖南省常德市HBV基因型以B、D混合型为主,B型次之,C型较少,C、D混合型及B、C混合型更少,可能存在其他基因型.

  6. Enhancing cellular immune response to HBV M DNA vaccine in mice by codelivery of interleukin-18 recombinant

    Institute of Scientific and Technical Information of China (English)

    陈建忠; 朱海红; 刘克洲; 陈智

    2004-01-01

    Objective:To investigate the effect of interleukin-18 (IL-18) on immune response induced by plasmid encoding hepatitis B virus middle protein antigen and to explore new strategies for prophylactic and therapeutic HBV DNA vaccines.Methods:BALB/c mice were immunized with pCMV-M alone or co-immunized with pcDNA3-18 and pCMV-M and then their sera were collected for analysing anti-HBsAg antibody by ELISA;splenocytes were isolated for detecting specific CTL response and cytokine assay in vitro.Results:The anti-HBs antibody level of mice co-immunized with pcDNA3-18 and pCMV-M was slightly higher than that of mice immunized with pCMV-M alone,but there was not significantly different (P>0.05).Compared with mice injected with pCMV-M, the specific CTL cytotoxity activity of mice immunized with pcDNA3-18 and pCMV-M was significantly enhanced (P0.05).Conclusion:The plasmid encoding IL-18 together with HBV M gene DNA vaccines may enhance specific TH1 cells and CTL cellular immune response induced in mice, so that IL-18 is a promising immune adjuvant.

  7. Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination.

    Science.gov (United States)

    Zhang, Wenjuan; Du, Xiaogang; Zhao, Gang; Jin, Huali; Kang, Youmin; Xiao, Chong; Liu, Mingyu; Wang, Bin

    2009-08-01

    Chemical compounds activating innate responses may present potential adjuvants for the vaccine development. Levamisole (LMS), demonstrated as a potent adjuvant for DNA and viral killed vaccines in our previous studies, may activate such responses. To confirm this notion, LMS combined with the recombinant HBsAg (rHBsAg) was investigated. Compared to the vaccination with rHBsAg alone, LMS could up-regulate the expressions of TLR7&8, MyD88, IRF7 and their downstream pro-inflammatory cytokines including IFN-alpha and TNF-alpha, which promote DCs activation. Strikingly, we find that the combination of LMS and alum adjuvant synergistically enhances immunogenicity of rHBsAg and leads to a robust cell-mediated response demonstrated by the higher level of IgG2a/IgG1, T cell proliferation, and importantly, a high level of antigen-specific CTL and IFN-gamma production within these activated CD8(+) T cells. The achieved robust responses are at a comparative level with CpG+alum used as a positive control adjuvant in mice. The combination of LMS+alum with rHBsAg may provide a cost-effective, safe, and effective therapy to treat those individuals chronically infected by HBV, since antigen-specific cellular immunity is implicated for the clearance of HBV chronic infection. PMID:19549606

  8. Enhancing cellular immune response to HBV M DNA vaccine in mice by codelivery of interleukin-18 recombinant

    Institute of Scientific and Technical Information of China (English)

    陈建忠; 朱海红; 刘克洲; 陈智

    2004-01-01

    Objective: To investigate the effect of interleukin-18 (IL-18) on immune response induced by plasmid encoding hepatitis B virus middle protein antigen and to explore new strategies for prophylactic and therapeutic HBV DNA vaccines. Methods: BALB/c mice were immunized with pCMV-M alone or co-immunized with pcDNA3-18 and pCMV-M and then their sera were collected for analysing anti-HBsAg antibody by ELISA; splenocytes were isolated for detecting specific CTL response and cytokine assay in vitro. Results: The anti-HBs antibody level of mice co-immunized with pcDNA3-18 and pCMV-M was slightly higher than that of mice immunized with pCMV-M alone, but there was not significantly different (P>0.05). Compared with mice injected with pCMV-M, the specific CTL cytotoxity activity of mice immunized with pcDNA3-18 and pCMV-M was significantly enhanced (P0.05). Conclusion: The plasmid encoding IL-18 together with HBV M gene DNA vaccines may enhance specific TH1 cells and CTL cellular immune response induced in mice, so that IL-18 is a promising immune adjuvant.

  9. 母婴乙肝标志物结果的探讨%Investigation of HBV markers in mothers and newborn infants

    Institute of Scientific and Technical Information of China (English)

    李增新; 葛晓婧; 王鑫

    2013-01-01

    目的 探讨现阶段乙肝病毒宫内感染的状况与新生儿乙肝标志物的阳性率及其临床应用.方法 检测898例乙肝病毒携带者产妇及其新生儿乙肝标志物,并对新生儿HBcAb阳性者进一步作HBcAb-lgM检测.结果 所有新生儿均未检测到HBsAg和HBeAg阳性;HBeAb和HBcAb结果与母亲结果高度相关;所有新生儿HBcAb-lgM全部阴性.结论 阻断方法的应用使得宫内感染的情况已极少发生,新生儿HBeAb和HBcAb阳性不能作为感染过乙肝病毒的标志.%To investigate intrauterine infection of hepatitis B virus (HBV) and its relationship with positive rate of HBV markers of newborn infants, HBV makers of 898 HBV carriers of puerperants and their newborn infants had been analyzed. For HBcAb positive infants, a further detection of HBcAb-IgM was performed. The study showed that all newborn infants demonstrated HBsAg- and HBeAg-negative. Furthermore, the detection results of HBsAg and HBeAg were closely correlated with the results of the mothers'; all infants showed HBcAb -IgM negative. From above we presumed that HBV intrauterine infection could be prevented significantly by the use of interception method. And the positive results of HBeAb and HBcAb can not be regarded as the HBV-infected markers in newborn infants.

  10. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.

    Directory of Open Access Journals (Sweden)

    Gail V Matthews

    Full Text Available OBJECTIVE: Anti-HBe seroconversion and HBsAg loss are important therapeutic endpoints in patients with hepatitis B virus (HBV infection. Quantitative measures of hepatitis B surface antigen (qHBsAg and e antigen (qHBeAg have been identified as potentially useful indicators of therapeutic response in HBV monoinfection. The aim of this study was to examine serological change including quantitative biomarkers in HIV-HBV coinfected patients initiating HBV active antiretroviral therapy (ART. METHODS: HIV-HBV coinfected individuals from Thailand were followed for up to 168 weeks post ART. Rates and associations of qualitative serological change were determined. Longitudinal changes in qHBsAg and qHBeAg were measured and their utility as predictors of response examined. RESULTS: Forty seven patients were included of whom 27 (57% were HBeAg positive at baseline. Median CD4 count was 48 cells/mm(3. Over a median follow-up of 108 weeks 48% (13/27 lost HBeAg, 12/27 (44% achieved anti-HBe seroconversion and 13% (6/47 HBsAg loss. Anti-HBe seroconversion was associated with higher baseline ALT (p = 0.034, lower qHBsAg (p = 0.015, lower qHBeAg (p = 0.031 and greater HBV DNA decline to week 24 (p = 0.045. Sensitivity and specificity for qHBsAg and qHBeAg decline of >0.5 log at week 12 and >1.0 log at week 24 were high for both anti-HBe seroconversion and HBsAg loss. CONCLUSIONS: Rates of serological change in these HIV-HBV coinfected individuals with advanced immunodeficiency initiating HBV-active ART were high. Baseline and on treatment factors were identified that were associated with a greater likelihood of subsequent anti-HBe seroconversion, including both quantitative HBsAg and HBeAg, suggesting these biomarkers may have utility in this clinical setting.

  11. Persistence of HBV Vaccine’s Protection and Response to Hepatitis B Booster Immunization in 5- to 7-Year-Old Children in the Kohgiloyeh and Boyerahmad Province, Iran

    Directory of Open Access Journals (Sweden)

    Shahrzad Yazdanpanah

    2010-01-01

    Full Text Available Background and Aims: The duration of the protection of hepatitis B vaccination for infants and the necessity of a booster dose administration is unknown. The aim of the present study was to evaluate the persistence of seroprotection after hepatitis B virus (HBV vaccination in order to determine the necessity of a single booster dose in 5- to 7-year-old children.Methods: This clinical trial study was conducted from 2004 to 2005. The study population included all children aged 5 to 7 years old in the Kohgiloyeh and Boyerahmad province who had been vaccinated starting at birth with hepatitis B vaccine. Among these children, 729 were selected via a multiple-stage sampling method. Parents gave their informed consent, and blood specimens (3 ml were obtained from children. Hepatitis B surface antibody (HBsAb and hepatitis B surface antigen (HBsAg were determined by enzyme-linked immunosorbent assay (ELISA. Subjects with nonprotective titer levels (< 10 mIU/ml received a booster does of the DNA recombinant vaccine. Four weeks after the administration of a booster dose, the antibody to HBsAg (anti-HBs titer was measured. Data were analyzed using SPSS software, and analyses included chi-square, ANOVA, and independent-samples and paired-samples t-tests.Results: 615 children (84.4% had a protective antibody titer. The mean antibody titer was 230.5 ± 308.9 IU/ml, with a range of 10.6 to 1175 IU/ml. 15.6% of subjects had a nonprotective antibody titer, and the mean antibody titer was 4.97 ± 3.5 IU/ml. All subjects were HBsAg negative. No statistically significant differences were found by sex or by urban versus rural area of residence. The seroprotection rates significantly decreased by as the age of the children increased. Following the booster dose, 78.1 % of the children had a protective titer, and the mean titer significantly increased from 4.97 ± 3.5 at birth to 332.1 ± 402 IU/ml after the booster (P < 0.001. Conclusions: According to our results

  12. 广州市1324名吸毒人员HIV、 HBV、 HCV及梅毒感染状况调查%Investigation on infection status of HIV, HBV, HCV and syphilis among 1324 drug addicts in Guangzhou City

    Institute of Scientific and Technical Information of China (English)

    钟秋林; 刘展翅

    2012-01-01

    [Objective] To understand the infection status of HIV, HBV, HCV and syphilis among drug addicts in Guangzhou City provide the basis for developing the prevention and control measures of common infectious diseases among drug addicts in Guanj zhou. [ Methods] From July 2009 to June 2011, the venous blood samples were collected from 1 324 drug addicts in a detoxificatk center of Guangzhou city, and the anti-HIV , anti-HCV, HBsAg and syphilis antibody were tested. [ Results] Among 1 324 dnifc addicts, 74 cases were positive for anti-HIV with the positive rate of 4,2% f the positive rate of HBsAg was 12.2% , that of anti-HCV was 40.5% , and that of treponema pallidum particle agglutination assay (TPPA) was 6. 1%. 21.8% of drug addicts were dectected with two infectious diseases, and 2,2% were detected with three infectious diseases. [ Conclusion]The infection rates of HIV, HBV, HCV and syphilis among drug addicts in Guangzhou city are high, and it is important to pay attention to supervision, monitoring and education in this population.%目的 了解广州市吸毒人群HIV 、HBV 、HCV及梅毒感染状况,为制定针对该地区吸毒人群常见传染病的防治措施提供依据.方法 于2009年7月-2011年6月,抽取广州市某戒毒所收入的1324例吸毒人员静脉血,检测HIV 、HCV和梅毒抗体以及HBV表面抗原.结果 1324例吸毒人群中,HIV抗体阳性74例,阳性率4.2%;乙肝表面抗原阳性率12.2%,丙肝抗体阳性率40.5%,梅毒螺旋体明胶颗粒凝集试验(TPPA)阳性率6.1%. 21.8%的吸毒人员同时检出2种传染病,2.2%的吸毒者同时检出3种传染病.结论 广州市吸毒人群中HCV、HBV、梅毒及HIV仍存在较高的感染率,应继续重视对该人群的监管监测及宣传教育.

  13. Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso, West Africa.

    Science.gov (United States)

    Kania, D; Bekalé, A M; Nagot, N; Mondain, A-M; Ottomani, L; Meda, N; Traoré, M; Ouédraogo, J B; Ducos, J; Van de Perre, P; Tuaillon, E

    2013-12-01

    People screened for human immunodeficiency virus (HIV) using rapid diagnostic tests (RDTs) in Africa remain generally unaware of their status for hepatitis B (HBV) and hepatitis C (HCV) infections. We evaluated a two-step screening strategy in Burkina Faso, using both HIV RDTs and Dried Blood Spot (DBS) assays to confirm an HIV-positive test, and to test for HBV and HCV infections. HIV counselling and point-of-care testing were performed at a voluntary counselling and testing centre with HBV, HCV status and HIV confirmation using DBS specimens, being assessed at a central laboratory. Serological testing on plasma was used as the reference standard assay to control for the performance of DBS assays. Nineteen out of 218 participants included in the study were positive for HIV using RDTs. A fourth-generation HIV ELISA and immunoblot assays on DBS confirmed HIV status. Twenty-four out of 25 participants infected with HBV were found positive for hepatitis B surface antigen (HBsAg) using DBS. One sample with a low HBsAg concentration on plasma was not detected on DBS. Five participants tested positive for HCV antibodies were confirmed positive with an immunoblot assay using DBS specimens. Laboratory results were communicated within 7 days to participants with no loss to follow up of participants between the first and second post-test counselling sessions. In conclusion, DBS collection during HIV point-of-care testing enables screening and confirmation of HBV, HCV and HIV infections. Diagnosis using DBS may assist with implementation of national programmes for HBV, HCV and HIV screening and clinical care in middle- to low-income countries. PMID:23902574

  14. Detection of serum hepatitis B virus large envelope protein and its relationship with viral replication%乙肝病毒外膜大蛋白检测及其对判定HBV DNA复制的意义

    Institute of Scientific and Technical Information of China (English)

    张红娟; 崔辰莹; 张洁; 王丽伟; 张雪丽

    2011-01-01

    目的 探讨血清乙肝病毒外膜大蛋白(LHBs)检测对于判定HBV DNA复制的临床意义.方法采用酶联免疫方法检测LHBs,Pre - S1和HBV M,采用实时荧光定量PCR法检测HBV DNA.结果(1)在HBeAg阳性血清中,HBV DNA与LHBs、Pre -S1之间的阳性率差异均无统计学意义(P>0.05);(2)在HBeAg阴性血清中,HBV DNA与LHBs的阳性率差异无统计学意义(P>0.05).HBV DNA与Pre -S1之间的阳性率差异有统计学意义(P<0.05);(3) 90份乙肝患者血清中LHBs水平与HBV DNA拷贝数呈良好相关性(r=0.918),Pre - S1水平与HBV DNA拷贝数的相关系数为0.765.结论 血清LHBs水平能反映HBV DNA复制程度,其与HBV DNA的相关性优于pre - S1,可作为评判HBV DNA复制新的血清学指标.%Objective To study the clinical significance of HBV large envelope protein in diagnosing viral replication in chronic hepatitis B patienis. Methods ELISA was used to measure the level of serum LHBs and pre -SI. HBV markers were detected by enzyme linked immunosorbenl assay. HBV DNA was detected using quantitative fluorescent PCR - Results In terms of the positive rale, there was no difference between HBV DNA and LHBs,but the difference was significant between HBV DNA and pre - SI as in HBeAk positive samples (P >0. 05). In HBeAg negative samples, both the posivite rate of HBV DNA and that of LHBs were 72. 22% . The difference between the rale of HBV DNA and that of pre - SI was significant ( P <0. 05). LHBs levels were correlated with the number of HBV DNA copies(r =0. 918) , and the correlation between HBV DNA and pre-SI was 0. 765. Conclusions The level of serum l,HBs can be used to estimate the state of viral replication and the correlation is superior to that of pre -SI. So it can be used as a new serologioal marker to delect viral replication.

  15. Relationship between positive anti- Hbe and HBV- DNA in 101 patients with chronic hepatitis%慢性乙型肝炎抗-HBe阳性与HBV-DNA检出关系分析

    Institute of Scientific and Technical Information of China (English)

    黄丹文; 周水英

    2002-01-01

    目的分析慢性乙型肝炎抗-HBe阳性与HBV-DNA检出关系.方法采用斑点杂交法检测101例抗-HBe阳性的慢性乙型肝炎患者HBV-DNA.结果HBV-DNA阳性36例,阳性率35.64%,HBV-DNA阳性检出率,以慢性重型肝炎最高,其次慢性乙型肝炎重度、中度患者,轻度慢性乙型肝炎最低.检出率随着病程的延长而升高.结论表明抗-HBe阳转,体内HBV-DNA并未彻底清除,HBV的持续存在是变异发生的基础.

  16. Molecular modelling and immunological activity of glycosylated CTL epitope of HBV Pre-S(2)%O-糖基化HBV Pre-S(2)CTL表位分子模建及免疫学活性研究

    Institute of Scientific and Technical Information of China (English)

    周吉军; 吴玉章; 王祥智; 石统东

    2000-01-01

    目的研究O-糖基化(Glycosylation)修饰对HBV Pre-S(2)上CTL表位结构及其免疫学活性的影响.方法选择HBV Pre-S(2)上公认的HLA-A2限制性CTL表位44~53(SILSKTGDPV),以Ser44为糖基化位点,进行计算机分子模建,并利用糖肽合成技术,固相合成α-GalNAc糖基化CTL表位,免疫BALB/c(H-2Db)小鼠,观察其诱导CTL活性.结果α-GalNAc-糖基化可改变表位形态使之更适宜与HLA-A2类分子结合,糖基部分基团可从HLA-A2结合沟中向外伸出.与对照组比Ser44α-D-GalNAc O-糖基化44~53肽,诱导出较强的针对经抗原预刺激P815细胞的CTL应答,特别是50 μg和500 μg组,而且有明显的剂量-效应关系.结论Ser44α-D-GalNAc-糖基化修饰能改变Pre-S(2)上CTL表位44~53的结构,并促进特异性CTL应答,表明表位糖基化修饰可以调节CTL应答.

  17. 治疗性双质粒HBV DNA疫苗的纯化与检定%Purification and Quality Control of Two Recombinant Plasmids as Therapeutic HBV DNA Vaccine

    Institute of Scientific and Technical Information of China (English)

    饶桂荣; 黄明; 杨富强; 莫国玉; 刘惠萍; 陈光明

    2007-01-01

    目的 研究双质粒HBV DNA疫苗(pS2.S和pFP)的纯化工艺,并建立质控标准.方法 首先对两工程菌(DHSα/pS2.S和DH5α/pFP)的高效发酵菌体采用碱裂解法进行质粒初提;然后通过三步柱层析(依次为分子筛层析、亲和层析、阴离子层析)进行质粒纯化,并检测质粒含量、超螺旋比例、内毒素等,最后对终产品质粒溶液进行全面质量检定.结果 质粒初提液通过分子筛层析后,去除了大量的RNA、宿主DNA、内毒素等,再经亲和柱纯化后获得了高比例的超螺旋质粒DNA,达95%,最后经阴离子柱层析有效去除内毒素,并浓缩了质粒,质粒得率为0.9~1.1 mg/g菌,质粒总回收率达78%.三批终产品全面质量检定均符合规定.结论 建立了稳定的双质粒HBV DNA疫苗(pS2.S和pFP)的纯化工艺及质量控制标准,为进一步研究奠定基础.

  18. Prevalence of HCV Infections and Co-Infection With HBV and HIV and Associated Risk Factors Among Addicts in Drug Treatment Centers, Lorestan Province, Iran

    Science.gov (United States)

    Norouzian, Hossein; Gholami, Mohammadreza; Shakib, Pegah; Goudarzi, Gholamreza; Ghobadian Diali, Hamze; Rezvani, Azam

    2016-01-01

    Background: Hepatitis C is an infectious disease caused by blood-borne pathogen, hepatitis C virus (HCV). Objectives: The purpose of this study was to investigate the prevalence of HCV infection and associated risk factors among addicts in drug treatment centers in Lorestan Province, Iran. Patients and Methods: A cross-sectional sero-behavioral survey was given to drug addicts in the drug treatment centers of Khorramabad, Lorestan Province, Iran during June 2012 - March 2013. Drug addicts were interviewed using a standard questionnaire including demographic, imprisonment history, and HCV-related risk behavior items. Thereafter, the sera drawn from the participants were tested for anti-HCV antibody (Ab), anti-human immunodeficiency virus (HIV) Ab, and hepatitis B surface antigen (HBsAg). Results: The mean age of the cohorts was 31.7. Up to 60.2% of drug users had educational levels less than high school, 67.5% were self-employed, and 32.5% were office workers. The mean duration of drug injection was 6.8 years. Statistical analyses indicated that the prevalence of HCV among drug addicts was positively associated with age, past incarceration, drug injection history, the duration of drug use, and tattooing. In addition, 16.23% of volunteers were HCV-positive. Of those infected with HCV, 1.10% was co-infected with HBV, 2.95% were positive for HIV, and 0.36% of HCV-positive cases were infected with all three viruses. Conclusions: The high prevalence of HCV infection among this group implies a high rate of transmission and exposure to the risk of serious diseases. It is important that the high prevalence of HCV infection be taken into consideration to control further transmission of this infection. PMID:27162762

  19. The Associated Ion between the VDR Gene Polymorphisms and Susceptibility to Hepatocellular Carcinoma and the Clinicopathological Features in Subjects Infected with HBV

    Directory of Open Access Journals (Sweden)

    Xing Yao

    2013-01-01

    Full Text Available Aim. To evaluate the possible association between the vitamin D receptor (VDR, single-nucleotide polymorphisms (SNPs, and hepatocellular carcinoma (HCC in patients with chronic hepatitis B virus (HBV infection. Method. 968 chronic HBV infection patients were enrolled, of which 436 patients were diagnosed HCC patients, and 532 were non-HCC patients. The clinicopathological characteristics of HCC were evaluated. The genotypes of VDR gene at FokI, BsmI, ApaI, and TaqI were determined. Results. The genotype frequencies of VDR FokI C>T polymorphism were significantly different between HCC and non-HCC groups. HCC patients had a higher prevalence of FokI TT genotype than non-HCC subjects. With FokI CC as reference, the TT carriage had a significantly higher risk for development of HCC after adjustments with age, sex, HBV infection time, α-fetoprotein, smoking status, and alcohol intake. In addition, we also found that the TT genotype carriage of FokI polymorphisms were associated with advanced tumor stage, presence of cirrhosis, and lymph node metastasis. The SNP at BsmI, ApaI, and TaqI did not show positive association with the risk and clinicopathological features of HCC. Conclusion. The FokI C>T polymorphisms may be used as a molecular marker to predict the risk and to evaluate the disease severity of HCC in those infected with HBV.

  20. Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment

    NARCIS (Netherlands)

    H.G.M. Niesters (Bert); F. Zoulim (Fabien); C. Pichoud (Christian); M. Buti (Miquel); F. Shapiro; N. D'Heuvaert; L. Celis (Linda); J. Doutreloigne (Joke); E. Sablon (Erwin)

    2010-01-01

    textabstractHepatitis B virus (HBV) antiviral drug resistance mutations prevent successful outcome of treatment and lead to worsening of liver disease. Detection of its emergence permits opportune treatment with alternative drugs. Unfortunately, the use of newly approved antivirals, including adefov

  1. Ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances HBV-specific humoral and CTL immune responses in vivo.

    Science.gov (United States)

    Song, Linlin; Zhuo, Meng; Tang, Yuyan; Chen, Xiaohua; Tang, Zhenghao; Zang, Guoqing

    2014-11-01

    Therapeutic strategies based on an enhanced hepatitis B virus (HBV)-specific cytotoxic T lymphocyte (CTL) activity may eradicate HBV. We previously verified that a fusion protein ubiquitin (Ub)-hepatitis B core antigen (HBcAg)-cytoplasmic transduction peptide (CTP) can enter the cytoplasm of dendritic cells and enhance T cell response to generate HBV-specific CTLs efficiently in vitro. Ub, a marker of protein degradation, may promote the generation of peptides appropriate for major histocompatibility complex class I presentation. In the present study, the specific immune responses of the fusion protein Ub-HBcAg-CTP in BALB/c mice were evaluated and the underlying mechanisms were investigated. Results showed that Ub-HBcAg-CTP increased the anti-HBcAg titer and produced the cytokines IFN-γ and IL-2. This fusion protein also induced higher percentages of IFN-γ(+)CD8(+) cells and specific CTL responses. Ub-HBcAg-CTP could also upregulate the expressions of Jak2, Tyk2, STAT1, and STAT4 in T lymphocytes. In conclusion, Ub-HBcAg-CTP enhanced cellular and humoral immune responses and induced robust HBV-specific CTL activities in BALB/c mice. PMID:25135878

  2. the denver tube Combined with antiviral drugs In the treatment of HBV-related Cirrhosis with Refractory ascites:a Report of three Cases

    Institute of Scientific and Technical Information of China (English)

    Xiao-jin Wang; Li-qin Shi; Qing-chun Fu; Liu-da Ni; Feng Zhou; Jin-wei Chen; Cheng-wei Chen

    2014-01-01

    Treatment of nucleos(t)ide antiviral drugs for decompensated HBV-related cirrhosis can signiifcantly improve the prognosis. But those patients with refractory ascites possibly deteriorate due to the complications of ascites before any beneift from anti-viral drugs could be observed. Therefore, it is important to ifnd a way to help the patients with HBV-related cirrhosis and refractory ascites to receive the full beneifts from antiviral therapy. Peritoneovenous shunt (PVS) using Denver tube enables ascites to continuously bypass into systemic circulation, thereby reducing ascites and albumin input and improving quality of life. We report herein 3 cases of decompensated HBV-related cirrhosis with refractory ascites, PVS using Denver tube was combined with lamivudine for antiviral treatment before and after. Then, ascites was alleviated significantly or disapeared and viral responsed well. All patients achieved a satisfactory long-term survival from 6.7 to 14.7 years. It was suggested that the Denver shunt could be used as an adjuvant method to antiviral drugs for decompensated HBV-related cirrhosis with refractory ascites to help the patients reap the full beneifts and maximize efifcacy of antiviral treatment.

  3. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance

    Institute of Scientific and Technical Information of China (English)

    LI Min-wei; HOU Wei; WO Jian-er; LIU Ke-zhou

    2005-01-01

    Objectives: To investigate the relationship between HBV (hepatitis B virus) polymerase gene 180 and 204 sites mutation and lamivudine resistance. Methods: One hundred forty-one patients with lamivudine resistance after lamivudine treatment and 60 chronic hepatitis B patients without lamivudine treatment were enrolled in this study. The serum HBV DNA mutation was analyzed by sequence detection via polymerase chain reaction (PCR). The sequences of the same patient were analyzed before and after lamivudine treatment. Results: One hundred and nine lamivudine resistance patients had HBV YMDD (tyrosine-methionine-aspartate-aspartate) mutation. Among them, 45 patients had rtL 180M/M204V mutation (41.28%), 28patients had rtL180M/M204I mutation (25.70%) and 36 patients had rtM204I mutation (33.02%). There were 6 patients with rtL180M mutation in 32 lamivudine resistance patients. Sixty chronic hepatitis patients without lamivudine treatment had no mutations. Conclusions: HBV mutations, which play an important role in lamivudine resistance usually locate at polymerase gene 204 site; 180 site mutation was also observed in these patients. Evaluation of the anti-virus therapy by surveillance of the two sites mutations is of importance.

  4. Individual donor-nucleic acid testing for human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and its role in blood safety

    Directory of Open Access Journals (Sweden)

    Rajesh Kumar

    2015-01-01

    Full Text Available Background: Transfusion-transmitted infections (TTIs are one of the biggest threats to blood transfusion safety. Nucleic acid testing (NAT in blood donor screening has been implemented in many countries to reduce the risk of TTIs. NAT shortens this window period, thereby offering blood centers a much higher sensitivity for detecting viral infections. Aims: The objective was to assess the role of individual donor-NAT (ID-NAT for human immunodeficiency virus-1 (HIV-1, hepatitis C virus (HCV and hepatitis B virus (HBV and its role in blood safety. Materials and Methods: A total of 32978 donations were tested for all three viruses using enzyme-linked immuno-sorbent assay (Vironostika ® HIV Ag-Ab, Hepanostika ® HCV ultra and hepatitis B surface antigen ultra by Biomerieux and ID-NAT using Procleix Ultrio plus ® Assay (Novartis Diagnostic, USA. All initial NAT reactive samples and serology nonreactive were retested in triplicate and NAT discriminatory assay for HIV-1, HCV and HBV were performed. Results: Of the 32978 samples, 43 (0.13% were found to be ID-NAT reactive but seronegative. Out of 43, one for HIV-1, 13 for HCV and 27 for HBV were reactive by discriminatory assays. There were two samples that were reactive for both HCV-HBV and counted as HCV-HBV co-infection NAT yield. The prevalence of these viruses in our sample, tested by ID-NAT is 0.06%, 0.71%, and 0.63% for HIV-1, HCV and HBV respectively. The combined NAT yield among blood donors was 1 in 753. Conclusion: ID-NAT testing for HIV-1, HCV and HBV can tremendously improve the efficacy of screening for protecting blood recipient from TTIs. It enables detection of these viruses that were undetected by serological test and thus helped in providing safe blood to the patients.

  5. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

    Directory of Open Access Journals (Sweden)

    James S Cavenaugh

    Full Text Available BACKGROUND: Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safety and efficacy of plasmid DNA (pSG2.HBs vaccine, followed by recombinant modified vaccinia virus Ankara (MVA.HBs, encoding the surface antigen of HBV as therapy for chronic HBV. A secondary goal was to characterize the immune responses. METHODS: Firstly 32 HBV e antigen negative (eAg(- participants were randomly assigned to one of four groups: to receive vaccines alone, lamivudine (3TC alone, both, or neither. Later 16 eAg(+ volunteers in two groups received either 3TC alone or both 3TC and vaccines. Finally, 12 eAg(- and 12 eAg(+ subjects were enrolled into higher-dose treatment groups. Healthy but chronically HBV-infected males between the ages of 15-25 who lived in the western part of The Gambia were eligible. Participants in some groups received 1 mg or 2 mg of pSG2.HBs intramuscularly twice followed by 5×10(7 pfu or 1.5×10(8 pfu of MVA.HBs intradermally at 3-weekly intervals with or without concomitant 3TC for 11-14 weeks. Intradermal rabies vaccine was administered to a negative control group. Safety was assessed clinically and biochemically. The primary measure of efficacy was a quantitative PCR assay of plasma HBV. Immunity was assessed by IFN-γ ELISpot and intracellular cytokine staining. RESULTS: Mild local and systemic adverse events were observed following the vaccines. A small shiny scar was observed in some cases after MVA.HBs. There were no significant changes in AST or ALT. HBeAg was lost in one participant in the higher-dose group. As expected, the 3TC therapy reduced viraemia levels during therapy, but the prime-boost vaccine regimen did not reduce the viraemia. The immune responses were variable. The majority of IFN-γ was made by antigen non-specific CD16(+ cells (both CD3(+ and CD3(-. CONCLUSIONS: The vaccines were well tolerated but did not control HBV infection. TRIAL REGISTRATION: ISRCTN ISRCTN67270384.

  6. 乙型肝炎病毒相关线粒体致病机制研究进展%Progress in HBV related mitochondrial pathogenesis

    Institute of Scientific and Technical Information of China (English)

    杨松; 邢卉春; 成军

    2016-01-01

    线粒体是参与细胞内能量、细胞凋亡、免疫应答与细胞周期调控等的重要细胞器。在乙型肝炎病毒(hepatitis B virus,HBV)致病机制中,HBV主要通过HBx与HBsAg作用于线粒体。HBV可以影响线粒体途径的细胞凋亡,但HBV对线粒体凋亡的影响在不同环境下呈现不同的作用。HBV还可影响氧化应激损伤、细胞周期调控以及线粒体相关抗病毒免疫。HBV作用于线粒体,一方面为完成HBV生命周期创造有利的细胞内环境,另一方面会造成肝细胞损伤。阐明线粒体在HBV致病机制中的作用,进一步深入阐释HBV导致细胞损伤尤其是肝细胞癌发生的可能机制,可为相关药物研发提供新的靶位。%Mitochondria is an important cell organelle which is involved in energy metabolism, cell apoptosis, immune regulation and cell cycle regulation. In hepatitis B virus (HBV) pathogenesis, HBV interact with mitochondria through HBx and HBsAg. HBV may act on the mitochondria related intrinsic apoptosis, but the results are different in different situations. Besides, HBV is also related to oxygen stress injury, cell cycle regulation and antiviral immune response. Effect of HBV on mitochondria is to build the circumstance for HBV life cycle and cause liver injury. Further studies are needed to elucidate the role of mitochondria in HBV pathogenesis.

  7. Serum levels of macrophage migration inhibitory factor,Interleukin-17 and Interleukin-10 in patients with HBV-related liver disease%Serum levels of macrophage migration inhibitory factor, Interleukin-17 and Interleukin-10 in patients with HBV-related liver disease

    Institute of Scientific and Technical Information of China (English)

    YU Xiaohui; DUAN Huichun; WEI Wang

    2012-01-01

    Objective To study the potential role of macrophage migration inhibitory factor ( MIF),Interleukin-17 (IL-17) and lnterleukin-10 (IL-10) in the development of HBV-related liver disease.Methods 48 patients with chronic hepatitis B ( HBeAg negative and positive,24 cases; 21 cases of HBV-DNA negative and 27 cases of HBV-DNA positive),81 cases of hepatitis B patients with decompensated cirrhosis and 48 cases of primary liver cancer patients were collected as the experimental group,26 healthy people were as control group.Serum MIF,IL-17 and IL-10 were measured.Results MIF and IL-17 significantly increased,IL-10 significantly decreased in experimental group,compared with the control group ( P < 0.05 ),there was significant difference. In addition,there was no significant difference (P >0.05) between positive and negative of chronic hepatitis B.MIF,IL-17 and ALT levels were positively correlated ( r =0.693,P < 0.0 1 ; r =0.897,P < 0.001 ),IL-10 and ALT was negatively correlated ( r =-0.285,P =0.037).Conclusion These results indicated that MIF,IL-17 and IL-10 may participate in the pathological process of HBV-related liver disease,serum levels of MIF,IL-17 and IL-10 appear to reflect the severity of tissue injury in HBV-related liver disease.

  8. Construction of two hepatocellular carcinoma cell models for the expression of HBV X gene with different selection characteristics%两个不同筛选特性的表达HBV X基因肝癌细胞模型的建立

    Institute of Scientific and Technical Information of China (English)

    贺兴鄂; 雷建华; 杨旭; 王文龙; 罗红雨; 梁骏

    2005-01-01

    目的:构建两个不同筛选特性的表达HBV X基因肝癌细胞模型.方法:应用脂质体介导转染克隆有HBV X全基因真核表达载体pCEP4-X和pcDNA3.1(+)-X入肝癌细胞HepG2,hygromycin和neomycin筛选单细胞克隆,传代培养一定时期后应用PCR,RT-PCR和Western blot方法鉴定HBV X基因的表达.结果:转染后成功筛选出耐hygromycin或neomycin的单细胞克隆,并能传代培养一定时期.PCR,RT-PCR和Western blot结果显示HBV X基因获得表达.结论:成功构建不同筛选特性的两个HBV X基因表达肝癌细胞模型.

  9. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation.

    Directory of Open Access Journals (Sweden)

    Guo-Ying Wang

    Full Text Available BACKGROUND: Neutrophil to lymphocyte ratio (NLR has been proposed to predict prognosis of hepatocellular carcinoma (HCC. However, the cut-off values are empirical. We determined the optimal cut-off value to predict HCC recurrence after liver transplantation (LT and further established a scoring model based on NLR. METHODOLOGY/PRINCIPAL FINDINGS: We analyzed the outcome of 101 HBV-associated HCC patients undergoing LT. Preoperative risk factors for tumor recurrence were evaluated by univariate analysis. By using ROC analysis, NLR≥3 was considered elevated. The disease-free survival (DFS and overall survival (OS for patients with high NLR was significantly worse than that for patients with normal NLR (the 5-year DFS and OS of 28.5% and 19.5% vs. 64.9% and 61.8%, respectively; P5 cm, tumor number >3, macrovascular invasion, AFP≥400 µg/L, NLR≥3, and HBV-DNA level >5 log10 copies/mL were preoperative predictors of DFS. Cox regression analysis showed macrovascular invasion, tumor number, and high NLR were independent prognostic factors. We then established a preoperative prognostic score based on multivariate analysis. Each factor was given a score of 1. Area under the ROC curve of the score was 0.781. All nine patients with score 3 developed recurrence within 6 months after LT. Of 71 patients without vascular invasion, three patients with both tumor number >3 and NLR≥3 developed recurrence within 14 months after LT while the 5-year DFS and OS for patients with a score of 0 or 1 were 68.1% and 62.8%, respectively. CONCLUSIONS/SIGNIFICANCE: Preoperative elevated NLR significantly increases the risk of recurrence in patients underwent LT for HCC. Patients with both NLR≥3 and tumor number >3 are not a good indication for LT. Our score model may aid in the selection of patients that would most benefit from transplantation for HCC.

  10. The Study of IgG Subclass Profiles of Anti-HBc in Populations with Different Status of HBV Infection

    Institute of Scientific and Technical Information of China (English)

    Yu-Yen Yang; Chi-Chiang Yang; Chien-Fu Huang; James Cheng-Chung Wei; Mei-Shang Ho; Lina Wang; Shyh-Jye Lin; Wei-Yu Tsai; Chien-Chou Lin; Fangling Xu

    2005-01-01

    To study IgG subclasses for the hepatitis B virus (HBV) core antigen (anti-HBc) in different populations, a comparison was made between 104 chronic carriers (60 male and 44 female) and 434 recovered individuals (247 male and 192 female). Biochemistry analyses of AST (aspartate aminotransferase) and ALT (alanine aminotransferase) were also performed. Among the 104 chronic carriers, 21 patients were found to be ALT and AST abnormal (> 25 IU/ml). After comparing these ALT and AST abnormal patients with other ALT and AST normal chronic carriers, no statistical difference was observed in the OD values of the anti-HBe (p > 0.05). The ELISA results showed the anti-HBc IgG subclass pattern was IgG1 > IgG3 > IgG4 in chronic carriers and IgG3 > IgG1 > IgG4 in recovered individuals (p < 0.05). This result suggests the IgG1/IgG3 ratio may be related with HBV status. However, in spite of the different anti-HBc IgG1/IgG3 patterns demonstrated in different populations, both anti-HBc IgG1 and IgG3 concentrations were significantly higher in chronic carriers (p < 0.05). Therefore, both the anti-HBc IgG1/IgG3 ratio and their amounts differed. They may play a significant role in chronic carriers and recovered individuals. The anti-HBc IgG subclass profiles of chronic carriers were not changed regardless of liver inflammation, and were independent of sex and age. Cellular & Molecular Immunology.

  11. The silence of MUC2 mRNA induced by promoter hypermethylation associated with HBV in Hepatocellular Carcinoma

    Directory of Open Access Journals (Sweden)

    Ling Yang

    2013-01-01

    Full Text Available Abstract Background To evaluate the promoter methylation status of MUC2 gene and mRNA expression in patients with hepatocellular carcinoma. Methods We analyzed MUC2 methylation by MSP, and MUC2 mRNA by real-time PCR in 74 HCC. Results MUC2 mRNA were lower in HCC tissues (Mean -ΔCt = −4.70 than that in Non-HCC tissues (Mean -ΔCt = −2.98. Expression of MUC2 was elevated in only 23 (31.08% of the 74 HCC patients. MUC2 promoter was hypermethylated in 62.2% (46/74 of HCCs, and in only 18.9% (14/74 of non-tumor samples. MUC2 mRNA were lower in HCC patients with hypermethylation (Mean -ΔΔCt = −2.25 than those with demethylation (Mean -ΔΔCt = −0.22, and there is a decreased tendency for MUC2 mRNA in HCC patients with promoter hypermethylation (p = 0.011. There was a significantly correlation found between MUC2 mRNA and HBV and AFP in HCC. The loss of MUC2 mRNA and hypermethylation could be poor prognostic factors. After treated by 5-Aza-CdR and TSA, we found that MUC2 mRNA induced significantly in 7721, Huh7 and HepG2 cells. Conclusion The results suggested that MUC2 mRNA silenced by promoter hypermethylation is associated with high levels HBV in HCC.

  12. "Know Hepatitis B:" A Multilingual Communications Campaign Promoting Testing for Hepatitis B Among Asian Americans and Pacific Islanders.

    Science.gov (United States)

    Jorgensen, Cynthia; Chen, Sherry; Carnes, C Amanda; Block, Joan; Chen, Daniel; Caballero, Jeffrey; Moraras, Kate; Cohen, Chari

    2016-01-01

    The "Know Hepatitis B" campaign was the first national, multilingual communications campaign to promote testing for hepatitis B virus (HBV) among Asian Americans and Pacific Islanders (AAPIs). This population comprises fewer than 5% of the total U.S. population but accounts for more than half of the up to 1.4 million Americans living with chronic HBV infection. To address this health disparity with a national campaign, CDC partnered with Hep B United, a national coalition of community-based partners working to educate AAPIs about hepatitis B and the need for testing. Guided by formative research, the "Know Hepatitis B" campaign was implemented in 2013 with a two-pronged communications strategy. CDC used available Chinese, Korean, and Vietnamese media outlets on a national level and relied on Hep B United to incorporate campaign materials into educational efforts at the local level. This partnership helped facilitate HBV testing among the priority population. PMID:27168659

  13. TACE联合艾迪注射液对乙肝合并肝癌患者HBV DNA和AFP的影响

    Institute of Scientific and Technical Information of China (English)

    张小灵; 陈立宇

    2015-01-01

    To compare the effects of transarterial chemoembolization (TACE) combined with Aidi (AD) injection or entecavir on reduction of AFP levels of hepatitis B (HVB) patients complicated with liver cancer and study the impacts on negative conversion ratio of HBV DNA. Total 70 HVB patients complicated with liver cancers to receive treatment in our department from June 2010 to November 2011 were taken as the study subjects and randomly divided into entecavir group and AD group. The two groups received TACE combination therapy. The changes of HBV DNA and AFP in the two groups in different postoperative times were observed. The overall efficacy in entecavir group (77.14%) and AD group (85.71%) had no statistic difference ( >0.05). In 4-48 weeks after the operation, AFP in AD group was obviously lower than that in entecavir group ( 0.05), but in the 2nd and 3rd year, the negative conversion ratio of HBV DNA in entecavir group was 57.14%and 71.43%, respectively, lower than that in AD group ( 80.00%and 91.43%)( 0.05);艾迪组TACE术后4~48 w的AFP均显著低于恩替卡韦组(0.05)外,第2、3年恩替卡韦组HBV DNA转阴率分别为57.14%、71.43%,均显著低于艾迪组的80.00%和91.43%(<0.05)。艾迪注射液与恩替卡韦治疗乙肝合并肝癌均有显著疗效,比较而言,艾迪注射液可显著降低AFP水平,提高HBV DNA转阴率,故应将TACE联合艾迪注射液作为首选方案。

  14. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis

    Directory of Open Access Journals (Sweden)

    Fabrizio Cantini

    2014-01-01

    Full Text Available Introduction. Antitumor necrosis factor-alpha (TNF-α agents are widely used for treatment of rheumatic and dermatological diseases. We conducted the systematic review and meta-analysis to assess the prevalence of HBV reactivation among patients treated with anti-TNF-α. Methods and Findings. A comprehensive literature search of MEDLINE, Scopus, and ISI Web of Knowledge databases was conducted. From 21 studies included in the systematic review, 9 included patients with occult chronic HBV infection and 6 included patients with overt infection while 6 addressed both groups. Based on 10 studies eligible for meta-analysis we report pooled estimate of HBV reactivation of 4.2% (95% CI: 1.4–8.2%, I2: 74.7%. The pooled prevalence of reactivation was 3.0% (95% CI: 0.6–7.2, I2: 77.1% for patients with occult infection, and 15.4% (95% CI: 1.2–41.2%, I2: 79.9% for overt infection. The prevalence of reactivation was 3.9% (95% CI: 1.1–8.4%, I2: 51.1% for treatment with etanercept and 4.6% (95% CI: 0.5–12.5%, I2: 28.7% for adalimumab. For subgroup of patients without any antiviral prophylaxis the pooled reactivation was 4.0% (95% CI: 1.2–8.3%, I2: 75.6%. Conclusion. Although HBV reactivation rate is relatively low in patients treated with anti-TNF-α for rheumatic and dermatological conditions, the antiviral prophylaxis would be recommended in patients with overt chronic HBV infection.

  15. Application of the HBV model for assessment of climate change impacts on the elements of hydrological cycle for the Struma River Basin

    International Nuclear Information System (INIS)

    The model used in this report is a version of the HBV model developed for the project Climate Change and Energy Production, a Nordic project aimed at evaluating the impacts of climate change on the water resources. It has a simple vegetation parametrization including interception, temperature based evapotranspiration. calculations, lake evaporation, lake routing, glacier mass balance simulation, special functions for climate change simulations etc. The HBV model, originally developed at the Swedish Meteorological and Hydrological Institute in the first half of the seventies (Bergstroem 1976) has gained widespread use for a large range of applications both in Scandinavia and beyond. It can be classified as a semi-distributed conceptual model. The version described in this report was developed for the Nordic project 'Climate change and Energy Production' (Saelthun 1996), as a synthesis of several versions used in the different Nordic countries. The main input variables are the average daily temperature, daily totals of the precipitation, the potential evapotranspiration and the daily discharges. The HBV model was applied for assessment of climate change impacts on the elements of hydrological cycle for the Struma river basin. The river Struma flows from North to South up to the Aegean Sea. Considerable part of the river basin is situated in northwest part of Bulgaria, heaving an area of more than 10 000 km2 and average elevation about 900m asl (cross-section Marino pole). The period of 16 years (1973-1988), four precipitation and temperature stations were used for the model parameters evaluation. The achieved value of R2 (Nash criterion) is 0.55. The climate change impact calculations (monthly values of temperatures change in oC and precipitation change in %) for two scenarios were used for the input data correction to the HBV model. The obtained results are promising and they show the potential possibility for the HBV model use to assess the climate change impacts

  16. Investigating the Effect of HBV Amplification Affected by APRIL Serum and IgD Expression on the B Cells of Liver in Chronic Hepatitis B Patients

    Directory of Open Access Journals (Sweden)

    F Bastani

    2015-10-01

    Full Text Available Introduction: Host immune responses are considered as an an important factor concerning the progression of HBV infection. B cells population following Hepatitis B infection has received scant attention. A Poroliferation-Inducing Ligand (APRIL can be introduced as a stimulator of B cell activities. Therefore, this study intended to investigate the proportion of IgD positive B lymphocytes in liver as well as to determine the level of APRIL serum in relation to the clinical findings in chronic hepatitis B patients. Methods: Fifty-seven subjects suffering from chronic hepatitis B(CHB were selected, who  attended the Hepatitis Clinic of Shariati Hospital. APRIL ELISA kit was used in order to measure the APRIL serum concentration. HBV DNA was quantified by RealArtTM HBV LC PCR. Liver biopsy sections were stained with immunohistochemistry in order to indentify IgD. Results: The mean score of liver fibrosis and inflammation was reported 4.20 according to the modified histologic activity index system. The mean score for patients with liver IgD positive B-cells was 1.9. Moreover, linear regression analysis showed that increasing the score of intrahepatic IgD positive B cells was propotionate to the increase of HBV DNA amplification, whereas it revealed a negative relationship with the APRIL serum level. Conclusion: The study findings revealed that IgD positive B-cells imply the presence of naïve B cells, more within patients who had higher level of HBV DNA. Moreover, higher score of IgD positive B cells population was negatively related with the serum level of APRIL.

  17. Effect of the HBV Capsid Assembly Inhibitor Bayer 41-4109 on the Intracellular Localization of EGFP-Core Fusion Proteins

    Directory of Open Access Journals (Sweden)

    Aris Haryanto

    2015-11-01

    Full Text Available Bayer 41-4109 is heteroarylpyrimidine (HAP which has been identified as potent of HBV capsid assemblyinhibitor. The present study was to study effect of Bayer 41-4109 treatment on the intracellular localization ofEGFP-Core fusion proteins into HepG2 cells. Three recombinant plasmids of pEGFP-Core with single, double andtriple NLS of HBV core (EGFP-Core 1C, 2C and 3C and two recombinant plasmids with single and triple NLS ofSV-40 (EGFP-Core 1 and 3 SV-40 were used in this work. After transient transfected into HepG2 cells and treatedwith Bayer 41-4109, the intracellular localization of expressed fusion proteins from all plasmid constructions weredetermined and quantified under confocal laser microscope. Results shown that Bayer 41-4109 treatment in HepG2cells inhibited the nuclear localization of EGFP-Core with single of triple HBV core NLS. As well as the constructionsof expressed fusion protein with single and triple SV-40 NLS (EGFP-Core 1 and 3 SV-40 NLS showeddecreasing the nuclear localization after treated with Bayer 41-4109, even not as strong as EGFP-Core 1C and 3CNLS. Bayer 41-4109 has been identified as a potent inhibitors of HBV replication which has multiple effects on HBVcapsid assembly. It may inhibit virus replication by inducing assembly inappropriately and by misdirectingassembly decreasing the stability of normal capsids.Keywords: HBV capsid, Bayer 41-4109, EGFP-Core fusion protein, HepG2 cell

  18. Changes and Significance of peripheral Th17 cells and Treg cells in HBV infected patients%Th17细胞与 Treg 细胞在 HBV 感染患者中的检测意义

    Institute of Scientific and Technical Information of China (English)

    邓永佳; 张房英; 赖小丽

    2015-01-01

    Objective To investigate the changes of T helper 17 (Th17)cells and regulatory T (Treg)cells in the peripheral blood of hepatitis B virus(HBV)infected patients and their correlations with liver injury.Methods One hundred and nine cases of hepatitis B patients were chosen in our hospital from March 2010 to January 2013 and were divided into four groups in accordance with the condition of diseases.The peripheral blood of 32 asymptomatic HBV carriers (ASC group),47 chronic hepatitis B patients (CHB group),30 hepatocellular carcinoma patients (HCC group)and 30 healthy controls (control group)were collected.The percentages of Th17 and Treg cells were detected by flow cytometry.Alanine aminotransferase (ALT)and aspartate aminotransferase (AST)were detected by automatic biochemistry analyzer.Results Compared with control group,the percentages of both Treg and Th17 cells in the peripheral blood of ASC group were higher,but no statistical difference was detected (t =0.809,P >0.05 for Treg cells;t =1 .459,P >0.05 for Th17 cells, respectively).While significant increase of percentages of Treg cells and Th17 cells in CHB group and HCC group was found(t=2.988,7.569,P <0.05 for Treg cells;t=3.910,6.725,P <0.05 for Th17 cells,respectively).And Treg cells increase in HCC group was higher than that in CHB group (t=6.580,P <0.01).Treg cells and Th17 cells were correlated positively with ALT and AST(r=0.546,0.587,P <0.01 for Treg cells;r =0.546、0.617,P <0.01 for Th17 cells),and Th17 cell percentage was positively correlated with Treg cell percentage (r =0.487,P <0.01).The rate of Th17/Treg in control group was the lowest (0.15%±0.14%),while significantly higher Th17/Treg ratio in CHB group and HCC group were observed (t=2.015,5.056,P <0.05).Conclusion With the development of HBV infection,the percentages of Th17 and Treg cells increased.The destruetion of the immune balance leads to the increased of Th17 cells that induced immune injury and induce the inflammation of liver cells

  19. SNP loci detection method based on HBV sequence%一种基于HBV序列的SNP位点检测方法研究

    Institute of Scientific and Technical Information of China (English)

    张琪; 刘立芳; 马磊; 贺建峰

    2014-01-01

    乙型肝炎病毒(Hepatitis B Virus,HBV)感染作为严重影响人类健康的疾病之一,是导致慢性肝脏疾病、肝硬化和肝癌的主要元凶。HBV由于其自身复制的特殊性,具有高变异特性,据研究表明HBV基因变异是HBV持续感染的根本原因。为了了解HBV的基因变异情况,检测HBV序列的SNP位点即单突变位点已广泛应用于大量的研究,所检测出的SNP位点对指导临床有重要意义。但是目前关于SNP位点检测的方法多因技术难度较高,费用大等不利因素而受到制约。因此,探讨一种基于计算机的SNP位点检测方法成为一种趋势。针对HBV序列的 SNP位点的特点,提出了一种基于最优风险与预防模型的HBV序列的SNP位点检测方法。方法首次应用于HBV序列的SNP位点检测,实验结果表明:该方法不仅有效地检测出HBV序列的X基因片段和前C区基因片段中已经报道的位点,而且还发现了一些新的SNP位点。与硬件检测SNP位点不同的是,所提出的计算机方法具有操作简单和费用低的优点,而且普通实验室和医疗机构均可以承受。%As one of the severe diseases, HBV(Hepatitis B Virus)infection is seriously affecting human health. This kind of virus infection is the main reason that leads to chronic liver disease, cirrhosis and liver cancer. Due to the particularity of HBV replication and high variability characteristics, related studies have revealed that the HBV gene mutation is the basic reason of persistent HBV infection. In order to understand the genetic variation of HBV, the SNP detection from HBV sequences has been widely applied in the large number of research, the detected SNP loci may contain great clinical significance. However, currently, the SNP loci detection methods are restricted by some negative factors, such as high technical difficulty, high expense and so on. Therefore, to explore a computer-based method for SNP loci

  20. 广州地区吸毒人员HBV、HCV感染流行病学特征%HBV and HCV infection among drug addicts in Guangzhou

    Institute of Scientific and Technical Information of China (English)

    熊华平; 花文峰; 王敏; 廖峭; 戎霞; 黄杰庭; 黄珂; 许茹; 付涌水

    2013-01-01

    Objective To investigate the infection rates and the impact of HBV and HCV infection among drug addicts in Guangzhou.Methods Questionnaire survey was conducted in this study.Blood samples from the drug addicts were collected.HBsAg and HCV antibodies were detected by ELISA assays.The correlation between infection and possible impact factors were analyzed by SPSS16.0 software.Results Of the 1 375 drug addicts,the percentage of HBV and HCV infection was 20.8% and 39.2%,respectively.106 cases (7.7%) were found to have HBV and HCV co-infection.412 cases were intravenous drug users (IDUs),in which the HBV and HCV infection rate was 24.5% and 84.5%,respectively.Elderly and those with a long history of drug addiction had a higher risk of having HBV and HCV infection.Conclusions Drug addiction,especially through the intravenous injection,is the risk factor of HBV and HCV infection.Age,the history of drug addiction,and intravenous drug injection are correlated with HBV and HCV infection.%目的 了解广州地区吸毒人员乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)的感染状况及其影响因素.方法 收集广州地区吸毒人员的血液标本,采用ELISA检测HBsAg及HCV抗体,并对吸毒人员采取统一调查表进行问卷调查,采用统计学方法进行相关性分析.结果 1 375名吸毒者HBV、HCV的感染率分别为20.8%、39.2%,HBV/HCV合并感染率为7.7%(106/1 375).其中采用静脉吸毒者HBV、HCV的感染率分别24.5%、84.5%,均高于非静脉吸毒者的19.2%、19.8%,差异有统计学意义(P<0.05).吸毒者年龄越大、吸毒时间越长越容易发生HBV或HCV感染.结论 吸毒尤其是静脉吸毒是HBV、HCV感染的高危因素.吸毒者年龄、吸毒时间长短及吸毒方式与HBV、HCV感染相关.

  1. Correlation of the genotype and mutation of HBV and X protein with HCC%HBV基因型、变异、X蛋白与HCC相关性的研究

    Institute of Scientific and Technical Information of China (English)

    杨春霞; 迟晓伟; 张艳梅; 游晶; 范晶华; 杨微波

    2016-01-01

    ASC组外均高于PC变异阴性感染者所占比例,但差异无统计学意义。结论HBV基因型、变异位点1762/1764和1896、X蛋白之间存在相互关系,与肝细胞癌的发生与发展有关。%Objective To understand the correlation of the genotype of hepatitis B virus(HBV), muta⁃tion loci of 1762/1764 and 1896, and HBV transactivator protein X with hepatocellular carcinoma(HCC) for theoretical evidences in early diagnosis and therapy of this entity. Methods HBV genotypes and their mutation loci were tested by nucleic acid amplification in 159 blood samples obtained from asymptomatic chronic HBV carriers, patients of chronic Hepatitis B, hepatitis B induced cirrhosis and HBV-associated HCC, and se⁃quenced by the auto genotype analyzer and measured with quantitative method. Expression of X protein in the liver tissues from the aforementioned 4 groups were detected by immunohistochemistry staining, and the results were estimated by semi-quantitative integration. Results 1) In the 159 cases infected with chronic HBV, 56 were associated with genotype B(35.2%, 56/159) and 103 with genotype C (64.8%, 103/159). Genotype C in groups of asymptomatic chronic hepatitis B virus carrier(ASC), patients of chronic hepatitis B(CHB), patients with liver cirrhosis(LC) and HCC accounted for. The difference was significant(χ2=8.462, P=0.037);2)Muta⁃tions of basal core promoter(BCP)were 44.0%(11/25), 63.2%(36/57), 85.7%(36/46) and 64.5%(20/31), respec⁃tively for the four groups of HBV patients with genotype C, and cases with precore(PC) mutation were 45.5%(5/11), 66.7%(24/36), 77.8%(28/36) and 70.0%(14/20), respectively. Cases with two mutations were over those with genotype B, and the difference was significant except for ASC group(P<0.05);3) Protein X expres⁃sion was the strongest in group LC, with a positive rate of 71.7%, and came next by group HCC(71.0%), CHB (59.6%) and ASC(52.0%). The difference was significant among groups(P<0.05); 4)Positive rate

  2. 妊娠后期拉米夫定抗病毒治疗HBV DNA高载量孕妇的母婴结局分析%Maternal-fetal outcomes of lamivudine treatment administered during late pregnancy to highly viremic mothers with HBeAg+ chronic hepatitis B

    Institute of Scientific and Technical Information of China (English)

    江红秀; 韩国荣; 王翠敏; 季莹

    2012-01-01

    Ag)-positivity and highly viremic status.Methods A total of 256 pregnant women in the second or third trimester with monoinfected CHB,HBeAg-positivity,and HBV DNA > 6 log10 copies/mL were divided into two groups:lamivudme (lam) treatment (n =164) or no treatment (controls; n =92).All infants were treated with hepatitis B immune globin (HBIg; 200 IU) within 12 hrs of birth and 15 days later,and were given the recombinant HBV vaccine (20 μg) at 0,1 and 6 months.All infants were followed-up to at least seven months and hepatitis B surface antigen (HBsAg) and HBV DNA levels were used to determine perinatal transmission (PT) rates.The mothers' data from routine blood analysis,tests of hepatic and renal function,detection of HBV markers and HBV DNA were retrospectively analyzed to determine changes associated with the lam treatment.Correlations of lam treatment with HBV PT rate,alanine aminotransferase (ALT) normalization,adverse reactions,pregnancy complications,congenital deformities,and infants' growth/development were determined by statistical analyses.Results Prior to delivery,the lam-treated mothers had significantly lower HBV DNA levels (3.72 ± 1.78 vs.controls:7.83 ± 0.67 log10 c/ml; t=-22.359,P< 0.001).The rate of virological response in the lam-treated group was 97.56% (160/164).The lam-treated group had significantly higher ALT normalization rate (90.20% vs.controls:55.88%; x2 =13.349,P<0.001) and significantly lower HBeAg titer (957.73 ±458.42 vs.controls:1296.35 ± 383.14 S/CO; t=-5.410,P< 0.001).At birth,the infants from lam-treated mothers had significantly lower HBsAg-positivity (15.24% (25/164) vs.controls:30.43% (28/92); x2 =8.284,P=0.004).By 7-12 months after birth,none of the infants born to lamtreated mothers tested positive for HBsAg,compared to 8.70% (8/92) of the infants born to mothers in the control group (x2 =14.721,P< 0.001).None of the lam-treated mothers required treatment discontinuation due to adverse events or lam

  3. Development of a Novel, Ultra-rapid Biosensor for the Qualitative Detection of Hepatitis B Virus-associated Antigens and Anti-HBV, Based on “Membrane-engineered” Fibroblast Cells with Virus-Specific Antibodies and Antigens

    OpenAIRE

    Antonios Perdikaris; Nikos Alexandropoulos; Spiridon Kintzios

    2009-01-01

    A novel miniature cell biosensor detection system for the detection of Hepatis B virus (HBV)-associated antigens and anti-HBV is described. The biosensor is based on “membrane-engineered” Vero fibroblast cells immobilized in an alginate matrix. The membrane-engineering process involved the electroinsertion of anti-HBV specific antibodies (anti-HBs, anti-HBe) or antigens (HBsAg) in the membranes of the Vero cells. The attachment of a homologous antigen to the electroinserted antibody (or, resp...

  4. 治疗性双质粒HBV DNA疫苗工程菌的中试发酵工艺研究%Pilot Fermentation Procedure of Recombinant E. coli Strain Containing Two Plasmids as Therapeutic HBV DNA Vaccine

    Institute of Scientific and Technical Information of China (English)

    饶桂荣; 黄英; 王鹏; 何晓嫱; 杨富强; 莫国玉; 陈光明

    2007-01-01

    目的 研究双质粒HBV DNA疫苗工程菌的中试发酵工艺.方法 首先通过计算质粒拷贝数,检测工程菌DH5α/pS2.S和DH5α/pFP在传代过程中的遗传稳定性,通过摇瓶培养确定培养基组成,再在30 L发酵罐内,通过改变培养基成分、培养时间、补料方式,确定最佳发酵参数.并将确定的最佳发酵参数应用于50 L发酵罐连续3批中试规模的发酵,同时考察在发酵培养过程中质粒稳定性和超螺旋质粒DNA的比例.结果 工程菌DH5α/pS2.S和